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Reduced bone mineral density (BMD) and muscle dysfunction are recognised secondary 
complications of Crohn’s disease (CD), likely to be as a result of proinflammatory cytokines, 
glucocorticoid usage and malnutrition. The perceived benefits of exercise has been suggested 
to counteract these disease-specific complications with different exercise training stimuli 
eliciting corresponding psychological and physiological adaptations. However, the role of 
exercise as a therapeutic option remains poorly understood, with few prospective trials 
conducted in this high-risk group. Moreover, these existing studies are significantly limited 
by their small sample size, methodological robustness and lack of blinded outcome assessors 
highlighting the need for robust clinical research. Therefore, the overarching aim of this 
thesis is to expand the existing body of knowledge and provide novel data on the impact of 
exercise on bone and muscle health in CD.  
 
Firstly, a systematic review (Chapter 3) utilising the current literature was undertaken to 
evaluate the evidence of the benefits and harms of exercise interventions to allow the 
integration of the best evidence available to inform exercise recommendations. Results 
identified that the benefits of exercise have not been sufficiently researched, particularly in 
outcomes such as immune parameters, BMD, muscular function and fatigue. However, it did 
demonstrate that low to moderate-intensity exercise was safe, feasible and potentially 
beneficial at counteracting some disease-specific complications in persons with an inactive to 
mildly active disease. Further supporting the perceived benefits of exercise. However, the 
majority of interventions involved modes of exercise such as yoga or walking that are sub-
optimal for improving bone health.  
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As a prelude to experimental research, Chapter 5 investigated the test-retest reliability of 
outcome measures grip strength, isokinetic muscular strength, muscular endurance and BMD. 
Test-retest reliability was excellent in all outcome measures, highlighting these methods as 
reliable to facilitate the assessment and effectiveness of an intervention. Chapter 6 reports the 
prevalence and risk factors associated with bone and muscle health in inactive to mildly 
active CD participants. These data strengthen the evidence base that adults with CD are at an 
increased risk of osteopenia or osteoporosis, in addition to identifying longer disease 
duration, lower physical activity habits, females and smokers as correlates of BMD. 
Moreover, adults with CD also showed a significantly reduced upper and lower muscular 
endurance and lower muscular strength when matched to healthy controls.  
 
These findings informed the design of Chapter 7. This two arm, parallel-group, assessor-blind 
randomised controlled trial explored the effects of a 6-month combined impact and resistance 
home-based exercise intervention on primary outcomes BMD and muscular function. This 
study provided novel findings, identifying significant improvements between groups in lower 
and upper muscular endurance and strength, handgrip strength and BMD at the lumbar spine 
and femoral neck. In view of these results, a combined impact and resistance training 
programme is a potent stimulator for skeletal growth, structure and maintenance and should 
be considered as therapeutic option for the perseveration of bone and muscle parameters. 
Collectively, these studies provide corroborating evidence that exercise is a safe and feasible 
option and can be used to elicit favourable physiological and psychological changes in adults 
with CD. 
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1.1 Background 
Crohn’s disease (CD) and ulcerative colitis (UC) are immunologically mediated idiopathic 
chronic inflammatory disorders of the gastrointestinal tract, collectively referred to as 
inflammatory bowel disease (IBD) (Sartor, 2006). The peak age of onset for IBD is 15 to 30 
years, although it can occur at any age and affects approximately one person in every 250 of 
the UK population (Crohn’s and Colitis UK, 2016). Despite extensive studies, the aetiology 
and pathophysiology of IBD remains largely unknown, however the general consensus is that 
the condition is thought to result from a combination between genetic and environmental 
factors that initiate a dysfunctional mucosal immune response (Fedorak and Madsen, 2004; 
Baumgart and Sandborn, 2007).  
CD and UC are characterised by a cyclical nature alternating between active and quiescent 
states that can negatively impact a person’s quality of life (QOL) (Abraham and Cho, 2009). 
Over 75% of adults with CD and 23-45% with UC require surgery, and up to half relapse 
every year experiencing typical clinical features such as malnutrition, diarrhoea, abdominal 
pain and blood loss (Carter et al., 2004; Levine and Burakoff, 2011). However, even when 
the disease is in remission, more than one third of adults with IBD are affected by extra-
intestinal manifestations beyond the intestinal tract such as musculoskeletal, specifically 
reduced bone mineral density and muscle dysfunction and dermatological disorders, liver 
disease and ocular, renal and pulmonary system involvement, which can be just as 
debilitating as the primary disease (Narula and Fedorak, 2008; Ott and Scholmerich, 2013). 
Although these manifestations have been observed in both CD and UC, a greater prevalence 
has been reported in CD, likely as a result of disease specific proinflammatory cytokines, 
medications, malnutrition and surgical interventions (Repiso et al., 2006; Vavrikca et al., 
2015). 
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With limited treatment options, the need for effective symptom management is becoming 
ever more pressing. Dietary manipulation and psychological strategies, while not mainstream 
therapies combat high-risk factors such as poor nutrition, depression, stress and anxiety that 
negatively affect disease activity. Physical activity and exercise  has been suggested to 
counteract aforementioned disease-specific complications with different exercise training 
stimuli eliciting corresponding psychological and physiological adaptations (Buchman, 1999; 
Peters et al., 2001; Perez, 2009). However, the role of exercise as a therapeutic option 
remains poorly understood, with exercise guidelines being based on the beneficial effects 
found among healthy individuals and not specifically within this population (Narula and 
Fedorak, 2008). To date the evidence for exercise in this population remains sparse, with only 
a few intervention studies, which are significantly limited by their small sample size, 
methodological robustness, lack of long-term follow up and lack of blinded outcome 
assessors. Therefore, the purpose of this thesis is to expand the existing body of knowledge 
and provide novel data on the impact of exercise on bone and muscle health in CD. The 
specific focus of each subsequent chapter is as follows: 
Chapter Two: A comprehensive summary of the current knowledge surrounding IBD, 
including the pathophysiology, epidemiology, impact and disease management. In addition to 
highlighting the prevalence of extraintestinal manifestations and the susceptibility to the 
development of these complications varying greatly depending on archetypal phenotypes: CD 
and UC, which will provide a focus of this thesis.  
Chapter Three: A systematic review to assess, utilise and synthesise the literature on the 
benefits and harms of physical activity interventions in this population to allow the 
integration of the best evidence available to inform physical activity recommendations.  
Chapter Four: A justification and rationale of the design and methods employed.   
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Chapter Five: Prior to experimental research, this study aimed to determine the test-retest 
reliability of outcome measures to evaluate and facilitate the assessment and effectiveness of 
an intervention.   
Chapter Six: The prevalence and risk factors associated with bone and muscle health in CD 
vary significantly depending on the study population, study location and study design. 
Therefore, the aims of this study were to assess current bone and muscle health and identify 
possible risk factors associated with and contributing to low BMD in CD in the UK. 
Chapter Seven: Despite the mechanical properties of weight bearing exercises and its 
widespread clinical use in osteoporosis, sarcopenia and postmenopausal women to increase 
BMD, muscular strength and endurance, little is known about the beneficial effects in adults 
with CD. Therefore, the primary aim of this study were to investigate the effects of a 
combined impact and resistance training programme on muscle function and BMD in adults 
with CD.  
Chapter 8: An overall discussion interpreting and supporting the implications of the research 
findings.  
Overall, with the lack of sufficient evidence and exercise guidelines for individuals with CD 
it remains unclear what type, duration, frequency or intensity is safe and beneficial to 
recommend as a therapy to counteract these disease-specific complications. It is intended that 
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2.1 What is Inflammatory Bowel Disease? 
Inflammatory bowel disease (IBD) is an immunologically mediated idiopathic chronic 
inflammatory disorder of the gastrointestinal (GI) tract, classified into two most common 
archetypal phenotypes; Crohn’s disease (CD) and ulcerative colitis (UC) (figure 1) (Sartor, 
2006). These chronic diseases are characterised by a cyclical nature alternating between 
active and quiescent states. Although they may share overlapping epidemiological, clinical 
and therapeutic characteristics, they present distinguishable endoscopic, pathological and 










CD presents as a deep transmural pattern of cobblestone inflammation involving 
discontinuous mucosal segments of lesions intervened with portions of otherwise normal 
areas of mucosa (Zhang and Li, 2014). In approximately 27% of cases, there are non-
necrotising granulomas composed of epitheliod histiocytes (Mazor et al., 2010). Whilst 
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initially only small segments are involved, there is potential for the disease to progress 
extensively throughout the gastrointestinal tract from the orpharynx to the perianal area, with 
the ileocecal region most frequently involved (Hendy and Hart, 2013). In contrast, UC is 
confined to the colon, consisting of a continuous pattern of inflammation involving variable 
severity with ulceration, oedema and haemorrhage extending proximally from the rectum 
involving the mucosa and superficial submucosa. Histological features include goblet cell 
depletion, crypt abscesses and distortion (Nielson et al., 2001; Strober, 2007). However with 
no differentiating single gold standard measure, distinguishing between the two disorders can 
be difficult when making a definitive diagnosis. Indeterminate colitis, while somewhat 
controversial has been adopted by clinicians when no endoscopic, pathological or 
radiological features of CD or UC are present due to the overlapping features and unusual 
presentation of disease (Guindi and Riddell, 2004). Approximately, 10-15% of patients are 
categorised as indeterminate colitis, a figure that has not changed over the past 30 years. 
Although the majority of these individuals develop UC, there are also individuals who persist 
at in-between stages, not responding to medication as well as UC patients but faring better 
than patients with CD, suggesting IC may be a third disease entity (Wells et al, 1991; 
Tremaine, 2011).  
 
2.2 Aetiology and pathogenesis 
Despite extensive studies the aetiology and pathophysiology of IBD remains largely 
unknown. The general consensus suggests that IBD is initiated by a combination of 
environmental agents along with a dysfunctional mucosal immune response or imbalanced 
interaction with microbes in genetically susceptible individuals (figure 2) (Fedorak and 
Madsen, 2004; Baumgart and Sandborn, 2007).  
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2.2.1 Immunological factors 
Despite its complexity, investigations into the pathogenesis of IBD has been dominated by 
studies of mucosal immunity, in particular abnormal T cell responses. Recently, the concept 
that CD was an interleukin (IL)-12 driven T-helper (Th) 1 mediated disease and that UC was 
an IL-13 driven Th2 mediated disease became largely eclipsed following the discovery of 
new T-helper cells, particularly Th17 through the over production of proinflammatory 
cytokines: IL-17, IL-21 and IL-22 (Aggarwal et al., 2003: Yen et al., 2006). These 
proinflammatory cytokines are induced by a combination of IL-6, transforming growth factor 
(TGF)-β and IFN-y and promoted by IL-23, a heterodimeric cytokine that shares a subunit 
chain with IL-12, which could potentially explain why IL-12 was initially thought to be a 
disease mediator (Oppman et al., 2000: Strober and Fuss, 2011).  
The involvement of Th17 cells and its signature cytokine IL-17 in intestinal inflammation has 
been extensively studied with evidence suggesting IL-17 induces IL-21 production and 
prompts its interaction with TGF-β and IL-23 to promote the differentiation of Th17 cells 
(Veldhoen et al., 2006). However, there is evidence that differentiation of Th17 cells induced 
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in the absence of IL-23 lack the potential to induce inflammation, possibly due to the under-
production of IL-10 under these circumstances, an anti-inflammatory cytokine and a poor 
inducer of inflammation (McGeachey et al., 2007: Strober et al., 2010). Regardless, the 
differentiated Th17 cells interact with IL-23, expressing an IL-23 receptor (IL-23R) which 
triggers a series of chemical signals that promote inflammation (Teng et al., 2015). Several 
variations of the IL-23R have been found to influence the risk of developing IBD, as 
researchers believe that the receptors role in triggering inflammation in the intestinal walls 
may underlie its connection with this disease (Tsianos et al., 2012). The stimulation of IL-
23R, under the influence of IL-23 signalling is essential for the terminal differentiation and 
persistence of IL-17 producing cells, which trigger and amplify inflammation reflected in the 
increased mucosal levels in IBD (Sakuraba et al., 2009: Rovedatti et al., 2009). However, 
these associations have only been found in murine studies and further exploration of the role 
of IL-23R variations in the pathogenesis of IBD is now required. 
At present, Th17 cells are considered a main pathogenic factor in IBD, however many 
questions still remain. Although murine models of intestinal inflammation provide a useful 
insight into the pathogenesis of the complex inflammatory response in IBD, reproducing 
these studies in humans may not have the same effect and therefore it continues to be a work 
in progress with the constant discovery of additional information.  
 
2.2.2 Genetic factors 
Huge advances in the understanding of genetic contributions to IBD have been made over the 
past decade, due to improvements in molecular techniques, generation sequencing of human 
genomes and availability of multinational databases (Duerr, 2007; Durmaz et al., 2015). At 
present, genome-wide association studies have found a significant link between 
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chromosomes 1, 3, 6, 7, 12, 14, 16 and 19 and the development of IBD (Hanauer, 2006). In 
addition, 163 gene loci, a position on a chromosome where a genetic marker is located, 
appear to influence the likelihood of developing IBD, some of which are more specific to CD 
and some of which are more specific to UC (figure 3) (Weronica et al., 2014). A mutation in 
the nucleotide-binding oligomerization domain containing 2 (NOD2) gene and protein, was 
the first susceptibility gene identified for CD, but not UC (Khor et al., 2011; Liu and 
Stappenbeck, 2016). Defects in the NOD2 account for 17-27% of cases with CD, with 
individuals who are homozygous (that is, who have two identical alleles of the variant 
NOD2) have a 20=fold increase risk of developing CD (Hugot et al., 2001). The mechanisms 
that cause the defect in the NOD2 gene to lead to the development of IBD remains unclear. 
The onset of UC, on the other hand, is thought to establish from a dysregulation of key 
epithelial barrier genes such as ECM1 and HNF4a have shown to predispose individuals to 
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An aggregation of cases in family studies in IBD have been widely researched, with 5-30% of 
participants reporting a parent or sibling has been diagnosed with IBD (Weronica et al., 
2014). However, these figures vary greatly depending on the study type, with referral-based 
studies reporting 20-30% of cases and population-based surveys reporting 5-23% (Binder, 
1998; Weronica et al., 2014). The estimated relative risk, however to a sibling of a person 
with IBD is higher, ranging from 13-36 for CD whereas figures for UC are 7-17 (Ahmad et 
al., 2001). Although these estimates are difficult to be precise due to difficulties in correcting 
for age-adjusted incidence rates (Bennett et al., 1991; Ahmad et al., 2001; Laharie et al., 
2001). Concordance rates are even higher in twins, with monozygotic ‘identical’ twins more 
likely to develop IBD rather than dizygotic ‘fraternal’ twins, reflecting the influence of 
genetics in the disease pathogenies (Tysk et al., 1988). Studies from Sweden, Denmark and 
Germany demonstrated a concordance rate for CD to be between 52.4-63.6% in monozygotic 
twins and 0-6.7% in dizygotic twins and for UC to be 6.6-27.9% in monozygotic twins and 0-
4.5% in dizygotic twins (Tysk et al., 1988; Orholm et al., 2000; Halfvarson et al., 2006; 
Spehlmann et al., 2008; Halfvarson, 2011). Overall, the concordance rates are higher in 
monozygotic twins and more pronounced in CD than UC. However, the genetic 
predisposition cannot be solely responsible for disease aetiology when only one monozygotic 
twin is affected by the disease.  
Although population-based studies have provided compelling evidence of the influence of 
genetic predisposition in the aetiology of IBD by demonstrating differences in prevalence 
rates among different members, twins and association with genetic syndromes, the major 
influence appears to be due to environmental factors (Zhang and Li, 2014; Guan, 2019).  
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2.2.3 Environmental factors 
Several environmental factors have been considered as risk factors that may interact with the 
immune system, resulting in an abnormal inflammatory response to intestinal microflora 
(Koloski et al., 2008). Factors that have been explored include smoking, diet, drugs, stress 
and sleep (Loftus et al., 2004; Abedunde et al., 2016). A meta-analysis of smoking in IBD 
concluded that current smokers were less likely to develop UC than those who had never 
smoked or were previous smokers, with Cosnes (2001) adding heavy smokers had a lower 
rate of relapse (Cosnes 2008; Lakatos et al., 2007). Contrary to its protective effect on UC, 
smoking has been shown to increase the risk of developing CD with a higher rate of 
postoperative disease (Birrenbach and Bocker, 2004). Although the exact mechanisms around 
how smoking influences IBD are unknown, it is thought to result from nicotine which has an 
inhibitory effect on Th2 cell function, but no effect on Th1 cell function (Razani-Boroujerdi 
et al., 2007).  
There is a growing appreciation between nutrition and microbes in susceptible individuals, 
with a higher intake of fibre, fruit and vegetables consumption associated with a decreased 
risk of IBD, thought to be related to their ability to modify enzymes (Sakamoto et al., 2005; 
Amre et al., 2007). Fast foods containing higher levels of total, monounsaturated, saturated 
and polyunsaturated fats may exacerbate the development of IBD due to their role in the 
modification of receptors in macrophages, which are important in maintaining the delicate 
immune balance (Geerling et al., 2000; Lee et al., 2004; Amre et al., 2007). Limited high-
quality evidence exists to support the notion that nonsteroidal anti-inflammatory drugs 
(NSAIDs) are associated with the onset of IBD. Two studies have explored the relationship 
between NSAIDs and IBD, finding a positive association for both UC and CD (Felder et al., 
2000; Ananthakrishnan et al., 2012), adding that high dose, frequent and prolonged use was 
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associated with an increased risk. NSAIDs are thought to cause damage to the intestinal 
mucosa of the small bowel and colon and increase intestinal permeability (Berg et al., 2002).  
Stress has been suggested to play a role in the onset of IBD. In animal studies, psychological 
stress has demonstrated an increase in intestinal permeability, and stimulated the secretion of 
ions, water, mucus and immunoglobulin A (IgA) as a result of alterations in the cholinergic 
nervous system and mucosal mast cell function (Hisamatsu et al., 2007). In turn, this 
increased intestinal permeability then reduces mucosal barrier function and alters bacteria-
host interaction which, if broken, could cause damage to the stomach itself (Söderholm and 
Perdue, 2001; Hisamatsu et al., 2007). Lastly, poor sleep quality has been significantly 
associated with increased levels of IL-17, C-reactive protein (CRP) and markers of systemic 
inflammation in healthy adults, a determinant that if prolonged may lead to persistent changes 
in the immune system (Graff et al., 2011).  
Overall, it is hard to dispute the general consensus that IBD is initiated from a complex 
interaction among environmental agents, genetically susceptible individuals and a 
dysfunctional mucosal immune response, and that one of these factors alone is unlikely to 
cause the disease. Although progress in the understanding of the pathogenesis of IBD has 
been achieved, further insight into the mechanisms and pathways of how and why these 
factors impact immunity and inflammation in susceptible individuals.  
 
2.3 Classification of IBD 
The Montreal classification (2005) (Table 1) took over the Vienna classification in adults and 
was established to address the complex issues involved in classifying the extent and 
behaviour in IBD. From the clinician’s perspective, accurate classification of these two 
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phenotypes is important for choosing the most appropriate medical and surgical therapy, 
monitoring changes in disease location, surveillance and to assess the disease prognosis. A 
recent systematic review in UC (n=15,316) established that the likelihood of colectomy is 
dependent on disease extent, demonstrating that the 10-year colectomy rate was highest in 
individuals with extensive colitis (19%), left-sided colitis (8%) and proctitis (5%), with rates 
increased further if the individual was male, young and had elevated inflammatory markers at 
diagnosis (Fumery et al., 2018). Likewise with CD, individuals who present with ileocolonic 
or isolated upper CD disease are more likely to experience more stricturing behaviour and 
require more abdominal surgeries (Lazarev et al., 2013). This is an association that is 
dependent greatly upon the duration of disease, with the majority of individuals presenting 
with non-stricturing non-penetrating disease at diagnosis. However, the behaviour of CD 
changes during the course of the disease and after 25 years the majority present with a 
stricturing or penetrating pattern in which environmental, genetic and immunological factors 
may influence the disease behaviours inclination and speed of evolution (Louis et al., 2001; 
Louis et al., 2003).  
Table 1. Montreal Classification in CD and UC 
Crohn’s Disease Ulcerative Colitis 
Age at diagnosis A1 <17 Extent E1 Ulcerative Proctitis 
 A2 17-40  E2 Left-sided UC (distal UC) 
 A3 >40  E3 Extensive UC (pancolitis) 
Location L1 Ileal Disease 
Severity  
S0 Remission 
 L2 Colonic S1 Mild 
 L3 Ileocolonic S2 Moderate 
 L4 Isolated upper disease S3 Severe 
Behaviour B1 Non-stricturing, Non-penetrating    
 B2 Stricturing    
 B3 Penetrating    
 P Perianal disease modifier    
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2.4 Prevalence and incidence  
The onset of this heterogeneous disease can occur at any age but the incidence rate typically 
peaks at 15 to 30 years of age, with no differences noted between males and females (Crohn’s 
and Colitis UK, 2015). Approximately 20-25% of people are diagnosed before 16 years of 
age, a predictor associated with a more extensive disease, complications and more frequent 
disease activity (Malmborg et al., 2013). The number of individuals worldwide living with 
IBD is approximately 6.8 million, with North America noting the highest prevalence of 1.8 
million and Oceania reporting the lowest prevalence of 2302 individuals (figure 4) (GBD 
2017 IBD Collaborators, 2020). Nevertheless, the incidence rates and prevalence of IBD has 
increased remarkably in recent years, with an increase of 85.1% in global prevalent cases 
from 1990 to 2017 (GBD 2017 IBD Collaborators, 2020). The highest percentage change in 
prevalence were seen in the Soloman Islands (139.8%) and Kiribati (138.1%), while the 








In the UK IBD affects approximately 396 people in every 100,000, however with an 83.7% 
increase in cases from 1990 to 2017 projected annual costs to the NHS are expected to 
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increase from £720 million to £1.5 billion by 2040 (Stone et al., 2003; Ghosh and 
Premchand, 2015). These trends demonstrate that the prevalence of IBD in the UK is 
expected to continue increasing, with detrimental health and economic effects. Cost effective 
health innovations implemented by health-care professionals need to be addressed to manage 
this complex and costly disease.  
 
2.5 The impact of IBD 
2.5.1 Mortality/ life expectancy 
Population based data are sparse and conflicting when it comes to life expectancy in adults 
with IBD. Eight studies in CD reported a slight decrease (95% CI 1.29-3.01) in life 
expectancy compared to the general population, identifying disease duration, disease location 
and being female has been associated to increased mortality (Weterman et al., 1990; Ekbom 
et al., 1992; Persson et al., 1996; Palli et al., 1998; Farrokhyar et al., 2001; Jess et al., 2002; 
Masala et al., 2004; Jess et al., 2006). In contrast to these findings, two studies reported no 
differences in life expectancy in CD individuals (Probert et al., 1992; Cottone et al., 1996). 
The majority of UC population based studies have demonstrated a normal or increased life 
expectancy than the general population (Palli et al., 1998; Loftus et al., 2000; Farrokhyar et 
al., 2001; Viscido et al., 2001; Winther et al., 2003). Interestingly, geographical differences 
may influence these findings, as four studies all conducted in Scandinavia, reported a reduced 
life expectancy in UC, as a result of colorectal cancer (CRC), pulmonary embolisms and/or 
chronic lung diseases. However, these studies do not account for the recent major advances in 
pharmacological, non-pharmacological and surgical interventions for CD and UC. Most 
recently, a systematic analysis of the global burden of IBD in 195 countries from 1990-2017 
 CHAPTER 2: LITERATURE REVIEW 
W12018030  16 | P a g e  
 
identified an increase in the number of IBD-related deaths worldwide, increasing from 23,000 
to 38,000 (67%). However, this increase in mortality could be the result of a substantial 
increase of 85.1% in the prevalence of IBD worldwide. Nevertheless, in 2017 0.07% of 
deaths worldwide were caused by IBD, with the highest numbers reported in females aged 
85-89 and males 80-84 (GBD 2017 IBD Collaborators, 2020), perhaps due to comorbidities, 
longer disease course, polypharmacy and slower recovery following surgery. Thus, attention 
needs to be directed toward elderly individuals with IBD to address risk factors that may help 
decrease IBD-related mortality.  
 
2.5.2 Clinical features 
Although CD and UC share similar symptoms including diarrhoea, abdominal pain, fatigue, 
blood loss and joint pain, these symptoms can vary greatly depending on the location and 
depth of the inflammation (Kim and Cheon, 2017). Individuals with severe UC (figure 5a), 
often as a result of a subtotal disease (pancolitis) experience frequent diarrhoea, urgency, 
blood with mucus, abdominal pain and unintentional weight loss. Moderately active UC 
(figure 5b) individuals often experience lower left-sided abdominal pain, rectal bleeding and 
sometimes urgency. Proctitis UC (figure 5c) causes rectal bleeding and mucous discharge 
(Rampton and Shanahan, 2016). Whereas individuals with ileocecal and terminal ileal (figure 
5d) CD experience abdominal pain, tender mass in the right iliac fossa sometimes with 
diarrhoea and weight loss. As well as the symptoms mentioned individuals with ileocolonic 
CD (figure 5e) may also experience malabsorption, anaemia and altered body composition as 
a result of poor absorption. Lastly, colonic CD (figure 5e) symptoms are similar to those with 
a severe UC, however bleeding is less common. (Levine and Burakoff, 2011).  
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2.5.3 Intestinal Complications  
Even when the disease is in remission, impaired nutritional status is estimated in 65-75% of 
individuals with CD and 18-62% with UC, as a result of poor food intake, impaired digestion 
and absorption, medication side effects, surgical intervention and systemic inflammation due 
to active disease (Ispas et al., 2015; Spooren et al., 2015). These deficiencies can lead to 
premature and accelerated development of sarcopenia, a degenerate disease, identified in up 
to 60% of individuals with IBD, characterised by low muscle mass, strength and physical 
performance. Although considered to be age-related, deficits have been associated with 
morbidity, mortality and reduced QOL (Greenland and Nair, 2003). 
Tears or splits in the anal tissue are common in IBD, also known as fissures (figure 6). This is 
as a result of increased toilet frequency, typically causing pain and bleeding (D’Ugo et al., 
2015). Unlike UC, CD is commonly associated with fistulas, an abnormal passageway in the 
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digestive tract causing gastric fluid to seep through the intestinal lining (figure 6), which then 
causes abdominal pain, fevers and dehydration. Strictures are also a complication of CD, with 
at least one-third of individuals developing a stricture within the first 10 years of diagnosis. 
Strictures (figure 6) are a narrowing in the intestine that can lead to bowel obstruction. 
Another complication is abscesses (figure 6), collections of pus formed due to deep 
inflammation in the wall of the intestine, which occur in approximately 10-30% of people 
with CD causing severe abdominal pain and which then often require surgical drainage. If not 
properly managed these complications could lead to further tissue damage, uncontrolled 









2.5.4 Extraintestinal Complications  
Even when the disease is in remission, more than one third of individuals with IBD are 
affected by extra-intestinal manifestations (EIM) beyond the intestinal tract such as 
musculoskeletal and dermatological disorders, liver disease and ocular, renal and pulmonary 
system involvement. These can be just as debilitating as the primary disease (figure 7) 
 CHAPTER 2: LITERATURE REVIEW 
W12018030  19 | P a g e  
 
(Narula and Fedorak, 2008; Ott and Scholmerich, 2013). The EIM that are most prevalent in 
IBD are at the bones (osteopenia:22-77%; osteoporosis:17-41%), joints (ankylosing 
spondylitis:5-10%, enteropathic arthropathy:30%), skin (erythema nodosum:10-20%; 
psoriasis:10%; pyoderma gangrenous:<1%) and eyes (uveitis:3-11%; episcleritis:<1%; 
scleritis:<1%) (Rudwaleit and Baeten, 2006; Arvikar and Fisher, 2011; Ferreira et al., 2018; 
National Psoriasis Foundation, 2019). Although these manifestations have been observed in 
both CD and UC, a greater prevalence, has been reported in CD compared to UC (Repiso et 
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2.5.4.1 Osteoporosis and related fractures 
Osteoporosis and osteopenia, are skeletal disorders characterised by microarchitectural 
deterioration of bone tissue and strength, consequently resulting in increased bone fragility 
and high propensity to fractures (National Institutes of Health, 2014). Skeletal disorders that 
contribute to poor quality of life, increased morbidity, loss of independence and huge 
economic burden of £4.4 billion a year attributable to hip and vertebrae in the UK (Berstein 
et al, 2000; National Osteoporosis Society, 2017). 
2.5.4.1.1 Assessment of BMD  
Although there are different imaging modalities to diagnose these skeletal disorders through 
the assessment of BMD, the dual energy X-ray absorptiometry is the preferred method due to 
its versatility, high precision, accuracy and reproducibility (Zack et al., 2002; Small et al., 
2005). Current evidence recommends scans are undertaken at the hip (femoral neck, 
trochanteric region and wards triangle) as this is the most reliable site for predicting fracture 
risk and the spine to monitor treatment (Arabi et al., 2007; Blake et al., 2007; National 
Osteoporosis Foundation, 2008). The quantitative computed tomography (QCT) is another 
method to determine BMD. This non-invasive method, is quick, not limited by a person’s 
size and can be used as an alternative for individuals suspected of having osteoarthritis, due 
to the DEXA demonstrating falsely elevated BMD (Adams, 2009). However, the QCT is not 
without limitations including higher doses of radiation, fewer standardised scoring ranges and 
occasionally producing low results in an individual with normal T-scores on other imaging 
modalities, thought to be as a result of increased marrow fat with advancing age (Sheu and 
Diamond, 2016). Ultrasonography is also another method to calculate BMD, with no ionising 
radiation and portability, this method may seem as an attractive alternative (Gluer et al., 
2004). However, the manufacturer and operator guidelines vary significantly, making it 
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difficult for comparison and at the time of writing the ultrasound is not currently 
recommended for screening of these skeletal disorders (Sheu and Diamond, 2016).  
2.5.4.1.2 Prevalence and aetiology 
The prevalence of these skeletal disorders in IBD varies significantly depending on the study 
population, design and location, but ranges between 22-77% for osteopenia (T score between 
-1 and -2.5) with 17-41% subsequently progressing to develop osteoporosis (T score <-2.5) 
(Lee et al., 2005; Ali et al., 2009). A risk that has been reported greater in CD when 
compared to UC, as discussed below (Ghosh et al., 1994; Jahnsen et al., 1997; Gokhale et al., 
1998; Targownik et al., 2013; Miznerova et al).  
The aetiology and the exact mechanisms that may underpin the relationship between 
osteoporosis and osteopenia and IBD are yet to be fully elucidated. However are likely to be 
multifactorial with several contributing factors. One hypothesised contributing factor is the 
elevated proinflammatory osteoclast activators including IL-1 (α and β), IL-6, IL-11, IL-15, 
and IL-17, TNF-α and prostaglandin E2 that interfere with the pathway involved in bone 
metabolism, known as RANK-RANKL-OPG, and thus change the rate of bone formation, 
bone resorption and overall bone homeostasis (Bernstein and Leslie, 2003; Bernstein et al., 
2005; Mundy, 2007). RANKL (receptor activator of NF-kB ligand) stimulates mature 
osteoclasts to resorb bone by binding to osteoprotegerin (OPG), which is produced by 
osteoblasts and responsible for blocking the interaction between RANK and RANKL, an 
interaction that causes osteoclasts to differentiate and mature resulting in bone loss (Wei et 
al., 2001; Ali et al., 2009).  
Corticosteroids (CS) have been thought to impair osteoblast function, induce osteoblast 
apoptosis, reduce intestinal calcium absorption and increase renal excretion of calcium 
(Mitra, 2011; Targownik et al., 2013). In high concentrations CS have been shown to impair 
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osteoblast function and synthesis of OPG. While the production of RANKL is stimulated, the 
interaction with receptor involved in signally RANKL is inhibited causing an increase in the 
activity, proliferation and maturation of osteoclasts (American College of Rhumatology, 
1996; Bernstein et al., 2003). Reid and Heap (1990) supported this finding demonstrating 
participants (n=35) receiving greater than 12.5mg of prednisone per day had significantly 
greater bone loss (r= -0.380) than those who were on a lower dose. A cross-sectional study of 
117 adults with CD found both current steroid use and long-term use as major determinants 
of BMD at the lumbar spine (p<0.02) and femoral neck (p=0.02) (Robinson et al., 1998). 
Similarly, Jahnsen et al’s (1997) cross-sectional study showed that cumulative steroid dose 
correlated significantly with BMD at the lumbar spine (r= -0.313, p=0.018) and total body (r= 
-0.421, p=0.0008) in CD, but interestingly not in UC. However, the calculated dose of CS use 
was significantly higher in the CD group in comparison to the UC group (7.2g vs 1.8g), 
partially supporting the previous theory where the GS threshold has been exceeded. 
Moreover, CS decrease the synthesis of calcium binding, leading to increased calcium 
excretion, particularly in CD individuals who have demonstrated significantly higher calcium 
excretion rates than UC (Abreu et al., 2004; Barnes, 2007).This could contribute to the higher 
prevalence of reduced BMD in CD.   
Other pathogenic mechanisms considered as risk factors for bone loss in IBD include diet and 
malabsorption. In disease states where the function of the digestive system may be 
compromised it is essential that nutritional intake is sufficient, particularly calcium and 
vitamin D, for skeletal health. However, this can pose as a problem, as people living with 
IBD often avoid or limit certain foods believing they may aggravate gastrointestinal 
symptoms and it is thus not surprising that up to 75% and 62% of CD and UC individuals, 
respectively suffer from nutritional deficiencies (Prince et al., 2011; Li et al., 2019). 
Furthermore, prolonged low concentrations of calcium and vitamin D have inversely been 
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associated with elevated levels of markers of bone turnover and increased concentrations of 
uncarboxylated osteocalcin, a predictor of risk fracture (Szulc et al., 1996; Duggan et al., 
2004). In particular, in CD the involvement of the terminal ileum may affect the bile salt 
enterohepatic circulation, consequently resulting in reduced vitamin D concentrations 
(Sgambato et al., 2019). Supporting the higher prevalence of reduced BMD in CD 
individuals. Vitamin K may also be reduced in IBD, especially CD with distal ileum 
involvement, which plays a major role in regulating osteoblastic markers, suppressing bone 
resorption and regulating osteoclasts formation (Ghishan and Kiela, 2017). Potential causes 
for these deficiencies could be as a result of intestinal resection, more commonly performed 
in CD, the efficiency of intestinal absorption or the increased cytokines released by the 
disease itself (Hylander et al., 1990; Gilman et al., 2006).  
Measures to treat osteoporosis and osteopenia in this high-risk group have not yet been well 
established. Despite the benefits of resistance training interventions being well documented in 
the healthy population and chronic conditions, the role of gravitational and muscle loading 
exercises in the prevention or treatment of CD-related bone loss has received little attention. 
To prevent further disability and future personal and socio-economical costs, clinical trials 
are warranted to identify the optimal exercise prescription (mode, intensity, duration and 
frequency) for bone health in IBD, particularly focusing on CD individuals who are at an 
increased risk. 
 
2.5.4.2 Muscular Dysfunction 
The maintenance of skeletal muscle involves underlying molecular mechanisms between 
multiple signalling pathways that interplay to control and coordinate hypertrophic and 
atrophic messages between muscle protein synthesis and proteolysis (Egerman and Glass, 
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2014). IGF-1 (insulin-like growth factor) and insulin are responsible for stimulating protein 
synthesis in skeletal muscle through the phosphatidylinositol 3-kinase-Akt signalling 
pathway (PI3K/AKT) which inhibits protein degradation and results in skeletal muscle 
hypertrophy, an increase in muscle mass and cross-sectional area (CSA) and improving work 
capacity (Minetti, 2002; Zamparo et al., 2002). Evidence suggests that increasing skeletal 
muscle hypertrophy can produce muscle strength gains and the ability to produce force 
against an external resistance, as a result of increased muscle fibre CSA that alter the force-
velocity of the muscle (Stone et al., 2016; Suchomel et al., 2018). Whereas improving the 
working capacity of skeletal muscle, allows the oxidisation of substrates to produce 
adenosine triphosphate, a protein that regulates muscle endurance, defined as the ability to 
hold or repeat a muscular contraction for a long time (Wan et al., 2017; Hody et al., 2019). 
2.5.4.2.1 Assessment of Muscular Function  
Muscle dysfunction is defined by the loss of strength, the ability to perform or develop 
maximal effort, and/or endurance and the ability to maintain submaximal effort for a certain 
timeframe (Gea et al., 2015). Muscular strength and endurance of upper and lower limbs are 
key components of daily living tasks, evaluating the physical performance of these limbs is 
important to identify areas of weakness and imbalance (Zaltman et al., 2014; Bohannon, 
2019). Although there are different modalities to assess muscular strength, dynamometric 
testing is seen as the ‘gold standard’ to evaluate how much tension a muscle exerts during a 
contraction. In particular, the isokinetic dynamometer allows for the isolation of particular 
muscle groups, ROM and muscle contraction type to be determined (Meyer et al., 2013). This 
provides an objective way to obtain muscular strength measures that have demonstrated the 
highest correlation coefficients for reliability, accuracy, validity and reproducibility that 
remain unmatched. Although this method provides accurate assessments of dynamic and 
static muscle strength, it is costly, not portable and requires operator training. Therefore, the 
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use of hand-held devices such as a handgrip strength dynamometer are becoming more 
widely used, due to accessibility, low costs and standardised scoring (Martin et al., 2006; 
Bliven and Anderson, 2013).  
Another commonly used method, often used by physiotherapists, is the Medical Research 
Council Manual Muscle Testing scale. This method involves the participant resisting pressure 
from the examiner who then grades the assessment on a scale from 0-5, 0 reflecting no 
muscle activation and 5 reflecting muscle activation against the examiners full resistance, 
with full range of motion. Although commonly used, due to its inexpensive nature, readily 
available and no need for any specialised equipment this method relies heavily on subjective 
observation. Therefore, results may vary greatly depending on the examiner taking the 
measurement. The one repetition maximum test (1-RM), is another method to assess 
muscular strength. This method involves readily available equipment (free weights or other 
gym equipment) and is cost effective, given its practicality and ease although this is seen as 
the preferred method for personal trainers performing a maximum weight lift is not 
recommended for novices, due to the increased risk of more serious injury as these 
individuals are not accustomed to weight training (Braith et al., 1993; Dohoney et al., 2002). 
Numerous methods have been developed to measure muscular endurance including the: squat 
test, single leg squat, wall squat test, 30-s bicep curl test, 30-s chair stand test, push up test, 
60-s sit up test, box jumps and pull ups. Although there is no ‘gold standard’ for determining 
muscular endurance, it is recommended that tests are selected based on the participants age, 
physical limitations, current training status and muscle group of interest (Mayo and Kravitz, 
1997).   
 
 CHAPTER 2: LITERATURE REVIEW 
W12018030  26 | P a g e  
 
2.5.4.2.2 Prevalence and aetiology  
Despite the importance of skeletal muscle strength and endurance in daily living and future 
disability, loss of muscular strength and endurance are two of the least researched EIM 
associated with IBD (van Langenberg and Gibson, 2010; Hommes et al., 2012). Even during 
states of remission, up to 60% of people living with IBD have a reduced muscular CSA, 
mass, strength and endurance when compared to healthy controls (Geerling et al., 2000; 
Wiroth et al., 2005; Werksetter et al., 2011; van Langenberg, 2013). Werksetter et al (2012) 
reported a significantly lower grip strength (-1.02 [-1.58; -0.47]) in paediatric IBD 
individuals with a median disease duration of 3.5 years when compared to healthy controls. 
They also identified a significantly lower grip strength in those who were newly diagnosed 
when compared to those with a longstanding disease, thus highlighting the importance of 
introducing interventions at diagnosis to increase muscular strength. Strength parameters 
were also assessed in 41 adults with CD in clinical remission, with findings demonstrating a 
significant reduction in maximal isometric strength (-24.6%, p<0.001) and endurance (-
25.8%; p<0.001) of the leg extensors and functional capacity (-25.1%, p<0.001), assessed by 
the 12-repetition sit-up test (Wiroth et al., 2005). Interestingly, a more recent study assessing 
upper and lower limb muscle strength in UC individuals reported significantly decreased 
maximal quadriceps strength (-6%; p=0.012), sit-up test (-32%; p=0.00001) and gait speed (-
17%; p=0.0004), but not in handgrip strength (HGS) (p=0.362) (Zaltman et al., 2014).  
The aetiology of muscle dysfunction in IBD is not fully understood and is likely to be 
multifactorial involving several contributing factors. One hypothesised contributing factor is 
the decreased circulating IGF-1 levels, a hormone that stimulates the proliferation of muscle 
progenitor cells and their integration with existing muscle fibres during the muscle repair 
process, and the elevation of thiobarbituric acid reactive substances (TBARS), a marker of 
oxidative stress (Machida and Booth, 2004). The combination of these changes decreases the 
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PI3K/AKT signalling pathway, which is involved in inducing skeletal muscle hypertrophy 
and therefore is thought to play a role in the reduction in muscle mass and muscle CSA in 
IBD (Cominelli, 2004). This is supported by the findings from a cross-sectional study that 
obtained muscle biopsies from 27 adults with CD and compared them to healthy controls. 
Results demonstrated a 37% reduction in IGF-1 (p<0.01), a 54% lower phosphorylated:total 
Akt ratio (p<0.05) and increased serum TBARS (p<0.05). Suggesting impaired activation of 
muscle protein IGF-1-Akt pathway to play a role in the regulation and reduction of skeletal 
muscle growth (van Langenberg et al., 2014). Additionally, proinflammatory cytokines such 
as TNF-α and IL-6 are also, elevated and have shown to be associated with lower muscle 
mass and strength in an elderly population (Visser et al., 2002). Interestingly, several groups 
have reported that circulating IL-6 concentrations are higher in CD compared to UC and 
healthy controls (Mahida et al., 1991; Duclos et al., 1991; Gross et al., 1992). This may 
explain why the rate of sarcopenia, defined as “progressive and generalised loss of skeletal 
muscle mass and strength” (Santilli et al., 2014), has been reported in a recent meta-analysis 
as significantly higher in patients with CD than those with UC (60.7% vs 36.7%, p=0.044) 
(Eros et al., 2019).   
The use of glucocorticoids has been suggested to induce loss of skeletal muscle mass and 
muscle weakness, contributing to a reduction in muscular strength and endurance (Sato et al., 
2017). The debilitating effects of glucocorticoids in muscle deterioration are rapid and 
detected as early as 7 days after administration (Minetto et al., 2015). As muscles are a large 
site of protein, it is thought this deterioration occurs due to glucocorticoids suppressing 
protein synthesis, the naturally occurring process in which protein is produced to repair 
muscle damage, by glucocorticoids (Al-Jaouni et al., 2002). This causes a protein imbalance 
resulting in muscle wasting. A similar finding was noted in the elderly population, whereby 
there is a gradual decrease (3-5% every 10 years) in lower limb muscles and fewer changes in 
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the upper body while taking steroids. However, it also showed that muscle performance was 
not independently associated with cumulative dose of corticosteroids or disease duration or 
severity (Izquierdo et al., 1999). 
Malnutrition, particularly deficiencies in vitamin D as discussed previously is more prevalent 
in CD, has also been considered to contribute to muscle wasting and dysfunction. As skeletal 
muscle is a major reservoir for vitamin D, which is expressed in muscle cells and considered 
critical in the mediation of myogenesis, formation of muscle tissue, and contractility, changes 
in the length of muscle (Boland, 2011). These findings were supported by a cross-sectional 
study assessing strength performance in malnourished and well-nourished IBD individuals 
(n=94 CD, n=50 UC) and BMI, age and gender matched healthy controls (Valentini et al., 
2008). This study identified significant reductions in HGS in malnourished people with CD 
(32.8kg; 95% CI 26.0-41.1; p=0.005) and with UC (31.0kg; 27.3–37.8; p=0.001) compared to 
well-nourished IBD participants. Interestingly, they also identified HGS was significantly 
decreased (p=0.005) in well-nourished IBD individuals in comparison to the healthy control 
group. These findings highlight the importance of detecting muscle weakness in people with 
IBD, particularly CD, and introducing interventions to stop any further impairment and 
improve physical performance. 
 
2.5.4.3 Health-related quality of life 
Quality of life (QOL) and health-related quality of life (HRQOL) are often used 
interchangeably in the literature and are complex, multidimensional concepts that usually 
involve subjective evaluations of both positive and negative aspects of life. QOL is a broader 
term covering all aspects of life. The World Health Organisation (WHO) (2019) define QOL 
as “an individual’s perception of their position in life in the context of the culture and value 
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systems in which they live and in relation to their goals, expectations, standards and 
concerns” (WHO, 2019). Whereas, HRQOL is defined as “the state of well-being that is a 
composite of two components: (1) the ability to perform everyday activities that reflect 
physical, psychological and social well-being and (2) patient satisfaction with levels of 
functioning and control of the disease” (The Centre of Disease Control, 2018). It focuses on 
the socio-demographic, clinical and psychological effects of illness and the treatment-related 
determinants, encompassing several dimensions of life including physical functioning, 
psychosocial functioning, role functioning, mental health and general health perceptions 
(Cohen, 2002; Sainsbury and Heatley, 2005). 
Although the presenting symptoms of IBD are mostly physical, the variability between active 
and quiescent disease states, uncertain disease course and prognosis, medical and surgical 
side effects and social and financial repercussions all contribute to an increased risk of 
depression and anxiety and further profoundly affect a person’s QOL (Sainsbury and Heatley, 
2005; Graff et al., 2010). Bannaga and Selinger (2015) identified that up to 40% of people 
with IBD experience abnormal anxiety levels, and further went on to report higher rates of 
anxiety in IBD in comparison to the general population and other types of chronic diseases 
(Bannaga and Selinger, 2015). Similarly, rates of depression were three times higher 
compared to the healthy population in a large Canadian population-based study (Fuller-
Thomson and Sulman, 2006). This is worrying, as 40-50% of people with IBD reporting high 
anxiety and depression scores were identified as more likely to flare-up within 6 months than 
those reporting lower scores (Bannaga and Selinger, 2015). The presence of these 
psychological co-morbidities has also been significantly associated with increased rates of 
hospitalisation (van Langenberg et al., 2010), poor sleep (Kinnucan et al., 2013) and fatigue 
(Jelsness-Jordensen et al., 2010). These are determinants that have all significantly been 
associated with reduced QOL scores at univariate analyses (all p<0.003) (Habibi et al., 2017).  
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Disease activity remains the most significant predictor of physical and mental HRQOL and 
psychological impairments in IBD (Zhang et al., 2015). With moderate correlations identified 
between the Clinical Activity Index (CAI) (r= -0.623, p=0.0003), Endoscopic Activity Index 
(r= -0.511, p=0.005), Crohn’s Disease Activity Index (CDAI) (r= -0.506, p<0.001) and 
Harvey Bradshaw Index (HBI) (r= -0.600, p<0.001) to disease specific, self-assessed QOL 
questionnaire (Kim et al., 1999; Zahn et al., 2006). However, disease activity does not 
explain the decrements completely, with more than 30% of asymptomatic individuals 
reporting an impaired QOL, suggesting a role for other determinants (Sajadinejad et al., 2012; 
Theede et al., 2015). While the American College of Sports Medicine (ACSM) (2014) 
suggests that individuals with chronic illnesses should counteract these detrimental 
psychological effects with exercise, the beneficial effects of exercise on the gastrointestinal 
tract in IBD have so far been little studied, with recommendations being based on studies 
involving healthy individuals (Moeller, 2005). 
 
2.5.4.4 Fatigue 
Fatigue is one of the most burgeoning and prevalent symptoms reported in people with IBD, 
experienced in nearly 80% of those with an active disease and in more than 50% of those 
with a quiescent disease it remains one of the leading and greater concerns identified by 
people with IBD, after diarrhoea (Levenstein et al., 2001; Romkens et al., 2011; Czuber-
Dochan et al., 2015). It is understandable that fatigue increases during periods of active gut 
inflammation, however for it to persist in half of individuals with clinical and endoscopic 
remission affects both direct and indirect health costs (Bassi et al., 2004; Odes et al., 2006; 
Gibson et al., 2008). Although research in this area remains sparse, it has suggested that 
 CHAPTER 2: LITERATURE REVIEW 
W12018030  31 | P a g e  
 
fatigue may be more common in women, and may be worse in people with Crohn’s (Crohn’s 
and Colitis UK, 2017).  
A frequently used definition of fatigue is ‘difficulty or inability to initiate or maintain 
activity’, although given its multifactorial nature a simple definition may not capture the 
complexity of fatigue (Narayanan and Koshy, 2009). Fatigue can universally affect everyone, 
as much as 8% of the general population at any given time (Cullen et al., 2002) however in 
individuals with IBD it can appear differently and qualitatively of greater severity than in the 
general population (van Langenberg and Gibson, 2010). People with IBD have described 
fatigue as subjective, distressing and debilitating causing poor physical function and 
continued tiredness with sudden phases of overwhelming lack of energy, weariness and 
exhaustion that is not relieved following rest or sleep (Minderhoud et al., 2007; Czuber-
Dochan et al., 2014). Similar fatigue components have been identified in other chronic 
conditions and end of life care, consisting of weakness, inability or difficulty initiating or 
maintaining everyday activities and poor concentration, memory and emotional stability 
(Carlson et al., 2004; Markowitz and Rabow, 2007).  
Although it remains a major concern for people with IBD, optimal management of fatigue is 
poorly understood and literature on treatment strategies remain scarce. The Global Burden of 
Disease Study (2010) described ‘health as more than avoiding death’, with growing 
recognition of the importance of subjective symptoms. When applied to IBD this could mean 
more than ‘achieving endoscopic and clinical remission’.  Fatigue remains an under-
recognised symptom and given its subjective and multifaceted nature it remains difficult to 
understand, measure and diagnose, a key obstacle in fatigue-related research (Graff et al., 
2011). Several self-reported questionnaires have been developed to define and quantify 
fatigue, assessing fatigue for single to multiple dimensions covering domains such as mental, 
physical and social contexts (Guyatt et al., 1989; Czuber-Dochan et al., 2014). However, such 
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questionnaires are not frequently used by clinicians due to time constraints and lack of 
knowledge of supportive tools when assessing individual needs, despite recommendations of 
national guidelines (National Institute for Clinical Excellence, 2004).   
Research into the pathophysiological basis of fatigue is severely lacking and in need of a 
multidisciplinary approach to identify contributing factors, non-uniform mechanisms and 
subtypes of fatigue within the IBD population. There is an important need for prospective 
clinical trials involving pharmacological and non-pharmacological interventions to better 
understand this problematic burgeoning symptom, to compare effectiveness and allow the 
discovery of better treatment algorithms, therapeutic interventions and structured support for 
people with IBD.  
 
2.6 Costs 
The most recent care model in the UK estimated annual costs for treating UC to be £3084 and 
CD to be estimated at £6156 per individual (Ghosh and Premchand, 2015). However, these 
costs varied greatly depending on disease activity, with estimated annual costs for UC and 
CD in clinical remission ranging between £1693-£1800, respectively, and with a severely 
active disease between £10,513-£10,760 for CD and UC, respectively (Table 2).  
A breakdown of these costs was based on the major medical and surgical treatment options, 
the adverse events of treatment therapies and IBD-specific complications (Appendix 2a).  In 
contrast, another retrospective study identified mean costs for UC and CD to be £1256 and 
£1652 per person, respectively (Bassi et al., 2004). However, this study was conducted in 
2004 when prevalence rates were significantly lower. Moreover, the use of biologics such as 
infliximab and adalimumab were not routinely used and as identified in Appendix 2a, these 
 CHAPTER 2: LITERATURE REVIEW 
W12018030  33 | P a g e  
 
two different drug therapies are considerably more expensive than mesalaszines and 
prednisolone which were the first line of treatment. While a UK audit estimated costs to be 
approximately £3,000 per person per year (UK IBD Audit Steering Group, 2012). This study 
did not take into consideration the adverse events of treatment or the complications 
associated with IBD and therefore is not thought to fully reflect the costs of IBD. With up to 
half of people  relapsing every year and over 10,000 newly diagnosed cases every year, non-
pharmacological interventions targeting secondary complications and thereby avoiding 
adverse events caused by treatment are warranted to reduce the financial burden and 
projected financial burden on the NHS. 
Table 2. Cost per person per year with UC and CD 
 Treatment Adverse Events Complications Total Cost 
UC     
   Clinical Remission £891.18 £40.60 £761.47 £1693.25 
   Mild to Moderate-Disease £1263.57 £878.19 £761.47 £2903.24 
   Severe Disease £8016.82 £1981.94 £761.47 £10,760.23 
   Any individual with UC £1752.70 £569.77 £761.47 £3083.94 
CD     
   Clinical Remission £975.59 £145.83 £678.43 £1799.85 
   Clinical Relapse £8627.50 £1207.10 £678.43 £10,513.03 
   Any individual with CD £4801.54 £676.43 £678.43 £6156.44 
 
2.7 Detection and diagnosis 
Generally, the diagnosis of IBD is established on clinical presentation, physical examination, 
imaging studies and endoscopic/histological findings, however in some cases extra-intestinal 
manifestations, particularly in CD, such as ankylosing spondylitis, arthritis, erythema 
nodosum and uveitis are the initial presentation of IBD. The first line of investigations in 
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people presenting symptoms such as abdominal pain and change in bowel habits are 
haematology and biochemistry blood tests, normally requested by a general practitioner (GP). 
Test results revealing anaemia, raised platelet count, low serum B12, low folate, iron 
deficiency, raised CRP and/or low serum albumin levels may suggest or detect an active IBD, 
but are not diagnostic (Crohn’s and Colitis Foundation of America, 2010). However, tests 
could warrant further investigation and/ or referral to a gastroenterologist. A 
gastroenterologist suspecting a person with IBD would then request a faecal calprotectin 
(FC), if not already done by the GP, this provides an overview of the intestinal inflammatory 
status, if inflammation of the intestinal mucosa is present, polymorphoneculea neutrophils 
circulate around the inflammation and release calprotectin. FC concentration is positively 
associated with the intensity of the neutrophilic infiltration in the gut mucosa, i.e. the more 
inflammation present the higher the concentration of calprotectin (Roseth et al., 1999). 
Although not yet widely used, FC is a useful adjunct to routine outpatient clinical assessment.  
Endoscopies remain part of the first line investigations for IBD, providing immediate 
confirmation of the disease and its activity (figure 8a). Although an ileo-colonoscopy 
including segmental colonic and ileal biopsies is established as the first line of investigation 
for suspected CD, other methods such as computed tomography (CT), barium x-rays (figure 
8b) and other radiological imagery are used to complement this diagnosis and determine ileal 
CD which is unreachable during a endoscopy. In UC, a colonoscopy of the large intestine is 
performed and biopsies obtained to determine the location and severity. However, as the 
disease extent can change after diagnosis, with up to half of individuals with ulcerative 
proctitis expected to develop a more extensive disease, usually within a year an ileo-
colonoscopy is performed to definitively confirm the diagnosis of UC not CD and biopsies 
are taken to map the extent of the disease (Lanholz et al., 1996; Fumery et al., 2018). 
Abdominal X-rays can also be performed in people with UC presenting with an active 
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disease, to exclude colonic dilation (figure 8c). If histologic and clinical features are not 
typical of UC, an evaluation through CT or magnetic resonance imaging (MRI) of the small 








2.8 Pathway of care 
Figure 9 illustrates the National Institute for Health and Care Excellence [NICE] (2019) 
overview pathway of care for CD and UC, respectively. Following the diagnosis of IBD, 
information and support is provided. Discussions about the disease, associated symptoms, 
treatment options, side effects and disease monitoring with the individual, family members 
and the multidisciplinary team are conducted and applied within the NICE’s 
recommendations on a person’s experience in adult NHS services. Individuals are advised in 
line with published NICE guidance on smoking cessation, medicine adherence, fertility, 
prognosis, cancer risk, surgery, diet and nutrition and contact details for support groups are 
provided.  
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Maintaining remission in IBD (figure 10 and 11) involves discussing how a person can 
manage their disease during periods of remission, including both no treatment and treatment 
options. Discussions that include the risk of exacerbations with and without drug therapies 
and potential side effects of drug treatments. Depending on the severity and location of the 
disease, medications such as aminosalicylates and immunosuppressant in UC and 
immunosuppressants and biologics in CD are suggested to maintain remission (NICE, 2019).  
However, maintaining and achieving clinical remission remains a clinical challenge with 
nearly half of people with IBD relapsing every year (Levine and Burakoff, 2011). 
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Monitoring the effects of drug treatment for toxicity, infection and liver cirrhosis in IBD is 
advised in the British National Formulary and often involves monitoring full blood count on a 
weekly basis for a set time and thereafter at reduced frequency to at least every 3 months. For 
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monitoring infusions, individuals are observed for 1-2 hours with resuscitation equipment 
available, until at least 6 months into the treatment (BNF, 2019). NICE guidelines also 
recommend DEXA (dual-energy X-ray absorptiometry) screening in people with IBD with a 
history of vertebral fractures, are postmenopausal or male >50 years of age and vitamin D 
(400-800 IU/day) and calcium (0.5-1g/day) supplements for people with IBD with low BMD 
(American Gastroenterological Association, 2003; NICE, 2019).  
 
2.9 Measuring disease activity 
A summary of the tools available to measure disease activity are detailed in table 3. 
Measuring inflammatory activity remains important to assess the efficacy of medication, 
prevent disease progression and rule out the presence of intestinal complications, as discussed 
previously (Section 2.5.3). Disease activity has also been identified as a predictive factor of 
clinical relapse, surgery and refractoriness to medical treatments (Hanauer et al., 2002; 
Schnitzler et al., 2009), thus emphasising the importance of measuring and monitoring 
inflammation.  
 
Considered the ‘gold standard’ for examining mucosal activity, an endoscopy provides direct 
evaluation and visualisation of mucosal healing, against validated scoring (D’Inca and 
Caccaro, 2014). Despite its benefits and important step in assessing disease activity, this 
method is invasive and is limited to examination of the mucosa and not deeper layers of the 
intestinal wall. In addition, the small bowel remains inaccessible by a conventional 
endoscopy method and an endoluminal examination of the small bowel involving a capsule 
endoscopy, push enteroscopy or balloon-assisted technology is required (Benitez et al., 
2013). Therefore, cross sectional imaging techniques such as magnetic resonance imaging 
 CHAPTER 2: LITERATURE REVIEW 
W12018030  39 | P a g e  
 
(MRI), computed technology (CT) and ultrasound (US) are emerging as appealing alternative 
tools to determine disease activity. These imaging techniques, particularly MRI, can provide 
information and evaluation of small bowel and colon, transmucosal activity and rule out 
complications such as wall thickening or stiffness, strictures, fistulae, narrowing or abscesses 
(Mizio et al., 2004; Maconi et al., 2006; Panes et al., 2011; D’Inca and Caccaro, 2014). 
Although cross-sectional imaging techniques provide objective methods for assessing disease 
activity, they are not without their individual limitations and risks as reported in table 3. In 
addition, neither endoscopic or cross-sectional imaging are suitable for frequent assessment. 
Therefore, biomarkers such as C-reactive protein (CRP) and faecal calprotectin (FC) have 
been proposed as surrogate markers of intestinal inflammation. Despite the paucity of 
research to support the use of these non-invasive markers in the management and monitoring 
of IBD, they can confirm the presence of intestinal inflammation and should be used as a 
preliminary step to identify individuals requiring further investigation (D’Inca and Caccaro, 
2014). Nevertheless, clinicians have a wide range of tools and should adopt a patient-tailored 
strategy combining these procedures to assess to determine disease activity, complications 
and efficacy of medication for the purpose of adjusting or changing treatment or for surgical 
referrals, as appropriate.  
 
Table 3. Advantages and disadvantages of endoscopic, cross-sectional imaging and biomarker 
techniques for monitoring disease activity in IBD 
Method Advantages Disadvantages 
Endoscopy • Direct evaluation and visualisation of 
mucosal healing 
• Validated scores 
• High quality images comparable to 
other imaging modality  
• Biopsies can be taken 
• Invasive 
• Bowel preparation 
• Costs 
• Increased operative time and extensive 
knowledge 
• Limited to the examination of the mucosa 
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• No radiation exposure • Incomplete small-bowel examination  
• Poorly received by patients  
• Generally safe, but complications may occur 
• Sedation required 
Cross-Sectional Imaging 
MRI • Evaluation of small bowel 
• Detect complications 
• Non-invasive  
• No sedation required 
• No radiation exposure  
• Assessment of transmural and 
extramural activity  
• Costs 
• Requires bowel preparation/ contrast 
• Not suitable for some patients due to 
enclosed space (claustrophobic, obesity) or 
pacemakers  
• Time consuming 
• Movement impacts results 
• Technological expertise  
CT • Evaluation of small bowel 
• Detect complications 
• Quick nature  
• High quality images 
• Widely available and standardised use 
• Highly sensitive  
• Assessment of transmural and 
extramural activity 
• Radiation exposure 
• No validated scores 
• Requires IV contrast 
US • No radiation exposure 
• Non-invasive 
• Widely available 
• Useful for examining the terminal 
ileum and colon 
• Detect complications 
• Quick nature 
• Results depending on the knowledge and 
experience of the sonologist  
• Difficult to assess the proximal ileum, 





• Cost-effective  
• Identify presence of inflammation  
• Quick to analyse 
• Can’t determine the specific location of 
inflammation  
 
FC • Non-invasive 
• Cost-effective  
• May behave differently between patients  
• Uniform cut-off values  
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• Identify presence of inflammation 
• Quick to analyse 
• High sensitivity  
IBD, Inflammatory Bowel Disease; MRI, Magnetic Resonance Imaging; CT, Computed Technology; US, 
Ultrasound; CRP, C-Reactive Protein; FC, Faecal Calprotectin  
 
2.10 Management strategies 
The primary target of medical therapy in IBD is a controversial issue, with many parameters 
suggesting remission is both clinical and endoscopic. However, there is no agreed definition. 
An Australian retrospective study of 246 participants of whom 61% were in clinical 
remission, showed that only 35% demonstrated clinical and endoscopic remission features 
according to the Mayo endoscopic score (subscore of <1). Moreover only 16% were in 
histological remission (Bryant et al., 2017). There is a lack of evidence around histological 
remission, despite it being used as an outcome in many drug trials (Ardizzone et al., 2011; 
Colombel et al., 2011; Walsh et al., 2014; Bryant et al., 2014). Therefore, the growing 
consensus is that the treatment aim for IBD should be symptomatic remission combined with 
mucosal healing, from clinical, individual-reported and endoscopic features in addition to 
reducing rates of disease-related complications, surgery and hospitalisation (Levesque et al., 
2015; Lamb et al., 2019). However, a widely used definition for clinical, endoscopic and 
histological remission is needed in clinical practice. 
At present, there is no known cure for IBD, with overall disease management and treatment 
aims focused on reducing symptoms and maintaining or improving QOL (NICE, 2019). 
Treating IBD often involves medications that can diminish symptoms and reduce the 
inflammation in the colon lining. Therapeutic decisions depend greatly on the disease activity 
and severity, however the most commonly used drug therapies in IBD are: 
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• Aminosalicylates such as mesalazine or 5-aminsalicylic acid (5-ASA) which act on 
the epithelial cells to moderate the release of cytokines and other mediators (Carter et 
al., 2004).  
• Immunomodulators such as mercaptopurine or azathioprine suppress the immune 
system from attacking itself and thereby reduce the levels of inflammation (Lee et al., 
2014).  
• Corticosteroids (CS) such as prednisolone and budesonide are superior to 
aminosalicylates and immunosuppressants for inducing remission in IBD by reducing 
the activity of the immune system. However, the systemic side effects such as 
hypertension, cataracts, osteoporosis and hyperglycaemia have prompted a search for 
a safer alternative (Rampton and Shanahan, 2016). Guidance from the latest British 
Society of Gastroenterology consensus guidelines (Lamb et al., 2019) recommend that 
CS should be reserved for individuals with a mild to severe disease, with failure of 
response or those who are intolerant to other medical therapies.  
• Anti-TNF-a drugs such as infliximab, adalimumab, vedolizumab, ustekinumab and 
methotrexate have changed the way of treating IBD and have been shown to be more 
effective for inducing and maintaining remission in CD than other drug therapies. 
However, using anti-TNF-a therapies in UC remains controversial with cohort studies 
demonstrating 67-78% of people with UC failing to respond to infliximab and 70-
73% to methotrexate (Ferrante et al., 2008; Oussalah et al., 2010; Herfarth et al., 
2018). Data around the use of vedolizumab and adalimumab in UC remain sparse and 
limited, however initial studies have demonstrated maintained remission in up to 25% 
of individuals (Colombel et al., 2014; Feagan et al., 2017). At the time of writing, 
ustekinumab does not have a licence or NICE approval for use in UC. 
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While efficient in reducing the extent of the inflammation, most pharmaceutical compounds 
present a wide range of side effects such as insomnia, drowsiness, vomiting, weight gain and 
immune susceptibility that can reduce compliance, QOL and result in worsening of the 
condition (Rampton and Shanahan, 2016). In addition, when medical therapy fails or 
complications occur, surgical interventions may be required. With up to 8 in 10 people with 
CD and 23-45% with UC requiring surgery at some point throughout their diagnosis, the 
most common surgical procedures for IBD include (Crohn’s and Colitis UK, 2019): 
• Colectomy with ileostomy (figure 12a) involves the removal of all (subtotal) or most 
of the large intestine. The small intestine is then brought out through an opening in the 
abdomen wall and a bag is fitted.  
• Stricturoplasty (figure 12b) to repair strictures and blockages by opening the 
narrowing that has occurred 
• Resection (figure 12c) to remove the inflamed part of the intestinal tract and joining 
(anastomosis) the two ends together. Ileocaecal resection is similar, however involves 






A nutritional approach is also important in the management of IBD, however, nutritional 
education provided to people with IBD is given less attention in routine clinical practice due 
to lack of time and low quality and inconclusive evidence-based nutritional 
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recommendations. Up to 68% of people with IBD manipulate their diet in an attempt to avoid 
the exacerbation of their disease and control symptoms (Cohen et al., 2013; Limdi et al., 
2016). However, individuals often seek dietary advice from the internet, social media, friends 
and family or even other people with the condition, which may not be applicable to them, 
rather than from a healthcare professional (Hou et al., 2014). In an attempt to manage their 
disease by avoiding or limiting certain foods, up to 75% of CD and 62% of people with UC 
in remission experience an impaired nutritional status, often leading to nutritional 
deficiencies in B12, folic acid, calcium, iron and vitamin D that require supplementation 
(Ispas et al., 2015; Spooren et al., 2015). It is important that consistent advice, based on an 
individual basis, is provided to set realistic, evidence-based therapeutic expectations for the 
treatment and management of IBD.  
 
2.11 The potential role of exercise as a management strategy   
Defined as ‘any bodily movement produced by skeletal muscles that results in energy 
expenditure’, physical activity can be categorised into household, occupational or other 
activities (Caspersen et al., 1985). The ACSM (2017) defines exercise as the “planned, 
structured and repetitive bodily movement done to improve or maintain one or more 
components of physical fitness”, including gait, balance, functional, strength, endurance and 
flexibility training.  
As discussed previously, although EIMs such as reduced BMD and muscle dysfunction have 
been observed in both CD and UC, a greater prevalence has been reported in CD, likely to be 
as a result of proinflammatory cytokines, malnutrition and glucocorticoid usage (Repiso et 
al., 2006; Miznerova et al., 2013; Vavrikca et al., 2015). Therefore, exercise interventions 
focusing purely on CD individuals and targeting these EIMs are warranted. Although 
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exercise represents as a line of treatment and has been recognised to counteract secondary 
complications in two diabetes mellitus, osteoporosis and arthritis, the potential benefits of 
exercise in CD has received little attention despite these conditions presenting similar 
characteristics and symptoms to CD (Schwingshacki et al., 2014; Hallsworth et al., 2015). 
During exercise, an osteogenic stimulus occurs, in which bone is subjected to forces induced 
by gravitational and muscle loading. Gravitational loads are typically reaction forces between 
the body weight and a substrate, whereas muscle loads involve contractile forces transmitted 
through the tendon that induce mechanical signals to the bone (Carter and Hinton, 2014). The 
size of the osteogenic effect relies greatly on the loading frequency, intensity and mode of 
exercise. During high strains of mechanical loading, substrate reaction forces can be up to 20 
times the body weight, thus resulting in higher peak strains and a greater osteogenic effect 
than endurance exercises that have an approximate-substrate reaction force equivalent to 
body weight (Judex and Carlson, 2009). To resist the increase in mechanical strains, the bone 
initiates an adaptive response involving osteocytes that transduce the energy from the 
mechanical forces into biological signals that impact bone formation and resorption. These 
elicit bone deformation, stimulating the stretch-activated ion channel on osteocytes and 
trigger the expression of genes that mediate bone growth and increase the threshold of stress 
tolerance, thus eliciting an architectural modification (Zagdsuren, 2014). This explains why 
weight bearing and resistance exercise is often prescribed as a management or treatment 
option in other chronic diseases and for this reason, it is generally assumed that exercise is 
the best potent stimulator for skeletal growth, structure and maintenance to enhance BMD in 
people with IBD (Turner and Robling, 2004; Brotto and Johnson, 2014). 
In 2016, the European Crohn’s and Colitis Organisation (ECCO) consensus/guidelines stated 
that weight-bearing or resistive exercise, the cessation of smoking and excess alcohol 
consumption and maintaining adequate calcium intake (1g/day) should be implemented to 
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prevent bone loss (Harbord et al, 2016). Despite this, few preventative interventions have 
been conducted in this high risk group and evidence remains inconsistent and weak with 
studies significantly limited by their small sample size, methodological robustness and lack 
of blinded outcome assessors, resulting in exercise guidelines being based on the beneficial 




In recent years, medical and surgical advances have been made, and a better understanding on 
the immune mediators of intestinal inflammation have become apparent. Although 
pharmaceutical and surgical interventions are effective in treating symptoms and preventing 
relapse, adherence to therapy can be as low as 40%, a contribution of the undesirable side 
effects (Kane et al., 2001). Complementary and alternative treatments or nonallopathic 
therapies as a primary or adjunctive therapy is widely prevalent among adults with CD with 
reports of 44-56% of individuals seeking alternate options (Weizman et al., 2012; Cheifetz et 
al., 2017). Given the benefits of exercise widely illustrated in the general population and 
chronic conditions including coronary heart disease, heart failure, cancer and metabolic 
syndrome it has become an important alternative therapy (Piña et al., 2003; Zou et al., 2014; 
Courneya et al., 2014). The role of exercise in the prevention, treatment and management of 
CD is poorly understood. Therefore, a review of the current literature on the benefits and 
harms of physical activity in CD will be discussed in more detail in Chapter 3 to support the 
development of providing safe and beneficial physical activity solutions instead of, or 
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       CHAPTER 3: SYSTEMATIC REVIEW 




Although the focus of this thesis is around CD, due to insufficient experimental studies 
looking specifically at CD and disease-specific extraintestinal manifestations this review will 
focus on the potential benefits of any mode of exercise, on any psychological or 
physiological outcome in individuals with IBD.    
The burden of IBD is rising, affecting approximately 396 people in every 100,000, however 
with an 83.7% increase in cases from 1990 to 2017 in the UK projected annual costs to the 
NHS are expected to increase from £720 million to £1.5 billion by 2040 (Stone et al., 2003; 
Ghosh and Premchand, 2015; British Society of Gastroenterology, 2016). However, these 
estimates do not consider the ‘real price’ of IBD, which can impair QOL, impede career 
aspirations and profoundly affect psychological well-being (Bannaga and Selinger, 2015). 
Moreover, even during remission more than one third of adults with IBD are affected by 
disease-specific EIM’s beyond the intestinal tract such as low BMD, reduced muscular 
strength and endurance, impaired aerobic capacity and psychological well-being, which can 
be just as debilitating as the primary disease (Ott and Scholmerich, 2013). With detrimental 
health and economic effects, cost effective health innovations need to be identified and 
implemented to help manage this complex and costly disease. 
Exercise has been suggested to counteract several IBD-specific complications, with different 
types of exercise eliciting corresponding physiological adaptations. Increases in stroke 
volume, cardiac output and oxygen uptake occurring as a result of aerobic training and 
adaptions of the skeletal system and muscle hypertrophy occurring as a result of resistance 
training (Peters et al., 2001; Perez, 2009; Rivera-Brown and Frontera, 2012). The role of 
exercise as a therapeutic option in IBD remains poorly understood, with exercise guidelines 
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IBD individuals (Narula and Fedorak, 2008). Given the insufficient evidence it remains 
unclear what type, duration, frequency or intensity is safe and beneficial for people with IBD. 
With the substantial costs to the individual and health care system and 44-56% of individuals 
seeking complementary therapy it is important to evaluate the potential benefits of different 
modes, intensities, frequencies and durations of exercise regimens and to explore the safety, 
attrition, adherence and acceptability of these interventions. In doing so, it will allow the 
integration of the best evidence available to inform evidence-based recommendations. The 
purpose of this review, therefore, was to systematically review experimental studies that 
investigated the effects of any mode of exercise intervention on physiological and 




This systematic review was prospectively registered in an international database of 
systematic reviews in health-related research (CRD42017077992; 
https://www.crd.york.ac.uk/prospero/). Deviations from the study protocol are detailed in 
Appendix 3a. The Cochrane Handbook and the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines were adhered to (Higgins and Green, 2008; 
Moher et al., 2009).  
 
3.2.1 Study Selection 
Types of studies 
Experimental studies such as randomised controlled trials (RCT) and non-RCT’s assessing 
the effects of exercise training, of at least 4 weeks duration, in adults with IBD were 
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methodological descriptions were provided, either in written form or by direct contact with 
the authors. Short papers with incomplete data presented, such as case reports, case series or 
qualitative research were excluded. All other study designs were excluded.  
Types of participants 
Participants had to be aged >18 years with a clinical diagnosis of IBD (CD, UC or IBD-
unclassified) of at least 6 weeks duration (using conventional clinical, radiographic, 
histologic and endoscopic criteria). Any other type of colitis or irritable bowel disease were 
excluded. There were no restrictions on gender, previous medication, disease severity and 
disease activity status.  
Types of interventions 
All modes of exercise interventions such as aerobic, resistance, aquatic, balance and co-
ordination training were included. Trials comparing one form of exercise versus another, 
different intensities, another non-exercise intervention, no intervention or receiving usual care 
were included. There were no restrictions on the exercise intervention setting or mode of 
supervision (e.g. inpatient, outpatient, home-based, unsupervised, supervised). Studies 
reporting an exercise programme with duration of less than 4 weeks were excluded. 
Types of outcome measures 
Studies must have reported at least one of the following outcomes for inclusion: bone health, 
muscular function, QOL, psychological well-being, disease activity, physical activity, body 
composition, cardiorespiratory fitness, immune function, fatigue, safety, feasibility and 
acceptability. A detailed list of outcome measures can be found in Appendix 3b. Where 
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3.2.2 Search Strategy 
Electronic databases from inception to May 2019 were searched: MEDLINE, EMBASE, 
CINHAL, Cochrane Central Register of Controlled Trials (CENTRAL) and SPORTDiscus. 
The search strategy and MESH terms used included: physical activity, exercise, exercise 
therapy, sports, resistance training, endurance training, aerobic training and physical fitness. 
These terms were paired with inflammatory bowel disease, IBD, Crohn’s disease, ulcerative 
colitis and indeterminate colitis. The full strategy can be found in Appendix 3c. Reference 
lists and citation tracking of all included studies were searched to locate relevant further 
studies of interest. Search strategy terms were limited to those in English and pertaining to 
human participants.  
Ongoing clinical trials and unpublished studies were searched on the following research 
registers: clinicaltrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) 
and International Standard Randomised Controlled Trial Number Registry (ISRCTN). All 
searches were carried out by the same author (KJ) and search results generated by the 
electronic databases were exported to EndNote (V8.2), where duplicates were removed. The 
first 10% of abstracts and titles were examined independently by two review authors (KJ and 
RK), due to good agreement (k 0.855, indicating an almost perfect agreement) (McHugh, 
2012), the remaining texts were screened by one reviewer (KJ). If a study appeared to meet 
some criteria, but was unclear, the full text article was retrieved for clarification. 
Discrepancies were referred to by a third author (GT or KB) and disagreements were resolved 
by consensus. Review authors were not blinded to the author, institution or the publication 
source of the study. Full text articles were retrieved for further screening and independently 





       CHAPTER 3: SYSTEMATIC REVIEW 
W12018030  52 | P a g e  
 
3.2.3 Data Extraction 
To facilitate data extraction, the ‘Cochrane Data Collection Form for Interventions: RCTs 
and non-RCT’s’ was used to extract and record information. This form was used to adhere to 
the Methodological Expectations of Cochrane Intervention Review standards for collecting 
and reporting information, recommended by Cochrane to improve and maintain quality of the 
systematic review (Higgins et al., 2017). One review author (KJ) independently extracted 
data from the included studies with a second review author (RK) independently checking the 
data extraction forms for accuracy and completeness, with disagreements resolved through 
consensus of a third review author (GT or KB). Extracted information included general 
information, trial characteristics, intervention details, participant characteristics, outcomes 
and results  
Data were entered in Review Manager (RevMan 5.3) by one reviewer (KJ) and random 
checks on accuracy were performed by the second reviewer (RK), who kept a record of any 
discrepancies. 
 
3.2.3.1 Dealing with Missing Data 
Where data were missing or unclear, the primary author of the trial was contacted via email 
and relevant information was requested. At least two emails were sent out to the 
corresponding author(s). 
 
3.2.4 Risk of Bias (RoB) 
The internal validity and methodological rigor of each study was assessed independently by 
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randomised trials and the ‘Risk of Bias In Non-randomised studies-of Interventions’ 
(ROBINS-I) for non-randomised studies (Higgins et al., 2016). Discussion between the two 
review authors was utilised to resolve any discrepancies in judgment of RoB or justifications 
for judgement, with a third author (GT or KB) referred to in the case of any unresolved 
discrepancies. The RoB 2.0 addressed five domains and each domain was judged as ‘low’, 
‘some concerns’ or ‘high’ risk. The ROBINS-I response for each domain was defined as 
‘low’, ‘moderate’, ‘no information’, ‘serious’ or ‘critical’ risk.  
 
3.2.5 Data Synthesis 
Where appropriate, data were inputted into Review Manager and clinical and methodological 
diversity was independently assessed by two review authors (KJ and RK) in terms of 
participants, interventions, outcomes and study characteristics to determine the 
appropriateness of a meta-analysis. However, due to the unavailability of data, lack of 
intention-to-treat analysis and heterogeneity in interventions, outcome measures, metric used 
and study designs it was deemed that a subgroup analysis, sensitivity analysis and meta-




The search strategy generated 3,322 potentially eligible articles. After excluding 609 
duplicates and screening 2,713 titles and abstracts, 31 articles were retrieved and examined 
for full-text screening.  On completion of full-text screening a further 21 were excluded. 
Therefore, 10 articles were eligible for inclusion in this review. The PRISMA flow chart 
depicting the flow of study information through the different phases of this systematic review 
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3.3.1 Characteristics of included studies 
Study characteristics are detailed in table 4. Of the ten included studies published between 
1998 to 2019, five were RCT’s (Robinson et al., 1998; Ng et al., 2007; Sharma et al., 2015; 
Klare et al., 2015; Cramer et al., 2017), one employed a feasibility RCT design (Tew et al., 
2019), one delivered a randomised cross-over design (Cronin et al., 2019) and three used a 
quasi-experimental design: an uncontrolled pilot study (Loudon et al., 1999), an uncontrolled 
cohort study, published as a conference abstract (Candow et al., 2002) and one uncontrolled 
pilot study, published as a letter to the editor (De Souza-Tajiri et al., 2014). The conference 
abstract and letter to the editor were included in this review due to their relevance. Excluding 
the three studies with no control group (Loudon et al., 1999; Candow et al., 2002; De Souza-
Tajiri et al., 2014), six studies employed a stratified block randomisation and one study 
(Cronin et al., 2019) employed a simple randomisation process.  
The ten included articles comprised of 429 participants (39% males). Information on 
participant’s age were unavailable for one study (De Souza-Tajiri et al., 2014), excluding this 
conference abstract, the mean age was 36. Four of the studies included both CD and UC 
participants, five included CD participants only and one included UC participants only. In 
seven studies, participants had inactive or mildly active disease (n=7), in one study 
participants had a mild to moderately active disease (n=1) and in two studies disease activity 
status was not specified.  
Of the ten studies, two delivered a walking programme, two delivered a yoga intervention, 
one delivered a running programme, one delivered high-intensity interval training (HIIT) and 
moderate-intensity continuous training (MICT) programmes, three delivered a resistance 
training intervention and one delivered a combined resistance and aerobic training 
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Klare et al., 2015; Cramer et al., 2017; Cronin et al., 2019; Tew et al., 2019), home-based in 
Ng et al’s (2007) study, supervised and home-based in Robinson et al’s (1998) study and 
home-based following an introductory session in Sharma et al’s (2015) study. Two studies 
did not provide information on the mode of delivery (Candow et al., 2002; De Souza-Tajiri et 
al., 2014).  
Included studies had a median sample size of 31 (range 12–107) per study, 12 to 60 per 
exercise intervention and 0 to 57 per control group. Study duration was between 8 weeks and 
12 months, with a median duration of 12 weeks ranging from 1 to 3 sessions a week and 20 
minutes to 90 minutes per session, excluding 5 studies (Robinson et al., 1998; Loudon et al., 
1999; Candow et al., 2002; Klare et al., 2015; Cronin et al., 2019) who did not report exercise 
duration or had a progressive programme that increased duration throughout the study. A low 
intensity exercise intervention was delivered in four studies, two studies implemented a 
moderate intensity programme and one study delivered HIIT and MICT. Three studies did 
not quantify exercise intensity (Loudon et al., 1999; Candow et al., 2002; De Souza-Tajiri et 
al., 2014). A usual care group was included in six out of the ten studies, there was no control 
group in three studies and one study included a self-care group involving books on the 
pathology and pathophysiology of UC (Cramer et al., 2017).  
Of the outcome variables measured in the ten included studies, two studies measured stress 
using the IBD Stress Index (IBDSI) (n=2). Six studies assessed disease activity using the HBI 
(n=4), CDAI (n=1), Rachmilewitz Index (RI) (n=2), CRP (n=2), FC (n=1) and Simple Colitis 
Index (SCI) (n=1). Immune parameters such as leucocytes (n=1), T lymphocyte subsets 
[Th1/Th2/Th17] (n=1), serum eosinophilic cationic protein (n=1), soluble interleikin-2 
receptor (n=1), IL-8 (n=1), IL-10 (n=1), IL-6 (n=1), and TNF-a (n=1) were examined in two 
studies. BMD at the femoral neck, greater trochanter and lumbar spine was measured using a 
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(IBDQ) (n=5), EuroQol EQ-5D-5L (n=1) and the short form 36 (SF-36) (n=1).  
Maximal isometric knee extension strength (n=1), knee extension 1 repetition maximum (1-
RM) (n=1), 1-RM leg press and chest press (n=1) were examined in two studies. 
Cardiorespiratory fitness was assessed using the Canadian fitness step test to measure ?̇?O2 
max in one study and a cycle ergometer to measure ventilatory threshold and peak oxygen 
uptake in another study. Two studies measured anxiety using the State and Trait Anxiety 
Scale (STAI) and depression using the Hospital Anxiety and Depression Scale (HADS), the 
Beck Depression Inventory II (BDI-II) was used in one study. Three studies determined body 
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Table 4. Characteristics of included studies  
Author/Year Study Design Participants Interventions Outcome-measures 
Robinson et al 
(1998) 
RCT 107 CD participants with mild 
to moderate disease activity 
[IG=60, CG=57]. 48 males. 
Mean age 40.7  
IG: 12-month twice-weekly home-based low-impact 
progressive resistance training programme 
BMD (DEXA) at the femoral neck, greater 
trochanter and lumbar spine taken at 
baseline and 12 months  CG: Usual care 




12 CD inactive or mildly 
active participants, no 
controls. 2 males. Mean age 
38.5 
12-week supervised (indoor track) and unsupervised 
(outdoors) walking programme 3 sessions (20 min per 
session, leading to 35 min) a week 
Stress (IBBSI), HRQOL (IBDQ), disease 
activity (HBI), aerobic fitness (VO2 Max), 
BMI at 1 and 3 months 





12 CD participants, no 
controls. 5 males. Age range 
34-51 
Resistance training programme consisting of 3 sets, 8-
10 repetitions, 12 exercises working at 60-70% of 1RM 
3 times a week over 12 weeks 
Disease activity (HBI), 
muscle strength (1-repetition maximum leg 
press and chest press) at 1 and 3 months 




Inactive or mildly active 32 
CD participants [IG=16, 
CG=16]. 14 males. Mean age 
38.8  
IG: 3-month independent low intensity walking 
programme, working at 40% of aerobic capacity for 30 
minutes, 3 times a week 
HRQOL (IBDQ), stress (IBDSI) disease 
activity (HBI) at baseline, 1, 2 and 3 
months. PA habits (IPAQ-Long) at 
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De Souza-
Tajiri et al 
(2014) 
Letter to the editor; 
Uncontrolled pilot 
study 
19 women with IBD [CD=10, 
UC=9] and quadriceps 
weakness. No controls 
8-week progressive supervised resistance training 
programme twice a week lasting 20 minutes  
 
 
HRQOL (IBDQ) and quadriceps strength 
(maximal isometric quadriceps strength 
and quadriceps 1-RM)  
Sharma et al 
(2015) 
RCT 87 IBD [CD=36, UC=51] 
participants in clinical 
remission [IG=50, CG=50]. 
54 males. Mean age 34.7  
IG: One supervised yoga session, followed by 7 weeks 
1 hour daily home-based sessions  
Cardiovascular autonomic functions (heart 
rate variability through ECG), immune 
markers (ECP, sIL-2R) and anxiety (STAI) 
at baseline and 2 months. Clinical 
symptoms (diary) were recorded  
CG: Usual care 
Klare et al 
(2015) 
RCT 30 IBD participants [CD=19, 
UC=11] with an inactive to 
moderate disease [IG=15, 
CG=15]. 8 males. Mean age 
41.1  
IG: Supervised moderate intensity outdoor running, 3 
times a week for 10 weeks 
HRQOL (IBDQ), disease activity (CDAI 
and RI), BMI, inflammatory markers (CRP 
and FC) and immune parameters (LC) at 
baseline and 10-week follow-up 
CG: Asked to maintain their current lifestyle 
behaviours and avoid PA exceeding two hours per 
week 
Cramer et al 
(2017) 
RCT 77 UC participants [IG=39, 
CG=38] in clinical remission. 
19 males. Mean age 45.8  
IG: 12-week traditional hatha yoga programme, 90 
minutes per week  
HRQOL (IBDQ) and disease activity 
(CAI) at week 1, 12 and 24 
CG: Received two evidence-based self-care books and 
were offered the same yoga classes at week 24 
  




17 IBD participants [CD=7, 
UC=13] in clinical remission. 
IG: Combined progressive aerobic and resistance, 3 
times a week for 8 weeks.  
QOL (SF-36), disease activity (HBI and 
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15 males. Median age of 
IG=33 and CG=31  
 STAI and BDI-II), body composition 
(DEXA), pro-inflammatory cytokines 
(IL6, IL8, IL10 and TNF-a), gut 
microbiome (α and b-diversity) at baseline 
and 8 weeks 
CG: Usual care, followed by exercise phase after 8 
weeks 
Tew et al 
(2019) 
Pilot RCT Inactive or mildly active 36 
CD participants [IG1=13, 
IG2=12, CG=11]. 17 males. 
Mean age of IG1=37, 
IG2=38.5 and CG=25 
IG1: HIIT of ten 1-minute bouts of cycling at 90% of 
Wpeak interspersed with 1-minute bouts of 15% of 
Wpeak 3 times a week for 12 weeks 
Feasibility, acceptability, safety, HRQOL 
(IBDQ), QOL (EQ-5D), Fatigue (IBD-F), 
psychological well-being (HADS) and 
physical activity habits (IPAQ) at week 1, 
13 and 26. Body mass, waist 
circumference, blood pressure, resting 
heart rate, cardiorespiratory fitness 
(Ventilatory threshold and peak oxygen 
uptake), disease status (CDAI) and 
inflammatory status (FC) at week 1 and 
week 13. 
IG2: MICT of 30 minutes of cycling at 35% Wpeak. 3 
times a week for 12 weeks 
CG: Usual care group, offered an exercise consultation 
following study completion 
IG, Intervention Group; CG, Control Group; CD, Crohn’s Disease; UC, Ulcerative Colitis; HRQOL, Health-Related Quality of Life; BMI, Body Mass Index; IBD, 
Inflammatory Bowel Disease; IBDQ Inflammatory Bowel Disease Questionnaire; HBI, Harvey Bradshaw Index; RCT, Randomised Controlled Trial; FC, Faecal Calprotectin; 
CRP, C-reactive Protein; RI, Rachmilewitz Index; DEXA, Dual-Energy X-Ray Absorptiometry; PA, Physical Activity; IPAQ, International Physical Activity Questionnaire; 
ECG, Electrocardiogram; CAI, Clinical Activity Index; SCI, Simple Colitis Index; STAI, State and Trait Anxiety Index; BDI-II, Beck Depression Inventory-II; SF-36, Short-
Form 36; LC, Leucocytes; sIL-2R, Soluble Interleukin-2 Receptor; ECP, Eosinophilic Cationic Protein; HIIT, High-Intensity Interval Training; MICT, Moderate-Intensity 
Continuous Training; WPeak, Peak Power Output 
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3.3.2 Risk of Bias 
Figure 14 and 15 illustrates a graph (A) and summary (B) of the risk of bias decisions made 
per category using the RoB 2.0 tool and ROBINS-I, respectively. Regarding the no 
information domain, study authors were contacted for further clarification. Due to the nature 
of the interventions, all participants in all studies were aware of their group allocation which 
is of particular importance when considering outcome measures such as physical activity 
habits that could be influenced by the lack of blinding. Following the elaboration and 
algorithm guidance from the RoB 2.0 tool (2019), only 3 of these studies (Ng et al., 2007; 
Sharma et al., 2015; Cramer et al., 2017) were considered to have some concerns due to lack 
of a blinded outcome assessor, no information reported on whether deviations arose and no 
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Following the elaboration and algorithm guidance from the ROBINS-I tool (2016), all studies 
were suggested to have a moderate risk for bias of cofounding due to them being non-
randomised studies and they therefore cannot be considered comparable to a well-performed 
RCT. No information for bias of deviations from intended intervention, incomplete data and 
selective reporting were available for two studies, as one was an abstract and the other a letter 
to the editor. Measurement of outcome(s) bias was moderate to serious for all studies due to 
the lack of blinded outcome assessor.  
 
3.3.3 Bone Health Outcomes 
Only one included study explored the effects of an exercise intervention on bone health. This 
study evaluated a 12-month home-based low-impact resistance training programme on BMD, 
measured by dual energy x-ray absorptiometry (Lunar DPX) in 107 CD participants with 
mild to moderate disease activity (Robinson et al., 1998). This twice-weekly resistance 
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training programme involved 12 floor exercises using resistance tubing or free weights. 
Following the conclusion of this RCT, although differences in means were seen at the greater 
trochanter  (∆=0.86%; 95% CI -1.95-3.65; p=0.55), femoral neck (∆=0.50%; 95% CI -1.39-
2.39; p=0.60) and lumbar spine (∆=0.77%; 95% CI -0.97-2.51; p=0.32) in the exercise group 
(n=53) compared to the control group (n=54), the 95% confidence intervals and p values at 
all sites do not demonstrate strong evidence of BMD improving. However, due to the cyclical 
nature of CD only 13% of the exercise cohort were fully compliant, interestingly those who 
were fully compliant (n=14) showed a statistically significant difference at the greater 
trochanter (∆=4.67%; 95% CI 0.86-8.48; p=0.02) and greater mean difference improvements 
at the femoral neck (∆=2.99%; 95% CI -7.67-1.68; p=0.19) and lumbar spine (∆=2.21%; 95% 
CI -6.74-2.30; p=0.30).  
 
3.3.4 Muscular Function 
Two studies examined the effect of resistance training on muscular function. The first study 
(Candow et al., 2002) examined the effects of a thrice-weekly supervised intervention in 12 
CD participants. This programme consisted of 3 sets of 8-10 repetitions using 12 different 
machines working at 60-70% of 1-RM. Similarly, De Souza-Tajiri et al’s (2014) supervised 
study of 19 IBD participants (CD=10, UC=9), focusing on the quadriceps only, twice weekly 
for 8 weeks consisted of 20 minute sessions working at 50% maximum load with a gradual 
increase of 10% every week until 80% maximum load was reached, performing 3 sets of 12 
repetitions. Both of these uncontrolled studies identified a significant increase in muscle 
strength (p<0.05 and p<0.01, respectively), with Candow et al (2002) reporting no changes in 
disease activity assessed using the HBI. This indicates that, although more research is needed, 
these preliminary studies provide support to resistance training being safe for individuals with 
IBD. 
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3.3.5 Fatigue 
Only one study assessed fatigue; the study of Tew et al. (2019), which explored the effects of 
12 weeks of HIIT or MICT in adults with inactive or mildly active CD. This recent pilot trial 
randomised 36 participants to either HIIT, MICT or usual care. Participants allocated to the 
HIIT took part in ten 1-minute bouts of cycling at 90% of peak power output (Wpeak) 
interspersed with 1-minute bouts of 15% Wpeak, The MICT involved 30 minutes of cycling 
at 35% Wpeak. Intensity for both groups was progressed after weeks 4 and 8 based on Wpeak 
recordings during testing visits. After the initial 12-week supervised intervention, exercise 
participants were encouraged to continue exercising at a similar intensity, duration, frequency 
and type at their home or in a community setting.  
Following the intervention the mean change in total fatigue severity, frequency and duration, 
assessed using the IBD-F from baseline to 3 months and 6 months was (0.1;-0.7) in the HIIT 
group and (0.5;-0.5) in the MICT group. However, given the intentionally small sample size 
the study was underpowered to detect effect and therefore results should be interpreted with 
caution. Nevertheless, post exit interviews confirmed 8 participants reported feeling more 
energised.  
 
3.3.6 QOL and Psychological Well-Being 
The effects of an exercise intervention on QOL and psychological well-being has been 
explored in seven and three studies, respectively. The first study (Loudon et al., 1999) 
examined the effects of a supervised (indoor track) and unsupervised (outdoors) thrice-
weekly progressive low-intensity walking programme in CD participants (n=12) in clinical 
remission or with a mildly active disease. Sessions started at 20 minutes and were progressed 
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to 35 minutes for 12 weeks. HRQOL, assessed using the total IBDQ score, was significantly 
improved from baseline to follow-up (∆= 17; p=0.01). Improvements in stress (IBDSI) were 
also reported (p<0.001). Ng et al (2007) built on this preliminary work by examining the 
effects of a thrice-weekly independent low intensity intervention on HRQOL and stress in 
CD participants (n=16) and a control group (n=16), which Loudon et al’s (1999) study 
lacked. Participants with an inactive or mildly active disease walked at 40% of aerobic 
capacity for 30 minutes over 3 months. This prospective RCT reported mean change 
improvements in HRQOL (baseline= 5.19, follow-up= 5.98; p<0.05) and reductions in stress 
(baseline= 31.4, follow-up= 18.75; p<0.05) at 3 months, determined using the IBDQ and 
IBDSI, respectively.  
De Souza-Tajiri et al’s (2014) pilot study, as mentioned previously, also identified significant 
improvements in all HRQOL components: bowel symptoms, emotional health, systemic 
systems and social function (p=0.0001) measured using the IBDQ following an 8-week 
progressive resistance training programme. In another study (Klare et al., 2015), exploring 
the effects of a thrice-weekly supervised moderate intensity outdoor running programme, 
defined as ‘still able to talk while running’, in participants with mild to moderate IBD 
(CD=19, UC=11) observed significant within-group differences in all IBDQ domains (all 
p<0.01) in the exercise cohort. However, significant between-group differences were only 
observed in the social function IBDQ dimension (p=0.026) following the conclusion of this 
10-week intervention.  
More recently, improvements in HRQOL were demonstrated in a 12-week traditional hatha 
yoga programme vs self-care of 77 UC participants in clinical remission (Cramer et al., 
2017). This 90-minute supervised weekly intervention demonstrated significant group 
differences in HRQOL using the total IBDQ from week 1 to week 12 (∆=14.7; 95% CI 2.4-
26.9; p=0.018) and were sustained at week 24 (∆=16.4; 95% CI 2.5-30.3; p=0.022) (Cramer 
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et al., 2017). Group differences were also identified to favour the intervention over self-care 
at week 12 and week 24 in subscales of the IBDQ bowel symptoms (∆=4.9; p=0.014, ∆=5.7; 
p=0.015), systemic symptoms (∆=2.5; p=0.016, ∆=2.8; p=0.006) and emotional function 
(∆=5.4; p=0.023, ∆=5.8; p=0.030), respectively. No changes were reported in social function. 
Tew et al’s (2019) supervised HIIT and MICT study also reported QOL and psychological 
well-being, using the total IBDQ, EQ-5D and HADS. From baseline to 3 months, 
improvements were seen in all indices [(IBDQ= HIIT 184 vs 186; MICT 181 vs 192), EQ-
5D= HIIT 0.85 vs 0.85; MICT 0.83 vs 0.87), (anxiety= HIIT 5.5 vs 5.2; MICT 6.8 vs 5.5), 
(depression HIIT=3.6 to 2.7; MICT=3.8 to 2.7)]. Following the intervention end point (3 
months) and at the 6-month follow-up results were not sustained in QOL or depression 
scales, but improvements were seen in anxiety measures (HIIT -1.4; MICT -0.2). However 
between-group comparisons were not conducted due to the study’s feasibility and 
underpowered nature to assess efficacy.  
Interestingly, a randomised controlled cross-over trial exploring the influence of an 8-week 
combined moderate aerobic and resistance training programme in 17 IBD participants in 
clinical remission reported no changes in QOL using the Short form-36 (SF-36), or 
depression and anxiety scores measured using the HADS, STAI and BDI-II (Cronin et al., 
2019). However, an 8-week home-based yoga RCT of 87 IBD participants (CD=36, UC=51) 
in clinical remission identified significant within pre and post differences in the STAI 
(p=0.01), although only in the UC group (Sharma et al., 2015).  
 
3.3.7 Body Composition 
Body composition changes were assessed in three out of the ten included studies. Cronin et 
al’s (2019) randomised controlled cross-over trial explored the influence of a combined 
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moderate aerobic and resistance training programme in 17 IBD participants in clinical 
remission (Cronin et al., 2019). Participants were initially randomised 1:1 to the exercise 
cohort (n=8) or control group (n=7). Following the 8-week intervention period/control phase 
the control group then received the same training programme as the exercise cohort (n=13). 
This thrice-weekly moderate intensity progressive aerobic exercise programme consisted of 
walking and jogging between 5 and 7 of 10 on the modified Borg rating of perceived exertion 
scale. The progressive resistance programme involved 3 sets of 8 repetitions using 7 
machine-based resistance exercises, starting at an intensity of 70% of the participants 1-RM 
and increasing 15-20% over the 8 weeks. Following the conclusion, significant improvements 
in body composition assessed by DEXA were achieved by the exercise group demonstrating 
a median decrease of 2.1% (-2.15, -0.45) (p=0.022) body fat and a median increase of 1.59kg 
(0.68, 2.69) (p=0.0003) lean tissue mass when compared to the non-exercising cohort. Lower 
intensity programmes also identified improvements in BMI in two studies (Loudon et al., 
1999; Klare et al., 2015), however neither of these were statistically significant (both 
p=0.07).  
 
3.3.8 Disease Activity and Immune Parameters  
Six studies included in this review examined the effects of exercise on disease activity and 
three on immune parameters. In three studies, disease activity improvements were identified. 
Firstly, in Loudon et al’s (1999) thrice-weekly progressive walking programme in adults with 
CD, following this 12-week pilot study significant improvements were seen in the HBI (pre-
and post-exercise scores 5.9 ± 5.0 vs 3.6 ± 3.1; p=0.02). Ng et al’s (2007) follow-up study, 
also involving a thrice-weekly walking programme in adults with CD for 12 weeks, identified 
similar improvements in the HBI (6.69 vs 3.63, p<0.01). This suggests that a low-intensity 
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progressive walking programme is feasible to reduce disease activity in people with IBD. 
Lastly, Cramer et al’s (2017) 12-week yoga intervention in adults with UC reported  
significant group differences at week 24 between the yoga group and self-care group (∆= -
1.2; p=0.029) assessed using the CAI. Interestingly, although at week 12 CAI scores 
increased in the self-care group (2.0 ± 1.5 to 2.6 ± 2.6) and decreased in the yoga group (2.5 
± 1.4 to 2.4 ± 2.2) these did not reach statistical significance within or between-group 
differences suggesting that, to achieve significant disease activity differences in yoga, a 
longer intervention is required.  
In contrast, Candow et al’s (2002) 12-week resistance training programme found no 
improvements in disease activity scores using the HBI. Although Klare et al’s (2015) 10-
week running programme in inactive to moderately active IBD detected a change in FC 
within the exercise cohort (mean increase 185.0 ± 324.8 mg/kg; p=0.062), this was not 
statistically significant. Similarly, significant within-group differences were observed in 
leucocyte counts (7.0 ± 2.2 vs 5.6 ± 1.5; p=0.016), however significant between-group 
differences were not reported (p=0.390). No other differences in disease activity markers 
(CRP, haemoglobin, CDAI and Rachmilewitz Index) were observed in Klare et al’s (2015) 
RCT. No disease activity, immune parameter or inflammatory biomarker changes were 
identified in Cronin et al’s (2019) 8-week combined aerobic and resistance programme 
determined with CRP, HBI, SCI or proinflammatory cytokines (IL-8, IL-10, IL-6 and TNF-a) 
and although not statistically significant there was a modest increase in gut microbiota a-
diversity after the study period. However, no differences were detected between the exercise 
and control groups in a-diversity or in taxonomic b-diversity. Similarly, Sharma et al’s (2015) 
yoga intervention in 87 IBD participants in clinical remission identified no changes in 
immune markers (serum eosinophilic cationic protein and soluble interleukin-2 receptor) 
following the conclusion of this 8-week RCT. A HIIT and MICT programme, thrice-weekly 
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for 12 weeks observed no changes on disease activity parameters (CDAI and FC) (Tew et al., 
2019). Thus supporting previous data that exercise is feasible in IBD and furthermore 
suggesting that individuals in remission or suffering from a mild to moderately active disease 
are capable of performing symptom-free without experiencing an exacerbation of symptoms. 
 
3.3.9 Cardiopulmonary Outcomes 
Three studies examined the effect of cardiovascular training on cardiorespiratory fitness. 
Using the Canadian Aerobic Fitness Step Test, Loudon et al’s (1999) walking programme 
demonstrated significant improvements in VO2 max between pre and post measures (30.6 ± 
4.7, 32.4 ± 4.8, p=0.0013). Combining progressive resistance training and cardiovascular 
training also demonstrated significant improvements in physical fitness determined with a 
submaximal assessment of peak aerobic capacity of the Rockport one-mile walk test (Cronin 
et al., 2019). Following the conclusion of this 8-week randomised cross-over trial, median 
physical fitness (VO2 max) scores improved from 43.4 mL/kg/min to 46.0 mL/kg/min 
(p=0.03). Similarly, Tew et al’s (2019) feasibility RCT, saw a mean change in peak oxygen 
uptake and ventilatory threshold from baseline to 3 months in the HIIT (27.3 vs 29.7 
mL/kg/min; 16.5 vs 16.8 mL/kg/min, respectively) and MICT (28.7 vs 29.3 mL/kg/min; 16.0 
vs 18.2 mL/kg/min) groups.  
Sharma et al (2015) evaluated cardiovascular autonomic functions in an RCT of 87 IBD 
participants (CD=36, UC=51) in clinical remission. Participants were block randomised to 
either a one hour daily home-based 8-week yoga programme working at the same intensity or 
usual care. No group differences or within group differences were reported in cardiovascular 
autonomic activity, however there was a strong trend towards a reduction in low sympathetic 
activity frequency in the yoga group [median= 404.95 ms2 (IQR= 145.04 ms2, 659.57 ms2) vs 
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171.54 ms2 (72.08 ms2, 498.01 ms2), p=0.052]. No group or within differences were reported 
on cardiovascular parasympathetic, sympathetic reactivity, heart rate responses or blood 
pressure. 
 
3.3.10 Feasibility and Acceptability Outcomes  
Eight studies provided data on compliance and withdrawals. Compliance to the interventions 
was well received ranging from 52% to 87.5%. Withdrawals were reported in 6 studies. Out 
of 250 exercising participants 34 withdrew due reasons such as lack of motivation/ loss of 
interest (n=9), scheduling issues (n=8), active disease (n=4), pregnancy (n=4), moved away 
(n=2) or other (n=7). Excluding the studies with no controls, 23 withdrawals were reported in 
control groups and 28 in the exercise groups.  
 
3.3.11 Safety 
Eight studies provided data on adverse events. Exercise-related non-serious adverse events 
were reported in two studies (Cramer et al., 2017; Tew et al., 2019). Events included acute 
flares (n=3), colorectal cancer diagnosis (n=1) (Cramer et al., 2017) and mild headaches 
(n=1), vomiting following exercise (n=1) and chest infection following randomisation (n=1) 
(Tew et al., 2019). No serious adverse events were reported. 
 
3.3.12 Ongoing Trials 
Ongoing clinical trials and unpublished studies were searched on ClinicalTrials.gov, WHO 
ICTRP and ISRCTN registry. One study was identified on ClinicalTrials.gov 
(NCT02463916) with a status of ongoing. The author was contacted to obtain an update on its 
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progress. The study title and clinical population detailed on this record had since changed and 
the recent study was included in this review (Cronin et al., 2019). Two studies remain 
classified as ongoing (ISRCTN registry: ISRCTN11470370, ClinicalTrials.gov: 
NCT02861053). The first study is being conducted as part of this thesis and remains in an 
ongoing status with recruitment completed. Attempts were made to obtain an update on the 




This systematic review investigated the effects of any mode of exercise intervention on 
physiological and psychological outcomes in adults with IBD. Results provide corroborating 
evidence that exercise is safe, feasible and acceptable and may be potentially beneficial in 
improving BMD, QOL, muscle function, psychological well-being, fatigue, immune markers, 
body composition, disease activity and cardiopulmonary measures for inactive to mildly 
active CD. The safety or potential benefits in people with a severely active disease has yet be 
to established.  
 
3.4.1 BMD 
The prevalence of bone loss in people with IBD ranges from 70-80%, with 22-77% of these 
individuals later going on to be diagnosed with osteopenia and a further 17-41% subsequently 
developing osteoporosis (Lee et al., 2005; Ali et al., 2009). Despite this only one published 
study (Robinson et al., 1998) has explored the potential of a progressive resistance training 
programme (PRT) as an adjunct therapy for BMD in CD. Although the results of this study 
suggests that improvements in BMD are positively related to the amount of exercise 
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performed, 95% confidence intervals do not support strong improvements at the femoral neck 
or lumbar spine. As discussed in Chapter 2, the higher the strains of mechanical loading the 
greater the osteogenic effect. Robinson et al’s (1998) study was limited to resistance training 
only, therefore to maximise the potential bone loading effects integrating high-impact 
exercise may be more effective for preserving BMD. In addition, this study did not take into 
consideration a person’s past or present medication, smoking history, disease location or 
surgical history, variables that may contribute to BMD loss (Grey, 2007). 
An unpublished study also assessed the impact of a 12-month thrice-weekly PRT programme, 
with supplementation in 60 participants with UC in clinical remission (Sanges et al., 2013). 
Both the exercise and control cohorts were prescribed 1g of calcium carbonate and 800 IU 
vitamin D. Findings demonstrated that although improvements in BMD were seen in both 
groups, greater improvements were seen in the exercise group at the lumbar spine and 
femoral neck (p<0.05). This demonstrates that supplementation alone is not as effective as a 
combination approach including exercise. However, this study was excluded from this review 
as results were limited to exercise interventions only and, due to the use of a combined 
intervention, it was unfeasible to distinguish against the specific effects of exercise. In 
addition, this study reported little information on protocol deviations, adherence or allocation 
variables that influence the validity and methodological quality of the study.  
Measures to treat osteoporosis and osteopenia in this high-risk group have not yet been well 
established. Despite the benefits of PRT interventions being well documented in other 
populations, the role of gravitational and muscle loading exercises in the prevention or 
treatment of IBD-related bone loss has received little attention. To prevent further disability 
and future personal and socio-economical costs, clinical trials are warranted to identify the 
optimal exercise prescription (mode, intensity, duration and frequency) for bone health in the 
IBD population. 
CHAPTER 3: SYSTEMATIC REVIEW 
W12018030  73 | P a g e  
 
 3.4.2 Muscular Function 
Despite the importance of skeletal muscle strength and endurance in daily living, loss of 
muscular strength and endurance are two of the least researched EIM’s associated with IBD, 
yet are important predictors of future disability (van Langenberg and Gibson, 2010; Hommes 
et al., 2012). Even during states of remission, up to 60% of people with IBD have a reduced 
muscular CSA, mass, strength and endurance when compared to healthy controls (Geerling et 
al., 2000; Wiroth et al., 2005; Werksetter et al., 2011; van Langenberg, 2013). To date, only 
two studies (Candow et al., 2002; De Souza-Tajiri et al., 2014) have assessed the impact of an 
exercise intervention on muscle function parameters. Although both studies, one unpublished 
conference abstract and one letter to the editor, found significant improvements in muscle 
strength indices following a PRT 8 and 12-week programme, respectively, both studies were 
subject to validity and methodological limitations. Both studies lacked a control group and 
provided no information on the method of analysis, adherences rates to the intervention or the 
amount of exercise completed outside of the programme. There was no information on 
whether there was blinding to the intervention received or if an outcome assessor was 
present, factors that could influence results. In De Souza-Tajiri et al’s (2014) pilot study, 
participants were also selected based on pre-established quadriceps weakness prior to 
recruitment and thus do not represent the sample of the target population or benefiting 
implications to be made to practice.  
In addition, no trials have explored the benefits of exercise on upper muscular function or 
lower and upper muscular endurance. Reduced muscular strength and endurance indices have 
been associated with reduced QOL, morbidity and mortality in the elderly populations and in 
other chronic conditions such as sarcopenia, chronic obstructive pulmonary disease and 
Parkinson’s disease. The deficiencies are responsible for a considerable health care 
expenditure costing an estimated annual excess cost of £2.5 billion in the UK (Pinedo-
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Villanueva et al., 2018). Therefore, exercise programmes, particularly targeting muscular 
endurance impairments and upper muscular function in IBD, are warranted to prevent future 
disability and reduce the cost of health care in the UK.  
 
3.4.3 Fatigue  
Population-based and clinical studies reported 86% of people with active IBD and 41% of 
people with quiescent disease reported significant fatigue (Romkens et al., 2011; Czuber-
Dochan et al., 2015). Given its high prevalence during states of remission, it is evident that 
fatigue is not solely linked to disease activity. Despite it being considered one of the most 
burdensome symptom of IBD, only one study has assessed the impact of an exercise 
intervention in relation to fatigue (Tew et al., 2019). This randomised controlled feasibility 
trial assessed fatigue severity, frequency and duration, using the IBD-F, found no reductions 
in either the HIIT or MICT group at 3 months, however small reductions in fatigue were 
reported in both groups from baseline to 6 months in the HIIT (∆= -0.7) and MICT (∆= -0.5) 
groups. In addition, the second part of the IBD-F scale determining the impact fatigue has on 
day to day activities did not decrease in either the HIIT or MICT at 3 or 6 months. However, 
the reason for this non improvement could be due to an intentionally small sample size, the 
study is underpowered to detect a true effect and results should be interpreted cautiously. 
Nevertheless, it did demonstrate that a HIIT and MICT exercise programme is feasible in this 
population warranting future large-scale trials. 
 
3.4.4 Disease activity and Inflammatory biomarkers 
Only a few of the included studies reported laboratory markers (Sharma et al., 2015; Klare et 
al., 2015; Cronin et al., 2019; Tew et al., 2019), including Lc, IL-6, IL-8, IL-10 and TNF-a 
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with no studies finding any significant differences. Despite the importance of TNF-a and IL-6 
demonstrating protective anti-inflammatory effects when exercising, only one study (Cronin 
et al., 2019) has assessed these immune parameters. Although this study observed no 
significant differences, there was no deterioration during or after the intervention, suggesting 
that, following a moderate intensity combined exercise programme, disease state remained 
stable throughout. However, to induce more favourable changes in the bacterial microbiome 
future research is needed to look at the effects of high intensity training. Interestingly, a 
paediatric study involving 15 CD participants examined inflammatory cells, cytokines and 
growth factors after an acute (30 minutes) bout of MICT and HIIT when compared to 
healthy-matched controls (n=15) (Ploeger et al., 2012). A significant increase in IL-6 and 
decrease in IGF-1 (both p<0.05) were observed in both exercise groups. However, this article 
was excluded from this review as results were limited to adults with IBD only and limited by 
the individuals gender and pubertal status and drug intake, factors that have been shown to 
impact the exercise response of immune cells and inflammatory cytokines (Tirakitsoontorn et 
al., 2001).  
The anti-inflammatory effect of exercise has been well investigated in mice studies. A 
controlled study involving 3 bouts of sustained vigorous treadmill running, observed 
increased levels of the anti-inflammatory cytokine IL-10 and decreased levels or TNF-a 
(Hoffman-Goetz et al., 2008). Similar effects were reported in other health conditions such as 
cardiovascular disease, cancer and type 2 diabetes, where an increase was observed in IL-6 
production by muscle fibres (Lee et al., 1997; Thune et al., 2001; Lamonte et al., 2005). The 
increase in IL-6 stimulates the circulation of other anti-inflammatory cytokines such as IL-10 
and IL-1ra that inhibit the production of the pro-inflammatory cytokine TNF-a, which 
explains the decrease in TNF-a values. This is a promising framework for people with IBD as 
TNF-a is a major pathological marker that correlates with intestinal inflammation (Muzes et 
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al., 2012; Levin et al., 2016). However, the release of these cytokines is dependent upon the 
frequency, intensity, duration and type of exercise, with higher intensity exercise observing a 
5 times higher IL-6 concentration than lower intensity exercise that requires fewer 
contracting muscles (Pedersen et al., 2004).  
Disease activity was assessed in seven of the 10 included studies using validated metrics such 
as CDAI (n=1), RI (n=1), HBI (n=3) CAI (n=1), FC (n=2) and CRP (n=3). Three of the 
studies, two walking programmes (Loudon et al., 1999; Ng et al., 2007) and one yoga 
intervention (Cramer et al., 2017) demonstrated a significant positive change on disease 
activity using objective measures. These three programmes were all of a low intensity, 
suggesting that a low intensity exercise programme is feasible to inflict positive changes in 
disease activity in people with IBD. However, two of these studies (Loudon et al., 1999; Ng 
et al., 2007) used the HBI, which does not take into account whether the individual currently 
takes anti-diarrhoeal medication, haematocrit or person’s weight, important determinants of 
disease activity. Therefore future research exploring higher intensity programmes using 
different markers of inflammation are warranted. To date, no studies using subjective markers 
of inflammation (FC and CRP) have observed any positive changes on disease activity, 
however, no negative changes were reported either. This suggests people with IBD in 
remission or suffering from a mild to moderately active disease are capable of performing 
symptom-free without experiencing an exacerbation of symptoms.  
 
3.4.5 Quality of Life 
Life expectancy is not affected by IBD, however with the relapsing nature of IBD, medical 
and surgical side effects and disease-specific complications it is not surprising that people 
with IBD have an impaired QOL. Seven of the studies reported similar effects on total 
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HRQOL and subscales of HRQOL using validated metrics such as IBDQ (n=6), SF-36 (n=1) 
and EQ-5D (n=1). Only one study found no significant changes in QOL using the SF-36 
(Cronin et al., 2019). However, this was a cross-over trial and assumptions were made that no 
carryover effects occurred. Contradictory results were also identified in the IBDQ sub-scale 
social function with Klare et al (2015) observing a significant difference (p=0.026) between-
groups and Cramer et al (2017) finding no group differences. Potential reasons for this could 
be attributed to the mode, duration or intensity of exercise or the integrity of the programme 
was delivered, supervised (Klare et al., 2015) or unsupervised (Cramer et al., 2017). Another 
potential reason could be attributed to disease activity. Significant changes were seen in 
participants with an inactive to moderate disease who were recruited in Klare et al’s (2015) 
prospective RCT, whereas no significant changes were identified in participants all in clinical 
remission (Cramer et al., 2017). It is widely known that people with IBD often get anxious or 
nervous when leaving the house, especially during states of an active disease (Bannaga and 
Selinger, 2015). Aspects that impair mental and social well-being, by introducing the social 
aspect of supervised sessions, like Klare et al (2015), could counteract these feelings of 
anxiety and prompt individuals to leave the house. 
 
3.4.6 Stress, Anxiety and Depression 
While the presenting symptoms of IBD are mostly physical, the worries and concerns 
identified above together with the uncertain disease course and prognosis, are all likely to 
contribute to an increased risk of stress, depression and anxiety and further profoundly affect 
a person’s QOL (Sainsbury and Heatley, 2005; Graff et al., 2010). Increased rates of stress, 
anxiety and depression have all been associated with increased rates in hospitalisation (van 
Langenberg et al., 2010), lower compliance to treatment (Nigro et al., 2001) and clinical 
recurrence (Mikocka-Walus et al., 2016).  In two out of three studies, both walking 
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programmes (Loudon et al., 1999; Ng et al., 2007), showed a significant reduction in stress, 
using the IBDSI. With 90% of people with IBD believing that stress influences their disease 
activity and played a major part in the development of their disease (Drossman and Ringel, 
2004; Hisamatsu et al., 2007), it is important to recognise the potential for exercise to be 
implemented into clinical practice and policies to benefit the individual.  
Depression was assessed in two out of the 10 included studies using the HADS (Cronin et al., 
2019; Tew et al., 2019). No significant differences were found in one study (Cronin et al., 
2019), however depression scores were reduced from baseline to 3 months in the HIIT and 
MICT groups in Tew et al’s (2019) feasibility study. However, Cronin et al’s (2019) cross-
over study had a small sample size of 17 participants, 4 of whom dropped out, leading to 
higher variability which may in turn lead to bias. Anxiety was assessed in three out of 10 
included studies using the STAI (n=1) and HADS (n=2) (Sharma et al., 2015; Cronin et al., 
2019; Tew et al., 2019). Cronin et al’s (2019) cross-over design study found no significant 
differences in anxiety scores. Significant reductions in state and trait anxiety were seen only 
in the UC intervention group (Sharma et al., 2015) and anxiety reductions were observed in 
both the HIIT and MICT groups in Tew et al’s (2019) feasibility study. However, there is a 
paucity of evidence that, depending on the type, duration or intensity of exercise, positive 
changes can be seen in stress, anxiety and depression following an exercise intervention. 
Possible reasons for these reductions have been suggested as a result of improved health-
related self-efficacy, perceived control, fitness gains and improved self-confidence (Anderson 
and Shivakumar, 2013; Infurna and Gerstorf, 2014). Nevertheless, results are met with 
variation between studies and, with people with IBD reporting high anxiety and depression 
scores 40-50% are more likely to flare-up within 6 months than those with low scores 
(Crohn’s and Colitis UK, 2014; Bannaga and Selinger, 2015), further exercise trials are 
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warranted to explore the impact of different modes, intensities, durations and frequencies on 
depression and anxiety levels.   
 
3.5 Limitations 
Several limitations should be noted. Firstly, a meta-analysis of the data was not possible due 
to the heterogeneity of included studies. The included studies were thought to be limited and 
too different, either statistically or methodologically. Demonstrating differences in the type of 
intervention, outcomes evaluated, metric of the same outcome, non-randomised design and 
other design issues, and variation in follow-up time points. Therefore, were unable to explore 
the potential impact of study bias, statistical heterogeneity and methodological weaknesses. It 
is also important to acknowledge the methodological limitations of some of the studies 
included such as lack of control group, lack of blinded outcome assessor, no information 
reported on whether deviations arose and no information provided on adherence to the 
intervention that could have impacted the results. In addition, some of the included studies 
analysed results only on participants who adequately completed the training intervention 
rather than using an intention-to-treat method. Lastly, despite the extensive search of the 
literature using clinical trial registries and major databases considered, by The Cochrane 
Collaboration (Higgins and Green, 2011), as the most important sources for reports of trials 
there is still a possibility that studies eligible for inclusion may have been missed. Lastly, the 
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3.6 Conclusion 
In summary, the benefits of exercise in IBD have not been sufficiently researched. 
Nevertheless, low to moderate-intensity exercise has demonstrated to be safe and potentially 
beneficial at counteracting some IBD-specific complications in persons with an inactive to 
mildly active disease. With individuals looking for alternative modalities, further research is 
needed to explore optimal exercise prescription in regards to type, intensity, duration and 
frequency, tailored to meet the physical and psychological needs of the individual. Involving 
interventions that deliver high intensity programmes, including the least researched outcomes 
such as immune parameters, BMD, muscular function and fatigue in different disease states, 
particularly those with a more moderate to severe disease. In addition, disease type 
comparisons (CD vs UC) were unable to be distinguished in this review. Future studies 
should consider reporting the disease types separately and not collectively as IBD so any 
potential differences between disease type undertaking the same intervention can be 
identified. Lastly, methodological considerations such as the use of combination disease-
specific parameters for the quantitative synthesis of future research, larger cohorts and longer 
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4.1 Introduction 
As discussed in Chapter 1, this chapter provides justification and rationale for the design and 
methods employed in: 
• Chapter 5: A test-retest reliability study of outcome measures used to evaluate and 
facilitate the assessment of an intervention. 
• Chapter 6: A case-control and cross-sectional study assessing current bone and 
muscle health and identifying correlates contributing to low BMD in people with CD 
compared to healthy controls.  
• Chapter 7: An RCT evaluating the effects of an exercise intervention as a prevention, 
treatment or management on muscular function and BMD.  
 
4.2 Study Design 
To begin evaluating a clinically relevant question, sufficient literature needs to be searched 
and evaluated in order to design clinical treatment with the best possible scientific evidence. 
Firstly, a test-retest study design approach was deemed appropriate to determine the 
reliability of candidate outcome measures (Chapter 5) for an experimental research. To assess 
whether there was a significant difference in bone and muscle parameters in people with CD 
compared to healthy controls, a case-control study design was employed (Chapter 6). Case 
control studies are acknowledged to generate a high level of evidence and have the potential 
for a high external validity, enabling the data to be extrapolated to the CD population 
(Bondemark and Ruf, 2015). Therefore, an observational approach was deemed appropriate 
to provide an evidential basis for the intervention treatment. To further evaluate the evidence 
before implementing an intervention, a cross-sectional approach examining the relationship 
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between the disease and risk factors associated with bone loss was explored (Chapter 6). This 
approach allowed multiple variables to be studied, to support the hypothesis that risk factors 
of bone loss are present in CD and to determine the risk factors to people with CD that are 
important for health care professionals when considering the appropriateness of DEXA 
scanning.  
To investigate the effects of a 6-month combined impact and resistance training intervention 
on muscle function and BMD in adults with CD, a single-centre, two-arm, parallel-group, 
RCT was conducted (Chapter 7). To implement evidence-based care supported by the best 
level of evidence, it was important that the highest level evidence-based, ‘gold standard’ 
approach was used (Bondemark and Ruf, 2015; Hariton and Locascio, 2018). Although no 
study on its own is likely to prove causality, randomisation of participants will ensure that 
both known and unknown determinants were evenly distributed, thus minimising bias and 
providing a rigorous tool to examine cause-effect relationships between the intervention and 
the outcome. No other study designs, apart from RCT’s, allow this.  
 
4.3 Eligibility Criteria and Recruitment 
Details and justification on the eligibility criteria and recruitment can be found in respective 
chapters.  
 
4.4 Outcome Measures  
Outcome measures of each study are identified in table 5 and described in this chapter.  
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Table 5. 











(Chapter 7) OUTCOME MEASURE 
BMD ✓ ✓ ✓ ✓ 
Muscular Strength  ✓ ✓  ✓ 
Muscular Endurance ✓ ✓  ✓ 
QOL: EQ-5D-5L  ✓  ✓ 
QOL: IBDQ    ✓ 
Fatigue: IBD-F     ✓ 
Physical Activity Habits  ✓  ✓ 
Disease Activity and  
Inflammatory Markers 
   ✓ 
EQ-5D-5L, EuroQol five dimensions self-assessment questionnaire; IBDQ, Inflammatory Bowel Disease 
Questionnaire 
 
4.4.1 Assessment of Anthropometric Measures 
Stature was measured to the nearest 0.1 cm via a stadiometer (SECA 217). Participants were 
asked to remove their shoes, stand with their back and heels against the stadiometer and 
asked if the research assistant could place their hands under their jaw to ensure an upward 
pressure is transferred through the mastoid process. Participants were instructed to take a 
deep breath in and a gentle upward lift applied.  
 
Body mass was measured to the nearest 0.1 kg using Avery scales (SECA 711). Participants 
were asked to empty their pockets, remove their shoes and asked to stand still centre on the 
scales with their feet wide ensuring accurate assessment.  
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4.4.2 Assessment of BMD 
A DEXA scanner (Hologic Horizon W DEXA) was used to quantify BMD at the femoral 
neck, greater trochanter and lumbar spine (L2-L4), the sites most reliable for predicting 
fracture risk, monitoring treatment, and associated with the highest mortality and 
complications rates (Teng et al., 2008). Prior to every scan the DEXA machine underwent a 
quality control check and calibrated using a spine phantom, allowing for slight variations in 
tube output. To establish appropriateness for exposure, an eligibility bone health assessment 
form (Appendix 4a) was completed before every scan. The participant lay supine on the x-ray 
table for approximately 10 minutes. For the lumbar spine assessment, the participant was 
centred in the middle of the table with their arms resting flat on the table and their knees 
flexed over a 90° soft cube-shaped support to reduce the lumbar lordosis and open the 








For the left hip scan, the left leg was rotated at the knee and abducted, then fixed to the 
positioning fixture around the foot (figure 17). While remaining still, a large scanning arm 
was slowly passed over the participant, emitting a narrow beam of low-dose radiation. 
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Following the DEXA, scans were analysed in accordance with the Royal Osteoporosis 
Society Protocol (2018). The participants gastroenterologist and GP were notified of any scan 
indicative of requiring treatment (Appendix 4b). A copy of the participants scans were filed 







Seen as the ‘gold standard’ measurement tool for assessing BMD, this tool was selected due 
to its simple, quick and non-invasive nature that requires no special preparation, causes no 
physical harm and allows the participant to go home straight after (Zack et al., 2002; NHS, 
2016). The reproducibility of a DEXA scan is a key issue throughout clinical research as 
changes in BMD are small and gradual. Several studies have explored the reliability of 
DEXA scans, demonstrating a high degree of reliability with low coefficients of variation 
(CV%) at the lumbar spine 0.92%, total proximal femur 0.92%, total forearm 0.69% and 
whole body 0.73% and high consistency, with correlation coefficients ranging from 0.993-
0.996 (p<0.01) (Zack et al., 2002; Small et al., 2005; Humadi et al., 2010). The validity of 
DEXA when comparing two different sites, whole body and distal tibia, when excluding 
outliers, demonstrated correlations of 0.689 and 0.715 (p<0.01) (Zack et al., 2002). Although 
valid and reliable, results rely heavily on the expertise of the technical staff and positioning of 
the participant. In addition, due to constraints within this study the use of serum bone 
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turnover biomarkers such as bone-specific alkaline phosphatase or osteocalcin that estimate 
the rate of bone formation could not be measured. However, would be a useful addition to 
future studies to reflect and support findings.  
 
4.4.3 Assessment of Muscle Strength 
A calibrated isokinetic dynamometer (Biodex system 4 Pro) was used to evaluate three to five 
maximum voluntary isokinetic strength (Nm) repetitions of concentric contractions of the 
knee extensors on both legs and elbow flexors on both arms performed at angular velocities 
between 60°/s and 180°/s, depending on the limb as detailed below. The participant was 
seated and strapped securely to the chair to minimise and prevent accessory movements of 
segments that could result in higher torque values. The muscle groups were assessed in the 
same order for every participant: right elbow, left elbow, right leg then left leg.  
4.4.3.1 Upper extremities 
The chair and dynamometer controls were rotated and set at 15° and the elbow attachment 
adjusted to align the centre of trochlea and capitulum of humerus (figure 18a), based on 
manufacturer guidelines. Starting in the fully flexed position, participants performed three 
maximal repetitions of reciprocal concentric elbow extension and flexion contractions at 
60°/s, a 60-s rest interval followed by five repetitions at 120°/s. The total range of motion 
(ROM) for the elbow was 110°. Very high intraclass correlations (ICC) were demonstrated, 
between 0.92-0.98, for these angular velocities in other clinical populations (Pentland et al., 
1993; Ekstrand et al., 2015).  
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4.4.3.2 Lower extremities 
The chair and dynamometer were set at 90° and the knee attachment adjusted to align 
proximal to the medial malleoli (figure 18b), based on manufacturer guidelines. Starting in 
the fully flexed position, participants performed three maximal concentric knee extension and 
flexion contractions at 60°/s, 60-s rest interval followed by five maximal repetitions at 180°/s. 
The total ROM for the knee was 90°. Excellent ICC (>0.75-0.95) (Feiring et al., 1990; Fagher 
et al., 2016) and high reproducibility were identified at these speeds in other clinical 








Chair and dynamometer settings were recorded for every participant. Once the limb 
attachments were attached and aligned, the participant moved into position, the ROM set and 
the participant was educated about the procedure. Prior to any data collection, a warm-up 
consisting of three submaximal (60% effort) contractions on the limb being assessed were 
completed to allow muscles to function more efficiently and safely and to familiarise the 
participant with the machine. To maximise performance during testing, all participants were 
provided with standardised verbal encouragement ‘as hard and as fast as you can’ and ‘keep 
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it going’. The highest muscle force output, known as peak torque values were taken for the 
left and right limbs and averaged for analysis.  
Seen as the ‘gold standard’ for assessment of muscle strength, the isokinetic dynamometer 
allows for the isolation of particular muscle groups, ROM and muscle contraction type to be 
determined (Meyer et al., 2013). This provides an objective way to obtain muscular strength 
measures that have demonstrated the highest correlation coefficients for reliability, accuracy, 
validity and reproducibility that remain unmatched. Peak torque, average peak torque and 
average power of knee flexors and extensors have all demonstrated good reliability 
(ICC=0.80), with peak torque of knee extensors observing the highest reliability (ICC=0.99) 
(Maffiulett et al., 2007; Santos et al., 2013; Biodex, 2017).  Similar results were observed for 
upper extremities, with peak torque of elbow extensors and flexors demonstrating the highest 
reliability (ICC=0.87) and good reliability for the average peak torque and average power of 
the elbow extensors and flexors (ICC=0.82) (Starsky et al., 2005; Bassan et al., 2015). 
The angular velocities and ROM protocols for muscle groups of the upper and lower 
extremities were selected to achieve optimal peak capacity for maximal concentric isokinetic 
strength while demonstrating very high to excellent reliability and reproducibility (Harbo et 
al., 2012). Performing maximal knee extension and flexion contractions at 60°/s and 180°/s 
has demonstrated excellent ICC (>0.75) (Fagher et al., 2016) (0.95, 0.96, respectively) 
(Feiring et al., 1990) and very high reproducibility (Alvares et al., 2015). Maximal elbow 
extension and flexion contractions at 60°/s and 120°/s have demonstrated ICC ranges 
between 0.92-0.98 and 0.91-0.98, respectively (Pentland et al., 1993; Ekstrand et al., 2015). 
Testing through a 90° and 110° ROM was determined based on maximal isokinetic strength 
of the lower and upper extremities occurring at angle-specific torques, between 25°-67° for 
knee flexion and extension (Ha and Han, 2017), respectively and 56°-84° for elbow flexion 
and extension (Yang et al., 2014), respectively.  
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4.4.3.3 Grip Strength 
Grip Strength, the result of forceful flexion of the finger joins with maximum voluntary force, 
was determined using a calibrated handgrip dynamometer (JAMAR Hydraulic). Participants 
were required to stand shoulder width apart, with their elbow by their side, flexed at 90° and 
in a neutral wrist position. The handgrip dynamometer was placed in the participants 
nondominant hand, to avoid training bias and the wrist strap placed around the participants 
wrist to prevent the dynamometer from falling (figure 19). Prior to testing, a demonstration 
was performed by the outcome assessor and a practice attempt conducted by the participant to 
ensure the instrument felt comfortable. The position of the handle was adjusted if necessary 
and the new handle position was recorded for future visits. Participants were informed they 
would feel as if there was no resistance. On ‘Go’ the participant was instructed to grip the 
handle with maximum isometric effort and maintain for 5 seconds. Three attempts were 
recorded with 30 seconds rest between attempts and the highest score analysed. Throughout 
the testing all participants were encouraged, using the standard phrase “Squeeze, harder, 
harder, and stop squeezing”. If the participant’s arm was raised while squeezing, the test was 
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The Jamar dynamometer was selected due to its wide use in the clinical assessment of upper 
body strength, lack of invasive nature or laboratory testing and not requiring physician 
assessment (Bohannon et al., 2006; King, 2013). Results have demonstrated good reliability 
(ICC 0.84-0.93) and, when compared to certified standard weights, excellent concurrent 
validity (r=0.99) and strong concurrent validity with no significant difference (Niebuhr et al., 
1994; Svens and Lee, 2005). 
 
4.4.4 Assessment of Muscle Endurance 
The 30-s chair stand test (CST) was used to measure lower-limb muscular endurance. A chair 
was placed against the wall to ensure stability, the participant was instructed to start seated in 
the middle of the chair, back straight, hands placed on their opposite shoulders crossed at the 
wrist and feet flat on the floor (figure 20) (Rikli and Jones, 1999). Prior to testing, a 
demonstration was given, and a practice attempt conducted by the participant to ensure 
correct technique and adequate balance. On ‘Go’ the participant was instructed to rise to a 
full standing position and then sit back down again and repeat this for 30 seconds. The 
number of full stands were recorded. If the participant was over halfway to a standing 
position when the 30 seconds had elapsed, this repetition was included. Incorrectly executed 
stands were not counted.  
 
The 30-s CST was selected due to its extensive use throughout literature and efficient nature 
in assessing lower limb muscle endurance in a short period of time. Its excellent test-retest 
reliability (r=0.89: 95% CI 0.79-0.93), excellent criterion validity when compared to other 
assessments; leg press (r=0.77, 95% CI 0.64-0.85) and squat test (r=0.71, 95% CI 0.53-0.84); 
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and excellent correlation to the 50ft walk test ICC= -0.64 (95% CI -0.75 to -0.49) were also 









Upper limb muscular endurance was determined using the 30-s bicep curl test (BCT). The 
participant was directed to sit in the middle of the chair, back straight and feet flat on the 
floor (figure 21). A 5lb and 8lb weight was given to women and men, respectively to be held 
in the nondominant hand and held palm facing towards the body with the arm in a vertically 
down position beside the chair. Prior to testing, a demonstration was given and a practice 
attempt conducted by the participant to ensure correct technique. On ‘Go’ the participant was 
instructed to curl their arm up through a full ROM, turning the palm up (flexion with 
supination) to a fully flexed position and gradually return to the starting position to a fully 
extended position and repeat this for 30 seconds (Rikli and Jones, 1999). The number of full 
arms curls were record. If the participant was over halfway to a full arm extension when the 
30 seconds had elapsed, this repetition was included. Incorrectly executed arm curls were not 
counted.  
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This clinical measure was selected due to its ease and efficient nature in assessing upper limb 
muscle endurance in a short length of time (Jones and Rikli, 2002; Bhattacharya et al., 2016). 
Furthermore, it demonstrates excellent relative test-retest reliability ICC=0.943 (95% CI 
0.883-0.973) and high absolute reliability (r=0.79).  
 
4.4.5 Assessment of QOL 
4.4.5.1 EQ-5D-5L 
To assess generic HRQOL the EuroQol five dimensions self-assessment questionnaire (EQ-
5D-5L) (Appendix 4c) was utilised by referring to health status that day (Herdman et al., 
2011). Consisting of 2 pages, the first page of the EQ-5D-5L descriptive system comprises of 
5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression 
scored on 5 levels: no problems, slight problems, moderate problems, severe problems and 
extreme problems. The participant was asked to indicate their health status by marking one of 
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the boxes for each dimension that was most applicable. The EQ-5D-5L descriptive system 
was scored and coded according to the level of perceived problems, no problems=1, slight 
problems=2, moderate problems=3, severe problems=4 and extreme problems=5. Overall, 
producing a 5-digit health state profile e.g. 11211 that represents the level of reported 
problem for each of the five dimensions of health. A summary score of the participant’s 
health state was derived by applying a formula (Crosswalk Index Value Calculator) to 
convert each domain to a single index value, reflecting the health state according to the 
general population specific to the United Kingdom. Scores ranged from 1.000 to -0.285, with 
1 representing perfect health, 0 representing the value of a health state equivalent to death and 
negative values representing values worse than death. This approach ensures that the values 
are representative of the societal perspective (EuroQol, 2019). 
The second page the EQ Visual Analogue scale (EQ VAS) records the participants’ self-rated 
health on a 20-cm vertical, visual analogue scale numbered 0 to 100 with end points labelled 
‘the worst health you can imagine’ and ‘the best health you can imagine’, respectively. 
Participants were asked to mark an X on the scale to indicate how their health was that day 
and to write the number marked on the scale in the box. If there were any discrepancies 
between the marked X and the number written in the box, as per instructions on scoring the 
EQ VAS, the number in the box was used. The EQ VAS provides important and 
complementary information on a participants’ perspective about their own health, with higher 
scores representing better health status.  
This standardised tool for measuring generic health status was selected due to its 
undemanding simplistic nature, taking only a few minutes to complete. It has been widely 
used throughout health surveys and in clinical research, providing a descriptive profile and 
value of health status for clinical appraisal (Bowling, 2005). The EQ-5D-5L has 
demonstrated good test-retest reliability (r=0.90) with Kappa coefficients up to 0.61. 
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Correlation coefficients with other measures of self-related health such as the SF-36 and the 
Health Utilities Index (HUI-3) indicated convergent validity (r=0.64 and r=0.69). 
 
4.4.5.2 IBDQ 
Questions regarding the effects of IBD on daily function and QOL were also determined 
using the IBDQ and IBDQ-Stoma (Appendix 4d) for participants with a colostomy or 
ileostomy (Guyatt et al., 1989). Six questions (Q’s 1, 5, 17, 22, 24 and 26) differ depending 
on the version, however both are comprised of 32 items that are graded between 1 through to 
7. Participants were asked to read the questions carefully and select the number they felt best 
described how they were feeling over the past two weeks. The total IBDQ score ranges 
between 32 to 224, calculated by adding scores for all 32 items, with higher scores indicating 
a better QOL. Scores can also be subdivided into four functional domains: bowel symptoms, 
emotional health, systemic systems and social function. Each of the 4 areas were evaluated by 
adding up the scores for selected questions and dividing by how many questions there are in 
each domain, with higher scores representative of better function in that domain.  
While numerous QOL assessment tools exist, the IBDQ was selected due to its multifaceted 
construct that has contributed to understanding the disease specific impact on HRQOL. Not 
only does this questionnaire provide a detailed view on a wide range of health domains 
(social, physical, emotional and systemic symptoms) it is easy to administer and clear to 
understand. Furthermore, the IBDQ has demonstrated good internal consistency, reliability 
and criterion validity and excellent content validity (Chen et al., 2017).  
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4.4.6 Assessment of Fatigue 
Fatigue was measured using the standardised IBD-F self-assessment scale (Appendix 4e) by 
referring to a person’s symptoms experienced during the previous two weeks (Czuber-
Dochan et al., 2014). For the purpose of the questionnaire, Czuber-Dochan et al (2014) 
defined fatigue ‘as a sense of continuing tiredness, with periods of sudden and overwhelming 
lack of energy or a feeling of exhaustion that is not relieved following rest or sleep’. The 
questions posed were predominantly quantitative, with an option to write comments for 
further clarification to allow for a comprehensive assessment of fatigue.  
The first section consists of 5 questions assessing the severity and frequency of fatigue. 
Questions 1-4 scores ranged on an ordinal scale from 0-4, with 0 representing no fatigue and 
4 severe fatigue and question 5 scored on a Likert scale of 0 representing none of the time 
and 4 representing all the time, with a possible total of 20. Section II consists of 30 questions 
rating the perceived impact and experience of fatigue on daily activities, with scores ranging 
on an ordinal scale from 0-4 with 0 representing none of the time and 4 representing all the 
time, with a possible total of 120. Six questions in section II have an option of not applicable. 
The last section of the IBD-F involves 5 free-text questions exploring additional issues and 
factors contributing to fatigue.  
After calculating the sum of results for section I, scores of 0 were suggestive of no fatigue, 
scores of 1-10 of slight to moderate fatigue and 11-20 of severe fatigue. To adjust for N/A 
answers in section II the total score was calculated by using the formula: adjusted score= 
actual total score/(120-number N/A’s x 4) x120. Scores of 0 suggested fatigue had no impact 
on daily activities, 1-60 considered to have a moderate effect and 61-120 considered of 
having a severe effect. Section III of the scale is not scored, however it provides a qualitative 
perspective of the impact fatigue has on an individual.  
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Due to its subjective and multifaceted nature, fatigue is difficult to understand and measure 
and thus poses a key obstacle in fatigue-related research as no single ‘gold standard’ 
assessment measure can be developed that adequately captures the complexity of this 
debilitating and invisible symptom (Graff et al., 2011). While numerous fatigue assessment 
tools exist, the IBD-F self-assessment scale was selected due to its primary focus on the 
specific needs and experiences of people with IBD through asking questions based on the 
self-reports gathered from in-depth, cognitive interviews and questionnaires (Czuber-Dochan 
et al., 2014). This scale provides a detailed view of the severity and frequency of IBD-related 
fatigue, it is easy and clear to use and short enough to encourage completion (Mota and 
Pimenta, 2006; Eichhorn et al., 2010). In addition, it has been identified as psychometrically 
robust with reliability estimates falling within statistically acceptable ranges (0.80-0.90), with 
good content validity, acceptable test-retest stability (Section I ICC=0.74; Section II 
ICC=0.83) and a high degree of internal consistency (Cronbach’s alpha >0.9) comparing 
favourably with the multidimensional assessment of fatigue (MAF) and multidimensional 
fatigue inventory (MFI). The IBD-F also demonstrated a moderate convergent validity with 
the MAF (Section I= 0.73; Section II=0.78; p<0.001) and MFI (Section I=0.47; Section 
II=0.65; p<0.001) (Czuber-Dochan et al., 2014). 
 
4.4.7 Assessment of Physical Activity Habits 
Physical activity habits were determined using the Scottish Physical Activity Questionnaire 
(SPAQ) (Appendix 4f) by recalling leisure and occupational physical activity habits over the 
previous seven days (Lowther et al., 1999). The questionnaire consists of three parts. The first 
part comprises of a seven-day diary of leisure time physical activity with participants asked to 
record in minutes the amount of time spent undertaking a particular activity. Participants 
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were asked to only include activities of either moderate or vigorous intensity, with examples 
given for each domain. Activities were sub-grouped into six domains: walking out of work, 
manual labour out of work, active housework, dancing, participating in a sport, leisure 
activity or training and other physical activity not already covered, with examples given on 
what activities to include. The second section compromising of a seven-day diary recorded 
physical activity at work, completed only if employed, with activities sub-grouped into two 
domains: walking at work and manual labour at work. The final section explores whether 
answers reflect the typical amount of physical activity usually performed, with options to 
identify by how much more or less.  
Although the SPAQ does not distinguish between moderate and vigorous intensity activity or 
calculate energy expenditure, it does record all leisure and work activities. It is also easy to 
use, giving examples of activities to include and short enough not to discourage completion. 
The SPAQ has been shown to be reliable and hold a strong concurrent validity (F[4,89] = 
7.19, p<0.05) and criterion validity between two measurement devices was 0.52 (p<0.05) 
(Lowther et al., 1999). Although, accelerometers are a preferred method to objectively 
capture intensity and quantity of physical activity. Due to the constraints within this study, 
the use of these devices were not feasible. However, would be a good addition to future 
studies to obtain objective physical activity habits.    
 
4.4.8 Assessment of Disease Activity 
Although endoscopy is considered the ‘gold standard’ for examining mucosal activity in CD, 
due to its invasive nature and potential complications, alternate methods were utilised. 
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4.4.8.1 CDAI 
Disease activity was quantified using the CDAI (Appendix 4g) by referring to disease history, 
disease complications and disease symptoms during the previous 7 days (Best et al., 1979). 
The index is comprised of eight clinical and laboratory variables. Each parameter is summed, 
weighting factor applied and subtotal calculated. Parameters with a cumulative total over the 
last 7 days include number of liquid stools, abdominal pain graded (0-3) on severity and 
general well-being, subjectively assessed between well (0) and terrible (4). A weighting 
factor of x 20 was applied to any extraintestinal complications: arthritis/arthralgia, 
iritis/uveitis, mouth lesions, erythema nodosum, pyoderma gangrenosum or aphthous 
stomatitis, anal fissure, fistula, abscess or temperature over 37.8oC in the last week.  Other 
parameters included antidiarrheal drug use in the previous 7 days, presence of an abdominal 
mass assessed by a medical physician (0=none, 2=questionable and 5=definite), haematocrit 
volume, based on typical haematocrit of 47% in men and 42% in women, computed using the 
formula: [(Typical–Current) x6] and percentage deviation from standard weight (Appendix 
4h)/ observed ratio computed using the formula: 100 x (1-current/standard).  
After calculating the sum of results, participants are categorised into four types, those in 
asymptomatic remission (CDAI<149), those with a mildly active disease (CDAI=150-219), 
moderately active (CDAI=220-450) and severely active (CDAI>450). The CDAI is 
considered the gold standard for assessing disease-specific activity in CD, by basing scores 
on self-reported disease activity and laboratory data. It is widely used in clinical trials 
enabling the comparison with previous results. Results are easy to calculate and provide a 
disease activity threshold, allowing for monitoring of the disease throughout.  
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4.4.8.2 CRP 
CRP, an annular pentameric protein, was used to determine inflammatory markers in the 
blood. Almost exclusively produced in the liver, CRP is stimulated by IL-6 produced at sites 
of inflammation. As CRP has a short half-life (approx. 19 hours) when compared to other 
acute phase proteins, it will rise early after the onset of inflammation and rapidly decrease 
after resolution. Elevated CRP levels, generally between 10-40mg/l, are considered 
suggestive of mild inflammation or viral infections, with severe active inflammation 
generating CRP levels of 50-200mg/l (Vermeire et al., 2006). CRP markers were selected due 
to its ease, ability to indicate the level of inflammation in the body and quick turnaround for 
determining results. However, as CRP is not specific for determining intestinal inflammation, 
other biomarkers were required to provide an overview of disease activity.  
4.4.8.3 Faecal Calprotectin (FC) 
FC, a nonglycosylated calcium and zinc binding protein biomarker, was used to detect 
intestinal inflammation. When inflamed intestinal mucosa is present, polymorphonuclear 
neutrophils circulate around the inflammation and release calprotectin.  Levels of calprotectin 
are directly proportional to the intensity of the neutrophilic infiltration in the gut mucosa; thus 
the more inflammation present the higher the concentration of calprotectin (Roseth et al., 
1999). This is amply confirmed in intestinal IBD with significant correlations between FC 
and acute inflammation (Bjarnason, 2017). FC scores below 50µg/g in CD are suggestive of 
an inactive disease, ranging to >250µg/g when results are indicative of an active disease 
(D’Haens et al., 2012; Lehmann et al., 2015). 
This non-invasive, simple and low-cost indicator was selected as it prevents the need for 
unnecessary endoscopy procedures and histological assessment (Sipponen et al., 2008; 
Langhorst et al., 2008). FC has also demonstrated a strong correlation with 111-indium-
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labelled leucocytes, a measure considered the ‘gold standard’ in determining intestinal 
inflammation and superior to CRP and CDAI (Costa et al., 2003).  
 
4.5 Ethics 
The principle within research ethics is that the participant should not be harmed in any way 
by the research. To ensure the safety of the participant all clinical measures were conducted 
by trained researchers and a risk assessment strategy, that complies with the current Health 
and Safety legislation including The Health and Safety at Work Act 1974 and the 
Management of Health and Safety at Work Regulations 1999, was undertaken.  
 
4.5.1 Case Control and Reliability Study 
Prior to commencement of the research, the study proposal was submitted to Northumbria 
University Faculty of Health and Life Sciences Research Ethics Committee (Ref: 10723) and 
approved. Given the nature of the research, risk assessments were carried out and adhered to 
with trained first aid members always present.  
 
4.5.2 Cross-sectional Study and RCT  
Prior to commencement of the research, the study proposal was then submitted and approved 
by Northumbria University Ethics Committee (Ref: 656). Following this approval, to allow 
for health research in the UK an application was submitted and obtained from the Health 
Research Authority (Appendix 4i) (Ref: 226369), NHS REC Newcastle and North Tyneside 
(Appendix 4j) (Ref: 17/NE/0308) and further approved by the research and development 
CHAPTER 4: GENERAL METHODS 
W12018030  102 | P a g e  
 
(R&D) department within the Newcastle Upon Tyne NHS Trust (NUTH) (Ref: 8488) 
(Appendix 4k). Following approval, an application was submitted to the National Institute for 
Health Research Clinical Research Network, a portfolio of high quality research studies that 
are eligible for support, and was deemed eligible (Ref: 35164). Given the nature of the 
research a research passport, an honorary research contract/letter of access, were obtained. In 
addition, non-NHS site approval was obtained to allow the research to be conducted at 
Northumbria University.   
To ensure the correct conduct within clinical research, guidance and legislations governed by 
good clinical practice were adhered to and research conducted in accordance with the 
principles of the Declaration of Helsinki.  
 
4.6 Data Management 
All data collected conformed to Northumbria University guidelines, the EU General Data 
Protection Regulations (GDPR) and Data Protection Act (2018). Paper records such as 
consent forms, completed questionnaires and clinical measurements were stored in numerical 
order and kept secure in a locked cabinet in Northumbria University.  
To ensure quality of data, all outcome data such as completed questionnaires were checked 
manually by the study coordinator for completeness, clarity of answers and consistency 
before being entered electronically into Microsoft Excel. Data entry involved labelling 
numeric codes (male=1, female=2), so data could be filtered. Checks after data entry were 
performed by the blinded outcome assessor, any discrepancies were checked against the 
original questionnaires and clinical measurement sheets.  
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Electronic data was stored on a password-protected computer and treated in accordance with 
the university and GDPR guidelines and all data gathered will be destroyed after 2 years 
following study conclusion. Personal data necessary for scientific research were treated in 
accordance with safeguards, transparency and fairness. Any identifiable information such as 
contact information was destroyed/deleted as soon as possible. Except for healthcare 
professionals, only the study-coordinator had access to identifiable information, which was 
kept separate from any documentation that could identify the participant. Additionally, for the 
safety of the participant, if clinical measures were indicative of requiring treatment, the 
participants named GP or gastroenterologist was informed. A complete back up of the 
electronic database was performed once a month, via a password protected hard drive, this 
storage device was stored off-site. Incremental data back-ups were performed daily. 
Passwords were changed on a regular basis.   
 
4.7 Harms 
Adverse event (AE) reporting was conducted in accordance with Northumbria University 
(Sponsor) AE reporting procedures. The principal investigator, or clinical co-investigator, 
was responsible for determining the causality and seriousness of AE and ensuring that 
appropriate action was taken. Information about AE’s were collected (Appendix 4l) from the 
beginning and procedures were in place to deal with participant change of status (Appendix 
4m). For the purpose of this thesis, this is defined as the point at which written informed 
consent is given by the participant. The AE reporting period stopped at the participant’s final 
trial contact.  
All serious adverse events (SAE) were reported and recorded, as well as all non-SAE that 
were either deemed to be related to participation in the research or to result in withdrawal 
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from the study. SAE’s were defined as any untoward medical occurrence that fell into one of 
the following criteria: results in death; is life threatening; requires unplanned or prolonged 
hospitalisation; persistent or significant disability or incapacity. Non-SAE were defined as 
any untoward medical occurrence that does not fulfil any of the SAE criteria. 
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5.1 Introduction  
A growing body of evidence, suggests that individuals with CD are at an increased risk of 
muscle dysfunction and reduced BMD, potentially resulting in further disability (Miheller et 
al., 2013; Lima et al., 2017). Given the importance of maintaining muscular function and 
preserving BMD, the reliable assessment of these variables is important to monitor and 
evaluate changes for healthcare professionals and researchers.  
One device used for evaluating muscular strength is the isokinetic dynamometer, considered 
the ‘gold standard’, valid and reliable tool to determine the force, or torque generated by a 
specific muscle group when undergoing a specific action. However, this tool is not 
universally accessible and rarely used due to costs, needed expertise and long testing 
protocols. Few studies have determined the test-retest reliability of an isokinetic 
dynamometer (Biodex system 4 Pro) which vary greatly in the number of limb repetitions 
completed, the angular velocity at which the repetition is completed and the position of the 
participant in the dynamometer chair. It is therefore, important to determine the test-retest 
reliability specific to the protocol of this study design. Similarly, handgrip dynamometer has 
been advocated as an alternate way to determine muscle strength due to its simplistic, quick 
and inexpensive nature (Trosclair et al., 2011). However, studies vary on how grip strength is 
undertaken, with some protocols holding the dynamometer above the head, some with a 
straight arm and some with the elbow at a 90° angle. The 30-s CST and 30-s BCT are 
appealing ways to determine muscular endurance, due to the ease of testing and its quick and 
non-invasive nature. However, study protocols vary in the way these measurements are 
undertaken and therefore it is important to determine reliability of these outcome measures 
when adhering to the study protocol. The DEXA is seen as the ‘gold standard’ for 
determining BMD. Although the DEXA has demonstrated a high degree of accuracy, high 
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coefficients of variation and a high consistency (Zack et al., 2002; Small et al., 2005; Humadi 
et al., 2010), the precisions of the scans are essential in obtaining meaningful results which 
relies heavily on the expertise of the technical staff and positioning of the participant.  
To ensure the appropriateness of a test, an understanding of its reliability needs to be 
established as often these outcome measures are applied before and/or after to evaluate 
change and facilitate the assessment and effectiveness of an intervention. To determine the 
consistency and reproducibility of these outcomes, prior to the implementation of an 
intervention, this study investigated the degree of test-retest reliability using the JAMAR 
Hydraulic, Biodex system 4 Pro, the 30-s CST, the 30-s BCT and Hologic Horizon W DEXA 
scanner to evaluate the change in grip strength, isokinetic muscular strength, muscular 
endurance and BMD, respectively.  
 
5.2 Methods 
Using the sample from Chapter 6, 33 self-reported healthy participants were required to 
attend two testing sessions, 7 days apart (+/-1 day) at similar times of the day. At present 
there is little evidence available to aid in the selection of the time interval between 
assessment visits for a test-retest reliability study. Due to the variation in the scope, nature 
and purpose of research, no ‘gold standard’ time interval exists. Therefore, the time interval 
for this test-retest reliability study was based on the current literature. Firstly, Marx et al 
(2003) compared the test-retest at 2 days and 2 weeks on subjective and objective outcomes, 
to determine if there was any statistically significant differences (ICC and limits of agreement 
statistics) for the two intervals. No clinically or significant differences were identified, thus 
an interval between 2 days and 2 weeks was deemed appropriate. Seven days between 
intervals was chosen as this duration was deemed long enough to ensure the participants 
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would not likely remember or be influenced by their first assessment, but short enough to 
ensure lifestyle behavioural changes, which may occur after exercise testing, would not 
influence results. 
Participants were asked to wear the same/similar clothing for both assessments, follow a 
similar routine the day of both tests (e.g. walking/driving or getting public transport to the 
assessment centre) and avoid any moderate to high intensity exercise prior to testing. To 
reduce the risk of any exercise testing-related injury and ensure the same/similar tasks were 
performed before each assessment visit. The eligibility criteria (section 6.2.1) and recruitment 
methods (section 6.2.2) from Chapter 6 apply to this study. Outcome measures included: 
BMD, muscular strength and endurance, detailed in Chapter 4.  
 
5.3 Data Collection 
All visits took place in the Neurophysiology and DEXA lab at Northumbria University. After 
written informed consent was gained, blood pressure and heart rate were assessed to deem it 
safe for the participant to conduct any exercise testing in accordance with the ASCM 
Guidelines (2017). Demographical and clinical characteristics such as age, stature, body mass 
and BMI were obtained. The same testing order was followed for session two. All 
assessments were performed by the same researcher. 
 
5.4 Statistical Analysis 
Differences between test and retest measures were analysed using the paired samples t test. 
To estimate the degree of test-retest reliability the intraclass correlation coefficient (ICC) was 
calculated. The ICC varies between 0 and 1, with 0 representing no reliability and 1 
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indicating perfect reliability. According to Shrout’s classification (1998), test-retest reliability 
is considered good when the ICC values range between 0.61 to 0.80 and excellent for values 
between 0.81 and 1.00. ICC for single measures was calculated using a two-way random 
effects model (ICC2,1) of absolute agreement for the computation of ICC. The ICC is a well-
accepted measure of relative reliability; however, it is difficult to interpret ICC values due to 
their high dependence on the variability of the group being assessed. Therefore, to determine 
the absolute reliability, the standard error of measurement (SEM) and the 95% limits of 
agreement (LOA) were calculated. Bland-Altman plots were utilised to examine the 
difference between test and retest against their mean (Bland and Altman, 1986). Variables 
were computed for each DEXA region (femoral neck. greater trochanter, lumbar spine [L2-
L4], handgrip dynamometer, 30-s CST, 30-s BCT and MVIS parameters (60°/s and 120°/s 
for elbow scores and 60°/s and 180°/s for knee scores) for healthy participants.   
 
5.5 Results 
5.5.1 Descriptive Statistics 
Demographic information and characteristics of study participants are summarised in table 6. 
A total of 33 participants volunteered to participate, 9 (27.3%) of whom were males and all of 
whom were of white ethnicity. Participants had a mean age of 50 years (SD=13.2), with a 
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 Men (n=9) Women (n=24) Total (n=33) 
Age (years) 51.1 ± 12.8 50.5 ± 13.7 50.6 ± 13.2 
Stature (cm) 172.3 ± 7.8 163.4 ± 6.3 166.3 ± 7.9 
Body Mass (kg) 78.1 ± 9.1 63.0 ± 7.9 68.1 ± 11.4 
BMI (kg/m2)  26.3 ± 2.6 23.6 ± 2.7 24.5 ± 3.0 
Mean ± S.D are indicated for all columns unless stated.  
 
5.5.1.1 BMD  
BMD of the lumbar spine (L2-L4) scores ranged from 0.804 to 1.393 g/cm2, with 0 (0%) 
participants in the osteoporotic range (T-score -2.5 and below) according to the WHO 
diagnostic criteria and 9 (27.3%) participants in the osteopenic range (T-score -1.0 to -2.5) 
and 0% in the osteoporotic range (T-score > -2.5). BMD of the femoral neck and greater 
trochanter scores ranged from 0.584 to 1.347 g/cm2 and 0.524 to 0.956 g/cm2, respectively, 
with 11 (33.3%) participants in the osteopenic range and 0% in the osteopenic range. BMD 
values obtained at the first testing session were 1.058 ± 0.153, 0.846 ± 0.222 and 0.713 ± 
0.111 for the lumbar spine, femoral neck and greater trochanter, respectively and 1.059 ± 
0.154, 0.849 ± 0.223 and 0.714 ± 0.115 for the second session (figure 22). Although there 
seems to be a large difference in males test and retest scores at the lumbar spine, this may be 
apparent due to the small increments in the scale of the graph and therefore appearing larger 
than it is. In addition, differences in test and retest scores could have been as a result of the 
positioning of the participant, or the participant moving on the DEXA machine after being 
positioned. 
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5.5.1.2 Muscular Function 
Knee extension and flexion scores, calculated separately, were computed as peak torque 
values averaged for both the left and right knee at 60°/s and 180°/s using extension and 
flexion values, respectively. Knee extension isokinetic strength measures obtained at the first 
Figure 22. 
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session were 77.4 ± 40.4 Nm and 52.6 ± 22.2 Nm and knee flexion strength measures were 
78.4 ± 38.0 Nm and 54.4 ± 20.2 Nm, respectively (figure 23). Elbow extension and flexion 
scores, calculated separately, were computed as peak torque values averaged for both the left 
and right elbow at 60°/s and 120°/s using extension and flexion values, respectively. Elbow 
extension isokinetic strength values for the first session were 35.7 ± 14.2 Nm and 24.1 ± 11.8 
Nm and elbow flexion strength measures were 37.1 ± 14.8 Nm and 24.9 ± 11.5 Nm, 
respectively (figure 24). Maximum voluntary force obtained during visit one and visit two 
using the JAMAR Hydraulic handgrip dynamometer were 32.2 ± 16.3 kg and 32.7 ± 16.8 kg, 
respectively. All measures reflect a mild learning effect.  
The 30-s CST and the 30-s BCT also reflected a mild learning effect. In the first session, 
participants performed 18 ± 4 chair stands and 19 ± 4 in the second session. Similarly, with 
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5.5.2 Reliability  
Table 7 represents the test and retest values and index of relative and absolute reliability of 
BMD and muscular function measures.  
Table 7. 
Test and retest values of bone mineral density and muscular function 
 Test Retest Bias ICC (95% CI) 95% LOA 
Lower Upper 
Lumbar Spine 1.06 ± 0.154 1.06 ± 0.155 0.00 0.998 (0.997-0.999) -0.006 0.006 
Femoral Neck 0.846 ± 0.22 0.849 ± 0.22 0.003 0.999 (0.998-0.999) -0.015 0.015 
Greater Trochanter 0.713 ± 0.11 0.714 ± 0.12 0.001 0.999 (0.997-0.999) -0.015 0.014 
Handgrip Strength 32.2 ± 16.3 32.7 ± 16.7 0.5 0.992 (0.984-0.996) -3.78 4.08 
Knee Extension 77.4 ± 40.4 78.4 ± 38.0 1.0 0.991 (0.982-0.996) -15.43 13.46 
Knee Flexion 52.6 ± 22.2 54.4 ± 20.2 1.8 0.978 (0.956-0.989) -13.93 10.25 
Elbow Extension 35.7 ± 14.2 37.1 ± 14.8 1.4 0.931 (0.860-0.966) -15.86 13.07 
Elbow Flexion 24.1 ± 11.8 24.9 ± 11.5 0.8 0.936 (0.870-0.968) -11.97 10.40 
30-s CST 18.4 ± 3.5 18.9 ± 3.6 0.5 0.881 (0.758-0.889) -5.69 2.29 
30-s BCT 20.8 ± 4.4 21.6 ± 2.7 0.8 0.875 (0.747-0.938) -5.95 3.23 
ICC, intraclass correlation; LOA, limits of agreement; CST, chair stand test; BCT, bicep curl test 
 
5.5.2.1 BMD 
Based on Shrout’s classification, BMD at the lumbar spine, femoral neck and greater 
trochanter demonstrated excellent test-retest reliability, with ICC2,1 values of 0.998 (95% CI 
0.997-0.999, p=0.335), 0.999 (95% CI 0.998-0.999, p=0.947) and 0.999 (95% CI 0.997-
0.999, p=0.475) respectively. SEM obtained in the first visit and second visit were the same 
at the lumbar spine (SEM1 and SEM2 0.03 g/cm
2), femoral neck (SEM1 and SEM2 0.04 
g/cm2) and greater trochanter (SEM1 and SEM2 0.02 g/cm
2). Bland-Altman plot analysis 
illustrated the upper and lower LOA were -0.006 to 0.007 with a 0.00055 g/cm2 mean 
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difference at the lumbar spine (figure 25), -0.0154 to 0.0152 with a -0.00009 g/cm2 mean 
difference at the femoral neck (figure 26) and -0.015 to 0.014 with a -0.00094 g/cm2 mean 
difference at the greater trochanter (figure 27). Most of the points for BMD scores lie 
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5.5.2.2 Muscular Function  
Test-retest reliability was also excellent for upper and lower-limb isokinetic strength 
performances. Elbow extension and elbow flexion values, computed as peak torque averaged 
for both the left and right elbow at 60°/s and 120°/s, demonstrated an ICC2,1 of 0.931 (95%-
CI 0.860-0.966, p=0.285) and 0.936 (95% CI 0.870-0.968, p=0.433), respectively. SEM 
obtained in the first visit for elbow extension (SEM1 2.58) and elbow flexion (SEM1 2.05) 
were slightly lower in comparison to the second testing visit (SEM2 2.48 and 2.00, 
respectively). Bland-Altman plot analysis were conducted for further examination of the 
differences, upper and lower LOA were -15.86 to 13.07 and -11.97 to 10.40, with a mean 
difference of -1.3967 Nm and 0.7885 Nm, respectively. Most of the points fall between the 
95% LOA suggesting a normal distribution of differences (figure 28) 
Knee extension and knee flexion values, computed as peak torque averaged for the left and 
right knee at 60°/s and 180°/s, demonstrated an ICC2,1 of 0.991 (95% CI 0.982-0.996, 
p=0.449) and 0.978 (95% CI 0.956-0.989, p=0.096). SEM obtained in the first visit for knee 
extension (SEM1 7.03) and knee extension (SEM1 3.87) were lower in comparison to the 
second testing visit (SEM2 6.61 and 3.51, respectively). Bland-Altman plot analysis were 
conducted for further examination of the differences, upper and lower LOA were -15.43 to 
13.46 and -13.93 to 10.25 with a mean difference of -0.9845 Nm and -1.84 Nm, respectively. 
Most of the points for lower limb strength scores lie between the 95% LOA, suggesting a 
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Based on Shrout’s classification, grip strength and muscular endurance measures: 30-s CST 
and 30-s BCT demonstrated excellent test-retest reliability (ICC2,1 0.992, 0.881 and 0.875, 
respectively). SEM obtained at the first was slightly higher for the grip strength measurement 
than the second visit (SEM1 =1.98, SEM2 =1.92), slightly higher for the 30-s CST (SEM1 
=0.57, SEM2 =0.51) and lower for the 30-s BCT (SEM1 =0.20, SEM2 =0.48). Bland-Altman 
plot analysis illustrated the upper and lower LOA were -3.78 to 4.08 with a mean difference 
of 0.15 kg for grip strength (figure 30), -5.96 to 2.29 with a mean difference of -1.69 for the 
30-s CST (figure 31a) and -5.95 to 3.23 with a mean difference of -1.36 for the 30-s BCT 
(figure 31b). Most of the points lie between the 95% LOA, suggesting a normal distribution 
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Through a test-retest design, this study aimed to determine the reliability of grip strength, 
isokinetic muscular strength, muscular endurance and BMD, adopting the Bland-Altman 
plots to explore the relationship between measurement errors and outcome measures. Overall, 
these results demonstrate that the 30-s BCT, 30-s CST, HGS, MVIS of the knee extensors 
and elbow flexors and BMD at the lumbar spine, femoral neck and greater trochanter have 
excellent test-retest reliability.  
 
5.6.1 BMD 
Results from this study revealed excellent test-retest reliability for BMD at the lumbar spine, 
femoral neck and greater trochanter demonstrating ICC2,1 values of 0.998 (95% CI 0.997-
0.999, p=0.335), 0.999 (95% CI 0.998-0.999, p=0.947) and 0.999 (95% CI 0.997-0.999, 
Figure 31. 
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p=0.475) respectively. Based on Shrout’s classification, the 95% confidence interval of the 
ICC2,1 reaffirmed that the test-retest reliability was excellent with lower and upper bounds 
remaining within the excellent scoring range at all sites, suggesting that these measures are 
reliable outcome measures, providing consistent and stable results.  
The reproducibility of a DEXA scan is a key issue in clinical research as changes in BMD are 
small and gradual. Several studies have explored the reliability of DEXA scans, 
demonstrating a high degree of reliability with high coefficients of variation (CV%) at the 
lumbar spine 0.92%, total proximal femur 0.92%, total forearm 0.69% and whole body 
0.73% and high consistency, with correlation coefficients ranging from 0.993 to 0.996 
(p<0.01) (Zack et al., 2002; Small et al., 2005; Humadi et al., 2010). These ICC ranges are 
similar to those demonstrated in this study (ICC2,1>0.998).  
 
5.6.2 Muscular Strength 
Results from this study revealed excellent test-retest reliability for HGS and upper and lower-
limb isokinetic strength performances, obtaining ICC2,1 values ranging from 0.931 to 0.992. 
The 95% confidence interval of the ICC2,1 reaffirmed that the test-retest reliability was 
excellent with lower and upper bounds remaining within the excellent scoring range for HGS 
(0.984-0.996, respectively) and MVIS of the knee extensors (0.982-0.996), knee flexors 
(0.956-0.996), elbow extensors (0.860-0.966) and elbow flexors (0.870-0.968) in accordance 
with Shrout’s Classification (1998), suggesting that these outcome measures are reliable, 
providing consistent and stable results. 
These findings are consistent with those of previous studies. Firstly, HGS reliability has been 
determined in symptomatic and asymptomatic populations, including individuals with 
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musculoskeletal disorder, shoulder injuries and cervical radiculopathy. Regardless of the 
population, both cohorts demonstrated excellent test-retest reliability. In the symptomatic 
populations, excellent levels of test-retest reliability (ICC2,1>0.91) were identified, 
highlighting its potential as an outcome measure in clinical populations (Coldham et al., 
2006; Savva et al., 2014; Villafane et al., 2015). Excellent test-retest reliability was also 
reported in the asymptomatic populations demonstrating ICC2,1 measures ranging from 0.87 
to 0.97 (Mathiowetz et al., 1984; Peolsson et al., 2001; Ng and Fan, 2001). However, most of 
these studies involving asymptomatic participants varied in the analysis method, some using 
a two-way random or fixed test and not reporting the measurement error, therefore not 
facilitating meaningful comparisons. Secondly, test-retest reliability of the MVIS of the knee 
extensors and elbow flexors has been determined in healthy, paediatric, elderly and clinical 
populations (Iga et al., 2006; Fagher et al., 2016; Van Driessche et al., 2018). All populations 
demonstrated an ICC2,1>0.87. However, these studies differed greatly in the protocol of 
assessing muscular strength, with some opting for an isometric or isotonic mode, some only 
using a single repetition and others varying the angular velocity in which peak torque was 
determined. Three studies did, however, follow a similar protocol, estimating peak torque at 
an angular velocity of 60°/s and 180°/s for knee extension both demonstrating an 
ICC2,1>0.95, although neither determined peak torque at the elbow flexors (Feiring et al., 
1990; Kellis et al., 1999; Tsiros et al., 2011).  
 
5.6.3 Muscular Endurance 
The 30-s CST and the 30-s BCT demonstrated excellent test-retest reliability in this study 
(ICC2,1>0.88). This finding was supported by Jones et al (1999) who demonstrated excellent 
test-retest reliability for values for the 30-s CST overall (ICC2,1 0.89) and for males (ICC2,1 
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0.84) and females (ICC2,1 0.92). Similarly, excellent test-retest reliability for the 30-s BCT 
were reported in asymptomatic populations (ICC2,1 0.90) and in community-dwelling elderly 
people with cognitive impairment (ICC2,1 0.93) (Hesseberg et al., 2014). However, both 
studies differed in the instructions provided, with the later study providing verbal instruction 
and the study by Jones et al (1999) providing verbal instruction and a demonstration. Future 
studies should consider the instruction provided to participants to allow for direct 
comparison. In addition, the 95% confidence interval of the ICC2,1 did not support the 
excellent test-retest reliability, with lower and upper bounds demonstrating a moderate to 
good reliability for both the 30-s BCT (0.747-0.938) and 30-s CST test (0.758-0.889). 
However, the SEM was low with only a small width of the 95% LOA in the Bland-Altman 
plot, reflecting a small variation in the differences between test 1 and test 2.  
 
5.7 Limitations 
There are limitations of this study that warrant discussion. Firstly, grip strength, isokinetic 
muscular strength and muscular endurance can be influenced by confounding variables e.g. 
the participants lifestyle (i.e. muscle soreness or fatigue caused by physical activity between 
the two testing sessions). Secondly, the health status of the healthy controls was self-reported 
and apparently healthy, and therefore ambulatory results may have limited applicability to the 
intervention in adults with CD. Lastly, only short-term reliability was assessed. Future 
research determining the long-term reliability of these outcome measures is important for 
healthcare professionals and researchers who require an awareness of the random error 
associated with each outcome measure over the time period of an intervention (Atkinson and 
Nevil, 1998). 
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5.8 Conclusion 
In summary, the test-retest reliability of grip strength, isokinetic muscular strength, muscular 
endurance and BMD in a healthy adult population was excellent. This highlights these 
methods as reliable outcome measures to facilitate the assessment and effectiveness of an 
intervention.  
 


























A case control study and correlates of bone 
mineral density and muscle function in adults 











CHAPTER 6: CASE CONTROL AND CROSS-SECTIONAL STUDY 





Bone loss, reduced QOL, impaired muscle function and overwhelming tiredness are all 
recognised complications of IBD and especially of CD (Narula and Fedorak, 2008; Bilski et 
al., 2014). Although CD is an intestinal disorder, secondary disorders such as low BMD, 
muscle dysfunction, fatigue and impaired QOL may frequently occur and are important 
predictors of further disability.  
As discussed in Chapter 2, the aetiology and the exact mechanisms that underpin the 
relationship between low BMD and CD are yet to be fully elucidated, however are likely to 
be multifactorial. Several hypothesised contributing factors are elevated pro-inflammatory 
cytokines, glucocorticoids, diet and malabsorption and surgical implications (Bernstein et al., 
2003; Duggan et al., 2004; Mundy, 2007). These mechanisms have been shown to cause 
osteoclasts to differentiate and mature, impact the efficiency of intestinal absorption and 
increase renal excretion of calcium resulting in elevated levels of bone turnover and bone loss 
(Tilg et al., 2008; Targownik et al., 2013). These factors have also been hypothesised to 
contribute to muscle dysfunction in CD, with elevated and decreased levels of 
proinflammatory cytokines, suppression of protein synthesis and deficiencies in vitamin D 
thought to impair the regulation and preservation of muscle mass, growth and size 
(Cominelli, 2004; Spooren et al., 2015).  
These cytokines-induced alterations also have a wide spectrum of peripheral central effects 
that contribute to the negative effects on energy, maintaining day-to-day activities and play 
an important role in the development of depression, anxiety and irritability (Miller and 
Timmie, 2009). With its chronic and unpredictable cyclical nature, and psychological and 
physiological comorbidities persisting even at times of remission, it is not surprising that 
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people with CD experience impaired QOL (Guthrie et al., 2002; Sainsbury and Heatley, 
2005). 
The occurrence of these disorders vary significantly depending on the study population (age, 
body weight, health status and other comorbidities), study location, study design (cross-
sectional vs prospective), statistical power for determining effect and technique used to 
determine outcome. To date, few studies have characterised BMD and muscle function in CD 
participants in the UK. To increase our understanding and attempt to close the gap in 
identifying comorbidities that are associated with CD a case control design comparing CD 
participants to healthy controls (CON)  was undertaken. Therefore, the objectives of this 
study were to a) evaluate BMD, muscular function and QOL in people with CD when 
matched for age, gender, BMI and physical activity habits to CON and b) identify possible 
risk factors associated with BMD in CD. 
 
6.2 Methods 
For this case control study, 33 healthy participants were matched according to age (+/-5 
years), gender, physical activity status (low [no activity or some activity but not enough to 
meet categories moderate or highly active], moderate [5 or more days of at least 30 minutes 
of activity reported per day], high [1.5-2 hours of activities everyday]), BMI (grouped by 
category: underweight [<18.5], healthy [18.5-24.9], overweight [25-29.9] and obese [30-
39.9]), ethnic origin and smoking status (group by: never smoked, previously smoked and 
currently smoking) to data already obtained on 33 CD participants (Chapter 7). Variables 
were selected based on their link in the development and risk of osteoporosis: older age, 
women, physical inactivity, low BMI, white and Asian women and smokers (National 
Institute of Arthritis and Musculoskeletal and Skin Disorders, 2018). 
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Using the data obtained on CD participants (Chapter 7), secondary objectives were evaluated 
using a cross-sectional design to identify the variables associated with BMD  in 33 CD 
participants with an inactive to mildly active disease. In considering potential factors that 
may be bone-related, variables that have been linked to the development of osteoporosis, 
identified from both cross-sectional and longitudinal studies in healthy and chronic 
conditions and from the International Osteoporosis Foundation (2017) were included:  
• Age: Older age increases the risk of low bone density, as with age bones become 
thinner and weaker (Xia et al., 2018).  
• Alcohol intake: Excessive alcohol consumption increases the risk of bone loss, due to 
increased levels of cortisol which decreases bone formation and increases the 
breakdown of bone (Department of Health and Human Services, 2012).  
• Physical activity habits: Inactivity or extended bed rest is related to weaker bones as a 
result of the lack of stress stimulated on the bone to initiate bone growth (Department 
of Health and Human Services, 2012). 
• Gender: Women are at a greater risk as they have less bone tissue and bone loss is 
faster than men due to changes with menopause (Sun et al., 2014; Xia et al., 2018). 
• Smoking status: Smokers are at a greater risk of bone loss, as the tobacco in smoking 
can cause an imbalance in bone turnover which can lead to lower BMD (Department 
of Health and Human Services, 2012). 
The rationale for including the disease-specific variables such as disease duration, behaviour 
and surgical history were: 
• Discussed in Chapter 2, elevated proinflammatory cytokines are present in CD and 
CS interferes with bone metabolism. It was thought, the longer the diagnosis the 
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longer this negative interaction occurs and the increased chance of accumulating a 
greater steroid usage and dosage. 
• The effects of disease behaviour on BMD is sparse, moreover it was thought 
stricturing or penetrating behaviour may result in higher rates of malabsorption, as 
discussed in Chapter 2. 
• Surgical interventions were also included due to malabsorption difficulties 
particularly in people who had undergone a resection(s), ileostomy or j-pouch 
surgery. 
 
6.2.1 Eligibility Criteria 
Healthy men and women aged 27-85 years of age, based on the age range of previously 
obtained data, were eligible to participate if they were able to provide written consent, 
complete study questionnaires and were able to travel to the research centre for assessments. 
The following exclusions were also applied: 
• Medical conditions or prescriptions such as, but not limited to: renal disease, thyroid 
disease, kidney disorders and auto-immune diseases who are/or have taken any 
steroidal or anti-inflammatory drugs or have done previously for longer than 3 
months. As these conditions and prescription medications can influence bone 
structure and muscular health.  
• Self-reported history of falls and poor mobility. Falls are one of the largest risk factors 
for fractures, with 95% of hip fractures caused by falling, and a reduction in BMD is 
an independent risk factor for fractures (Parkkari et al., 1999; Edwards et al., 2013). 
Therefore reducing the potential of participants having underlying bone health issues. 
• Absolute contraindications to exercise testing as defined by the ACSM (2017) 
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• Pregnant, due to radiation exposure 
• Currently participating in >2 sessions/week of resistance exercise (self-reported) to 
match the exclusion criteria applied in Chapter 7 
 
6.2.2 Recruitment 
Healthy adult’s (n=33) were identified and recruited from a non-clinical population on a 
volunteer basis by one of three methods: 
1. Recruitment posters (Appendix 6a) placed around Northumbria University  
2. Social media via twitter 
3. Brain, Performance and Nutrition Research database, a database of participants who 
have consented to being contacted regarding future research studies. The database of 
680 participants, as of March 2019, was screened and 378 potentially eligible 
participants were sent an email containing the recruitment poster.  
Participants who expressed an interest were sent a participant information sheet (Appendix 
6b) and an eligibility form (Appendix 6c), containing the SPAQ. Participants were asked to 
complete and return the form to assess suitability against the inclusion/exclusion criteria and 
to match the demographical and clinical characteristics to previously obtained CD data. The 
first 33 participants matching these criteria were recruited. 
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6.2.3 Outcome Measures  
6.2.3.1 Primary Outcome Measures 
• BMD (g/cm2) was assessed using a DEXA at the femoral neck, greater trochanter and 
lumbar spine (L2-L4) 
• Muscular strength was determined using an isokinetic dynamometer (Biodex system 4 
Pro) to measure maximum voluntary isokinetic strength (MVIS) of the knee extensors 
on both legs and elbow flexors on both arms. HGS was measured using a handgrip 
dynamometer (JAMAR Handgrip) on the nondominant forearm 
• Lower and upper extremity muscle endurance was measured using the 30-s CST and 
30-s BCT, respectively 
 
6.2.3.2 Secondary Outcome Measures 
• QOL was assessed using the EQ-5D-5L 
 
 
6.2.4 Sample Size 
The number of participants required in each group was powered based on the anticipated 
difference in BMD between CD participants and CON. This was on the basis of a cross-
sectional population-based study (Jahnsen et al., 1997). Jahnsen et al (1997) compared BMD 
in people with CD, UC and healthy participants and identified a significant reduction in BMD 
in people with CD compared to CON with mean difference results as follows; lumbar spine 
0.09g/cm2, femoral neck 0.07g/cm2 and total body 0.06g/cm2. 
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The sample size calculation used methods of Noordzij et al (2010) assuming 80% power and 
a 5% alpha level (2-sided). Assuming a mean difference of 0.09g/cm2 at the lumbar spine, 
based on the monitoring site suggested by the National Osteoporosis Foundation (NOF) 
(2008) and accounting for 10% attrition, the sample size required 66 participants (33 CON 
and 33 CD participants) to be recruited.  
 
6.3 Data Collection 
All visits took place in the Neurophysiology and DEXA lab at Northumbria University, 
within 10 days of confirming eligibility. After written informed consent (Appendix 6d) was 
gained, blood pressure and heart rate were assessed to determine if it was safe for the 
participant to undertake exercising test in accordance with ACSM guidelines (2017). A CRF 
(Appendix 6e) was used to obtain demographical information. Clinical characteristics such as 
stature and body mass were determined and outcome measures assessed (Chapter 4) in the 
same order for every participant: HGS, 30-s BCT, 30-s CST, EQ-5D-5L, MVIS and BMD.  
 
6.4 Statistical Analysis 
6.4.1 Case control study 
The purpose of the analysis was to obtain estimates of difference in BMD and muscular 
function between individuals with CD and healthy participants. Data were collated, coded 
and inputted into Microsoft Excel. Following data entry checks by the outcome assessor, data 
were analysed using SPSS statistics version 26. To present the distribution of data, 
descriptive statistics such as graphs, measures of central tendency, interquartile ranges (IQR), 
standard deviations (SD), frequencies and percentages were applied in accordance with the 
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user guidance of each questionnaire instrument. Analysis of covariance (ANCOVA) was 
implemented to compare the two data sets while adjusting for relevant covariates 
hypothesised to influence BMD and muscular function. The following variables were entered 
as covariates in the ANCOVA: age, gender, smoking status (current/previous/never) and 
physical activity habits.  
To assess whether the covariates were not varied across the dependent variable, analysis of 
variance (ANOVA) was employed and no significant correlations were identified (BMI 
p=0.357; adjusted physical activity scores p=0.506 and smoking status p=0.192). To assess 
the residuals are normally distributed, Shapiro-Wilk was employed and the handgrip, 
computed knee at 60°/s and 180°/s, computed elbow at 60°/s and 120°/s and BMD at the 
femoral neck underwent transformation, to best approximate a normal distribution. Levene’s 
test was carried out to determine the homogeneity of variances, all variables were p>0.05, 
therefore equal variances could be assumed. Scatterplots were applied to check the 
homoscedasticity of the data to explore residual distribution. Independency of residual errors 
were determined by the Durbin-Watson statistic. As results were between 1.5 and 2.5 it can 
be assumed that the data are not autocorrelated and that all assumptions for ANCOVA have 
been met. All tests were two-sided with a 5% significance level.  
 
6.4.2 Cross-sectional study 
The purpose of the analysis was to determine which factors best explain the variation in 
BMD levels in individuals with CD. Data were collated, coded and inputted into Microsoft 
Excel. Following data entry checks by the outcome assessor, data were analysed using SPSS 
statistics version 26. A backward, elimination log-linear regression model, a model 
incorporating all possible covariates and then sequentially eliminating variables based on the 
size of the t statistic, was implemented to assess the independent association of all variables 
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on BMD at the lumbar spine (L2-L4), femoral neck and greater trochanter, while allowing the 
retention of a large R-squared value. 
To assess for the assumption of normality, Shapiro-Wilk was employed and the lumbar spine 
data (L2-L4) underwent logarithmic transformation. The transformation provided residuals 
that best approximate to a normal distribution with constant variance. In the case of BMD of 
the lumbar spine (L2-L4), following logarithmic transformation parameters, data were not 
statistically significant (p=0.721) confirming that a log transformation of BMD was near-
optimal.  Scatterplots were applied to check the homoscedasticity of the data to explore 
residual distribution. To test for multicollinearity, a variance inflation factor was computed 
for each independent variable. All values were below this threshold, suggesting the 
assumption has been met. Alpha was set at 0.05 for all statistical procedures.  
 
6.5 Results 
Recruitment took place between October 2018 to April 2019. Of the 106 healthy control 
participants who expressed interest, 87 returned the eligibility form and were assessed against 
the inclusion criteria. The first 33 participants matching the criteria were recruited. The most 
common reason for exclusion was not matching on BMI status (n=21). Other reasons 
included age (n=12), medical history that could influence BMD (n=3) or not eligible for a 
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         Figure 32. Participant Study Flowchart  
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6.5.1 Descriptive Statistics  
Demographic information and characteristics of study participants are summarised in table 8. 
Of the total sample, 18 (27.3%) were males and all participants were of white ethnicity. CON 
(n=33) had a mean age of 50 years (SD=13.2), with a wide age range from 27-72 years. Just 
over a third of participants (36.4%) were in full-time employment. The next largest groups 
were retired (33.3%) and part-time employment (18.2%). Most participants (75.8%) were 
non-smokers with an average alcohol intake of 6.2 (SD=7.2) units a week. The CON had a 
mean BMI of 24.5 kg/m2 (SD=3.0), resting heart rate of 70 beats/min (SD=13) and resting 
blood pressure of 129 mmHg (SD=14.1)/ 74.4 (SD=10.4). CD participants (n=33) had a mean 
age of 49.9 years (SD=11.7), with a similarly wide age range of 27-71 years. Just less than 
half of participants (42.4%) were in full-time employment. The next largest groups were 
retired (21.2%) and unemployed (15.2%). Most participants (63.6%) were non-smokers with 
an average alcohol intake of 4.4 (SD=4.8) units a week. CD participants had a mean BMI of 
25.2 kg/m2 (SD=3.2), resting heart rate of 79 beats/min (SD=8) and resting blood pressure of 
130 mmHg (SD=18.4)/ 76.2 (SD=10.4). 
Table 9 illustrates participant characteristics at baseline. Median age at diagnosis was 30 
years (IQR=21-36.3) with a diagnosis duration of 222 months (IQR=78-388). Most 
participants (45.5%) had ileocolonic CD that presented as non-stricturing and non-penetrating 
(72.7%). Disease activity (CDAI) and intestinal inflammation (FC) markers were 114 
(SD=59.9) and 86.5μg/g (SD=59.5), respectively, with the majority of participants presenting 
with an inactive disease (60.6%). There were very few comorbidities (36.4%), of which 
included enteropathic arthritis (n=5), osteoporosis/ osteopenia (n=4), psoriasis (n=3),  bile 
salt malabsorption (n=2), erythema nodosum (n=1), orofacial granulomatosis (n=1), 
ankylosing spondylitis (n=1), lymphoma/malignancy (n=1) and serious infections (n=1). 
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Table 8.  
Demographical and health characteristics of CD participants and controls 
 CD (n=33)  CON (n=33) p valuea 
Age, mean (SD), years 49.9 ± 11.7  50.6 ± 13.2 .219 
Ethnicity, White British, n (%)  33(100)  33(100) 1.00b 
Employment Status, n (%)    .370b 
   Employed-Full Time 14(42.4)  12(36.4)  
   Employed-Part Time 3(9.1)  6(18.2)  
   Self-Employed 4(12.1)  1(3.0)  
   Unemployed 5(15.2)  0(0)  
   Student 0(0)  3(9.1)  
   Retired 7(21.2)  11(33.3)  
BMI, mean (SD), kg/m2 25.2 ± 3.2  24.5 ± 3.0 .310 
Body Mass, mean (SD), kg 72.5 ± 21.4  68.1 ± 11.4 .244 
Stature, mean (SD), cm 161.9 ± 20.9  166.3 ± 7.9 .237 
Resting Heart Rate, mean (SD), beats/min 79 ± 9   70 ± 13 .315 
Blood Pressure, mean (SD), mmHg     
   Systolic Blood Pressure  130 ± 18  129 ± 14 .838 
   Diastolic Blood Pressure 76 ± 10  74 ± 10 .525 
Smoking Status, n (CS/ FS/ NS) 0/12/21  0/8/25 .254 b 
Alcohol Intake, mean (SD), units 4.4 ± 4.8  6.2 ± 7.2 .213 
CD, Crohn’s Disease; CS, current smokers; FS, former smokers; NS, non-smokers. a indicates independent t-test, b 
indicates Chi-squared test 
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            6.5.2 Bone Mineral Density 
The BMD data (in g/cm2) for CD participants and CON, are summarised in figure 33. CD 
participants showed significantly reduced values at the femoral neck (mean difference= -
0.063; 95% CI 0.001-0.125; p=0.045) and lumbar spine (-0.063; 0.003-0.129; p=0.040), 
when adjusted for age, gender, smoking status and physical activity habits. No significant 
differences were identified at the greater trochanter (-0.031; -0.022-0.078; p=0.260).  
Table 9.  
CD Participant Characteristics  






Age at Diagnosis, median (IQR), years 31 (26.3-36.3) 30 (21-36.5) 30 (21-36.3) 
Diagnosis Duration, median (IQR), months 246.5 (204.1-222) 216 (72-404) 222 (78-388) 
Disease Location, n (Ileal/ Colonic/ Ileocolonic) 1/2/6 8/7/9 9/9/15 
Number of surgical episodes, n 10 33 43 
Disease Behaviour, n (N-S, N-P/ST/PE) 5/4/0 19/5/0 24/9/0 
Current immunosuppressant use, n (%) 3(33.3) 12(50) 15(45.5) 
Current anti-TNF use, n (%) 4(44.4) 7(29.2) 11(33.3) 
Disease Activity, mean (SD)    
   Faecal Calprotectin, μg/g 83.4(58.2) 90.0(60.1) 86.5(59.5) 
   CDAI 109.9(59.1) 116.4(60.9) 114.1(59.9) 
CDAI Activity Status,-n-(%)    
   Inactive 6(66.7) 14(58.3) 20(60.6) 
   Mildly Active  3(33.3) 10(41.7) 13(39.4) 
Extra-intestinal Manifestations, n    
   None 8 13 21 
   EA/ EN/ OG/ PS/ AS/ LY/ SI/ BSM/ OP 0/0/1/0/0/0/0/0/1 5/1/0/3/1/1/1/2/3 5/1/1/3/1/1/1/2/4 
CD, Crohn’s Disease; N-S, N-P, Non-Stricturing, Non-Penetrating; ST, Stricturing; PE, Penetrating; EA, 
Enteropathic Arthritis; EN, Erythema Nodosum; OG, Orofacial Granulomatosis; PS, Psoriasis; AS, 
Ankylosing Spondylitis; LY, Lymphoma/ Malignancy; SI, Serious Infections; BSM, Bile Salt 
Malabsorption; OP, Osteoporosis/ Osteopenia 
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Mean BMD scores are presented in table 10. Following the analysis, according to WHO 
(Czerwinski et al., 2007) diagnostic criteria, 48.5% of CD participants were indicative of 
having osteopenia (T-score between -1.0 and -2.5) at the left hip and 6% of osteoporosis (T-
score -2.5 and below) in comparison to 33.3% and 0% of CON, respectively. T-scores of the 
lumbar spine suggested osteopenia in 36.4% of people with CD and osteoporosis in 6% 
compared to 27.3% and 0% in CON, respectively.  
 
 
Table 10. Bone mineral density (g/cm2) values.  Data are presented as mean (SD)   
 CD (n=33) CON (n=33) P value 
Femoral Neck 0.734 ± 0.12 0.796 ± 0.16 0.045 
Greater Trochanter 0.671 ± 0.11 0.702 ± 0.10 0.260 
Lumbar Spine (L2-L4) 0.957 ± 0.12 1.020 ± 0.14 0.040 
Figure 33. 
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6.5.3 Muscular Function 
 Figure 34 demonstrates MVIS of the knee extensors on both legs at 60°/s and 180°/s (A) and 
elbow flexors on both arms at 60°/s and 120°/s (B). CD participants showed significantly 
reduced lower limb muscular strength compared to CON when performing isokinetic knee 
extension, working at angular velocities of 60°/s (df= -22.0Nm, 95% CI 10.6-37.3; p=0.001) 
and 180°/s (-13.9Nm; 3.4 to 34.6; p=0.011). There were no significant differences between 
CD participants and CON when performing upper limb elbow flexion at velocities of 60°/s (-
0.6Nm; -2.2-3.4; p=0.664) or 120°/s (-0.01Nm; -2.8-2.0; p=0.747). Negative differences in 
HGS were identified between CD participants and CON, however these were not significant 











Control Crohn’s Control Crohn’s 
Figure 34. 
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Mean muscular endurance results are presented in table 11. The 30-s CST and 30-s BCT 
results showed that people with CD completed fewer repetitions (both p<0.01), with an 
average difference of 5 repetitions and 4 repetitions for CST and BCT, respectively.  
 
 
6.5.4 Quality of life  
Mean QOL scores determined using the EQ-5D-5L are illustrated in table 12. CD participants 
experienced a significantly reduced QOL in comparison to CON in the EQ VAS (mean df= -
11.4; 95% CI -5.6 to -17.1, p<0.001) and in the ED-5Q-5L index scores (-0.098; -0.032 to -
0.165; p=0.004). 
 
Table 11.  
Muscular function variables of CD participants and controls 
 CD (n=33) CON (n=33) P value 
Muscle Strength  
   Knee Extension-60°/s a 72.6 ± 33.3 94.6 ± 46.6 0.001 
   Knee Extension-180°/s a 46.2 ± 23.0 60.1 ± 34.9 0.011 
   Elbow Flexion-60°/s b 25.4 ± 11.2 26.0 ± 12.4 0.664 
   Elbow Flexion-120°/s b 22.3 ± 9.1 22.2 ± 11.2 0.747 
   HGS, kg 32.7 ± 11.3 35.7 ± 11.7 0.109 
Muscle Endurance  
   30-s CST, repetitions 13.4 ± 3.2 17.3 ± 3.3 <0.001 
   30-s BCT, repetitions 16.4 ± 3.5 21.2 ± 4.1 <0.001 
HGS, Handgrip Strength; CST, Chair Stand Test; BCP, Bicep Curl Test;  CD, Crohn’s Disease; 
CON, Controls 
Mean ± S.D are indicated for all columns unless stated.  
a Computed as average MVIS on both legs 
b Computed as average MVIS on both arms 
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6.5.5 Correlates of Bone Mineral Density 
To identify factors associated with BMD at the lumbar spine, greater trochanter and femoral 
neck in adults with CD, a backwards stepwise regression analysis was performed. In this 
regression model, age, alcohol intake, disease behaviour, disease duration, physical activity 
habits, gender, smoking status and surgical history were included. The regression model 
accounted for 38.5% of variance (adjusted R2) in lumbar spine bone BMD scores, 16.1% of 
variance in the greater trochanter BMD scores and 31.3% of variance in the femoral neck 
BMD scores. Findings identified the variables significantly correlated in CD participants with 
a logarithmic transformed lumbar spine (L2-L4) BMD scores were disease duration (b= -
0.27, p=0.024), physical activity habits (b= 0.38, p<0.01), gender (b= -0.47, p<0.01) and 
smoking status (b= -0.26, p=0.033) (Appendix 6f). Similarly, disease duration (b= -0.34, 
p<0.01), physical activity habits (b= 0.36, p<0.01) and gender (b= -0.42, p<0.01) were 
significant correlates of femoral neck BMD scores (Appendix 6g), while only physical 
activity habits (b= 0.36, p=0.013) were significant correlates of greater trochanter BMD 
scores (Appendix 6h). Table 13 illustrates the final multivariable linear regression model for 
BMD scores. 
Table 12.  
Quality of life data in CD participants and healthy controls 







Quality of Lifea 
   EQ-5D-5L Index Scores 
   (-0.285 to 1)  
0.825 ± 0.16 
 
0.935 ± 0.10 -0.098 (-0.032 to -0.165)  0.004 
   EQ-5D-5L VAS Scores 
   (0 to 100) 
76.7 ± 14.0 88.1 ± 9.0 -11.4-(-5.6-to -17.1) <0.001 
Mean ± S.D are indicated for all columns unless stated.  
a  Higher values represent better outcomes 
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Final multivariable linear regression models for bone mineral density scores 
  Unstandardised coefficients Standardised coefficients   95% Confidence Interval for B 
BMD Region  B Std. Error Beta t Sig Upper Bound Lower Bound 
Lumbar Spinea Constant .156 .084  1.862 .070 -.013 .326 
 Disease Duration b -.046 .020 -.273 -2.350 .024* -.086 -.007 
 PA Habits c .062 .020 .375 3.125 .003** .022 .101 
 Gender -.074 .019 -.471 -3.904 .000** -.112 -.036 
 Smoking Status -.038 .017 -.259 -2.210 .033* -.073 -.003 
Femoral Neck Constant .910 .146  6.214 .000** .615 1.206 
 Disease Duration b -.108 .039 -.341 -2.784 .008* -.186 -.030 
 PA Habits c .110 .039 .360 2.843 .007* .032 .187 
 Gender -.123 .037 -.423 -3.350 .002* -.198 -.049 
Greater Trochanter Constant .681 .129  5.286 .000** .421 .940 
 PA Habits c .088 .034 .363 2.596 .013** .020 .156 
Note: The results presented here include only the variables that show significance in the final multivariate linear regression models 
D, Disease; PA, Physical Activity; Adj, Adjusted 
*. Correlation is significant at the 0.05 level (2-tailed) 
**. Correlation is significant at the 0.01 level (2-tailed) 
a Computed as the total bone mineral density (g/cm2) at the lumbar spine (L2-L4) (logarithmic transformed) 
b Presented as total months (logarithmic transformed) 
c Combined total physical activity minutes, computed as the sum of leisure time + work time scores -/+ typical week minutes (logarithmic transformed) 
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6.6 Discussion 
The present study identified that CD participants in remission or with a mildly active disease 
have a significantly reduced BMD at the lumbar spine and femoral neck, impaired lower limb 
muscular strength and endurance, impaired upper limb muscular endurance and reduced QOL 
when compared to healthy matched controls. Correlates of BMD in CD participants were 
explored and identified as disease duration, physical activity habits, gender and smoking 
status to be a significant predictor of BMD at the lumbar spine, disease duration, physical 
activity habits and gender at the femoral neck and physical activity habits at the greater 
trochanter.  
 
6.6.1 Primary Outcomes 
6.6.1.1 Bone Mineral Density  
In this study significant reductions in BMD were identified at the lumbar spine and femoral 
neck, between CD participants and healthy matched controls, but not at the greater trochanter. 
This non-significant difference could be explained by the composition and microarchitecture 
of the greater trochanter, which has demonstrated significantly higher mineralisation (+2%, 
p<0.05) than the femoral neck (Turunen et al., 2013). It is interesting to observe that when 
age, BMI, gender and physical activity matched that significant differences at the femoral 
neck and lumbar spine were observed. A potential reason for this significance could be 
explained by numerous factors such as genetic abnormalities, premature menopause and/or 
nutritional deficiencies, particularly of vitamin D and calcium none of which were controlled 
for (Rockville, 2004).  
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A frequency of 48.5% and 6% of CD participants were indicative of having osteopenia and 
osteoporosis, respectively at the left hip and 36.4% and 6% at the lumbar spine, supporting 
the rates reported by other observational studies in CD (Ghosh et al., 1994; Bjarnason et al., 
1997; Ardizzone et al., 2000; Szathmari et al., 2002; Lima et al., 2017). The clinical 
significance of low BMD is the increased bone fragility and high propensity to fractures, 
contributing to poor QOL, increased morbidity and mortality and loss of independence 
(National Institutes of Health, 2014). The relative risk of sustaining a fracture for people with 
CD is 40% higher in comparison to the general population and is significantly increased at 
the spine (incidence rate ratio [IRR], 1.74 [95% CI=1.34-2.24]; p<0.001), hip (IRR, 1.59 
[CI=1.27-2.00]; p<0.001), wrist/forearm (IRR, 1.33 [CI=1.11-1.58]; p=0.001) and ribs (IRR, 
1.25 [CI=1.02-1.52]; p=0.03) (Bernstein et al., 2000). These results lend support to CD being 
a risk factor for low BMD.  
Silvennoinen et al (1995) and Jahnsen et al (1997) also reported similar reductions in BMD in 
adults with CD at the femoral neck and lumbar spine when compared to CON. However, 
mean BMD (g/cm2) scores reported at the femoral neck (0.948; 0.910) and spine (1.177; 
1.140) by both studies, respectively, were considerably higher than the mean scores reported 
in this study (0.957; 0.734, respectively). Potential reasons for this variation could be 
explained by the use of older equipment used to assess BMD due to the age of the 
publications, since then modifications have been made that have resulted in better image 
quality, use of different software and type of scanning beam used, all of which are known to 
affect results (Genton et al., 2002). In contrast to the current findings, another observational 
study between 68 newly diagnosed (<6 months) IBD participants and healthy controls 
reported no significant group differences (Schoon et al., 2000). Suggesting that disease-
related factors seem to be responsible for the development of reduced BMD and thus, the 
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potential differences could also be explained by the variation in participant clinical 
characteristics. Findings were further supported by a more recent cross-sectional study of 
1230 IBD (CD=719, UC=511) participants, who identified adults with CD to be nearly 50% 
more likely to develop osteoporosis than CON (Targownik et al., 2013).  
However, comparisons and conclusions are difficult to deduce due to the variability in 
participant selection, statistical analysis method and the method of measurement. Studies 
comparing healthy controls to people with CD and identifying possible risk factors associated 
with low BMD are crucial. 
 
6.6.1.1.1 Correlates of Bone Mineral Density  
Statistically significant correlates of BMD in CD at the lumbar spine were disease duration, 
physical activity habits, gender and smoking status. Disease duration, physical activity habits 
and gender were identified as significant correlates at the femoral neck and physical activity 
at the greater trochanter. However, these coefficients only account for 16.1-38.5% of the 
variability and further evaluation of the potential association between BMD and 1) perianal 
disease, associated to higher disease recurrences and younger age of disease onset (Choi et 
al., 2015; Schule et al., 2016), 2) disease activity, associated to malabsorption and increased 
levels of proinflammatory cytokines that interfere in bone metabolism pathway (Sgambato et 
al., 2019), and 3) medication type, particularly corticosteroids which are associated with 
decreased serum markers of bone remodelling (Miheller et al., 2007). 
Several previous studies have explored whether gender affects BMD in CD, however with no 
definite answer. In this study, being female was a significant correlate at the lumbar spine and 
femoral neck. This is in line with published data from an earlier study. Andreassen et al’s 
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(1999) case control study matched 113 CD participants for gender, age and body weight 
identifying female sex as an independent risk for BMD. This was confirmed by Targownik et 
al’s (2013) study of 1230 IBD participants (n=719 CD; n=511 UC), who after controlling for 
age, gender, BMI, hormone replacement therapy, osteoprotective medications, and 
corticosteroid use identified female sex as risk factor for BMD. Women are thought to be at a 
greater risk as a result of hormonal changes. Oestrogen plays an important role in bone 
growth and maturation as well as in the regulation of bone turnover, levels of which decrease 
during and after menopause. As a result of oestrogen deficiencies, disturbed architecture and 
reduced bone mass and bone strength are induced (Riggs, 2000; Eastell et al., 2016; NHS, 
2019). Moreover, chances of developing osteoporosis are increased further if they have 
undergone a hysterectomy, partially when the ovaries are also removed due to the lack of 
oestrogen being produced (Eastell et al., 2016; NHS, 2019). However, contrary to the current 
study’s findings, males have also been identified as significant independent risk factor for 
low BMD in people with CD (Bartram et al., 2006; Lima et al., 2017). The exact cause of 
osteoporosis in males is unknown, however is thought to be linked to testosterone levels, 
made by dehydroepiandrosterone sulphate (DHEAS) (NHS, 2019). A study of 45 males with 
IBD (UC=25; CD=20) explored DHEAS levels in relation to BMD, identifying 23 
participants who had significantly reduced DHEAS levels and consequently lower lumbar 
spine and femoral neck BMD T-scores than participants within a normal DHEAS range 
(Szathmari et al., 2002), which may explain the variation in findings.  
Non-stricturing/ non-penetrating, stricturing and penetrating disease behaviour was not 
identified as a risk factor for low BMD at any site, contradicting the findings of Lima et al 
(2017). This cross-sectional prevalence study of 165 participants (60 with CD, 68 with UC 
and 67 CON) identified through multiple correspondence analysis that penetrating behaviour 
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was associated with low BMD. One possible reason for this difference could be that no 
participants in the current study presented with a penetrating disease behaviour, compared to 
30% in Lima et al’s (2017) study. In the current study, surgical history and alcohol intake 
were not identified as risk factors of low BMD in people with CD. However, there are 
inconsistent findings about the association of surgery with BMD and whether the association 
is influenced by the type of surgery. For example, initially it was thought that 
proctocolectomy with ileal pouch-anal anastomosis would benefit BMD, possibly due to the 
discontinuation of corticosteroids, improved nutritional intake and reduced cytokine release 
due to the removal of the diseased colon (Gupta and Shen, 2013). However, the anatomy and 
function of the small-intestine is altered in ileal pouch surgery, reducing the absorption of 
bile salts, thus reducing the absorption of vitamin D. In addition, inflammation of the ileal 
pouch has been shown to increase inflammatory cytokines IL-1, IL-6 and TNF-α, stimulators 
of osteoclast activity, which promotes bone loss (Gupta et al., 2014). Therefore, it remains 
unclear as to whether these metabolic consequences of surgery provide benefits or detriments 
to BMD. Longitudinal studies identifying BMD before and after surgery is needed to better 
evaluate the effect of the type of surgery on bone loss.  
Moderate to vigorous physical activity was identified as a correlate of BMD at the lumbar 
spine, femoral neck and greater trochanter. Supporting the positive relationship between 
physical activity and BMD identified in Nobile et al’s (2018) cross-sectional study of 216 
paediatric IBD participants. Without physical activity as a loading stimulus, sedentary 
behaviour promotes the activity of osteoclasts, which re-absorb bone tissue, and impairs IGF-
1 and TGF-beta (TGF-β) signalling involved in maintaining bone strength (Troy et al., 2018). 
Conversely, physical activity has shown a positive correlation with increased BMD in healthy 
individuals and as a treatment or prevention in metabolic diseases such as diabetes, 
CHAPTER 6: CASE CONTROL AND CROSS-SECTIONAL STUDY 
 
W12018030  149 | P a g e  
 
osteoporosis and lupus (Todd and Robinson, 2003; Vainionpaa et al., 2005; Pineau et al., 
2004). An osteogenic stimulus occurs during exercise, in which bone is subjected to forces 
induced by gravitational loading and muscle loading. This osteogenic stimulus initiates an 
adaptive response involving osteocytes that transduce the energy from the mechanical forces 
into biological signals that impact bone formation and resorption. This elicits bone 
deformation, stimulating the stretch-activated ion channel on osteocytes and triggers the 
expression of genes that mediate bone growth and increase the threshold of stress tolerance, 
thus eliciting an architectural modification (Zagdsuren, 2014).  
However, the strength of the relationship observed between physical activity and BMD in the 
current study may be impacted by the measurement tool used to quantify activity levels. The 
SPAQ does not take into consideration the type of activity performed, therefore participants 
could have reported being highly active but undertook no bone loading activities. Future 
research exploring this association using objective measures or questionnaires that quantify 
the type of exercise are needed.   
Disease duration was a significant predictor of BMD at the lumbar spine and femoral neck, 
supporting the findings of Pollak et al (1998) and Schulte et al (1998). However, due to the 
unknown pathogenesis of osteoporosis, it remains unclear at what phase BMD starts to 
decrease in CD. Sakellariou et al’s (2006) prospective study of 32 CD participants identified 
that participants with a disease duration of >6 months had a lower BMD when compared to 
those with a diagnosis of less than 6 months. Fifteen newly diagnosed CD participants were 
also identified as having a lower BMD (Ghosh et al., 1994). Ghosh et al (1994) determined 
BMD using Z-scores, a value comparing BMD to what is normal in someone of the same age 
and body size. However, it is thought that Z-scores can be misleading and, in accordance with 
the NOF, a diagnosis of osteoporosis using Z-scores should not be used in younger men, 
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premenopausal women and children (NOF, 2013). Therefore, deductions are difficult to 
make. A cross-sectional study observed 79 newly-diagnosed IBD participants, who had never 
used glucocorticoids, but had a low BMD (Bjarnason et al., 1997). One hypothesised 
explanation for this could be due to the disease itself, IL-1 (α and β), IL-6, IL-11, IL-15, and 
IL-17, TNF-α and prostaglandin E2 in IBD, are elevated in IBD. These proinflammatory 
cytokines interfere in the pathway involved in bone metabolism, known as RANK-RANKL-
OPG, and thus change the rate of bone formation, bone resorption and overall bone 
homeostasis (Bernstein and Leslie, 2003; Bernstein et al., 2005; Mundy, 2007). 
In this study, no correlations were identified between BMD and age at the lumbar spine, 
femoral neck or greater trochanter, contrary to previous findings (Ghosh et al., 1994; 
Bjarnason et al., 1997; Bartram et al., 2006). However, methodological limitations and 
differences in participant characteristics could explain these variations. Ghosh et al’s (1994) 
study was significantly limited by the recruitment of participants aged 14 and determining 
BMD through Z scores, as Z scores are not possible to apply to individuals under 20 years of 
age due to growth and development (NOF, 2013). Moreover, the average score for disease 
activity determined using the CDAI was 196, suggesting participants were only 
representative of having a mildly active disease, compared to the CDAI of 114 identified in 
this study. No participants in the present study were taking glucocorticoids, compared to 19 
participants in Bjarnason et al’s (1997) study. The use of glucocorticoids has been suggested 
to induce bone loss, by impairing osteoblast function and the synthesis of oteoprotegerin, 
allowing an interaction that causes osteoclasts to differentiate and mature resulting in bone 
loss (Ali et al., 2010). Additionally, in Bjarnason et al’s (1997) study and Bartram et al’s 
(2006) study, 15.2-32.2% participants, respectively, were current smokers, a determinant of 
BMD, compared to 0% in this study.  
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However, comparisons are difficult to make and it is more likely that these inconsistencies 
are due to the variability in participant selection/ characteristics (e.g. age, body weight, health 
status, other comorbidities), study design (cross-sectional vs prospective), statistical power 
for determining effect and technique used to determine outcome. Nevertheless, all studies 
reported a reduction in BMD, thus suggesting that people with CD are at an increased risk of 
osteopenia or osteoporosis. 
 
6.6.1.2 Muscular Function   
The findings of this study identified that people with CD have a significantly impaired lower 
limb muscle strength and impaired upper and lower limb muscle endurance than healthy 
matched controls. In regards to maximal isokinetic lower limb strength, our results partially 
contradict those of Geerling et al (1998) who reported a significantly lower hamstring peak 
torque in CD participants but similar quadriceps torque to CON at velocities of 60°/s and 
180°/s. These variances may be explained by the age and disease duration of study 
participants compared to the present study. Geerling et al (1998) reported a median age of 40 
and a median disease duration of 16 years compared to 51 and 21, respectively in this study. 
Moreover, 41% of participants in Geerling et al’s (1998) study were receiving prednisone 
treatment, perhaps because 47% were suggestive of having an CDAI>150. The use of 
glucocorticoids has been suggested to induce loss of skeletal muscle mass and muscle 
weakness, contributing to a reduction in muscular strength and endurance (Sato et al., 2017). 
As muscles are a large site of protein, it is thought this deterioration occurs due to the 
suppression of protein synthesis, the naturally occurring process in which protein is produced 
to repair muscle damage, by glucocorticoids (Al-Jaouni et al., 2002). This causes a protein 
imbalance resulting in muscle wasting. However, whole-body and muscle protein 
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metabolism, such as muscle strength and muscle mitochondrial function is not adversely 
affected by short term low doses of glucocorticoids as it uses epinephrine to mobilise energy 
and deliver it to the muscles, thus promoting energy replenishment (Short et al., 2004). It is 
therefore thought that chronic use or high dosage of GC administration is associated with 
muscle wasting. Our results are similar to those of Brevinge et al (1995) and Wiroth et al 
(2005) who both identified significant lower limb muscular strength in people with CD 
compared to CON. Brevinge et al (1995) found significantly reduced working capacity in CD 
participants while undertaking maximal exercise on a cycle ergometer involving extensor 
muscles of the lower limb. Wiroth et al’s (2005) study assessed strength parameters in 41 CD 
participants in clinical remission, with findings demonstrating a significant reduction in 
maximal isometric strength (-24.6%, p<0.001) and endurance (-25.8%, p<0.001) of the leg 
extensors.  
Upper limb isokinetic strength and HGS were similar in people with CD and controls, 
suggesting that upper limb strength is preserved in people with CD. This finding is consistent 
with those of Wiroth et al (2005) and Cabalzar et al (2017) who found no significant 
difference in either parameters. Interestingly, Zaltman et al’s (2014) study assessing upper 
and lower limb muscle strength in UC participants also reported significantly decreased 
maximal quadriceps strength (d= -6%; p=0.012), but not in HGS (p=0.362). A similar pattern 
is often observed within the elderly, where upper limb strength is preserved while lower body 
function is often decreased (Izquierdo et al., 1999). This is thought to result from sedentary 
behaviour, alternating behaviours such as avoiding climbing stairs, or individuals with 
weaker limbs supplementing lower body movements with arm muscles, such as rising from a 
chair (Macaluso and Devito, 2004). This constant sedentary behaviour can negatively 
influence muscular performance, by adversely affecting the recruitment of fast twitch muscle 
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fibres, reduce glycogen stores and suppress the ability to produce enough energy 
(Minderhoud et al., 2003; Wiroth et al., 2005).  
Impaired nutritional status as a result of poor food intake, impaired digestion and absorption, 
medication side effects, surgical intervention or systemic inflammation due to active disease 
could explain the variation in impaired muscle function (Ispas et al., 2015; Spooren et al., 
2015). IGF-1 is a marker for the nutritional state, with low level concentrations a sign of 
malabsorption. IGF-1 is a hormone that stimulates the proliferation of muscle progenitor cells 
and their integration with existing muscle fibres during the muscle repair process, and the 
elevation of TBARS is a marker of oxidative stress (Machida and Booth, 2004). The 
combination of these changes will decrease the PI3K/AKT signalling pathway that is 
involved in inducing skeletal muscle hypertrophy. Therefore, it is thought to play a role in the 
reduction in muscle mass and muscle CSA in CD (Cominelli, 2004). This was supported by 
the findings from a cross-sectional study that obtained muscle biopsies from 27 CD 
participants and compared them to CON. Results demonstrated a 37% reduction in IGF-1 
(p<0.01), a 54% lower phosphorylated:total Akt ratio (p<0.05) and increased serum TBARS 
(p<0.05), suggesting impaired activation of muscle protein IGF-1-Akt pathway plays a role in 
the regulation and reduction of skeletal muscle growth (van Langenberg et al., 2014). This 
rationale would therefore support the findings of Valentiti et al’s (2008) study in 94 CD 
participants, of whom 23.7% showed signs of malnutrition and demonstrated a significantly 
reduced HGS when compared to CON (23.1kg, 20.8–28.7, p=0.021). These variables could 
also provide an explanation for the impaired muscular endurance values.  
Similar reductions in muscular endurance were identified in Wiroth et al’s (2005) study 
which assessed muscular endurance using the 12-reptition sit-up test (-25.1%, p<0.001) and 
in Zaltman et al’s (2014) study of UC participants, using the sit-up test (d= -32%; p=0.00001) 
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and gait speeds (d= -17%; p=0.0004). These tests reflect tasks of daily living and therefore 
highlighting the importance of introducing interventions to increase muscular strength and 
endurance prior to the development of musculoskeletal EIM’s.  
 
6.6.2 Secondary Outcomes 
6.6.2.1 Quality of Life 
Quality of life, determined using the EQ-5D-5L was impaired in people with CD compared 
with CON. Five studies have measured QOL in CD participants compared with that in CON, 
two utilizing the IBDQ (Love et al., 1992; Casellas et al., 2000), one using the German 
KINDL and IMPACT III questionnaires (Werkstetter et al., 2012), one using the Sickness 
Impact Profile (Drossman et al., 1989), and one using the SF-36 (Cabalzar et al., 2017). 
Regardless of the questionnaire used, all studies found QOL scores to be worse in people 
with CD. However, none of these studies took into consideration the disease state of the 
participant which remains the most significant predictor of physical and mental HRQOL in 
IBD, with strong correlations identified between the CAI (r= -0.623, p=0.0003), Endoscopic 
Activity Index (r= -0.511, p=0.005), CDAI (r= -0.506, p<0.001) and HBI (r= -0.600, 
p<0.001) with disease-specific, self-assessed QOL questionnaire (Kim et al., 1999; Zahn et 
al., 2006). Although, disease activity does not explain the decrements in QOL completely, 
with more than 30% of asymptomatic individuals reporting an impaired QOL, so other 
correlates of QOL in CD such as stress (Mawdsley and Rampton, 2005), sleep (Graff et al., 
2011), surgical history or disease duration (Haapamaki, 2011) should be adjusted for. 
Nevertheless, with the variability between active and quiescent disease states, medical and 
surgical side effects, disease-specific complications and social, psychological and financial 
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repercussions it is not surprising that people with IBD have an impaired QOL (Bernklev et 
al., 2005; Moradkhani et al., 2013). 
 
6.7 Strengths and Limitations 
One of the strengths of this study was the matching of confounding factors (age, gender, 
BMI, smoking status and physical activity status) of CD participants with CON, this reduces 
the effect of the confounding factors on the variable investigated. CD participants were also 
randomly recruited from a clinical population and therefore considered to be more 
representative of the target population regarding age, gender, disease location and duration, 
treatment history/management and surgical implications. Lastly, this study also involved a 
comprehensive assessment of health outcomes, allowing for a detailed comparison of the 
participants health status.  
The study did have some limitations that are worth noting. Firstly, cytokines were not 
ascertained. Proinflammatory cytokines such as TNF-α and IL-6 have been shown to interfere 
with the pathway involved in bone metabolism and to impair muscle function through 
reducing secretions of IGF-1, important for muscular strength, mass and endurance (Barbieri 
et al., 2013). Future studies should consider studying inflammatory cytokines to better 
understand their role in muscle dysfunction and bone loss. Secondly, medications were not 
adjusted for. Anti-TNF therapies and immunosuppressants are commonly used as a treatment 
in CD and may influence the cytokine production, and thereby potentially positively 
impacting BMD and muscular function. Infliximab, an anti-TNF drug, was administered to 
45 CD participants over a period of 22 months and this treatment showed a significant 
increase in BMD at the lumbar spine, independent of nutritional status, from baseline to 22 
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months when compared to CD participants who had never had infliximab (p<0.01) (8.13% ± 
7.7) (Mauro et al., 2007). A retrospective study of 59 CD participants analysed the effects of 
azathioprine on BMD, finding that although azathioprine does not positively or negatively 
impact BMD itself, it seems to preserve BMD in people with CD (Floren et al., 1998). 
However, given the small sample size, it was unfeasible to adjust analysis according to 
medication type, particularly as many participants were currently taking both treatments, 
making it difficult to distinguish the impact of each. Moreover, many participants had been 
on these medication types in the past and the duration of these potentially preserving effects 
is unknown. 
Thirdly, nutritional state was not determined. Although participants included in this sample 
were in clinical remission or mildly active, impaired nutritional status was estimated in 65-
75% of people with CD, resulting in deficiencies in vitamin D and calcium (Ispas et al., 2015; 
Spooren et al., 2015). These deficiencies are inversely associated with elevated levels of 
markers of bone turnover and increased concentrations of uncarboxylated osteocalcin, a 
predictor of risk fracture and premature and accelerated development of low muscle mass, 
strength and physical performance (Greenland and Nair, 2003; Duggan et al., 2004). Given 
the effects of malnutrition on bone and muscle health, it is important that this is incorporated 
into future studies to better understand the effect of this risk factor. In addition, steroid 
history was not obtained due to recal problems. Glucocorticoid usage, particularly of long 
duration and high concentration has been suggested to induce loss of skeletal muscle mass 
and muscle weakness and impair osteoblast function causing an increased activity, 
proliferation and maturation of osteoclasts (Bernstein et al., 2003; Sato et al., 2017).  
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Lastly, the use of a cross-sectional design to determine the correlates of BMD was also a 
limitation of this study as correlation does not necessarily imply causation, therefore further 
research would be needed to determine a causal relationship.  
 
6.8 Conclusion 
Although the results of these studies do not provide novel findings, they strengthen the 
evidence base that adults with CD are at an increased risk of osteopenia or osteoporosis and 
provides support to the correlations associated with BMD, which might facilitate the decision 
in regards to BMD testing. Adults with CD in clinical remission or with a mildly active 
disease also show a reduced lower muscular strength and upper and lower muscular 
endurance when compared to CON. Consequently, these are two important predictors of 
future disability. Interestingly, upper muscular strength scores were similar in CD and healthy 
controls, suggesting upper limb strength is preserved. As discussed previously, this is thought 
to be as a result of sedentary behaviour and supplementing lower body movements with arm 
movements such as rising from a chair. Nevertheless,  a complete evaluation of participants 
BMD and muscular performance should be assessed as part of routine clinical care and 
specific pharmacological and non-pharmacological therapeutic strategies should aim at 
preventing, treating or avoiding further deterioration of these secondary complications.   
The potential role of non-pharmacological therapies in CD remains poorly understood. 
However, until the aetiology of the exact mechanisms of bone loss and muscle dysfunction is 
understood it is believed a combined impact and resistance training programme focusing on 
bone and muscle parameters may reduce the deleterious effects on CD while enhancing 
fatigue and QOL, as demonstrated in osteoporosis, sarcopenia and postmenopausal women.  
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7.1 Introduction 
A growing body of evidence suggests that individuals with CD are at an increased risk of 
muscle dysfunction and reduced BMD, potentially resulting in further disability. Despite 
pharmacological advances, the prevalence of these disorders remains high (Wiroth et al., 
2005; Ali et al., 2009). The aetiology and exact mechanisms that may under-pin the 
relationship between bone and muscle loss in CD are yet to be fully elucidated. However, 
they are likely to be multifactorial including proinflammatory cytokines, glucocorticoid usage 
and malnutrition (Bryant et al., 2015; Lima et al., 2017). Nevertheless, measures to treat these 
secondary complications in this high-risk group have not yet been well established.  
Despite the mechanical properties of weight-bearing exercises and its widespread clinical use 
in osteoporosis, sarcopenia and postmenopausal women to increase muscular strength, 
muscular endurance and BMD (Palombaro et al, 2013; Hong and Kim, 2018), little is known 
about the beneficial effects in people with CD. To our knowledge no studies have explored 
the potential for weight-bearing and impact training to minimise or reverse muscle strength or 
endurance impairments or improve BMD in people with CD. One RCT has explored the 
potential of a home-based resistance training programme as an adjunct therapy for BMD in 
CD, demonstrating that those participants who were fully compliant with the programme 
showed greater improvements at the femoral neck, lumbar spine and greater trochanter. This 
suggests that improvements in BMD are related to the amount of exercise performed and that 
a home-based resistance training programme is feasible in adults with CD. To address the 
lack of research in this area, this RCT aims to assess the effects of a 6-month combined 
impact and resistance training programme on BMD, muscle strength and muscular endurance 
in adults with CD. With a hypothesis that the implementation of a combined impact and 
resistance training programme improves primary outcomes 1) BMD and 2) muscular function 
in adults with inactive to mildly active CD. 
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7.1.1 Study Objectives 
Primary Objective 
1. To investigate the effects of a 6-month combined impact and resistance intervention 
on muscle function and BMD in adults with inactive or mildly active CD 
Secondary Objectives 
2. To examine the possible benefits on fatigue, HRQOL and disease activity 
3. To explore acceptability and safety of a 6-month combined impact and resistance 
intervention 
4. To evaluate the feasibility of conducting a larger, multi-centre RCT  
7.2 Methods 
There was one deviation from protocol. It was planned to use the Florence Telehealth App to 
act as a motivational support to exercise participants, however this method was unavailable. 
Participants were instead contacted every 4 weeks by the intervention facilitator via their 
preferred method of contact.  
 
7.2.1 Study Design 
PROTECT (PROgressive resistance Training Exercise and Crohn’s disease Trial) was a 
single centre, two arm, parallel-group, RCT. Following baseline assessments participants 
were randomly allocated 1:1 to either usual care plus a 6-month combined impact and 
resistance training programme or a control group, who received usual care alone. Study  
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outcomes were conducted at baseline, 3 and 6 months following randomisation. The study 
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7.2.2 Study Setting 
Adults with CD were recruited from a clinical population within NUTH Trust sites (The 
Royal Victoria Infirmary or the Freeman Hospital). Baseline, week 13, week 26 visits and 
exercise sessions were delivered at the University of Northumbria at Newcastle.  
 
7.2.3 Eligibility Criteria 
Men and women aged >16 years were eligible to participate if they were able to provide 
written consent, were able to travel to the research centre and had a verified (radiologically, 
histologically and endoscopically) diagnosis of CD of at least 4 weeks duration. This duration 
was applied to allow medications to be adjusted, symptoms to be better controlled and to 
allow time for individuals to educate themselves and manage their new diagnosis. The 
following exclusion were applied: 
• Adults with UC or IBD-U. Due to osteoporosis and osteopenia occurring more 
frequently in CD than UC or IBD-U.  
• Medication changes 4 weeks prior to the screening visit, or if the individual presented 
with an active disease determined, within 4 weeks, using the CDAI (>220) and FC 
(>250 mcg/g). These exclusions were applied due to these determinants indicating 
active inflammation. As nothing or little is known about the safety of exercise in 
people with a moderately or severely active disease, people with CD who presented 
with inflammatory markers above the threshold were excluded for safety reasons. 
• Deemed unsuitable to undertake resistance exercise (assessed by 
gastroenterologist/physician). 
• Participation in another clinical trial for which concurrent participation was deemed 
inappropriate and likely to influence the results of either study. 
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• Current participation in >2 sessions/week of resistance exercise (self-reported). This 
exclusion was applied as it would be difficult, if not impossible, to distinguish 
between the effects as a result of the intervention prescribed or the current training the 
participant was undertaking 
• Absolute contraindications to exercise testing and training as defined by the ACSM 
(2017) (Appendix 7a), for the safety of the participant and the potential risks of 
exercise testing outweighing the benefits. 
• Pregnant, female planning pregnancy or planned major surgery within 6 months after 
randomisation, due to the intervention type and radiation exposure.  
 
7.2.4 Recruitment 
Adults were recruited on a volunteer basis by one of four methods. Recruiting from a clinical 
population enabled the evaluation of interventions feasibility, acceptability and effectiveness 
when applied to a realistic, real-life, routine practice conditions to provide the best level of 
evidence-based care.  
1. IBD-specific database (Bioresource, United Kingdom) at the Newcastle Centre of 
Bowel Disease Research. A database of individuals who have consented to being 
contacted regarding future trials. The database of 786 CD, as of November 2018, was 
screened and potentially eligible participants were identified. If the 
inclusion/exclusion criteria appeared satisfactory, individuals were sent an 
information pack prior to attending the gastroenterology department for their routine 
appointment. This information pack contained a recruitment letter (Appendix 7b), 
participant information sheet (Appendix 7c), disease activity diary (Appendix 7d) and 
an example informed consent form. Interested potential participants were asked to 
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contact the study co-ordinator 24 hours after reading the information via phone or 
email for further information, to answer any questions and/or to arrange an eligibility 
visit. Arranged the same day as an upcoming appointment or at a date/time 
convenient. 
2. Recruitment posters (Appendix 7e) advertising the research study were placed in the 
gastroenterology waiting areas.  
3. Study posters (Appendix 7f) were also placed in examination rooms to act as a 
reminder to staff. Participants identified by their gastroenterologist were directed to 
see the study co-ordinator and an information pack provided. Those wishing to 
participate were asked to wait 24 hours before contacting a member of the research 
team. 
4. Social media and networking sites, the details of the study were uploaded and 
hashtags such as #Crohn’s and #IBD were used to generate interest.  
 
7.2.4.1 Eligibility Assessment  
Prior to attending the eligibility assessment, potential participants were asked to complete a 
7-day disease activity diary, contained in their information pack, and bring this along with 
them to their appointment. If lost/thrown away another copy was sent out via post. The 
disease diary recorded parameters such as number of liquid stools, abdominal pain and 
general well-being, information used towards assessing disease activity using the CDAI. 
During the eligibility assessment, the study was explained in more detail, any questions were 
answered and informed consent (Appendix 7g), participant contact details and GP details 
(Appendix 7h) were obtained. To assess eligibility a CRF was completed (Appendix 7i), 
acquiring demographical and clinical information established from self-reports and medical  
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records. Objective and subjective measures of disease activity were also assessed using FC 
markers, CRP and the CDAI. For the latter measure, body mass, extra-intestinal 
complications, anti-diarrhoeal medication, haematocrit and an abdominal examination to 
exclude the presence of an abdominal mass were assessed by a direct care team member.  
 
On the return of disease activity parameters, participants were contacted via their preferred 
method and eligible participants invited to attend a baseline assessment. Appointed 
gastroenterologists were informed of any inflammatory measures that came back suggestive 
of an active disease. Eligibility CRF’s were signed by the clinical principal investigator and a 
copy placed in medical records. 
 
7.2.5 Outcome Measures 
7.2.5.1 Primary Outcomes 
• BMD (g/cm2) was determined at baseline and 6 months using a DEXA (Hologic 
Horizon W DEXA scanner). Measurement sites included the femoral neck and greater 
trochanter of the left hip and lumbar spine (L2-L4) 
• An isokinetic dynamometer (Biodex system 4 Pro) was used to assess lower limb and 
upper limb muscle strength (Nm) at baseline, 3 and 6 months. Maximum voluntary 
isokinetic strength (MVIS) of the knee extensors on both legs and elbow flexors on 
both arms were evaluated. Handgrip strength (HGS) was measured using a handgrip 
dynamometer (JAMAR Hydraulic), taken from the nondominant forearm.  
• Muscle endurance was determined at baseline, 3 and 6 months. Lower extremity 
muscle endurance was assessed using the 30-s CST, upper extremity muscle 
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endurance was established using the 30-s BCT, conducted from the nondominant 
forearm  
 
7.2.5.2 Secondary Outcomes 
• The IBD-F was used to determine fatigue at baseline, 3 and 6 months  
• QOL was evaluated using the IBDQ and EQ-5D-5L at baseline, 3 and 6 months  
• Disease activity was assessed at baseline and 6 months using the CDAI 
• Intestinal inflammation was determined by measuring FC at baseline and 6 months  
• CRP was used to measure inflammatory markers in the body at baseline and 6 months  
• Physical activity habits were assessed using the SPAQ at baseline, 3 and 6 months 
 
7.2.5.3 Feasibility and Acceptability Outcomes 
Trial acceptability outcomes were assessed by recruitment rates and examining reasons for 
dropout in discontinuing participants and comparing attrition rates between the two study 
groups and between participants who did and did not receive their preferred group allocation, 
assessed at baseline and prior to randomisation. The acceptability of the exercise programme 
was determined by exercise adherence rates, measures of exercise enjoyment established by 
the Physical Activity Enjoyment Scale (PACES) at 3 and 6 months, and participant feedback 
via exit telephone interviews following 6-month assessments. Attrition rates were also 
established at discontinuation of intervention and loss to follow-up measurement for all 
groups. 
Trial feasibility outcomes were determined by examining and evaluating the suitability of 
outcome measurements, based on completion rates and rates of missing data. The safety of 
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exercise training was assessed by exploring rates of relapse at 3 months, through self-report, 
and at 6 months, defined by an increase in CDAI of >100 points to a score >150. Reasons for 
dropout from the exercise programme and the number and type of AE that occurred in each 
group were recorded.  
 
7.2.6 Data Collection 
Appendix 7j demonstrates the participant timeline of enrolment, interventions and 
assessments. All visits took place in the Neurophysiology and DEXA lab at Northumbria 
University. In accordance with ACSM guidelines (2017), for the safety of the participants, 
blood pressure and heart rate were determined prior to any exercise testing. 
 
7.2.6.1 Baseline Assessment 
Baseline assessments, conducted within 4 weeks of receiving disease activity results, were 
completed and a baseline CRF (Appendix 7k) gathered information on intervention 
preference, body mass, stature, resting heart rate and resting blood pressure. Outcome 
measures were recorded and obtained in the same order for every participant: HGS, 30-s 
BCT, 30-s CST, questionnaires (IBDQ, EQ-5D-5L, IBD-F, SPAQ), MVIS and BMD. A GP 
letter (Appendix 7l) was sent following randomisation.  
 
7.2.6.2 Randomisation and allocation 
Following the baseline assessment participants were randomly assigned 1:1 to either a 6-
month combined resistance and impact training programme plus usual care or a control group  
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who received usual care alone. An online randomisation programme 
(www.randomization.com) was used by a researcher, not involved in the recruitment process, 
to generate the randomisation sequence. Participants were randomly allocated by block-
randomisation with varying block size to ensure concealment, stratified by gender 
(male/female) and disease activity (inactive [CDAI <150]/mildly active [CDAI 150-219]). 
Control group participants were notified by letter (Appendix 7m).  
 
7.2.7 Interventions  
7.2.7.1 Combined impact and resistance training 
Participants allocated to the exercise group were provided with latex-free TheraBand 
equipment, skipping ropes and an exercise information booklet (Appendix 7n) and invited to 
complete three sessions of exercise a week on non-consecutive days for 6 months. The study 
co-ordinator went through the booklet in detail and answered any questions, participants were 
then asked to read the information on participation, monitoring, TheraBand care and safety, 
travel information and contact information at home. Sessions were primarily unsupervised 
and home-based with 12 supervised support sessions tapered over time: 
1. 2 sessions a week for 2 weeks (week 1 and week 2) =4 sessions 
2. 1 session a week for 2 weeks (week 3 and week 4) =2 sessions 
3. 2 fortnightly sessions (week 5/6 and week 7/8) =2 sessions 
4. 4 monthly visits (week 9 onwards) =4 sessions 
 
To facilitate attendance, sessions were offered in early mornings, evenings and weekends. 
The supervised sessions were conducted to provide participants with motivation, knowledge  
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and support regarding technique, posture and body alignment. Lasting approximately 60 
minutes, each session began with a 5-minute warm-up consisting of pulse raising dynamic 
exercises and stretches. Followed by 5 minutes of initial rope skipping. Participants then 
progressed to 10-15 minutes of plyometric jumping involving 2-3 sets, 10-15 reps of 5 
multidirectional jumps.  
Participants were instructed to perform these jumps explosively, quickly with maximum 
power and speed with 30-s rest after each rep. The main body of the programme involved 2-3 
sets, 10-15 reps of 10 high intensity exercises targeting the upper body, lower body and 
midsection using a resistance TheraBand. The session ended with a 5 minute cool down 
consisting of pulse lowering dynamic and static stretches.  
Each supervised session was delivered by the study co-ordinator who was trained in 
delivering the exercise protocol, CPR and automated external defibrillation. A maximum of 
three participants were trained per session. Prior to the exercise session and 10 minutes post 
exercise, heart rate and blood pressure were recorded to ensure the safety of the participant. 
An exercise CRF (Appendix 7o), monitoring heart rate, blood pressure and exercise difficulty 
(Resistance Intensity Scale for Exercise [RISE]) self-reported by participants were completed 
for each session with notes made regarding any serious or non-SAE that occurred.  
 
7.2.7.2 Exercise Progression 
The RISE (Figure 36) was used to rate perceived exertion to dose appropriate level of 
resistance, as recommended by the ACSM (2004). The RISE has demonstrated high validity 
coefficients for the active muscle (r2=0.87) and overall body (r2=0.76 to 0.85) (Colado et al., 
2014). Following each exercise session, participants were asked to rate (easy to maximal) on 
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the scale how hard they found the session and progression to the next band level occurred 







Based on plyometric jump training criteria (Hansen and Kennelly, 2017), the skipping and 
jumping phase were progressed on the principles that they were performed pain-free with no 
difficulty, such as muscle soreness or fatigue and the correct technique was performed. With 
the latter focusing on the landing/force absorption, distribution of landing, quick concentric 
movement with complete control while demonstrating good landing mechanics. Often 








Table 14. Exercise Progression  
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7.2.7.3 Discontinuation 
Throughout the trial, participants were encouraged to contact the study co-ordinator should 
they experience any problems in completing the exercise sessions or if any changes in their 
condition or medical history occurred. The criteria for discontinuing the intervention included 
any participant who experienced a disease flare-up requiring hospitalisation or a course of 
steroids, if the participant was unwilling/unable to comply with study procedures or if the 
investigator deemed it unsafe. Participants were also instructed to stop the exercise 
programme if they experienced chest pain or any other distressing symptoms and to contact 
emergency services. SAE and AE were reported in accordance with Northumbria 
University’s procedures (Chapter 4, Section 4.8). 
 
7.2.7.4 Compliance and adherence  
Exercise participants received 12 supervised sessions at the Northumbria University to allow 
for familiarisation and exercise progression. However, to promote long-term adherence, the 
frequency of these supervised sessions was tapered over time, with an increasing emphasis on 
home-based, unsupervised training. Increasing self-efficacy is a recognised and critical 
psychological determinant considered necessary for preparing the participant to adopt and 
maintain an exercise programme (Dijkstra et al., 2003). Significant support has accumulated 
in favour of exercise interventions targeting increasing self-efficacy with the use of 
behavioural techniques such as goal setting, self-monitoring and social support (Bandura, 
1997; Rovniak et al., 2002). These specific techniques have demonstrated an 80% 
improvement to adhering to exercise and maintaining and eliciting lifestyle behavioural 
changes post intervention (McAuley, 1993; Trost et al., 2002; Perri and Corsica, 2002). As 
adults with CD have been shown not to meet the recommend daily exercise guidelines it is 
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important to include these techniques to facilitate a transition in behavioural change (Mack et 
al., 2011; Chan et al., 2013; Tew et al., 2016). Strategies to improve and monitor adherence 
were employed throughout the study: 
• Goal setting: planning weekly specific, quantifiable and realistic goals following 
SMART guidelines (Doran, 1981). Goals were made, discussed at the next supervised 
session and addressed at completion  
• Support contact: participants were contacted via preferred method every 4 weeks, to 
provide a motivational climate through the delivery of personalised motivation and 
support 
• Self-monitoring: through a diary/log recording the completion of home-based 
sessions, whether each phase was managed, the perceived exertion based on RISE and 
any comments to be discussed, via support contact or at the next supervised session 
 
7.2.7.5 Intervention Rationale 
This RCT integrated a high-load resistance with high-impact exercises, to maximise the 
potential bone loading effects, based on a meta-analysis of 24 clinical trials on the 
preservation of BMD (Zhao et al., 2015). Results demonstrated that a combined protocol, 
integrating high-load resistance training with high-impact exercises, appeared more effective 
in improving BMD at the femoral neck (SMD=0.411, 95% CI 0.176–0.645, p=0.001) and 
lumbar spine (SMD=0.431, 95% CI 0.159–0.702, p=0.002), compared to resistance training 
alone which only produced a nonsignificant positive effect. Furthermore, similar training 
modes have shown to be safe and effective in other clinical populations such as diabetes, 
osteoarthritis and multiple sclerosis (Sabapathy et al., 2011; Latham and Liu, 2013). 
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Latex free resistance TheraBands were used in the exercise intervention. They came in a 
range of precisely calibrated strengths and lengths (figure 37), allowing participants to reach 
an exercise overload effect regardless of initial fitness levels. They are light, easily stored and 
transported which simplifies the integration of a home-based exercise programme into the 
lifestyle of the participant. TheraBands have shown to be easier on the joints and less likely 
to cause injury in comparison to weights (Page and Ellenbecker, 2010; TheraBand, 2016), 
thus better for people with CD who can experience symptoms of joint pain (Crohn’s and 







The frequency and duration of the intervention were based on 8 systematic reviews, of which 
3 included a meta-analysis, that explored the effects of strength and/or impact training in 
young and older adults, post-menopausal and premenopausal women on BMD (Zehnacker 
and Bemis-Dougherty, 2007; Martyn-St James and Carroll, 2009; Nikander et al., 2010; 
Babatunde et al., 2012; Gomez-Cabello et al., 2012; Bielemann et al., 2013; Bolam et al., 
2013; Vieira et al., 2013). Strength training programmes alone demonstrated more favourable 
changes in BMD in programmes of a longer duration (>6 months) with the majority 
delivering sessions 2 to 3 times a week. However, results of a combined programme 
demonstrated that a shorter intervention, from 4 months, generated significant improvements 
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in BMD. With the majority of the studies delivering sessions 3-4 times a week. Taking these 
systematic reviews into consideration and a pragmatic approach to the 3-year duration of the 
PhD, a programme of 6 month, 3 times a week was thought to be sufficient to produce 
significant gains in BMD. 
 
7.2.7.6 Usual Care 
Participants allocated to the control group received usual care only, comprised of high level 
evidence-based medical treatment. As part of the trial, participants did not receive any 
supervised exercise or any specific exercise recommendations. However, to minimise the 
potential for resentful demoralisation that may occur through control group allocation 
(Torgerson and Sibbald, 1998) following the completion of the 6-month outcome assessment 
participants were offered a one-to-one exercise consultation with the study co-ordinator. 
Exercise benefits, barriers, facilitators and guidelines were discussed and guidance on 
incorporating physical activity into their lifestyle was provided. 
 
7.2.7.7 Three month assessment 
A follow-up assessment was carried out at week 13, allowing a + 2 week window for the 
completion. A 13-week CRF (Appendix 7p) was used to record medication changes, body 
mass, stature, resting heart rate, blood pressure and the occurrence of any AE. Outcome 
measures (Chapter 4) were also recorded.  
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7.2.7.8 Six month assessment 
At 6 months, follow-up visits at Northumbria University and NUTH Trust sites were 
completed, with the allowance of a + 6 week window for the completion of both visits. A 6-
month CRF (Appendix 7q) was completed to record medication changes, body mass, stature, 
resting heart rate, blood pressure and the occurrence of any AE. Outcome measures (Chapter 
4) were also recorded. At this visit participants were given a 7-day disease activity diary to 
complete prior to their 6-month hospital assessment.  
At the 6-month hospital assessment, changes in medications or medical history were obtained 
and disease activity assessed through the FC, CRP and CDAI. For the latter measure, body 
mass, extra-intestinal complications, anti-diarrhoeal medication, haematocrit and a physical 
examination of abdominal mass were assessed by a direct care team member. Results were 
recorded in a 6-month hospital CRF (Appendix 7r) and signed when completed by the 
medical principal investigator and a copy placed in medical records. Following the 
conclusion of the study, participants were provided with an end of study information sheet 
(Appendix 7s) and debrief sheet (Appendix 7t) explaining the nature of the research, how 
they could withdraw their data and how they could find out about the results of the study. 
 
7.2.7.9 Exit Interview and Exercise Consultation 
Prior to the 6-month assessments, to enable the recording of the exit interviews, participants 
were sent an audio recording invitation letter (Appendix 7u), an audio recording informed 
consent form (Appendix 7v) and a pre-paid envelope. If participants gave their permission to 
be recorded they were asked to return the completed written consent form and post it back in 
the pre-paid envelope.  
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The exit interview and exercise consultation occurred following the completion of both 6-
month assessments, a window of 6 weeks was allowed for the completion of the telephone 
follow-up activities. All exit interviews adhered to a script (Appendix 7w), covering 
perceived benefits and negative consequences from participating in the study, feedback 
regarding specific study design features (exercise/assessment procedures), and perceptions of 
barriers and facilitators to intervention participation. The interviews took no longer than 30 
minutes and were audio-recorded if written informed consent was obtained.  
 
7.2.8 Sample Size and Statistical Analysis 
As the minimally clinical important difference has not been established for BMD measures in 
people with CD, a distribution-based approach was used to calculate sample size. A 
superiority design, which aims to demonstrate the superiority of a new therapy compared to 
an established therapy or placebo, was proposed to observe an effect size of 0.4 (i.e. a small-
to-moderate effect). This was based upon the effect size observed at the femoral neck in a 
meta-analysis of 24 clinical trials examining the effects of combined resistance training 
interventions on the preservation of BMD in postmenopausal women (Zhao et al., 2015). 
Using the sample size calculation methods of Borm et al (2007), and assuming 80% power, a 
5% alpha level (2-sided), and a correlation between pre and post femoral neck BMD 
measures of r=0.9, a total of 19 participants per group were required to detect a respective 
group difference. Accounting for a potential loss of power as a result of dropouts, after 
allowing for 20% attrition, it was planned to include at least 50 participants in total (25 
intervention, 25 control).  
Descriptive statistics such as percentages, means and SD were used to present participant and 
disease-related characteristics. All statistical tests were two-sided at the 5% significance 
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level. To determine whether the covariates varied across the dependent variable, ANOVA 
was employed and no significant correlations were identified. Intervention effects were 
evaluated using separate covariance models for outcomes at months 3 and 6. These models 
were adjusted for baseline value of the dependent variable, gender, and baseline disease 
status. Adjusted mean differences, 95% confidence intervals and p values between treatment 
groups at 3 and 6 months were extracted from the models. 
The key strength of an RCT design is the random allocation of participants and, if there are 
enough participants, similar baseline characteristics which is critical for avoiding selection 
bias and establishing causation. Therefore to maintain this baseline comparability and to 
better inform clinical implementations, where individuals do not always comply with 
treatment, all analyses were based on an intention-to-treat basis. Missing outcomes however, 
may seriously comprise the validity and ability to make correct inferences from the trial. 
However, due to low rates of missing data, primary analysis were conducted using a modified 
intention-to-treat population that included all randomised participants who had both baseline 
and follow-up outcome data (i.e. complete-case analysis). Although multiple imputation is 
generally viewed as the preferred analytical approach to preserve sample size, for low rates of 
missing data at random or completely at random, a complete case method has demonstrated 
estimates to generally remain unbiased and achieve similar to or better precision results to a 
multiple imputation method (Mukaka et al., 2016). Best-case and worst-case sensitivity 
analyses were also performed to explore the impact of missing data for primary outcomes. 
Assuming that all participants lost to follow-up in one group had a ‘beneficial outcome’ and 
all those with missing outcomes in the other group had a ‘harmful outcome’, the dataset was 
generated by using the group mean plus 1 standard deviation of the group mean as a 
‘beneficial outcome’ and the group mean minus 1 standard deviation of the group mean as a 
‘harmful outcome’ (Jakobsen et al., 2014).  
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All analyses were performed using the IBM Statistical Package for the Social Sciences 
software version 24 (IBM Corporation, UK). 
 
7.2.9 Blinding 
Due to the nature of the intervention, both the intervention facilitators and participants were 
aware of their group allocation. However, to reduce the risk of detection bias a blinded 
outcome assessor conducted the 3 and 6-month assessments. Participants were asked to 




Recruitment took place between February 2018 to March 2019, with all follow-up data 
completed by October 2019. Of those who expressed interest, 129 requested further study 
information, 18 would have liked to have taken part however could not due to travel 
constraints (n=9), current health status (n=6), work responsibilities (n=2) or family 
commitments (n=1). From the PROTECT trial log, 35 (74.5%) participants were recruited 
and randomised from the IBDBioresource Database, 1 (2.1%) from social media, 10 (21.3%) 
from outpatient clinics and 1 (2.1%) from recruitment posters.  
Out of 76 participants, 48 met the eligibility criteria and 47 were randomised into the exercise 
(n=23) or control (n=24) group (figure 38). The reasons for exclusion were elevated FC >250 
mcg/g (n=24), CDAI >220 (n=2) and unavailable FC result (n=2). Three participants had to 
repeat FC biomarkers as a result of falling outside the 4-week window to attend the baseline 
visit, due to family bereavement (n=2) and family illness (n=1). Prior to randomisation the 
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resistance exercise intervention was the group preference for 40 (85.1%) participants and 7 
(14.9%) participants stated that they did not have a preference on group allocation.   
Three participants formally withdrew from the study, due to self-reported acute flare (n=1) 
and an allergic reaction to infliximab (n=1) not trial related and one from the exercise group 
due to family commitments. One participant in the control group was also lost to the 3-month 















 Figure 38. 
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7.3.1 Participant Characteristics  
Demographic information and disease characteristics of study participants are summarised in 
table 15. Of the 47 eligible participants, 15 (31.9%) were males, all participants were of white 
ethnicity with a mean age of 49.3 (SD=13.0), with a wide age range from 25-85 years. Most 
participants were in full-time employment (40.4%). The next largest groups were retired 
(19.1%), part-time employment (14.9%), self-employed (12.8%) and unemployed (12.8%). 
Almost 60% of participants had never smoked before and had an average alcohol intake of 
4.5 (SD=4.7) units per week. Median age at diagnosis was 31 years, ranging from 11-56 
years and had a median diagnosis duration of 216 months (18 years), ranging from 12 (1 
year) to 660 months (55 years). A longer duration of disease was seen in the exercise group 
(216 months) than the control group (204 months). Inflammatory markers suggested that 
most participants had an inactive disease (66.0%), with a mean FC of 86.5 (SD=59.5) and 
CDAI of 114.1 (SD=59.5).  
Appendix 7x illustrates clinical characteristics at baseline. CD were located in the ileum and 
colon in 18 (38.3%) participants, in the ileum alone in 15 (31.9%) participants, in the colon 
alone in 12 (25.5%) participants and in both the ileum, colon and upper gastrointestinal tract 
in 2 (4.3%) participants. The disease presented itself as non-stricturing and non-penetrating in 
most participants (66.0%) with 13 (27.7%) of participants affected by perianal CD. 
Immunosuppressants (42.6%), anti-TNF treatment (40.4%) and vitamin D supplementation 
(25.5%) were the most commonly used medications. The most common surgical procedures 
were right hemicolectomy/ileocecal resection (40.5%), ileal/jejunal resection or 
stricturoplasty (25.5%) and colectomy and ileostomy (14.9%). Almost one third of 
participants, in addition to their CD, experienced an EIM, such as enteropathic arthritis 
(12.8%), psoriasis (8.5%), osteoporosis/osteopenia (8.5%), ankylosing spondylitis (6.4%), 
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bile salt malabsorption (4.3%), lymphoma/malignancy (4.3%), iritis/uveitis (4.3%), erythema 
nodosum (2.1%), orofacial granulomatosis (2.1%) or serious infections (2.1%).  
Table 15.  
Baseline demographic information and disease variables 
 
 Exercise [n=23] Control [n=24] Total [n=47] P valuea 
Age, mean (SD), years 46.1 ± 11.9 52.3 ± 13.6 49.3 ± 13.0 .293 
Gender, n (%)    .653 b 
   Female, n (%) 16(69.6) 16(66.7) 32(68.1) - 
   Male, n (%) 7(30.4) 8(33.3) 15(31.9) - 
White Ethnicity, n (%) 23(100) 24(100) 47(100) 1.00 b 
Employment Status, n (%)    .650 b 
   Employed Full-Time 10(43.5) 9(37.5) 19(40.4) - 
   Employed Part-Time 1(4.3) 6(25.0) 7(14.9) - 
   Self-employed 4(17.4) 2(8.3) 6(12.8) - 
   Unemployed 3(13.0) 3(12.5) 6(12.8) - 
   Retired 5(21.7) 4(16.7) 9(19.1) - 
Smoking Status, n (%)    .715 b 
   Previously 9(39.1) 11(45.8) 20(42.6) - 
   Never 14(60.9) 13(54.2) 27(57.4) - 
Alcohol Intake, mean (SD), 
units 
5.1 ± 5.4 3.9 ± 3.9 4.5 ± 4.7 .041 
Age at Diagnosis, median 
(IQR), years 
27(21-35) 31(27-41) 31(22-37) .999 
Duration of Diagnosis, 
median (IQR), months 
216(96-288) 204(60-396) 216(63-386) .121 
Disease Activity, mean (SD)    - 
   Faecal Calprotectin, μg/g 55.9 ± 28.9 113.3 ± 66.9 86.5 ± 59.5 .030 
   CDAI  104.7 ± 57.6 123.1 ± 61.9 114.1 ± 59.9 .575 
CDAI Activity Status, n (%)    .653 b 
   Inactive 15(65.2) 16(66.7) 31(66.0) - 
   Mildly Active 8(34.8) 8(33.3) 16(34.0) - 
CDAI, Crohn’s Disease Activity Index; a indicates independent t-test, b indicates Chi-squared test 
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These participant characteristics are similar to UK epidemiological data of 4546 CD 
participants across 21 centres (Bardhan et al., 2010). Median age at diagnosis was 30 years, 
and median disease duration ranged from 1 to 801 months. Disease extent was fairly even 
across all locations and resections were reported in 37-41% of participants. The use of 
biologics were not routinely used over ten years ago and therefore comparisons are unable to 
be made. However, in comparison to recent exercise interventions in CD, Cronin et al (2019) 
and Tew et al (2019) identified similar use of immunosuppressants, but not in biologics. It is 
therefore thought this is not atypical in a group of individuals presenting with an inactive to 
mildly active disease. 
 
7.3.2 BMD 
BMD (g/cm2) results are presented in figure 39. Following analysis, according to WHO 
diagnostic criteria, 21.3% of CD participants were indicative of having osteopenia (T-score 
between -1.0 and -2.5) at the lumbar spine and 4.3%, of osteoporosis (T-score -2.5 and 
below). T-scores of the left hip suggested osteoporosis in 6.3% and osteopenia in 38.3% of 
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Intervention changes in BMD are presented in table 16. At 6 months, the exercise group 
demonstrated favourable and statistically significant between group differences at the lumbar 
spine (adjusted mean df=0.036g/cm2; 95% CI 0.024-0.048; p<0.001) and femoral neck 
(0.018g/cm2; 95% CI 0.001-0.035; p=0.039), but not at the greater trochanter (0.013 g/cm2; 
95% CI -0.019-0.045; p=0.415).  
 
Table 16.  Means, adjusted means and group differences in BMD (g/cm2) from baseline to 6-month 
  Baselinea 6 Monthsb Adjusted Mean (95% CI) Difference (95% 
CI) 
p value 
Lumbar Spine  IG 1.068 ± 0.16 1.111 ± 0.15 1.091 (1.082-1.099) 0.036 (0.024-
0.048) 
<0.001 
CG 1.037 ± 0.22 1.032 ± 0.24 1.055 (1.046-1.063) 
Greater 
Trochanter 
IG 0.728 ± 0.11 0.737 ± 0.11 0.713 (0.691-0.735) 0.013 (-0.019 to 
0.045) 
0.415 
CG 0.678 ± 0.10 0.676 ± 0.11 0.700 (0.678-0.723) 
Femoral Neck IG 0.812 ± 0.14 0.845 ± 0.15 0.812 (0.800-0.823) 0.018 (0.001-
0.035) 
0.039 
CG 0.753 ± 0.13 0.759 ± 0.13 0.794 (0.782-0.806) 
Mean ± S.D are indicated for all columns unless stated 
IG, Intervention Group; CG, Control Group  
a IG n=23, CG n=24; b IG n=22, CG n=21  
 
 
Percent changes in BMD from baseline to 6 months are presented in figure 41. In the exercise 
group percentage changes ranged from 0.4%-4.1% (2.3%; p=0.018) at the femoral neck, -
2.2%-5.1% (1.4%; p=0.426) at the greater trochanter and 2.6%-5.1% (3.8%; p<0.001) at the 
lumbar spine. In the control group, the lumbar spine increased by an average of 0.79%, while 
the femoral neck and greater trochanter decreased by 0.29% and 0.48%, respectively.  
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7.3.3 Muscle Strength 
Table 17 demonstrates maximum voluntary isokinetic strength (MVIS) of the knee extensors 
and elbow flexors. Exercise participants experienced more favourable changes in muscular 
strength than the control group at week 13 and 26. When working lower limbs at a velocity of 
60°/s (figure 42a), statistically significant group differences were identified at week 13 
(adjusted mean df=12.9 Nm; 95% CI-2.5-23.3; p=0.16) and sustained at week 26 (22.4 Nm; 
95% CI 12.1-32.8; p<0.001). Isokinetic knee extension at a velocity of 180°/s (figure 42b) 
also demonstrated significant between group differences at week 13 (10.1 Nm; 95% CI 3.6-
Figure 41. 
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16.7; p=0.003) and 26 weeks (16.8 Nm; 95% CI 9.0-24.5; p<0.001). Statistically significant 
between group differences in the upper limbs at an angular velocity of 60°/s were identified at 
week 13 (5.2 Nm; 95% CI 2.8-7.6; p<0.001) and sustained at week 26 (6.8 Nm; 95% CI 3.9-
9.6; p<0.001) (figure 42c). Significant changes were also seen at an angular velocity of 120°/s 
at 13 weeks (5.8 Nm; 95% CI-3.5-8.1; p<0.001) and 26 weeks (6.3 Nm; 95% CI 3.3-9.3; 
p<0.001) (figure 42d). 
 
Figure 42. Adjusted mean differences of the knee extension at angular velocities of 60°/s (A) and 180°/s (B) 
and elbow flexion at angular velocities of 60°/s (C) and 120°/s (D) 
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Favourable significant between group differences in HGS, determined using the JAMAR 
Hydraulic dynamometer, were identified in the exercise group at week 13 (adjusted mean 
df=4.0 kg; 95% CI 2.1-5.9; p<0.001) and 26 weeks (8.3 kg; 95% CI 6.2-10.5; p<0.001) (table 
17).  
 
7.3.4 Muscle Endurance 
During the course of the 6-month study, upper and lower limb muscular endurance 
significantly improved in the exercise group at week 13, and were sustained at week 26  
(table 17) when compared to the control group. Significant upper muscular endurance 
between group differences were identified at 13 weeks (adjusted mean df= 3 reps; 95% CI 1-
5; p<0.001) and 26 weeks (7 reps; 95% CI 5-8; p<0.001) (Figure 43a). Significant 
improvements were also identified in lower muscular endurance at week 13 (3 reps; 95% CI 
1-4; p<0.001) and 26 weeks (4 reps; 95% CI 3-6; p<0.001) (Figure 43b) in the exercise group 






p = <0.001 
p = <0.001 
p = <0.001 
p = <0.001 
Figure 43. 
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Table 17.  Change in muscular function variables from baseline, 3 and 6 month 
 Group 
Allocation 
Baseline 3 Months Adjusted Mean 3 
Months (95% CI) 
Mean Difference 
(95% CI) 
P value 6 months Adjusted Mean 6 






   30-s CST IG 13.6 ± 2.8 16.5 ± 3.4 16 (15-17) 3 (1-4) <0.001 18.6 ± 3.3 18 (17-20) 4 (3-6) <0.001 
CG 13.5 ± 3.5 13.6 ± 3.0 14 (13-15)   14.3 ± 3.1 14 (13-16)   
   30-s BCT IG 16.1 ± 3.0 20.0 ± 2.80 20 (19-21) 3 (1-5) <0.001 23.5 ± 2.7 23 (22-25) 7 (5-8) <0.001 
CG 16.6 ± 4.1 16.8 ± 3.7 17 (16-18)   16.6 ± 3.1 17 (15-18)   
Muscle Strength 
   HGS IG 36·4 ± 13·1 39.4 ± 12.1 37.7 (36.4-39.0) 4.0 (2.1-5.9) <0.001 42.4 ± 12.6 40.9 (39.4-42.4) 8.3 (6.2-10.5) <0.001 
CG 32.2 ± 12.2 31.8 ± 10.8 33.6 (32.3-35.0)    32.5 (31.0-34.1)   
   Isokinetic Knee  
   Extension-60°/sa 
IG 82.5 ± 44.0 98.2 ± 47.5 94.6 (87.4-101.8) 12.9 (2.5-23.3) 0.016 104.3 ± 52.6 100.7 (93.4-107.9) 22.4 (12.1-32.8) <0.001 
CG 74.9 ± 36.2 77.9 ± 38.4 81.7 (74.3-89.1)    78.2 (70.8-85.6)   
   Isokinetic Knee  
   Extension-180°/s a  
IG 51.9 ± 32.7 62.7 ± 34.6 60.4 (55.8-65.0) 10.1 (3.6-16.7) 0.003 67.8 ± 34.2 65.8 (60.4-71.2) 16.8 (9.0-24.5) <0.001 
CG 47.6 ± 23.1 47.8 ± 26.4 50.3 (45.6-54.9)    49.1 (43.5-54.6)   
   Isokinetic Elbow  
   Flexion-60°/sb 
IG 30.2 ± 16.0 34.1 ± 16.4 32.3 (30.7-34.0) 5.2 (2.8-7.6) <0.001 36.5 ± 16.5 34.8 (32.8-36.7) 6.8 (3.9-9.6) <0.001 
CG 26.4 ± 10.9 25.3 ± 11.3 27.1 (25.4-28.8)    28.0 (26.0-30.0)   
   Isokinetic Elbow  
   Flexion-120°/sb 
IG 25.5 ± 12.1 29.6 ± 14.9 28.7 (27.1-30.4) 5.8 (3.5-8.1) <0.001 30.6 ± 14.0 29.8 (27.8-31.9) 6.3 (3.3-9.3) <0.001 
CG 23.6 ± 10.0 22.0 ± 10.1 23.0 (27.1-24.6)    23.6 (21.4-25.7)   
Mean ± S.D are indicated for all columns unless stated.  
IG, Intervention Group; CG, Control Group; CST, Chair Stand Test; BCT, Bicep Curl Test; HGS, Hand Grip Strength 
a Computed as average MVIS of both legs  
b Computed as average MVIS of both arms   
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Assessed using the EQ-5D-5L, the descriptive system comprised of five dimensions, 
illustrated that 19.1%, 6.4%, 29.8%, 51.1% and 51.1% of CD reported that their QOL was 
impacted by mobility problems, self-care problems, usual activities, pain/discomfort and 
anxiety/depression, respectively. The self-assessed visual analogue scale, indicated that 
participants aged 18-29 reported the poorest health and participants aged 50-59 and 70+ 










Intervention changes on the five descriptive domains are identified in table 18. In the exercise 
group, mobility, self-care, usual activities and pain/discomfort remained stable throughout the 
intervention. Five participants reported experiencing fewer feelings of anxiety/depression. 
Control group participants reported experiencing more problems in mobility, self-care and 
Figure 44. 
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pain/discomfort from baseline to week 26 with usual activities and anxiety/depression 




Table 19 demonstrates intervention changes in QOL data. Statistically significant between 
group differences were identified in the EQ-5D-5L utility index scores at 13 weeks (adjusted 
mean df=0.117; 95% CI 0.023- 0.211; p=0.016) and 26 weeks (0.109; 95% CI 0.038-0.181; 
p=0.004). Estimated marginal means in the EQ VAS scores demonstrated no significant 
between group differences at 3 month (10.4; 95% CI 1.4-19.4; p=0.24) or 6 months (8.3; 95% 
CI -1.5 to 18.3; p=0.095).  
 
Table 18.  




Exercise Group Control Group 
Baseline Week 13 Week 26 Baseline Week 13 Week 26 
Mobility No problems 18 20 19 17 12 12 
Problems 4 2 3 4 9 9 
Self-Care No problems 21 21 21 20 21 18 
Problems 1 1 1 1 0 3 
Usual 
Activity 
No problems 20 19 20 12 9 12 
Problems 2 3 2 9 12 9 
Pain/ 
Discomfort 
No problems 13 12 13 9 4 5 
Problems 9 10 9 12 17 16 
Anxiety/ 
Depression 
No problems 15 17 20 8 9 8 
Problems 7 5 2 13 12 13 
a ‘No problems’ dichotomised as level 1 and ‘problems’ as levels 2 to 5 
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7.3.5.2 IBDQ 
Intervention changes in IBDQ data are presented in table 19. Estimated marginal means from 
week 1 to week 13 demonstrated that the total IBDQ score increased from 182 ± 23 to 191 ± 
20 (∆=9) in the exercise group and decreased from 166 ± 25 to 162 ± 26 (∆= -4) in the control 
group, resulting in a significant adjusted between group difference of 17 (95% CI 7 to 26; 
p=0.001). However this was not sustained at week 26 (6; 95% CI 3-15; p=0.175). All IBDQ 
subscales illustrated significant between group differences at 13 weeks: bowel symptoms 
(5.4; 95% CI 1.4 to 9.3; p=0.010), systemic systems (3.2; 95% CI 1.0-5.3; p=0.006), 
emotional health (4.5; 95% CI 0.6-8.5; p=0.024) and social function (3.6; 95% CI 1.5-5.6; 
p=0.001). However, these between group differences were only sustained at 6-month in the 
subscale social function (3.1; 95% CI 1.2-4.9; p=0.002).  
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Table 19.  Change in QOL indices from baseline, 3 and 6-month  
 Group 
Allocation 
Baseline 3 Months Adjusted Mean 3 
Months (95% CI) 
Mean Difference 
(95% CI) 
P value 6 months Adjusted Mean 6 







   Index-scores 
   (-0.285 to 1) 
IG 0.856 ± 0.12 0.872 ± 0.12 0.859 (0.793-0.925) 0.117 (0.023-0.211) 0.016 0.885 ± 0.13 0.875 (0.825-0.924) 0.109 (0.038-0.181) 0.004 
CG 0.810 ± 0.113 0.729 ± 0.19 0.742 (0.677-0.808)   0.749 ± 0.14 0.765 (0.715-0.816)   
   VAS-scores  
    (0 to 100) 
IG 80.0 ± 14.6 84.5 ± 9.4 83.0 (76.9-89.2) 10.4 (1.4-19.4) 0.024 85.0 ± 14.4 82.8 (76.0-89.6) 8.3 (-1.5 to 18.3) 0.095 




   Total  
   (32 to 224) 
IG 182 ± 23.0 191 ± 20.0 185 (179-191) 17 (7-26)  0.001 187 ± 23.0 180 (174-186) 6 (-3 to 15) 0.175 
CG 166 ± 25.0 162 ± 26.0 169 (162-175)   166 ± 29.0 174 (167-180)   
   Bowel Symptoms 
   (10 to 70) 
IG 57.9 ± 8.6 59.6 ± 9.2 57.7 (55.0-60.4) 5.4 (1.4-9.3) 0.010 58.6 ± 9.3 56.4 (54.2-58.6) 3.1 (0.5-10.6) 0.084 
CG 52.1 ± 9.8 50.3 ± 8.8 52.3 (49.5-55.1)   51.2 ± 8.8 53.5 (51.2-55.8)   
   Systemic Systems 
   (5 to 35) 
IG 24.0 ± 4.8 26.1 ± 4.3 25.6 (24.0-27.1) 3.2 (1.0-5.3) 0.006 24.5 ± 6.1 24.0 (22.1-25.8) 1.2 (-2.0 to 4.5) 0.405 
CG 21.9 ± 5.6 21.8 ± 5.1 22.4 (20.9-24.0)   22.1 ± 4.8 22.8 (20.9-24.8)   
   Emotional Health 
   (12 to 84) 
IG 67.9 ± 10.2 71.6 ± 7.2 68.7 (66.0-71.4) 4.5 (0.6-8.5) 0.024 70.3 ± 10.7 66.8 (63.7-69.9) 0.2 (-2.3 to 12.0) 0.927 
CG 59.8 ± 12.4 61.1 ± 13.1 64.2 (61.4-66.9)   63.0 ± 13.9 66.6 (63.5-69.7)   
   Social Function 
   (5 to 35) 
IG 32.4 ± 3.7 33.8 ± 1.8 33.3 (31.9-34.7) 3.6 (1.5-5.6) 0.001 33.6 ± 2.1 33.1 (31.8-34.4) 3.1 (1.2-4.9) 0.002 
CG 30.4 ± 4.4 29.2 ± 5.1 29.7 (28.3-31.2)   29.5 ± 4.7 30.0 (28.7-31.3)   
Mean ± S.D are indicated for all columns unless stated.  
IG, Intervention Group; CG, Control Group; EQ-5D-5L, EuroQol; IBDQ, Inflammatory Bowel Disease QOL Questionnaire; VAS, Visual Analogue Scale 
a Higher scores represent a better quality of life 
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7.3.6 Fatigue 
Severity, frequency and duration of fatigue was higher at baseline in females (8.3 ± 4.4) than 
males (7.3 ± 3.7). Reports of experiencing no fatigue were reported in 2 (4.6%) participants, 
slight to moderate in 30 (62.8%) participants and severe in 15 (32.6%) participants. The 
perceived impact of fatigue on daily activities in the past two weeks was reported as having 
no effect in 4 (8.5%) participants, a moderate effect in 35 (74.5%) participants and a severe 
effect in 8 (17%) participants. Perceived effects of fatigue on daily activities at baseline were 
higher in males (26.2 ± 22.1) than females (25.6 ± 25.9). Figure 45 identifies the main causes 
of fatigue. The main causes identified were poor sleep/sleep quality (34%), work/travelling to 
work (26%), secondary complications (15%) and poor nutrition (13%). Figure 46 identifies 
the factors reported by participants that help reduce fatigue. The main alleviants identified 
were  resting/napping/sleeping (34%) and exercise (12.8%). 29.8% of participants stated 
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During the course of the study the exercise group reported reduced feelings of fatigue, 
assessed using the IBD-F, in both subcategories: assessment (Severity, frequency and 
duration) and perceived impact (table 20). In the assessment fatigue subcategory, 2 (8.7%) 
participants reported feeling no fatigue at baseline, week 13 and week 26. Slight to moderate 
fatigue was reported in 16 (69.6%) participants at baseline, 17 (72.7%) at week 13 and 19 
(86.4%) at week 26. Although numbers increased in this category, they decreased in the 
severe fatigue category with 5 (21.7%) reporting severe fatigue at baseline, 3 (13.6%) at 
week 13 and 1 (4.5%) at week 26. Suggesting that participants did feel some benefits of 
exercising on fatigue levels. However, no significant between group differences were 
identified at 13 weeks (adjusted mean df= -1; 95% CI -3 to 1; p=0.249), but statistically 
significant between group differences were achieved at 26 weeks (-2; 95% CI -4 to -1; 
p=0.005). 
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 In the perceived impact fatigue subcategory, 4 (17.4%) participants reported fatigue having 
no effect on daily activities at baseline, 5 (22.7%) at week 13 and 3 (13.6%) at week 26.  A 
moderate effect on daily activities was reported in 16 (69.9%) participants at baseline, 16 
(72.7%) at week 13 and 18 (81.8%) at week 26. Although numbers increased in this category, 
they decreased in the severe impact on daily activities with 3 (13%) reporting fatigue having 
a severe impact on daily activities at baseline and only 1 (4.5%) participant at week 13 and 
week 26. Although no significant between group differences were identified at week 13 (-6.5; 
95% CI -13.4 to 0.5; p=0.068), significant between group differences were seen at week 26 (-
6.8; 95% CI -13.0 to -0.619; p=0.032) (table 20). By week 26, 4 (18.2%) exercise participants 
reported their fatigued change from being constant to intermittent.  
 
7.3.7 Physical Activity 
No significant between group differences in physical activity levels were identified at week 
13 (p=0.077) or week 26 (p=0.930) (table 20). Larger between group differences were seen 
between baseline and 3 months (adjusted mean df= 414 minutes; 95% CI -47 to 875) than 
baseline to 6 months (-21 minutes; 95% CI -499 to 457). On average, in the exercise group, 
leisure physical activity time increased by 120 minutes from baseline to 13 weeks and 
decreased by 27 minutes at 26 weeks. On the other hand, the control group saw a decrease of 
72 minutes from baseline to week 13 and an increase of 71 minutes at week 26. Total work 
physical activity time, including only participants who worked, the exercise group saw an 
increase of 99 minutes from baseline to 13 weeks and a decrease of 37 minutes at week 26. 
Likewise, the control group decreased by 22 minutes of work physical activity by week 13, 
however by week 26 physical activity at work increased by 310 minutes.  
 
CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
 







   
Table 20.  Change in questionnaire variables from baseline, 3 and 6-month  
 Group 
Allocation 
Baseline 3 Months Adjusted Mean 3 
Months (95% CI) 
Mean Difference 
(95% CI) 
P value 6 months Adjusted Mean 6 







   Assessment  
   (0-20) 
IG 6.0 ± 4.0 6.0 ± 4.0 7 (5-8) -1 (-3 to 1) 0.249 5.0 ± 3.0 6 (5-7) -2 (-4 to -1) 0.005 
CG 9 ± 4.0 9 ± 4.0 8 (7-9)   10 ± 5.0 8 (7010)   
   Impact 
   (0-120) 
IG 17.7 ± 21.7 12.2 ± 14.1 16.4 (11.6-21.2) -6.5 (-13.4 to 0.5) 0.068 12.1 ± 15.9 17.0 (12.8-21.2) -6.8 (-13.0 to -.619) 0.032 
CG 33.6 ± 25.0 27.2 ± 21.3 22.9 (18.0-27.7)   28.9 ± 22.3 23.8 (19.5-28.1)   
Physical Activity 
Habits (min/week) 
IG 1498 ± 1049 1544 ± 1057 1348 (1037-1658) 414 (-47 to 875) 0.077 1456 ± 924 1239 (917-1561) -21 (-499 to 457) 0.930 
CG 794 ± 782 728 ± 621 934 (616-1253)   1032 ± 917 1260 (929-1590)   
Mean ± S.D are indicated for all columns unless stated.  
IG, Intervention Group; CG, Control Group 
a Lower scores represent better reported fatigue levels 
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7.3.8 Disease Activity 
To ensure participants did not flare up during the intervention, disease activity was assessed 
at baseline and at 6 months using the CDAI and FC. Baseline CDAI and FC scores in the 
exercise group were 104.7 ± 57.6 and 55.9 ± 28.9, respectively. At week 26, out of 22 
participants in the exercise group, 21 had completed all CDAI parameters (7-day disease 
activity diary unavailable n=1) and 17 had submitted a stool sample for FC testing. Mean 
CDAI scores had decreased to 77.8 ± 48.2, but FC scores had increased to 115.3 ± 121.4. In 
the control group, baseline CDAI and FC scores were 123.1 ± 61.9 and 113.3 ± 66.9, 
respectively. Out of the 21 participants in the control group, 20 had completed all CDAI 
parameters (7-day disease activity unavailable n=1) and 18 had submitted a stool sample for 
FC testing. Mean CDAI scores had decreased to 128.5 ± 69.1, but FC scores had increased to 
202.1 ± 154.1.  
 
7.3.9 Anthropometrics 
Significant between group differences in resting heart rate were identified at week 13 
(adjusted mean df= -5 beats per minute (bpm); 95% CI -10 to 0; p=0.032) and week 26 (-6 
bpm; 95% CI -12 to -1; p=0.032). No between group differences were identified in BMI or 
blood pressure, systolic or diastolic at week 13 or week 26 (Appendix 7y).  
 
7.3.10 Best-case and Worst-case Sensitivity Analysis 
Effect sizes and significant values for muscular function outcomes did not substantially alter, 
however BMD outcomes appeared to be more sensitive to missing data (Appendix 7z). Best-
case sensitivity analysis identified an increase in effect size for the lumbar spine (adjusted 
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mean df= 0·085 g/cm2; 95% CI 0·027 to 0·124; p=0·005), femoral neck (0·052 g/cm2; 95% 
CI 0·010 to 0·095; p=0·017) and greater trochanter (0.036 g/cm2; 95% CI -0.002 to 0.074; 
p=0.065). In contrast, effect sizes were reduced in the worst-case sensitivity analyses for the 
lumbar spine (adjusted mean df= 0·014 g/cm2; 95% CI -0·030 to 0·059; p=0·521), femoral 
neck (0·006 g/cm2; 95% CI -0·026 to 0·037; p=0·704) and greater trochanter (-0.002 g/cm2; 
95% CI -0.035 to 0.032; p=0.928).    
 
7.3.11 Compliance and exercise enjoyment 
Participants in the exercise group attended 214 ± 2.1 (81.1%) out of 264 supervised sessions 
and completed 843 ± 14.4 (58.1%) out of 1452 unsupervised sessions. From the total 1716 
exercise sessions offered, 1057 ± 15.0 (61.6%) were completed. A median (IQR) of 10 (8-12) 
supervised sessions were completed by each participant, 39 (24-48) out of 66 for 
unsupervised sessions and 50 (36-59) out of 78 for total number of exercise sessions. 
Exercise enjoyment was determined at 3 (figure 47) and 6 months (figure 48) using the 
PACES questionnaire. At 3 months the mean (SD) enjoyment score was 104 ± 13 out of a 
possible 126, with a median (IQR) of 107 (96-114) scored for each participant. Enjoyment 
scores were sustained at 6 months, with a mean (SD) score of 103 ± 15 out of a possible 126 
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7.3.12 Adverse Events 
A total of six AE were recorded, three exercise-related and three deemed unrelated to the 
research. The three exercise-related events recorded were: two instances of light-headedness 
due to lack of food during the day; and one instance of nausea as a result of the participant 
immediately eating prior to exercise. On all occasions the exercise was stopped and 
participants advised about appropriate dietary habits in relation to exercise. The three AE 
deemed unrelated to the research were: a transient ischaemic attack by a participant in the 
exercise group, the medical PI deemed this unrelated to the research; a self-reported disease 
flare by a participant in the control group and an allergic reaction to infliximab from a 
participant in the control group, the latter two resulted in both participants being withdrawn 
from the study. One control participant experienced disease relapse between baseline and 6 
months, defined by an increase in CDAI of >100 to a score >150, increasing from 46 at 
baseline to 175 at 6 months.  
 
7.4 Discussion  
To our knowledge, this is the first RCT to evaluate a combined impact and resistance training 
programme in adults with inactive to mildly active CD. Our results illustrate that a largely 
(85%) unsupervised 6-month intervention led to significant improvements in BMD, muscular 
strength, muscular endurance and fatigue at 6 months and without any deterioration in disease 
activity. Although the intervention group experienced significant improvements in QOL, 
determined using the IBDQ (total and subdomains) and EQ-5D-5L (VAS and index) at 3 
months, these improvements were only sustained in the EQ-5D-5L index scores and the 
IBDQ subdomain social function at 6 months. Given the significant pressure within the NHS 
to control expenditure and the secondary burdening complications associated with CD, the 
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implementation of these findings not only provide NHS clinicians, stakeholders and clinical 
commissioning groups but people with CD additional management options. Additionally, 
providing an essential step in the development of providing evidence-based exercise 
guidelines for individuals with CD to improve health and care outcomes, a primary aim of the 
NHS.  
 
7.4.1 Bone Mineral Density 
The results of this study show that a 6-month resistance and impact training programme has 
favourable improvements in BMD at the lumbar spine and femoral neck in adults with CD. 
To the best of our knowledge, only one published RCT so far has investigated the effects of 
resistance exercise on BMD in adults with CD (Robinson et al., 1998). Following the 
conclusion of this 12-month low-impact resistance-training programme, improvements in 
BMD were identified in the exercise group at the greater trochanter, femoral neck and lumbar 
spine in comparison to the control group. Although these differences did not reach statistical 
significance, after analysis of the fully compliant participants only, significant differences 
were seen at the greater trochanter, and greater improvements identified at the femoral neck 
and lumbar spine, suggesting that increased BMD is positively related to the amount of 
exercise performed. These findings partially contradict the results of the current study, which 
found significant improvements at the lumbar spine and femoral neck but not at the greater 
trochanter. Disease activity may explain this variation, with the current study only including 
participants in clinical remission or with a mildly active disease while Robinson et al (1998) 
included a more heterogeneous sample, which may explain why only 52% of participants 
where compliant with the exercise programme. Proinflammatory cytokines that correlate with 
disease activity such as IL-1 (α and β), IL-6, IL-17 and TNF-α, also activate osteoclasts that 
interfere with the pathway involved in bone metabolism, known as RANK-RANKL-OPG and 
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thus changing the rate of bone formation, bone resorption and overall bone homeostasis 
(Bernstein and Leslie, 2003; Bernstein et al., 2005; Mundy, 2007). RANKL (receptor 
activator of NF-kB ligand) stimulates mature osteoclasts to resorb bone by binding to OPG, 
which is produced by osteoblasts and responsible for blocking the interaction between RANK 
and RANKL, an interaction that causes osteoclasts to differentiate and mature resulting in 
bone loss (Wei et al., 2001; Ali et al., 2009). Another explanation could be the intensity of the 
intervention and lack of impact exercises, with Robinson and colleagues opting for a low 
intensity resistance programme alone involving twice-weekly, 12 floor-based exercises.  
Further unpublished randomised controlled trials have investigated the effects of a 
multimodal intervention (weight-bearing exercise and supplementation) and found effects 
partly in line with those of the current study. Sanges et al (2013) assessed the impact of 
prescribing 1g of calcium carbonate and 800 IU vitamin D with and without a thrice-weekly 
muscular training programme. Although improvements in BMD after 12 months were 
identified in both groups, greater improvements were seen in the exercise group at the lumbar 
spine and femoral neck (p<0.05), suggesting that supplementation alone is not as effective 
than a combination approach including exercise. However, analysis at 12 weeks of a 24-week 
progressive resistance-training programme alongside calcium and vitamin D supplementation 
did not significantly improve BMD and week 24 results remain unreported (Ponich et al., 
2003). However, this study was significantly limited by the unclear methods of 
randomisation, lack of control group and lack of a priori sample size calculation. Although 
these findings do suggest that to elicit significant and beneficial changes in BMD, a longer 
training intervention is required.  
The findings of the current study indicate that regular combined impact and resistance 
training can help improve BMD in adults with CD, significantly at the lumbar spine and 
femoral neck but not at the greater trochanter. This exercise programme was designed to load 
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the musculoskeletal system slowly, while providing enough time for bone growth and 
adaptation before incorporating small increases over an extended period. Although the 
optimum frequency and duration of exercise required to increase BMD has not yet been 
established, the greatest improvements in BMD have been reported in exercise interventions 
combining resistance exercise and high-impact jump training, which this study included and 
was based upon. In post-menopausal women, a meta-analysis of 24 RCT’s combining impact 
and resistance training interventions between 6 and 24 months illustrated mean changes of 
0.431 (1.8%) (95% CI 0.159 to 0.702; p=0.002) at the lumbar spine and 0.411 (2.4%) (95% 
CI 0.176 to 0.645; p=0.001) at the femoral neck (Zhao et al., 2015). A more recent 8 month, 
twice-weekly, high-intensity resistance and impact training RCT of 101 postmenopausal 
women with low bone mass found superior changes at the lumbar spine (2.9 ± 2.8%) and 
femoral neck (0.3 ± 3.0%) (Watson et al., 2017). Interestingly, none of these studies 
aforementioned measured the greater trochanter. Another systematic review of 43 RCT’s, 
identified 10 studies that examined combination exercise interventions, two of which 
measured the greater trochanter. These two studies identified mean change improvements of 
1.31% (95% CI 0.69 to 1.92), however the results of a meta-analysis showed that there was a 
statistically significant effect in favour of control in percentage change in BMD at the hip. A 
potential reason for this non-significance could be explained by the composition and 
microarchitecture of the greater trochanter, which has demonstrated significantly higher 
mineralisation (+2%, p<0.05) than the femoral neck (Turunen et al., 2013). Nevertheless, the 
mean percentage changes echo those of the current study indicate that bone density at the 
lumbar spine increased by 3.8% (95% CI 2.6 to 5.1), 2.3% (95% CI 0.4 to 4.1) at the femoral 
neck and 1.4% (95% CI -2.2 to 5.1) at the greater trochanter after 6 months compared to the 
control group.  
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The most important question is this of clinical importance. Bisphosphates remain the most 
common treatment for treating osteoporosis and are thought to induce an average increase 
between 7 to 8% at the spine and 5 to 7% at the hip following daily treatment over a three-
year period (Chestnut et al., 2004). Although the changes in this study do not meet the level 
of bisphosphonate treatment, the changes in this study occurred from a thrice-weekly 6-
month intervention and not following daily treatment for three years. However, recent meta-
regression analysis indicated that a 2% improvement in BMD to be associated with a 28% 
reduction in vertebral fracture risk and a 15-22% reduction in hip fracture risk (Bouxsein et 
al, 2019). Thus, could be considered clinically relevant. Given the relative risk of sustaining a 
fracture in CD is 40% higher in comparison to the general population, contributing to poor 
QOL, increased morbidity and mortality and loss of independence. The potential implications 
and importance of encouraging adults with CD to remain active and incorporate impact and 
weight-bearing exercises is essential to preserve BMD, improve person centred care and to 
support the effective use of NHS resources.  
 
7.4.2 Muscular Function  
7.4.2.1 Muscular Strength 
The findings of this study indicate that regular combined impact and resistance training can 
help significantly improve HGS and isokinetic knee-extension and elbow-flexion force in CD 
participants at 13 and 26 weeks. These statistically significant improvements were 
independent of covariates such as gender, baseline value and disease activity status. Despite 
aerobic exercise having the most well-known health benefits, the findings of this study 
support the ACSM (2012), NHS (2019b) and WHO (2020) recommendations that resistance 
training and jump training elicit gains in muscular strength. Although a predictor of future 
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disability, to date only two studies have assessed the impact of resistance exercise on 
muscular strength in CD, despite its widespread clinical use in sarcopenia, rheumatoid 
arthritis and aging (Santilli et al., 2014).  
The improvements in knee-extension force were in line with previous findings (Candow et 
al., 2002; De Souza-Tajiri et al., 2014). Both studies, one letter to the editor and one 
unpublished, found significant improvements in lower strength muscle indices following a 8 
and 12 weeks of PRT, respectively. The mean improvement in isokinetic knee extension 
force was greater in this sample than in the two previous studies, an explanation for this 
might be the type of intervention delivered of these studies which were resistance training 
only compared to a combination (impact and resistance) intervention in the current study. 
Interestingly, mean improvements in upper body strength were smaller than those identified 
in Candow et al’s (2002) quasi-experimental design study, who demonstrated a 21% 
improvement in upper body strength compared to 7-13% in the current study at 3 months. 
Reasons for this variation in improvement may be related to differences in the measurement 
equipment, population characteristics and disease activity. In addition, the intervention of the 
current study focused on impact training involving the lower body and did not include impact 
exercises for the upper-limbs, which could explain why there was a difference in upper and 
lower limb mean improvements. Future research should include a combination of upper and 
lower limb impact training.  
To our knowledge this is the first study to explore the benefits of exercise on HGS and find 
significant improvements in adults with CD. Further trials in other populations and chronic 
conditions, presenting similar symptoms as CD, have assessed the impact of resistance 
exercise on HGS. Statistically significant improvements were also reported in elderly 
hypertensive participants (n=12) following a 14-week PRT programme (Nascimento et al., 
2014), in 17 people with type 2 diabetes mellitus following a 12-week PRT programme 
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(Geirsdottir et al., 2012), in elderly adults (n=198) following a 12-week PRT programme 
(Geirsdottir et al., 2012) and after a 16-week PRT programme in 24 people with rheumatoid 
arthritis (Flint-Wagner et al., 2009). Contrary to the current findings, no improvements in 
HGS were identified in healthy older adults (n=40) following 8-week resistance training 
programme (Martins et al., 2015), in older men and women (n=12) after a 4-week PRT 
intervention (Cegielski et al., 2017) and after a 8-week resistance training programme in 
people with multiple sclerosis (n=16) (Sabapathy et al., 2011). Although there is evidence to 
suggest that a longer intervention period elicits gains in skeletal muscle hypertrophy and 
thereby muscle mass, CSA and working capacity. Adaptations in structural, metabolic, 
hormonal, neural and molecular composition that in turn increase the force and power exerted 
and sustained by the muscle depend greatly on the type, intensity, duration and frequency of 
the exercise stimuli. More research employing high-quality methodological designs are 
warranted to confirm and expand on these findings to provide an evidence-based rationale for 
using combination training as a therapy for people with CD.  
 
7.4.2.2 Muscular Endurance  
The findings of this study showed that a 6-month combination exercise programme improved 
upper and lower limb muscular endurance in adults with CD. To our knowledge this is the 
first study to explore and demonstrate statistically significant improvements in muscular 
endurance in the CD population.  The results are in broad agreement with similar previous 
intervention trials. A 17% and 32% increase in the 30-s CST from baseline to 3 month and to 
6 months, respectively, is consistent with previous research in older adults, which found 
following a 12-week combined exercise intervention improvements of 13.5% and 20%, 
respectively (Cao et al., 2007; Islam et al., 2004). Larger improvements of 54.7% and 66% 
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were also identified by two other research groups following a 10-week resistance training 
intervention in older adults, however exercises were focused on lower-body resistance 
training only (Hruda et al., 2003; Zhuang et al., 2014).  
A 24% and 42% increase in the 30-s BCT from baseline to 3 months and to 6 months, 
respectively, is consistent with previous research in older adults. With results demonstrating 
that after a 24-week resistance training programme, a 10-week combination intervention and 
a 4-month multicomponent intervention upper muscular endurance improved by 35%, 26% 
and 15%, respectively (Minges et al., 2011; Crandall et al., 2015; Belza et al., 2016). A 
potential reason why the shorter intervention period elicited more favourable results could be 
explained by the exercise type delivered. Belza et al’s (2016) 10-week exercise intervention 
incorporated moderate intensity aerobic, strength, flexibility and balance training, compared 
to Crandall et al’s (2015) bingocize programme involved walking in place, stretches, balance 
and strengthening exercises. During aerobic exercise, the metabolic stress stimulates an 
increase in mitochondrial content and respiratory capacity of muscle fibres, which, when 
repeated can accumulate into adaptations in mitochondrial function (Jacobs and Lunby, 
2013). These adaptations play an important role in the ability to perform prolonged strenuous 
exercise that occurs during physical activity. Further research is required to understand the 
cellular and molecular mechanisms responsible for the protective effect of regular combined 
impact and resistance training on skeletal muscle in CD.  
Muscle-strengthening activities, such as weight lifting, at least twice a week is recommended 
for the prevention of loss of muscle mass and impaired physical function in the aging 
population (Nelson et al., 2007). However, given the impaired muscular function parameters 
identified in people with CD, as demonstrated in Chapter 6, it could be argued that the 
prevention of loss of muscle mass and physical function is just as important in this 
population. Given the benefits of regular combined impact and resistance training on muscle 
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function parameters demonstrated in this study implies that it is a safe and effective option in 
the management of CD. 
 
7.4.3 Quality of life 
7.4.3.1 EQ-5D-5L 
In this RCT, a 6-month combination intervention induced more favourable improvements in 
QOL in adults with CD compared to the usual care group. Determined using the EQ VAS and 
EQ-5D index scores, the intervention group demonstrated superior QOL at 3 months 
compared with the control group. Significant group differences in the EQ-5D index scores 
were also demonstrated at 6 months, but not in the EQ VAS. Elsenbruh et al’s (2005) 10-
week mind-body therapy observed effects in line with those of the current study. This RCT 
involving stress management, moderate exercise, Mediterranean diet, behavioural techniques 
and self-care strategies in UC participants found significant improvements in QOL, assessed 
using the Short Form 36 (SF36). However, the results contradict those of Cronin et al (2019) 
who found no significant changes in QOL, determined using the SF36, following an 8-week 
combined aerobic and resistance training programme. However, while it assessed QOL, using 
a different QOL scale to the current study, the study’s main focus was on body composition. 
Moreover, the study had a number of major flaws including the crossover design, making it 
difficult to determine the estimates separately, and the small sample size that may have been 
underpowered to detect meaningful changes.  
Improved physical fitness, physical health, self-confidence, cognitive function and alleviating 
symptoms of anxiety, depression and stress are contributors of physical activity (Berger and 
Tobar, 2007; Gillison et al., 2009). Brain biochemistry changes as a result of physical 
activity, reducing the levels of stress hormones, adrenaline and cortisol while stimulating the 
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release neurotransmitters such as dopamine, norepinephrine and serotine that play an 
important part in regulating mood (Nabkasorn et al., 2005). Although disease-specific QOL 
questionnaires have been developed they tend to focus on an individual’s perception of their 
current health status, rather than assessing their life satisfaction i.e how satisfied are they with 
their health, as individuals may appreciate their health may not be perfect, they still express 
high life satisfaction. Understanding these perspective when it comes to exercise 
interventions in people with CD is imperative and therefore future studies should consider the 




The exercise intervention resulted in a profound impact on HRQOL and clinically relevant 
improvements, defined as an increase of 16 points or more and an total IBDQ score of 170 
points or more, in 6 participants from baseline to 3 months. Inspection of the separate sub 
dimensions at 3 months of the HRQOL scale revealed significant improvements in bowel 
symptoms, emotional health, systemic systems and social function. One unanticipated finding 
was that improvements in total HRQOL or in sub-dimensions: bowel symptoms, emotional 
health or systemic systems dimension were not sustained at 6 months. This non-significant 
result may be explained by the fact that at pre-intervention IBDQ scores were higher than 
those reported in other IBD exercise interventions (De Souza-Tajiri et al., 2014; Klare et al., 
2015; Cramer et al., 2017), which left not much potential for improvement. Another reason 
for this unanticipated finding maybe as a result of exercise adherence. Males have been found 
to have higher adherence rates in studies examining changes in physical activity (Simmons et 
al., 2010; Pavey et al., 2012), given this study was largely female based (68.1%) this could 
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have contributed to this non-significant result. In addition, lower exercise adherence rates 
have been reported towards the end of the programme (Kallings et al., 2009; Leijon et al., 
2010; Pavey et al., 2012). Therefore, to maintain improvements, strategies targeting 
enhancing adherence towards the end of an intervention should be employed. However, at 6 
months the mean change in social function dimension of HRQOL was significantly higher for 
the exercise group when compared to the control group, suggesting a beneficial effect of 
regular exercise on social well-being in adults with CD.  
Further trials have assessed the impact of exercise on HRQOL in IBD and found effects 
partly in line with those of the current study. In one uncontrolled trial, Loudon et al (1999) 
reported significant improvements in overall HRQOL, determined using the IBDQ, following 
a thrice-weekly three-month low intensity progressive walking programme in mildly active 
CD participants. Ng et al (2007) built on this preliminary work and incorporated a control 
group, which Loudon et al’s (1999) study lacked. Improvements in total and sub dimensions 
of IBDQ were also observed in Klare et al’s (2015) 10-week thrice-weekly running 
programme in inactive to moderately active adults with CD, but only through performing 
within group analysis. Significant differences between the intervention and control group 
only occurred in the social function domain, a finding similar to that of the current study. 
However, this finding is contrary to a recent finding from Cramer et al (2017), who observed 
no significant improvement in the IBDQ domain social function following a 24-week yoga 
intervention. On the other hand, Cramer and colleagues did observe a significant 
improvement in total IBDQ and sub dimensions bowel symptoms, systemic systems and 
emotional health. These variances may be explained by the disease state of the participants, 
with Cramer et al’s (2017) study only including participants in clinical remission while the 
present study and Klare et al’s (2015) study included inactive to mildly active participants. A 
major determinant of HRQOL is disease activity that remains the most significant predictor 
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of mental and physical HRQOL, because of the medical and surgical side effects, social, 
psychological and finical repercussions that are more prevalent during active periods. 
Nevertheless, disease activity does not explain the decrements in HRQOL completely, with 
more than 30% of asymptomatic individuals reporting an impaired QOL, suggesting a role 
for other determinants (Sajadinejad et al., 2012; Theede et al., 2015). Moreover, the 
participants in Cramer et al’s (2017) study had UC, which is associated with lower rates of 
surgery and inversely higher rates of HRQOL than CD, which could also explain the 
variation (Haapamaki, 2011).  
Based on these preliminary studies, exercise may be a useful adjunct to CD therapy to elicit 
psychological changes. However, further research is needed to explore optimal exercise 
prescription in regards to type, intensity, duration and frequency tailored to meet the physical 
and psychological needs of the individual, that involve larger cohorts and different disease 
states, particularly those with a more moderate to severe disease. 
 
7.4.4 Fatigue 
In this randomised clinical trial, a 6-month combined impact and resistance training 
programme induced a reduction in fatigue in adults with CD compared to the usual care 
group. However, the self-reported severity and frequency of fatigue and the impact of fatigue 
on daily activities only demonstrated significant reductions at 26 weeks. No significant group 
differences in either domain were identified at 13 weeks. However self-reported fatigue 
severity, frequency and day-to-day impact ratings by participants in this study were relatively 
lower to those reported by others (Chan et al., 2014; Tew et al., 2016). One explanation for 
which could be selection bias, with participants volunteering to participate in a thrice-weekly 
exercise intervention more likely to be at the lower end of the fatigue spectrum. Furthermore, 
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included study participants presented with an inactive or mildly active disease, disease states 
that are associated with experiencing fewer fatigue symptoms than those with a moderate to 
severely active disease (Levenstein et al., 2001; Romkens et al., 2011; Czuber-Dochan et al., 
2015). 
Further trials in other chronic conditions, presenting similar symptoms as CD, have assessed 
the impact of exercise on fatigue. Contrary to current findings, a meta-analysis of 28 RCT’s 
of at least 4 weeks duration demonstrated significant improvements in fatigue in people with 
fibromyalgia (-0.22; 95% CI -0.3 to -0.05; p=0.009) (Hauser et al., 2010). Similar findings 
were reported in people with multiple sclerosis following an 8 to 12-week intervention 
(Klefbeck and Nedjad, 2003; Roehers and Karst, 2004; Briken et al., 2014; Pilutti et al., 
2011). However, all these findings of shorter exercise durations were from moderate to high 
intensity aerobic interventions. Plausible explanation for this is the hypothesised theory is the 
relationship between fatigue and aerobic capacity. Aerobic capacity and muscular strength 
were assessed in 10 participants with quiescent IBD with self-reported fatigue, assessed using 
the CIS-fatigue (>35), and compared to gender and age matched (±5 years) to a non-fatigued 
group with IBD. Fatigued individuals displayed an impaired aerobic capacity and muscle 
strength in comparison to non-fatigued individuals, suggesting that fatigued individuals may 
benefit from an aerobic exercise programme. A potential explanation for this could be as a 
result of physical inactivity due to the release of IL-15 during skeletal muscle contraction 
which induces a direct anti-inflammatory effect (DeFilippis et al., 2016). Another explanation 
could be the enhanced presence of inflammatory cytokines such as TNF-α, IFN-γ, IL-6, IL-
10, IL-12 present in fatigued IBD participants (Vogelaar et al., 2017). A comparison between 
an aerobic vs resistance exercise intervention demonstrated a significant post intervention 
reduction in TNF-α, IL-6 and IL-10 in the aerobic intervention and no significant differences 
in the resistance intervention (Kader and Shreef, 2018). Suggesting that aerobic exercise is 
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more appropriate in modulating the immune system, thus symptoms of fatigue, than 
resistance exercise.  
Contrary to findings reported in other chronic conditions, Tew et al’s (2019) HIIT and MICT 
intervention observed similar findings to that of the current study. Observing mean 
improvements in the severity and frequency of fatigue reported by adults with CD at 6 
months, but not at 3 months. Although improvement in mean change in Tew et al’s (2019) 
feasibility study was small from baseline to 6 months, it is valuable for people with CD who 
describe fatigue as impacting their psychological, physiological, social and behavioural 
aspects of life and that continues to impair their QOL (Vogelaar et al., 2015). The variation 
between reported fatigue levels in CD and in other chronic conditions could be explained due 
to the heterogeneity in how the symptom presents itself and the proinflammatory cytokines 
present during quiescent states of inflammation. In addition, both the current and Tew et al’s 
(2019) study used a disease-specific fatigue questionnaire, in comparison to the previous 
studies mentioned who used generic fatigue measures such as the Fatigue Severity Scale or 
Fatigue Visual Analogue Scale. The two tools measure non-overlapping aspects of fatigue 
and therefore the comparison between the two are difficult to deduce due to the variability in 
the questions asked. 
Progressive resistance training, in other chronic conditions has also demonstrated significant 
improvements in self-reported fatigue. In people with fibromyalgia significant improvements 
in fatigue were reported after a 21-week (Hakkinen et al., 2000) and 15-week (Ericsson et al., 
2016) strength training programme working at 40-80% of 1-RM. Strength training 
programmes of a shorter duration, however, identified no significant improvements in 
fatigue. A systematic review of exercise therapy for the treatment of fatigue in multiple 
sclerosis identified three RCT’s with a duration of 8, 10 and 12 weeks comparing progressive 
resistance training with controls, identified no significant improvement in fatigue (Heine et 
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al., 2015). Suggesting that resistance-training programmes may need a longer duration in 
order to elicit these improvements. Interestingly a recent RCT in adults with rheumatoid 
arthritis, demonstrated significant improvements in physical and mental fatigue at 20 weeks 
following a resistance training intervention (Kucharski et al., 2019). However, following a 
52-week follow-up the end of the 20-week supervised intervention, resulted in the loss of the 
significant improvements in both physical and mental fatigue. Future research is warranted to 
establish what duration for the type of exercise performed is required to induce improvements 
in fatigue and evaluate if these are sustained after the intervention period.  
Overall, there are important methodological limitations future research need to overcome to 
better understand the exact mechanisms as to how exercise helps fatigue. These include high-
quality trials that are sufficiently powered and specifically aimed at fatigue, exploring 
different types, durations, frequencies and intensity of exercise and investigating the immune 
response to responders versus non-responders. 
 
7.4.5 Disease Activity  
A combination home-based intervention is feasible in inactive to mildly active CD and 
without CDAI or FC measures indicating a moderate to severely active disease. This is 
particular importance for individuals wanting to do unsupervised interventions. Our findings 
are similar to previous reports that exercise did not exacerbate symptoms (Loudon et al., 
1999; Candow et al., 2002; Ng et al., 2007; Klare et al., 2015; Sharma et al., 2015; Cramer et 
al., 2017; Cronin et al., 2019; Tew et al., 2019) and therefore it is possible that exercise has 
anti-inflammatory properties in people with CD. Despite the importance of TNF-a, IL-1β, IL-
6, IL-10 demonstrating protective anti-inflammatory effects of exercise in IBD mice studies 
and in other health conditions such as cancer and type two diabetes, little is known about 
CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W12018030                                                     215 | P a g e  
 
these immune parameters in adults with CD in relation to exercise (Lee et al., 1997; Thune et 
al., 2001; Lamonte et al., 2005; Hoffman-Goetz et al., 2008). Nevertheless, it is promising for 
people with CD as TNF-a is a major pathological marker that correlates with intestinal 
inflammation (Muzes et al., 2012; Levin et al., 2016). Therefore, future research needs to 
explore the frequency, intensity, duration and type of exercise needed to induce the release of 
these cytokines in CD.  
 
7.5 Strengths and Limitations 
7.5.1 Strengths 
The strengths of this study include the randomised controlled design and block randomisation 
of participants, minimising cofounding due to unequal distribution of prognostic factors and 
making groups comparable to cofounding factors which are both known and unknown, thus 
decreasing allocation and selection bias. The use of a blinded outcome assessor was also a 
strength of this study, minimising performance bias. Another strength of this study was the 
statistical reliability, through an adequately powered sample size and achieving statistical 
power and therefore avoiding the null hypothesis incorrectly being rejected or accepted. The 
study also included a well-defined population, including participants with different surgical 
history and on different treatment types. By including a well-defined population allows for 
findings to be applicable and acceptable to clinical practice. Moreover, the low rates of 
missing data and use of validated self-reported questionnaires and objective laboratory 
parameters are also strengths of this study. 
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7.5.2 Limitations 
There are a number of limitations in this study. Firstly, although participants were randomly 
allocated 1:1 to receive either the exercise intervention or usual care, participants in the latter 
group may have experienced some disheartening of their group allocation knowing their 
counterparts were doing exercise and may have become more physically active. It therefore 
cannot be ruled out that the differences between groups may have been influenced by the 
increase in physical activity at 6 months performed by the control group, who performed on 
average an additional 71 minutes of leisure time activity, and 310 minutes of work time 
activity compared to baseline. In addition, the lack of participant blinding to group allocation 
could also make the participant-reported outcomes susceptible to bias (Moustgaard et al., 
2020). Thirdly, the study was also limited to participants in clinical remission or with a 
mildly active disease and thus not reflective of the changes that may occur in participants 
with a moderate or severely active disease. Future studies should be extended to those with a 
more active disease, who may benefit from an exercise intervention. 
Although the use of laboratory measures such as FC and CRP were a strength of this study, 
there was an inconsistency between these markers and the CDAI when it came to screening 
potentially eligible participants. Potential participants were excluded for presenting with a 
FC>250 µg/g, however they presented with no symptoms and scored <149 in the CDAI 
which is suggestive of an inactive disease. Likewise, potential participants were excluded 
because they reported being symptomatic and scored >220 on the CDAI, however had a 
FC<250 µg/g. Therefore, future studies should consider endoscopies or imaging techniques 
such as MRI, CT or small intestine ultrasonography (SICUS) with or without contrast against 
to assess the extent and severity of CD.  
CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W12018030                                                     217 | P a g e  
 
Another limitation was the use a self-reported physical activity questionnaire and the lack of 
controlled exercise environment when participants were exercising at home, variables that 
may have been susceptible to social desirability bias. Future studies should consider using 
objective measures such as accelerometers, to reduce the risk of bias. The study was also 
limited to a single site and the homogeneity of the cohort in regards to ethnicity makes 
application of the results difficult. Nutritional intake, although important for bone health, was 
not taken into consideration. This was primarily due to the complexity of recording food 
intake for a prolonged period and the inability to determine absorption rates between 
individuals. Future research is needed to determine the potential influence of a nutritional 
intervention alongside different modes of exercise.  
Lack of follow-up post intervention was also a limitation and therefore it is unknown whether 
these improvements are sustained, and if so how long were they sustained for. In addition, 
although BMD is used to monitor osteoporosis, it only accounts for 60-70% of bone strength 
and therefore future research should consider using serum bone turnover markers. Lastly, the 
trial had several primary outcome measures, as one single measure would not sufficiently 
capture the range of clinically relevant intervention benefits and no adjustments were made 
for multiplicity. However, following Bonferroni adjustment (Bland and Altman, 1995), eight 
out of the ten outcomes would remain statistically significant supporting the beneficial effects 
of the intervention.  
 
7.6 Conclusion  
In view of these results, a resistance and impact training programme is a potent stimulator for 
skeletal growth, structure and maintenance to enhance BMD, and can induce statistically 
significant improvements in QOL, muscular function and fatigue in adults with CD compared 
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to usual care. The intervention not only represents an inexpensive strategy for the prevention 
and treatment of CD-related complications but it also appeared safe, without any 
deterioration in disease activity and with few AE and SAE reported that were equally 
balanced between groups. The exercises were simple, required little equipment, minimal 
instruction and were able to be performed by a participants aged between 27-85 of varying 
fitness abilities. Adults with CD should also be reassured that resistance and impact training 
did not exacerbate symptoms in those with an inactive or mildly active disease. Although the 
intervention demonstrated statistically significant improvements in BMD, it is unknown 
whether these improvements have been sustained after the intervention and for how long. In 
addition, moderately or severely active CD was not addressed in this research study and 
therefore caution should be applied before advising individuals who are presenting with a 
more active disease. It should also be highlighted that this research explores some of the 
unknowns relating to exercise in CD, and therefore more research is needed before 
conclusive statements and exercise guidelines can be established.  
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8.1 Overview 
Overall, this thesis explored the benefits and harms of exercise interventions in IBD (Chapter 
3), determined the test-retest reliability of outcome measures (Chapter 5), assessed bone and 
muscle health and identified possible risk factors associated with BMD in CD (Chapter 6), 
and investigated the effects of a combined impact and resistance training programme on 
BMD and muscle function in adults with CD (Chapter 7).  
 
8.2 Summary of Key Findings 
The systematic review described in Chapter 3 identified the effects of all modes of exercise 
interventions in adults with IBD and provided preliminary evidence that exercise is safe, 
feasible and acceptable in adults with an inactive to mildly disease. However, these studies 
were limited by their small cohort size, lack of blinded outcome accessor and follow-up. In 
addition, the majority of these studies involved exercise modalities, such as yoga or walking 
that are not optimal for improving bone health.  
The reliability study described in Chapter 5 illustrated excellent test-retest reliability of the 
outcome measures used to evaluate and facilitate the assessment and effectiveness of an 
intervention. Interestingly, largely studies have focused on assessing reliability using an 
isometric or isotonic mode. This is one of a few studies that has used an isokinetic mode, 
using the Biodex System 4 Pro at different angular velocities (60°/s, 120°/s and 180°/s). 
Moreover, the case control study (Chapter 6) provided novel findings as the first study to 
assess and identify reduced muscular endurance in adults with an inactive to mildly active 
CD. In addition to strengthening the evidence that adults with CD in the UK had a 
significantly reduced BMD, lower muscular strength and QOL when compared to matched 
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healthy controls. This study was also the first to match adults with CD to healthy controls on 
physical activity habits.  
Chapter 6 also demonstrated, through a cross-sectional design, that longer disease duration, 
low physical activity habits, being female and current smokers were correlated to BMD in 
CD. Supporting the current literature that gender, disease duration and smoking status were 
independent risk factors for BMD in CD participants. This study was also the second study to 
support the findings that identified a positive relationship between physical activity and 
BMD. However, the previous study (Nobile et al., 2018) included all IBD disease types 
whereas this one solely focused on CD. Results of this cross-sectional study also 
contraindicated the findings in disease behaviour, therefore more research in this area is 
needed to identify the potential risks different disease behaviours have upon BMD. 
These studies aided in the design of an RCT (Chapter 7), which was then conducted to 
evaluate the effects of a 6-month combined exercise intervention on primary outcomes of 
BMD and muscular function. This study provided novel findings, demonstrating that a 
combined impact and resistance home-based training programme is a feasible and effective 
method to elicit significant improvements in lower and upper muscular endurance, handgrip 
strength and BMD at the lumbar spine and femoral neck. Although findings support the 
significant improvement identified in upper and lower muscular strength, this was the first 
intervention to demonstrate that, using resistance TheraBands and not weighted machines. 
Another novel finding was a statistically significant improvement in fatigue at 6 months. 
Although one of two studies that included fatigue as an outcome measure, the previous MICT 
and HIIT intervention was a feasibility study (Tew et al., 2019) with an intentionally small 
sample size and therefore underpowered to detect effect. The combined intervention was also 
safe for CD participants, with no serious adverse events related to the intervention recorded. 
Furthermore, the utilisation of behavioural change techniques employed such as goal setting, 
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support contact and self-monitoring resulted in good adherence rates (62%) and low drop-out 
rates (n=3 control, n=1 exercise) for an exercise intervention study. Supported by the use of a 
home-based programme and the use of accessible equipment. Lastly, this is one of only two 
exercise interventions in adults with CD to employ a physical activity enjoyment scale, 
supporting the ‘enjoyment’ participants reported following the exercise sessions.  
  
 
8.3 Implications for Clinical Practice 
The current guidelines around screening for osteoporosis in this high-risk group differs 
depending on the organisation. However, the ECCO, the American College of 
Gastroenterology, the American Gastroenterological Association and the British Society of 
Gastroenterology all agree that individuals who are repeatedly exposed to steroids and/or 
have a persistently active disease should have a DEXA scan (Scott et al., 2000; Bernstein et 
al., 2003; Lichtenstein et al., 2009; Van-Assche et al., 2013). However, the results of the 
cross-sectional study, described in Chapter 6, identified those with a longer disease duration, 
less physically active, females and current smokers were also potential risk factors. Findings 
that will increase clinician awareness and help identify individuals who should be monitored 
closely. In addition, Chapter 6 also identified adults with inactive to mildly active CD, via a 
case control study, show a reduced muscle strength and endurance when compared to 
matched healthy controls. While more research is clearly needed in this area, these results 
suggest the assessment of muscle function should be integrated into clinical practice and 
interventions put in place to prevent the development of musculoskeletal EIM’s. 
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Although consensus from the ECCO (Harboard et al., 2016) addresses that weight-bearing or 
resistive exercises should be implemented to prevent bone loss, there are no specific 
guidelines for clinicians regarding the type, duration, frequency or intensity of exercise that is 
most appropriate to elicit favourable changes in adults with CD. With recommendations 
based largely on the general population who do not experience the same barriers to exercise 
such as fatigue, joint pain and abdominal pain as someone with CD. Thus, it is not surprising 
that exercise is infrequently discussed by gastroenterologists, GP’s and other healthcare 
professionals (Lambdin et al., 2018).  
 
The results of the RCT, described in Chapter 7, provide novel data on the efficacy of a 
combined intervention to elicit positive changes in BMD, muscular function, fatigue and 
QOL in this high-risk population. The current NICE pathway, following diagnosis and 
discussions about the disease, involves guidelines on smoking cessation, medication 
adherence, fertility, prognosis, cancer risk, surgery, diet and nutrition. Implementation of 
exercise guidelines would be best integrated into the clinical pathway at this stage, to educate 
individuals about alternative methods of managing and preventing the secondary 
complications associated with their condition while giving the individual an active role in 
their treatment. By also supporting and educating the CD multidisciplinary team on disease-
specific exercise guidelines will enable them to discuss and recommend exercise to optimise 
health outcomes. The RCT also supports using behavioural change strategies to improve self-
efficacy can achieve good levels of exercise adherence (Bandura, 1997; Rovniak et al., 2002). 
It is, however, important to stress that from a medical perspective exercise does not 
necessarily alter the disease course, it is intended as a complementary holistic approach in the 
management of CD and not to replace pharmacological treatment. 
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8.4 Limitations 
Specific study limitations are presented in each chapter, however there are some limitations 
which reoccur between studies. Firstly, the studies in this thesis focused primarily on adults 
with an inactive to mildly active CD and therefore results may not be generalisable to people 
with other forms and severities of IBD. A further limitation is the use of the SPAQ to 
determine physical activity habits, in Chapters 5 and 7. Many participants had some issues 
with recalling physical activity performed over the last 7 days and understanding the 
inclusion of moderate to vigorous activity only, which may have led to under or over-
reporting. Lastly, primarily due to time constraints, training requirements and additional 
costs, proinflammatory cytokines and nutritional state of individuals were not ascertained for 
Chapter 6 or 7. As discussed previously proinflammatory cytokines, particularly TNF-α and 
IL-6, and deficiencies, particularly in vitamin D and calcium, interfere with bone metabolism 
and muscular function (Duggan et al., 2004; Barbieri et al., 2013). Given the influence these 
variables can have on bone and muscle health, it is important that they are incorporated into 
future studies to better understand this relationship.  
 
8.5 Future Directions 
With individuals looking for alternative modalities, a series of larger-scale multi-centre 
RCT’s are needed focusing on different training regimens in regards to type, duration, 
frequency and intensity, particularly higher intensities, to refine optimal exercise prescription. 
Involving different participant sub-groups in regards to disease type (i.e. CD and/or UC) and 
disease states, particularly those with a moderate to severe disease. While addressing the 
incorporation of different support strategies and follow-ups examining whether the 
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participant is still exercising post intervention and whether improvements are sustained, and 
if so for how long. Future studies should also consider involving larger cohorts with a 
primary focus on the least researched areas including fatigue, cardiorespiratory fitness and 
immune function, particularly focusing on TNF-a and IL-6 which has demonstrated 
protective anti-inflammatory effects while exercising.   
Given the benefits of aerobic exercise in the general population, and the evidence indicating 
that it improves immune function and aerobic capacity and helps reduce fatigue in other 
chronic conditions (Oldervoll et al, 2004; Cramp and Byron-Daniel, 2012). It would be 
beneficial to explore the benefits of an aerobic programme alongside an impact/resistance 
intervention to determine whether this multi-component intervention has superior 
physiological and psychological effects. In addition, to incorporating nutritional aspects from 
the input of nutritionists/dietitians and exploring the cost effectiveness, with the aid of health 
economists, to support the implementation of this within the NHS.    
 
8.6 Conclusion  
The findings arising from this thesis have demonstrated that: 
• Aerobic and resistance exercise is safe and feasible in adults with inactive to mildly 
active CD and can potentially counteract some disease-specific complications. 
• CD is linked to the development of osteoporosis/osteopenia and contributes to an 
individual’s chance of developing muscular function and QOL impairments  
• BMD was correlated to disease duration, physical activity habits, gender and smoking 
status in participants with an inactive to mildly active CD 
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• Combined impact and resistance training of 3-6 months is a safe and effective mode 
of exercise for adults with inactive to mildly active CD, eliciting improvements in 
BMD, muscular strength and endurance, QOL and fatigue. Integration of impact and 
resistance exercise into the clinical pathway as a means of reducing risk of fractures 
and physical disability in this high-risk population is needed.  
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A breakdown of UK Costs per patient per year for CD and UC 
Treatment Cost Adverse Event Cost Complication Cost 
Pentasa £517 Blood Test a £152 Cancer £10,514 
Asacol £823 Pancreatitis a £2043.19 Uveitis £125.66 
Azathioprine £95.88 Myelotoxicity a £2036.14 Iritis £125.66 
6- mercaptopurine £540.96 Hepatotoxicity a £1209.81 Pyoderma 
gangrenosum 
£463.04 




Infliximab £12,584 Osteoporosis b £2267   
Adalimumab £10,368 Mild 
Neuropsychiatric b 
£1384   
Surgery for UC £16,226.23 Severe 
Neuropsychiatric b 
£2778   
Hospital bed day £440 Serious Infection c £4095.65   
Outpatient 
consultation 
£128 Bleeding d £561.48   







Appendix 2a: Breakdown of UK costs per patient per year for CD and UC 
 




Protocol Method Deviation from protocol method, with justification 
Planned to include RCTs only Initial reviewing of including only RCTs failed to identify any 
studies of interest. Following the search non-randomised 
controlled trials were included as another study of inclusion 
as a means to expand the volume of research evidence. To 
comply to this change, the risk of bias tool ROBINS-I was 
added to include non RCTs. 
 
Type of deviation: Addition 
 
Planned to only include outcome 
measures on bone mineral density 
and muscular function  
Again, due to limited available research in this field 
following the initial review more primary outcomes such as 
quality of life, psychological well-being, disease activity, 
physical activity levels, body composition measures, 
cardiopulmonary measures, immunological outcomes and 
fatigue were included.  
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1. Bone health outcomes- determined using validated standardised clinical measures (e.g. 
bone densitometry, ultrasound, calipers): 
• Bone mineral content (BMC) (g) of total body 
• BMD (g/cm2) (areal and volumetric) of total body at the lumbar spine, femoral 
neck and/ or total hip  
• Bone metabolism biomarkers including:  bone alkaline phosphate, alkaline 
hosphatase, serum osteocalcin, albumin, carboxy-terminal collagen type 1 
crosslinks, N-telpoptide collagen type 1 cross linked, deoxypyridinoline, bone 
specific alkaline phosphate, N-terminal propeptides of type I procollagen, C-
terminal propeptides of type I procollagen, pyridinoline, bone sialoprotein and 
isoform 5b of tartrate-resistant acid phosphatase. 
• Fractures at any site 
• Osteoporosis, osteopenia and osteomalacia 
2. Muscle function of lower and upper extremities including muscle mass, endurance, 
strength, flexibility and physical performance determined using validated standardised 
clinical tools (e.g. handgrip dynamometer, timed chair stands, isokinetic dynamometry, 
gait speed, timed up and go) 
3. QOL - including general measures (e.g. 36-item short form survey and EQ-5D) and 
disease-specific measures (e.g. Inflammatory Bowel Disease QOL questionnaire 
[IBDQ]) of HRQOL determined using validated standardised clinical tools 
4. Psychological well-being such as depression, anxiety or stress determined using 
validated standardised clinical tools (e.g. Hospital Anxiety and Depression Scale 
[HADS], PHQ-9, perceived stress scale and State Trait Anxiety Inventory [STAI]): 
Appendix 3b: Systematic review detailed outcome measures 
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5. Disease Activity - determined using validated standardised clinical measures (e.g. FC, 
CDAI, HBI, CRP and CAI) 
6. Physical Activity Levels - determined using validated standardised clinical measures 
(e.g. accelerometer, pedometer and International Physical Activity Questionnaire) 
7. Body Composition- determined using validated standardised clinical tools (e.g. DEXA, 
circumference and girth measures, bodpod, CT or MRI scans, bioelectrical impedance): 
• BMI (kg/m2) 
• Lean and fat mass (kg) (%) 
• Skeletal mass (%) and muscle mass (%) 
• Cross-sectional muscle area (mm2) 
• Percentage body fat (%) 
• Total body water (lt, %), potassium, nitrogen  
8. Cardiopulmonary outcomes - determined using validated standardised clinical tools 
(e.g. exercise stress test, cardiopulmonary exercise test, submaximal treadmill test and 
incremental shuttle walk test): 
• Maximal and peak oxygen consumption (?̇?O2 max) (mL·kg-1·min-1)  
• Peak aerobic and anaerobic mechanical power (Wpeak) (W·kg-1) 
• Oxygen pulse 
• Maximum, peak and resting heart rate (beats per min) 
• Maximum tidal volume  
• Respiratory exchange ratio 
9. Immune markers such as leukocytes, lymphocytes, granulocytes, monocytes and 
neutrophils determined using validated standardised clinical tools (e.g. 
endocrinological blood samples, inflammatory cytokines and immunotoxicity) 
10. Fatigue- determined using validated standardised clinical measures (e.g. Inflammatory 
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Bowel Disease- Fatigue Scale [IBD-F], fatigue severity scale, multidimensional 
assessment of fatigue and blood tests such as ferritin and haemoglobin) 
11. Safety: Exercise-related adverse events   
12. Feasibility and acceptability will be assessed using attrition, compliance and 





















1. exp Crohn disease/ or crohn*.mp.  
2. indeterminate colitis.mp. 
3. (colitis and ulcerat*).mp. 
4. ulcerative colitis.mp. or exp ulcerative colitis/ or colitis, ulcerative/ 
5. (inflammatory bowel disease* or IBD).mp. 
6. or/1-5 
7. exp exercise/ 
8. exp exercise therapy/  
9. (exercise* or exercising).mp. 
10. exp sports/ 
11. ((resist* or weight* or strength* or endurance or circuit* or aerobic* or cardio* or jump* or 
anaerobic or balance or interval or muscl* or isokinetic or isometric) adj2 training).mp. 
12. (‘walking’ or ‘running’ or ‘sprinting’ or ‘jogging’ or ‘swimming’ or ‘cycling’ or ‘rowing’ or 
‘dancing’ or ‘yoga’ or ‘boxing’ or ‘skipping’ or ‘pilates’ or ‘aqua’).mp. 
13. Or/7-12 
14. 6 and 13 
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or 
humans).ti.) 
16. 14 not 15 
17. 16 [Limit to English Language] 
 
EMBASE 
1. exp Crohn disease/ or crohn*.mp. 
2. indeterminate colitis.mp. 
3. (colitis and ulcerat*).mp. 
4. ulcerative colitis.mp. or exp ulcerative colitis/ or colitis, ulcerative/ 
5. (inflammatory bowel disease* or IBD).mp. 
6. or/1-5 
7. exp exercise/ 
8. exp exercise therapy/  
9. (exercise* or exercising).mp. 
10. exp sports/ 
Appendix 3c: Systematic review search strategy 
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11. ((resist* or weight* or strength* or endurance or circuit* or aerobic* or cardio* or jump* or 
anaerobic or balance or interval or muscl* or isokinetic or isometric) adj2 training).mp. 
12. (‘walking’ or ‘running’ or ‘sprinting’ or ‘jogging’ or ‘swimming’ or ‘cycling’ or ‘rowing’ or 
‘dancing’ or ‘yoga’ or ‘boxing’ or ‘skipping’ or ‘pilates’ or ‘aqua’).mp. 
13. Or/7-12 
14. 6 and 13 
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or 
humans).ti.) 
16. 14 not 15 
17. 16 [Limit to English Language] 
 
CINAHL 
1. ((MH “inflammatory bowel diseases”) or (MH “colitis, ulcerative”) or (MH “crohn disease”)) 
2. TI ((inflammatory bowel disease or IBD or Crohn* or ulcerative colitis or colitis* or 
indeterminate colitis) OR AB (inflammatory bowel disease or IBD or Crohn* or ulcerative 
colitis or colitis* or indeterminate colitis)) 
3. 1 or 2 
4. ((MH "exercise") or (MH “exercise therapy”) or (MH “sports”)) 
5. TI ((resist* or weight* or strength* or endurance or circuit* or aerobic* or cardio* or jump* 
or anaerobic or balance or interval or muscl* or isokinetic or isometric) N2 training) OR AB 
((resist* or weight* or strength* or endurance or circuit* or aerobic* or cardio* or jump* or 
anaerobic or balance or interval or muscl* or isokinetic or isometric) N2 training) 
6. TI (“walking” or “running” or “sprinting” or “jogging” or “swimming” or “cycling” or 
“rowing” or “dancing” or “yoga” or “boxing” or “skipping” or “pilates” or “aqua”) OR AB 
(“walking” or “running” or “sprinting” or “jogging” or “swimming” or “cycling” or 
“rowing” or “dancing” or “yoga” or “boxing” or “skipping” or “pilates” or “aqua”) 
7. 3 or 4 or 5 
8. 3 and 7 
9. 8 [Limit to English Language] 
10. 9 [Limit to Human] 
 
Cochrane Central Register of Controlled Trials (CENTRAL) 
1. MeSH descriptor: [inflammatory bowel disease] explode all trees 
2. TI ((IBD or Crohn* or ulcerative colitis or indeterminate colitis) or AB (IBD or Crohn* or 
ulcerative colitis or indeterminate colitis)) 
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3. #1 or #2 or #3 or #4 
4. MeSH descriptor [exercise] explode all trees 
5. MeSH descriptor [exercise therapy] explode all trees 
6. MeSH descriptor [sports] explode all trees 
7. ((resist* or weight* or strength* or endurance or circuit* or aerobic* or cardio* or jump* or 
anaerobic or balance or interval or muscl* or isokinetic or isometric) near/2 (training)) 
8. ‘walking’ or ‘running’ or ‘sprinting’ or ‘jogging’ or ‘swimming’ or ‘cycling’ or ‘rowing’ or 
‘dancing’ or ‘yoga’ or ‘boxing’ or ‘skipping’ or ‘pilates’ or ‘aqua’ 
9. #6 or #7 or #8 or #9 or #10 
10. #5 and #11 
 
SPORTDiscus 
1. “inflammatory bowel disease*”  
2. TI ((inflammatory bowel disease or IBD or Crohn* or ulcerative colitis or colitis* or 
indeterminate colitis) OR AB (inflammatory bowel disease or IBD or Crohn* or ulcerative 
colitis or colitis* or indeterminate colitis)) 
3. 1 or 2 
4. "exercis*" or “exercise therapy” or “sports”  
5. TI ((resist* or weight* or strength* or endurance or circuit* or aerobic* or cardio* or jump* 
or anaerobic or balance or interval or muscl* or isokinetic or isometric) N2 training) OR AB 
((resist* or weight* or strength* or endurance or circuit* or aerobic* or cardio* or jump* or 
anaerobic or balance or interval or muscl* or isokinetic or isometric) N2 training) 
6. TI (“walking” or “running” or “sprinting” or “jogging” or “swimming” or “cycling” or 
“rowing” or “dancing” or “yoga” or “boxing” or “skipping” or “pilates” or “aqua”) OR AB 
(“walking” or “running” or “sprinting” or “jogging” or “swimming” or “cycling” or “rowing” 
or “dancing” or “yoga” or “boxing” or “skipping” or “pilates” or “aqua”) 
7. 4 or 5 or 6 
8. 3 and 7 
9. 8 [Limit to English Language
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Criteria for Body Composition and Bone Health Assessment using 
Dual-energy X-ray Absorptiometry 
 
All information provided on this form will be kept confidential 
 
Name of GP              
Name of GP surgery           
 
Section 1.  Primary criteria 
Please tick the answer that applies to you. 
 
Are you younger than 18 years of age?      
 YES    
 NO 
 
Are you / is there a possibility that you could you be pregnant?    
 YES   
 NO 
 
Have you had or are you currently undergoing radiation therapy?  
 YES   
 NO 
 
Have you had a significant radiation dose in the last 12 months?    





Appendix 4a: Eligibility bone health assessment form 
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Section 2. Factors that may influence the result (Please note, deformities and 
implants will be visible on the DXA scan image) 
Have you had a major bone fracture that has not healed correctly? 
 YES   
 NO 
If yes, please give further details: 
___________________________________________________________________ 
Do you have any medical implants such as a pacemaker, any surgical pins or plates, 
or any synthetic joints e.g. knee or hip replacement?   





For use by the operational user: 
Section 1. 
The DXA scan must be refused if the answer is yes to any question in section 1. 
Section 2. 
If the participant/patient has a significant fracture deformity, the operator must assess 
































Appendix 4b: GP letter of bone health result 
 








I have no problems in walking about        ❑ 
I have slight problems in walking about                ❑ 
I have moderate problems in walking about      ❑ 
I have severe problems in walking about       ❑ 
I am unable to walk about          ❑ 
 
SELF-CARE 
I have no problems washing or dressing myself      ❑ 
I have slight problems washing or dressing myself      ❑ 
I have moderate problems washing or dressing myself     ❑ 
I have severe problems washing or dressing myself      ❑ 
I am unable to wash or dress myself        ❑ 
 
USUAL ACTIVITIES (e.g. work, study, housework, family or 
leisure activities) 
I have no problems doing my usual activities       ❑ 
I have slight problems doing my usual activities              ❑ 
I have moderate problems doing my usual activities     ❑ 
I have severe problems doing my usual activities     ❑ 
I am unable to do my usual activities        ❑ 
 
PAIN / DISCOMFORT 
I have no pain or discomfort         ❑ 
I have slight pain or discomfort         ❑ 
I have moderate pain or discomfort       ❑ 
I have severe pain or discomfort         ❑ 
I have extreme pain or discomfort        ❑ 
 
UK (English) © 2009 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group 
 
Appendix 4c: EQ-5D-5L Questionnaire 
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ANXIETY / DEPRESSION 
I am not anxious or depressed         ❑ 
I am slightly anxious or depressed        ❑ 
I am moderately anxious or depressed       ❑ 
I am severely anxious or depressed        ❑ 
I am extremely anxious or depressed        ❑ 
 
• We would like to know how good or bad your health is TODAY.  
 
• This scale is numbered from 0 to 100.  
 
• 100 means the best health you can imagine.  
0 means the worst health you can imagine.  
 
• Mark an X on the scale to indicate how your health is TODAY.  
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[Questions in bold are for IBDQ-Stoma, which replaced IBDQ questions and completed by patients 
who presented with an colostomy or ileostomy] 
 
This questionnaire is designed to find out how you have been feeling during the last 2 weeks. You 
will be asked about symptoms you have been having as a result of your inflammatory bowel disease, 
the way you have been feeling in general, and how your mood has been.  
 
1. How frequent have your bowel movements been during the last two weeks? Please indicate 
how frequent your bowel movements have been during the last two weeks by picking one of 
the options from  
1. BOWEL MOVEMENTS AS OR MORE FREQUENT THAN THEY HAVE EVER BEEN  
2. EXTREMELY FREQUENT 
3. VERY FREQUENT  
4. MODERATE INCREASE IN FREQUENCY OF BOWEL MOVEMENTS  
5. SOME INCREASE IN FREQUENCY OF BOWEL MOVEMENTS  
6. SLIGHT INCREASE IN FREQUENCY OF BOWEL MOVEMENTS  
7. NORMAL, NO INCREASE IN FREQUENCY OF BOWEL MOVEMENTS 
 
1. How frequent have you had to empty your colostomy or ileostomy appliance during the 
last two weeks? Please indicate how frequent your stomal output has been during the last 
two weeks by picking one of the options from 
1. AS OR MORE FREQUENT THAN EVER  
2. EXTREMELY FREQUENT 
3. VERY FREQUENT  
4. MODERATE INCREASE IN FREQUENCY OF EMPTYING  
5. SOME INCREASE IN FREQUENCY OF EMPTYING  
6. SLIGHT INCREASE IN FREQUENCY OF EMPTYING  
7. NORMAL, NO INCREASE IN FREQUENCY OF EMPTYING 
 
2.           How often has the feeling of fatigue or of being tired and worn out been a problem for you 
during the last 2 weeks? Please indicate how often the feeling of fatigue or tiredness has 
been a problem for you during the last 2 weeks by picking one of the options from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
Copyright © 1989 McMaster University, Hamilton, Ontario, Canada  
The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright 
©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed 
or used in any way without the prior written consent of McMaster University.  
 
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details. 
Appendix 4d: IBDQ and IBDQ-Stoma 
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3.           How often during the last 2 weeks have you felt frustrated, impatient, or restless? Please 
choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
4.  How often during the last 2 weeks have you been unable to attend school or do you work    
               because of your bowel problem? Please choose an option from  
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
5.           How much of the time during the last 2 weeks have your bowel movements been loose? 
Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
5.           How much of the time during the last 2 weeks have your stoma output  been looser than 
normal? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
Copyright © 1989 McMaster University, Hamilton, Ontario, Canada  
The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright 
©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed 
or used in any way without the prior written consent of McMaster University.  
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6.           How much energy have you had during the last 2 weeks? Please choose an option from 
1. NO ENERGY AT ALL  
2.           VERY LITTLE ENERGY 
3. A LITTLE ENERGY 
4. SOME ENERGY  
5. A MODERATE AMOUNT OF ENERGY  
6. A LOT OF ENERGY  
7. FULL OF ENERGY 
 
7.           How often during the last 2 weeks did you feel worried about the possibility of needing to 
have surgery because of your bowel problem? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
8.  How often during the last 2 weeks have you had to delay or cancel a social engagement   
               because of your bowel problem? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
9.           How often during the last 2 weeks have you been troubled by cramps in your abdomen? 
Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
Copyright © 1989 McMaster University, Hamilton, Ontario, Canada  
The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright 
©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed 
or used in any way without the prior written consent of McMaster University.  
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10.         How often during the last 2 weeks have you felt generally unwell? Please choose an option 
from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
11.         How often during the last 2 weeks have you been troubled because of fear of not finding a 
washroom? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
12.  How much difficulty have you had, as a result of your bowel problems, doing leisure or  
               sports activities you would have liked to have done during the last 2 weeks? Please choose  
               an option from 
1. A GREAT DEAL OF DIFFICULTY, ACTIVITIES MADE IMPOSSIBLE  
2. A LOT OF DIFFICULTY 
3. A FAIR BIT OF DIFFICULTY 
4. SOME DIFFICULTY  
5. A LITTLE DIFFICULTY  
6. HARDLY ANY DIFFICULTY  
7. NO DIFFICULTY; THE BOWEL PROBLEMS DID NO LIMIT SPORTS OR LEISURE ACTIVITIES 
 
13.         How often during the last 2 weeks have you been troubled by pain in the abdomen? Please 
choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
Copyright © 1989 McMaster University, Hamilton, Ontario, Canada  
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14.         How often during the last 2 weeks have you had problems getting a good night's sleep, or 
been troubled by waking up during the night? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
15.         How often during the last 2 weeks have you felt depressed or discouraged? Please choose 
an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
16.  How often during the last 2 weeks have you had to avoid attending events where there was  
              no washroom close at hand? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
17.         Overall, in the last 2 weeks, how much of a problem have you had with passing large 
amounts of gas? Please choose an option from 
1. A MAJOR PROBLEM  
2. A BIG PROBLEM 
3. A SIGNIFICANT PROBLEM 
4. SOME TROUBLE  
5. A LITTLE TROUBLE  
6. HARDLY ANY TROUBLE  
7. NO TROUBLE 
 
Copyright © 1989 McMaster University, Hamilton, Ontario, Canada  
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17.         Overall, in the last 2 weeks, how much of a problem have you had with your stomal 
appliance filling up with large amounts of gas? Please choose an option from 
1. A MAJOR PROBLEM  
2. A BIG PROBLEM 
3. A SIGNIFICANT PROBLEM 
4. SOME TROUBLE  
5. A LITTLE TROUBLE  
6. HARDLY ANY TROUBLE  
7. NO TROUBLE 
 
18.         Overall, in the last 2 weeks, how much of a problem have you had maintaining or getting to, 
the weight you would like to be at? Please choose an option from 
1. A MAJOR PROBLEM  
2. A BIG PROBLEM 
3. A SIGNIFICANT PROBLEM 
4. SOME TROUBLE  
5. A LITTLE TROUBLE  
6. HARDLY ANY TROUBLE  
7. NO TROUBLE 
 
19.         Many patients with bowel problems often have worries and anxieties related to their illness. 
These include worries about getting cancer, worries about never feeling any better, and 
worries about having a relapse. In general, how often during the last 2 weeks have you felt 
worried or anxious? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
20.  How much of the time during the last 2 weeks have you been troubled by a feeling of   
              abdominal bloating? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
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21.         How often during the last 2 weeks have you felt relaxed and free of tension? Please choose 
an option from 
1. NONE OF THE TIME  
2. A LITTLE OF THE TIME 
3. SOME OF THE TIME 
4. A GOOD BIT OF THE TIME  
5. MOST OF THE TIME 
6. ALMOST ALL OF THE TIME  
7. ALL OF THE TIME 
 
22.         How much of the time during the last 2 weeks have you had a problem with rectal bleeding 
with your bowel movements? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
22.         How much of the time during the last 2 weeks have you had a problem with blood in your 
stomal output or blood from the rectum? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
23.         How much of the time during the last 2 weeks have you felt embarrassed as a result 
of your bowel problem? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
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24.  How much of the time during the last 2 weeks have you been troubled by a feeling of having  
               to go to the bathroom even though your bowels were empty? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
24.  How much of the time during the last 2 weeks have you been troubled by a feeling of   
               having to go to the bathroom to empty your rectum, even though you have a stoma?  
               Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
25.         How much of the time during the last 2 weeks have you felt tearful or upset? Please choose 
an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
26.         How much of the time during the last 2 weeks have you been troubled by accidental soiling 
of your underpants? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
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26.         How much of the time during the last 2 weeks have you been troubled by accidental 
soiling of your clothing or bedding because of leaking from your stomal appliance? Please 
choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
27.         How much of the time during the last 2 weeks have you felt angry as a result of your bowel 
problem? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
28.  To what extent has your bowel problem limited sexual activity during the last 2 weeks?   
               Please choose an option from 
1. NO SEX AS A RESULT OF BOWEL DISEASE  
2. MAJOR LIMITATION AS A RESULT OF BOWEL DISEASE 
3. MODERATE LIMITATION AS A RESULT OF BOWEL DISEASE 
4. SOME LIMITATION AS A RESULT OF BOWEL DISEASE 
5. A LITTLE LIMITATION AS A RESULT OF BOWEL DISEASE 
6. HARDLY ANY LIMITATION AS A RESULT OF BOWEL DISEASE 
7. NO LIMITATION AS A RESULT OF BOWEL DISEASE 
 
29.         How much of the time during the last 2 weeks have you been troubled by nausea or feeling 
sick to your stomach? Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
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30.         How much of the time during the last 2 weeks have you felt irritable? Please choose an 
option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
31.         How often during the past 2 weeks have you felt a lack of understanding from others? 
Please choose an option from 
1. ALL OF THE TIME  
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME  
5. A LITTLE BIT OF THE TIME  
6. HARDLY ANY OF THE TIME  
7. NONE OF THE TIME 
 
32.         How satisfied, happy, or pleased have you been with your personal life during the past 2  
               weeks? Please choose one of the following options from 
1. VERY DISSATISFIED, UNHAPPY MOST OF THE TIME  
2. GENERALLY DISSATISFIED, UNHAPPY 
3. SOMEWHAT DISSATISFIED, UNHAPPY 
4. GENERALLY SATISFIED, PLEASED  
5. SATISFIED MOST OF THE TIME, HAPPY 
6. VERY SATISFIED MOST OF THE TIME, HAPPY  
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Date: ………………...  Time: ………....    
SECTION I - Fatigue Assessment Scale  
This section of the questionnaire will identify fatigue, its severity, frequency and duration.  
Sometimes people with inflammatory bowel disease feel fatigued. The term ‘fatigue’ is used throughout the questionnaire. Fatigue has been 
defined as a sense of continuing tiredness, with periods of sudden and overwhelming lack of energy or feeling of exhaustion that is not 
relieved following rest or sleep 
Please tick ONE number for each question  Score from 0 – 4 with 
 
  0 = no fatigue 
 
 
            Severe fatigue = 4 
1. What is your fatigue level right NOW 0 1 2 3 4 
2. What was your HIGHEST fatigue level in the past two 
weeks 
0 1 2 3 4 
3. What was your LOWEST fatigue level in the past two 
weeks 
0 1 2 3 4 
4. What was your AVERAGE fatigue level in the past two 
weeks 
0 1 2 3 4 
5. How much of your waking time have you felt fatigued  
in the past two weeks 
0 
None of the 
time 
1 








All the time 
 
Appendix 4e: IBD Fatigue Self-assessment Scale (IBD-F) 
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SECTION II - IBD-Fatigue Impact on Daily Activities Scale   
This section assesses the perceived impact of fatigue on your daily activities in the past two weeks.   
Please answer all the questions. The possible answers to the questions are:  
None of the time - 0; Some of the time – 1; Often - 2; Most of the time - 3; All of the time - 4.  
If a particular activity does not apply to you, for example you do not drive, please select N/A. 
 
Please tick  only ONE answer for each question reflecting on  





Often Most of 
the time 




1. I had to nap during the day because of fatigue 0 1 2 3 4  
2. Fatigue stopped me from going out to social events 0 1 2 3 4  
3. I was not able to go to work or college because of fatigue 0 1 2 3 4 N/A 
4. My performance at work or education was affected by fatigue 0 1 2 3 4 N/A 
5. I had problems concentrating because of fatigue 0 1 2 3 4  
6. I had difficulty motivating myself because of fatigue 0 1 2 3 4  
7. I could not wash and dress myself because of fatigue 0 1 2 3 4  
8. I had difficulty with walking because of fatigue 0 1 2 3 4  
9. I was unable to drive as much as I need to because of fatigue 0 1 2 3 4 N/A 
10.  I was not able to do as much physical exercise as I wanted to 
because of fatigue 
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Please tick  only ONE answer for each question reflecting on  





Often Most of 
the time 




11. I had difficulty continuing with my hobbies/interests because 
of fatigue 
0 1 2 3 4  
12. My emotional relationship with my partner was affected by 
fatigue 
0 1 2 3 4 N/A 
13. My sexual relationship with my partner was affected by fatigue 0 1 2 3 4 N/A 
14. My relationship with my children was affected by fatigue 0 1 2 3 4 N/A 
15. I was low in mood because of fatigue 0 1 2 3 4  
16. I felt isolated because of fatigue 0 1 2 3 4  
17. My memory was affected because of fatigue 0 1 2 3 4  
18. I made mistakes because of fatigue 0 1 2 3 4  
19. Fatigue made me irritable 0 1 2 3 4  
20. Fatigue made me frustrated 0 1 2 3 4  
21. I got words mixed up because of fatigue 0 1 2 3 4  
22. Fatigue stopped me from enjoying life 0 1 2 3 4  
23. Fatigue stopped me from having a fulfilling life 0 1 2 3 4  
24. My self-esteem was affected by fatigue 0 1 2 3 4  
25. Fatigue affected by confidence 0 1 2 3 4  
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Please tick  only ONE answer for each question reflecting on  





Often Most of 
the time 




26. Fatigue made me feel unhappy 0 1 2 3 4  
27. I had difficulties sleeping at night because of fatigue 0 1 2 3 4  
28. Fatigue affected my ability to do all my normal household 
activities 
0 1 2 3 4  
29. I had to ask others for help because of fatigue 0 1 2 3 4  
30. Quality of my life was affected by fatigue 0 1 2 3 4  
 
SECTION III – Additional Questions about your Fatigue 
     1.    What do you think is the main cause of your fatigue apart from IBD? ……………………………………………………………………………………………………………………. 
            
……………………………………………………………………………………………………………………….…………………………………………………………………………………………………………………. 
 
     2.    What do you think are the other causes of your fatigue? ………………………………………………………………………………………………………………………………………. 
            
……………………………………………………………………………………………………………………….…………………………………………………………………………………………………………………. 
 
     3.    Have you found anything that helps with your fatigue? ………………………………………………………………………………………………………………………………………… 
            
………………………………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
             
     4.    How long have you experienced fatigue? ……………… Years ………………… Months 
     5.    During this time has your fatigue been:                       a) Constant           b) Intermittent 
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 The following questions relate to your physical activity over the 
previous week. Please mark in the appropriate box the number of 
minutes spent doing a particular activity. Please try and think 
carefully and be as accurate as possible with your answers and only 
include activities of either moderate or vigorous intensity. 
Examples are given of what should and should not be included. 
✘ LIGHT INTENSITY - Your heart rate and breathing rate are no different from what they 
are when you are standing, sitting etc 
✓ MODERATE INTENSITY - Your heart rate and breathing rate are faster than normal. You 
may also sweat a little. Brisk walking or sweeping and mopping are good examples of 
how you might feel 
✓ VIGOROUS INTENSITY – Your heart rate is much faster and you have to breathe deeper 
and faster than normal. You will probably sweat. Playing football or squash are good 
examples of how you might feel 
 
LEISURE TIME PHYSICAL ACTIVTIY- remember, do not include light intensity 
activities 
 
In the past week how many minutes did you spend each day: MON TUE WED THUR FRI SAT SUN TOTAL 
Walking outside of work? 
Include ✓          e.g walking to the shops, walking to work, walking the dog or stair walking✓ 
Do NOT Include✘    e.g standing, sitting, driving, walking whilst at work ✘ 
        
Manual labour outside of work? 
Include ✓          e.g cutting the grass, decorating, washing the car, DIY, digging ✓ 
Do NOT Include ✘   e.g weeding, planting, pruning ✘ 
        
Active housework? 
Include ✓          e.g vacuuming, scrubbing floors, bed making, hanging out washing ✓ 
Do NOT Include✘    e.g. sewing, dusting, washing dishes, preparing food ✘ 
        
Dancing? 
Include ✓          e.g only include time actually spent dancing: disco, line, country ✓ 
Do NOT Include✘    e.g time spent not actually dancing ✘ 
        
Participating in a sport, leisure activity or training? 
Include ✓          e.g. exercise classes, cycling, football, swimming, golf, jogging, athletics ✓ 
Do NOT Include ✘   e.g darts, snooker/pool, fishing, playing a musical instrument ✘ 
        
 
Appendix 4f: Scottish Physical Activity Questionnaire (SPAQ) 
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Other Physical Activity if not already covered (please write in)         
         
 TOTAL  
PHYSICAL ACTIVTIY AT WORK- (Only complete if you are currently 
employed and remember not to include light intensity activities 
 
In the past week how many minutes did you spend each day: MON TUE WED THUR FRI SAT SUN TOTAL 
Walking whilst at work? 
Include ✓           e.g walking up or down stairs, to and from your desk, ‘doing the rounds’ ✓ 
Do NOT Include✘   e.g. standing, sitting at desk, time spent not actually walking ✘ 
        
Manual labour whilst at work? 
Include ✓          e.g. lifting, stacking shelves, climbing ladders, building work, cleaning ✓ 
Do NOT Include✘   e.g sitting at desk, answering telephone, driving, check-out operation✘  
        
         
       TOTAL  
Was last week typical of the amount of physical activity you already do? 
YES         
No- I usually do more  Normally, how much more?  Of which activity?  
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Parameter   Factor Subtotal 
Liquid stools  
(total over last 7 days) 
M T W T F S S  




       
Abdominal pain ꝉ 
(total over last 7 days) 





       
General wellbeing * 
(total over last 7 days) 





       
 
Extra-Intestinal 
Arthritis/arthralgia None = 0  
Score = 
x 20  
Yes = 1 
Iritis/uveitis None = 0  
Score = 
x 20  
Yes = 1 
Skin/mouth lesions None = 0  
Score = 
x 20  
Yes = 1 
Peri-anal disease None = 0  
Score = 
x 20  
Yes = 1 
Other fistula None = 0  
Score = 
x 20  
Yes = 1 
Fever > 37.8oC None = 0  
Score = 
x 20  
Yes = 1 
 
Anti-diarrhoeals None = 0  
Score = 
x 30  
Yes = 1 
 





Questionable = 2 
Definite = 5 
 
Haematocrit (Hct) Males (47- Hct)  
Score =              % 
( Typical – Current ) 
x 6 
 





Standard kg                      kg 
100 x ( 1 -         )   
Current kg                     kg  








      Current 
     Standard 
Abdominal pain ꝉ                     
None = 0 
Intermediate = 1 or 2 
Severe = 3 
General wellbeing * 
Well = 0 
Intermediate = 1, 2 or 3 
Terrible = 4 
Weight + 
Skip this section (0) unless weight changes related to 
Crohn’s are known. Maximum deduction of -10 for 
overweight patients) 
Appendix 4g: Crohn’s Disease Activity Index (CDAI) 
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RESISTANCE TRAINING IN ADULTS WITH CROHN’S DISEASE 
This document is to accompany Q8 on the CDAI calculation form. RECOMMENDATION: Unless weight 
changes related to Crohn’s are known, skip this section. Maximum deduction of -10 for overweight 
patients.  
Actual Height CM 
(Inches) 
Standard Weight- MEN KG 
(Pounds) 
Standard Weight- WOMEN KG 
(Pounds) 
147.3 (58.0)  52.2 (115.0) 
148.6 (58.5)  52.6 (116.0) 
149.9 (59.0)  53.1 (117.0) 
151.1 (59.5)  53.6 (118.3) 
152.4 (60.0)  54.2 (119.5) 
153.7 (60.5)  54.8 (120.8) 
154.9 (61.0)  55.3 (122.0)  
156.2 (61.5)  56.0 (123.5) 
157.5 (62.0) 61.7 (136.0) 56.7 (125.0) 
158.8 (62.5)  62.1 (137.0) 57.4 (126.5) 
160.0 (63.0) 62.6 (138.0) 58.0 (128.0) 
161.3 (63.5) 63.0 (139.0) 58.7 (129.5) 
162.6 (64.0) 63.5 (140.0) 59.4 (131.0) 
163.8 (64.5) 64.1 (141.3) 60.1 (132.5) 
165.1 (65.0) 64.6 (142.5) 60.8 (134.0) 
166.4 (65.5) 65.2 (143.6) 61.4 (135.5) 
167.6 (66.0)  65.8 (145.0) 62.1 (137.0) 
168.9 (66.5) 66.4 (146.5) 62.8 (138.5) 
170.2 (67.0) 67.1 (148.0) 63.5 (140.0) 
171.5 (67.5) 67.8 (149.5) 64.2 (141.5) 
172.7 (68.0) 68.5 (151.0) 64.9 (143.0) 
174.0 (68.5) 69.2 (152.5) 65.5 (144.5) 
175.3 (69.0)  69.8 (154.0) 66.2 (146.0) 
176.5 (69.5) 70.5 (155.5) 66.9 (147.5) 
177.8 (70.0) 71.2 (157.0) 67.6 (149.0) 
179.1 (70.5) 71.9 (158.5) 68.3 (150.5) 
180.3 (71.0) 72.6 (160.0) 68.9 (152.0) 
181.6 (71.5)  73.4 (161.8) 69.9 (153.5) 
182.9 (72.0) 74.1 (163.5) 70.3 (155.0) 
154.2 (72.5) 75.0 (165.3)  
185.4 (73.0) 75.7 (167.0)  
186.7 (73.5) 76.6 (169.0)  
188.0 (74.0) 77.5 (171.0)  
189.2 (74.5) 78.4 (172.8)  
190.5 (75.0) 79.1 (174.5)  
191.8 (75.5) 80.2 (176.8)  




Appendix 4h: Standard weight chart 
• Height in shoes with one-inch heels 
• Indoor clothing weight 5 pounds for men and 3 pounds for women 
• Centimetres x 0.3937 = inches • Pounds x 0.4535 = kilograms 
 





















Appendix 4i: HRA approval 
 





















Appendix 4j: REC approval 
 





















Appendix 4k: NUTH R&D approval 
 





















Appendix 4l: Adverse and serious adverse events procedure and reporting form 
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Adverse Event (AE) /Serious Adverse Event (SAE) Form 
STUDY TITLE: PROTECT- Progressive Resistance Training Exercise and Crohn’s Disease Trial 
SPONSOR: University of Northumbria at 
Newcastle 
CHIEF INVESTIGATOR: Dr Garry Tew 
 
Adverse Event                 OR  Serious Adverse Event 
 
    Initial       OR    Follow-up no _______ 
 
Participant identification number:            Today’s Date: ____/____/_______ 
 
Participant DoB: ___ ___ / ___ ___ / ___ ___ ___ ___             Male                               Female 
 
Main Event Outcome 
  
 





Start date:                        /                       /       
 
Stop date:                        /          /             
 
  Classification of Serious Adverse Event (please cross one box only): 
 Death       Prolonged hospitalisation  Life Threatening 
 Persistent or significant     Required hospitalisation              Congenital anomaly/ 
 disability/incapacity       birth defect 
 Other medically important  
    condition 
 
Duration if less than 24 hours 
(hrs:mins): 
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Please state outcome of event at time of this report 
 Resolved  Date resolved 
 Resolved with sequalae (specify below & give date)         Ongoing with sequelae (specify  






 Died   Date of death:          /     / 
    Cause of death 
 
 
  Action taken:            
  None         Therapy prescribed/ other likely action 
 Study treatment interrupted/ halted         Discontinued treatment 
 Other (please specify): 
 
Relationship of event to any of the research procedures 
  Not related   Unlikely to be related        Possibly related       Probably related       Definitely related 
 
 
Is this event expected?   Yes   No 
 
Researcher’s name  Researcher’s signature  Date (dd/mm/yyyy) 
     
CI or delegated medic- name  CI or delegated medic signature  Date (dd/mm/yyyy) 






Date: ___ / ___ / ___ 
 







Appendix 4m: Participant change of status procedure and form 
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Participant Change of Status Form 
STUDY TITLE: PROTECT- Progressive Resistance Training Exercise and Crohn’s Disease Trial 
SPONSOR: University of Northumbria at 
Newcastle 
CHIEF INVESTIGATOR: Dr Garry Tew 
 
Please complete this form when there is a change in the status of a participant 
 
Participant identification number: 
 
Date of change in status:       /     / 
    DAY              MONTH                         YEAR 
Reason(s) for change in patient follow-up (cross the appropriate box): 
 
 Participant is being withdrawn from exercise training and agrees to further follow up 
 
 Participant is being fully withdraw from the study 
Patient agrees to complete next study visit:   Yes   No 
 
 Participant eligibility status has changed prior to baseline visit: 
 
 Participant has died 
 
A serious adverse event form has been completed:  Yes   No 
 
   Date of death           /                          / 
            DAY       MONTH              YEAR 





Name of person completing form: __________________________________ 
Signature of person completing form: _______________________________ 
Date:             /          / 
 
 
































Appendix 6a: Recruitment poster 
 






Bone mineral density and muscle function in adults with inactive 
and mildly active Crohn’s disease: A case control study 










1. What is the purpose of the study? 
We are inviting healthy participants to take part in this research study to enable us to assess bone and 
muscle biomarkers and possible differences between a healthy population in comparison to Crohn’s 
disease patients. Crohn’s disease (CD) is an autoimmune lifelong disorder in which parts of the 
digestive system become inflamed and ulcerated causing abdominal pain, diarrhoea, fatigue, anaemia 
and weight loss. These symptoms are traditionally maintained with medical and surgical treatments, 
however problems outside the digestive system such as reduced bone and muscle health continue to 
reduce a person’s quality of life. It is thought that up to 60% of CD patients have a depletion in muscle 
mass, muscle strength and endurance, factors which are strongly associated with the onset of 
osteopenia and osteoporosis, skeletal disorders characterised by weakening of the bones.  
 
Therefore, it is important to assess bone and muscle health in Crohn’s disease patients and evaluate 
possible differences between the patient groups and healthy participants to identify concerns before 
the diagnosis of extraintestinal complications such as osteoporosis or osteopenia. In addition to 
assessing the prevalence, it’s is also important to determine the test-retest reliability of the measures 
determining bone mineral density and muscle function to ensure consistency and reproducibility.   
 
2. Who can take part? 
Healthy male and female participants who match according to BMI group and physical activity habits 
to data previously obtained from patients with Crohn’s disease. However, you should not take part if: 
• You are under the age of 18 
Appendix 6b: Participant information sheet 
You have been invited to take part in a research study. Before you decide whether or not 
to participate it is important for you to understand why the research is being carried out 
and what it will involve.  
Please take time to read the information carefully, discuss it with others and ask any 
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• Have a medical condition or currently take any medication (anti-inflammatory or steroidal 
drugs) that can cause or contribute to bone and muscle deficiencies. Please contact the 
researcher if you are unsure about a specific condition 
• Pregnant  
• Currently participating in 2 or more sessions a week of resistance exercise (i.e. weight training) 
• You have a history of falls or have poor mobility  
• Currently undergoing radiation therapy or had a significant amount of radiation in the last 12 
months 
• Have previously taken anti-inflammatory or steroidal medication for 3 months or more 
 
3. Do I have to take part?  
You are under no obligation to take part and you will not experience any loss of benefit or penalty if 
you choose not to participate, this information sheet is to help you make that decision. If you do 
decide to take part you are free to withdraw at any time with no reason required, just inform the 
researcher (contact details below) as soon as possible. They will facilitate your withdrawal and 
discuss how you would like your data to be treated. Unless you object the data collected up to that 
point of treatment will still be kept, as this is valuable to the study however as all data is anonymous 
your individual data will not be identifiable in any way.  
4. What would taking part involve? 
After you have consented to participate in this study you will be required to complete a short online 
form lasting approximately 5 minutes. Information such as your age, gender, weight, height and email 
address will be required and you will be asked to complete a short questionnaire based on your 
physical activity habits in the previous week. 
 
After completion, eligible participants will be contacted via the email address provided and invited to 
book in for two assessment visits, a week apart of each other at your soonest convivence (i.e Monday 
16th and Monday 23rd). Details of each visit can be found in the table below. Participants who aren’t 
eligible will also be contacted via the email address provided to inform them that their participation 
at present is not required. However, ineligible participants may be contacted up to 3 months after 
initial interest if this changes. 
 
Visit One Location: Northumbria University Northumberland 
Building, Floor 4 
Time: 1hr 45 mins 
During this you will be asked to answer a series of questions, complete a questionnaire and perform 
a series of physical assessments: 
1. Demographical information- smoking history, past medical history, past surgical history, 
fracture history and a record of any medications you are taking will be collected 
2. Height and weight 
3. Heart rate and blood pressure 
4. Questionnaire- Quality of Life and Fatigue 
5. Bone Mineral Density- lying flat and still on an X-ray table while a scanning arm is passed 
over your body (Figure 1) 
6. Muscle Strength- Warm up session. Strapped (like a seatbelt) onto a chair and required to 
kick your leg and arm at different speeds with force applied (Figure 2) 
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7. Grip Strength- Squeeze a handle with as much force as you can (Figure 3) 
8. Muscle endurance- complete as many chair rises to standing in 30 seconds. Complete as 
many arm curls in 30 seconds 
 
Visit Two Location: Northumbria University Northumberland 
Building, Floor 4 
Time: 1hr 45 mins 
During this you will be asked to answer a series of questions, complete a questionnaire and perform 
a series of physical assessments: 
1. Demographical information update- any changes to medications or any medical events 
since the previous visit 
2. Height and weight 
3. Heart rate and blood pressure 
4. Questionnaire- Quality of Life and Fatigue 
5. Bone Mineral Density- lying flat and still on an X-ray table while a scanning arm is passed 
over your body (Figure 1) 
6. Muscle Strength- Warm up session. Strapped (like a seatbelt) onto a chair and required to 
kick your leg and arm at different speeds with force applied (Figure 2) 
7. Grip Strength- Squeeze a handle with as much force as you can (Figure 3) 
8. Muscle endurance- complete as many chair rises to standing in 30 seconds. Complete as 










5. Are there any expenses of payments involved? 
Unfortunately there are no payments involved for taking part in this research study and we are unable 
to reimburse you for any travel expenses incurred. However, free on-site car parking is available at 
the University of Northumbria at Newcastle.  
 
6. If I decide to participate, will my GP be notified? 
Your named general practitioner, with your consent and for your safety will be notified if your results 
are indicative of requiring treatment. If any serious health problems are detected and require 
immediate attention, you will be referred to the nearest hospital.   
 
7. What are the possible benefits, disadvantages, risks or discomfort of taking part? 
The findings of this study may have a impact upon the screening guidelines for CD patients with low 
bone density and muscle deficiencies in the UK, while increasing physician awareness.  
All the procedures used throughout this study are well established clinical assessment measures which 
are routinely used throughout research and health care. However, like with many procedures there 
Figure 1. Bone mineral density Figure 2. Muscle Strength Figure 3. Grip Strength 
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are very small risks involved. The bone mineral density assessment (DEXA scan) uses x-rays to produce 
pictures and information from of inside the body. If you take part in this study you will have two of 
these scans which will be extra to those that you would have if you did not take part. The x-rays are a 
form of ionising radiation which can cause cell damage that may after many years or decades turn 
cancerous. We are all at risk of developing cancer during our lifetime. The normal risk is that this will 
happen to about half of the people in the population at some point in their life. Taking part in this 
study will add only a very small chance of this happening to you. 
You may also experience muscular fatigue or soreness as a result from the muscular performance 
testing, however, this is a completely normal short term experience but may cause slight discomfort. 
 
The researcher is trained in first aid procedures.  
 
8. How will my information be kept confidential? How will my data be stored? 
All data collected in this study will be fully anonymised using numerical coding to maintain 
confidentiality. Only the researcher will have access to any identifiable information which will be kept 
separate from any data that can identify you. All data will be stored on a password-protected 
computer in accordance with university guidelines and the Data Protection Act (2018). At no point will 
your personal information or data be revealed unless forced to do so by the courts. 
 
9. What if I change my mind about taking part during the study? Can I withdraw? 
If you do decide to take part during or after the study you are still free to withdraw at any time with 
no reason required. Inform the researcher as soon as possible (contact details provided below) and 
they will facilitate your withdrawal and discuss how you would like your data to be treated. We 
would like to use all your data collected up to this point to help with analysis, however if you would 
prefer your data not be used you may request it to be removed from the study. If you do complete 
the study, after one month of competition it may not be possible to withdraw your individual data as 
the results may have already been published. However, as all data are anonymous, your individual 
data will not be identifiable in any way.  
11. What will happen to the results of the study? 
The results will be used in the formation of a PhD thesis that will be examined as part of a 
postgraduate degree. Occasionally, some results might be reported in a scientific journal or 
presented at a research conference, however the data will always remain anonymous unless specific 
consent is obtained beforehand. Findings may also be shared with other organisations/ institutions 
that have been involved with the study. A summary of the study’s findings can be provided to you if 
the researcher is emailed, details found above and at the end of this document.  
All information and data gathered during this research will be stored in line with the Data Protection 
Act (2018).  
12. Who is funding the study? 
This study has not received any funding. 
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13. What happens if I have a complaint? 
If you are unhappy about the way you have been approached or treated before, during or after your 
participation, the researcher should be contacted. However, if you feel this is not appropriate you 
should contact the Chair of ethics for Sport, Exercise and Rehabilitation Dr Nick Neave, Email: 
nick.neave@northumbria.ac.uk.  
 
14. Who has reviewed this study? 
This study has received full ethical approval from the organisation Northumbria university, 
Department of Sport, Exercise and Rehabilitation postgraduate ethics committee. If you require 
confirmation of this please contact the chair of ethics committee using the details below, please 
state the full title of this project and the principle investigator.  
 
Dr Nick Neave 

























For further information please contact: 
 Katherine Jones (Study Co-ordinator): 
Email: katherine.jones@northumbria.ac.uk, Tel: 07434668536 
◦ Chief Investigator:  Dr Garry Tew,  
Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle 
Email: garry.tew@northumbria.ac.uk 
◦ Academic Supervisor:  Dr Katherine Baker,   












Eligibility Information  
(delete or highlight as appropriate) 
1. Please state your date of birth as 
MM/YYYY (e.g. 11/1980) 
  
2. What is your gender?   MALE FEMALE 
3. How tall are you (e.g. 5ft 9”/ 
179.8cm) please be as accurate as possible 
  
4. How much do you weigh (e.g. 9st 4lbs/ 
59.6kg) please be as accurate as possible 
  
5. Is there a possibility you may be 
pregnant? 
N/A YES NO 
6. Have you or are you currently 
undergoing radiation therapy? 
YES NO 
7. Have you had a significant radiation dose 
in the last 12 months? 
YES NO 
8. Have you had a major bone fracture that 
has no healed correctly? 
YES NO 


















Appendix 6c: Participant eligibility form 
 
































Appendix 6d: Informed consent 
 









CASE CONTROL STUDY 












Participant ID:  
Visit Date:               /               / 
             DAY                    MONTH                            YEAR 
 
 
Appendix 6e: Case control study case report form 
Faculty of Health and Life Sciences 
CRF Version 1.0: 10/11/2018 
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Section A: Demographical Data 
PERSONAL DETAILS 
1. Date of birth                                     /                         / 
                                          DAY                  MONTH       YEAR   
   
2. Gender                                             Male                        Female 
 
LIFESTYLE FACTORS  










5. On average over the last month, how many resistance-type exercise sessions (e.g weight 
lifting/ bearing- free weights and weight machines) has the patient undertaken? 
 
 
EMPLOYMENT HISTORY  
6. Primary employment status  
  Employed            If employed:    Full time  
Self-employed                        Part time 
Unemployed  
  Student  
  Retired   
  Any other employment group (please specify)  
  
 
How many ________ Stopped for ______________ 
How many _________ 
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CURRENT MEDICATIONS 
Provide details in the table below of all the prescribed medication, over-the-counter medication and 
supplements/ nutraceuticals that the participant is currently taking.  






















7. Have you ever taken any steroids- anabolic or corticosteroids? 
                                                                                             YES                               NO 
8. If ‘YES’, complete the table below 
 
MEDICAL CONDITIONS 
9. Medical History: 
………………………………………………………………………………..      ……………………………………………………………………. 
…………………………………………………………………………………     …………………………………………………………………….. 
…………………………………………………………………………………     …………………………………………………………………….. 
Steroid Type and Form 
(Tablet, IV, Inhaler) 
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SURGICAL TREATMENT  
10. Has the participant ever had any surgery?                                                  YES                   NO 
11.  If ‘YES’, please indicate the type of surgery and date of the procedure: 







1. Has the participant had any fractures?                                                          YES                   NO 
2. If ‘YES’, please indicate the fracture, date and treatment 
Fracture Location Date (Format mm/yyyy) Treatment (Cast, Splint) and for how long 
   
   
   
   
   
 
Section B: Physical Measurements 
1. Body Mass (kg to 1 decimal place):                                     . 
 
2. Stature (cm to 1 decimal place):                              . 
 
 
3. Resting Heart Rate (beats/minute): 
 
 
4. Resting Blood Pressure (mmHG):                                    /     
                                                                      SYSTOLIC                        DIASTOLIC 
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Section C: Questionnaires                                                                        
1. Has the participant completed the EQ-5D-5L?                               Yes                              No 
 
 
2. Has the participant completed the IBD-F?                                      Yes                              No 
 
 
If ‘No’ to Q1-5, state the reason(s) in the box below. Use this space for any other comments about 






Section D: Muscle Performance Testing 
Follow the study-specific procedure for muscle performance testing and complete the assessment 
testing data collection sheet contained within this case report form. 
 
1. Has the patient completed the lower muscle strength test?                  Yes                              No 
 
 
2. Has the patient completed the upper muscle strength test?                  Yes                              No 
  
 
3. Has the patient completed the 30’s chair stand test?                               Yes                              No 
 
 
4. Has the patient completed the 30’s arm curl test?                                    Yes                              No 
 
 
5. Has the patient completed the grip strength?                                            Yes                              No 
 
If ‘No’, state the reason(s) in the box below. Use this space for any other comments about muscle 
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Section E: Bone Health Assessment  
Follow the study-specific procedure for muscle performance testing and complete the exercise 
testing data collection sheet contained within this case report form. 
1. Has a DXA scan on the patient been carried out?                                  Yes                              No 
 
If ‘No’, state the reason(s) in the box below. Use this space for any other comments about the bone 





Section F: Check List and Investigator Sign-off 
1. Have all sections of this case report been completed?                   Yes                              No 
 
 
2. Any adverse events reported, or has the participant  
confirmed that no adverse events have occurred?                          Yes                              No 
 
3. Form completed by: 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                          /                       /  
                                                           DAY                  MONTH                       YEAR 
 








































Appendix 6f: Backwards stepwise logistic regression model for lumbar spine 
 
Table 7. 
Summary of backward stepwise logistic regression model for Lumbar Spinea 
Predictors B Std. Error Beta t Sig Adj R2 
Step 1      .373 
   Constant .051 .104  .489 .628  
   Age .001 .001 .167 .894 .377  
   Alcohol Intake -.001 .002 -.040 -.285 .778  
   D Behaviour .015 .014 .138 1.058 .297  
   D Durationb -.054 .031 -.317 -1.718 .094  
   PA Habitsc .067 .022 .407 2.988 .005  
   Gender -.077 .022 -.491 -3.467 .001  
   Smoking Status -.035 .019 -.233 -1.863 .070  
   Surgical History .018 .014 .174 1.248 .220  
Step 2      .388 
   Constant .056 .101  .554 583  
   Age .001 .001 .145 .862 .394  
   D Behaviour .015 .014 .137 1.061 .295  
   D Durationb -.052 .030 -.303 -1.725 .092  
   PA Habitsc .064 .020 .391 3.178 .003  
   Gender -.075 .021 -.477 -3.638 .001  
   Smoking Status -.036 .018 -.240 -1.985 .054  
   Surgical History .018 .014 .171 1.246 .220  
Step 3      .392 
   Constant .082 .096  .854 .398  
   D Behaviour .011 .013 .104 .847 .402  
   D Durationb -.034 .022 -.201 -1.554 .128  
   PA Habitsc .061 .020 .372 3.082 .004  
   Gender -.077 .020 -.489 -3.757 .001  
   Smoking Status -.039 .017 -.267 -2.284 .028  
   Surgical History .019 .014 .189 1.399 .170  
Step 4      .396 
   Constant .101 .093  1.088 .283  
   D Durationb -.033 .022 -.196 -1.521 .136  
   PA Habitsc .063 .020 .385 3.234 .002  
   Gender -.081 .020 -.518 -4.152 .000  
   Smoking Status -.040 .017 -.269 -2.313 .026  
   Surgical History .018 .014 .177 1.322 .193  
Step 5      .385 
   Constant .156 .084  1.862 .070  
   D Durationb -.046 .020 -.273 -2.350 .024  
   PA Habitsc .062 .020 .375 3.125 .003  
   Gender -.074 .019 -.471 -3.904 .000  
   Smoking Status -.038 .017 -.259 -2.210 .033  
D, Disease; PA, Physical Activity; Adj, Adjusted;  P-values significant at the <0.05 threshold are in bold 
a Computed as the total bone mineral density (g/cm2) at the lumbar spine (L2-L4) (logarithmic transformed) 
b Presented as total months (logarithmic transformed) 
c Combined total physical activity minutes, computed as the sum of leisure time + work time scores -/+ typical 
week minutes (logarithmic transformed) 
 
































Appendix 6g: Backwards stepwise logistic regression model for femoral neck 
 
Table 8. 
Summary of backward stepwise logistic regression model for Femoral Neck 
Predictors B Std. Error Beta t Sig Adj R2 
Step 1      .280 
   Constant .894 .206  4.331 .000  
   Age -.001 .002 -.136 -.680 .500  
   Alcohol Intake .004 .004 .131 .866 .392  
   D Behaviour .035 .028 .174 1.246 .220  
   D Durationb -.079 .062 -.250 -1.261 .215  
   PA Habitsc .084 .044 .277 1.900 .065  
   Gender -.096 .044 -.330 -2.176 .036  
   Smoking Status -.013 .037 -.047 -.352 .727  
   Surgical History .008 .029 .041 .278 .783  
Step 2      .297 
   Constant .917 .188  4.880 .000  
   Age -.001 .002 -.130 -.662 .512  
   Alcohol Intake .004 .004 .134 .899 .374  
   D Behaviour .034 .028 .172 1.248 .220  
   D Durationb -.086 .057 -.271 1.504 .141  
   PA Habitsc .084 .044 .275 1.911 .063  
   Gender -.093 .042 -.319 -2.208 .033  
   Smoking Status -.012 .036 -.044 -.334 .740  
Step 3      .313 
   Constant .884 .159  5.554 .000  
   Age -.001 .002 -.110 -.595 .555  
   Alcohol Intake .004 .004 .123 .857 .396  
   D Behaviour .035 .027 .177 1.306 .199  
   D Durationb -.090 .055 -.284 -1.631 .111  
   PA Habitsc .085 .043 .279 .1966 .056  
   Gender -.095 .041 -.327 -2.317 .026  
Step 4      .323 
   Constant .854 .150  5.710 .000  
   Alcohol Intake .003 .004 .091 .687 .496  
   D Behaviour .040 .026 .199 1.540 .131  
   D Durationb -.113 .039 -.357 -2.918 .006  
   PA Habitsc .093 .041 .306 2.289 .027  
   Gender -.096 .041 -.331 -2.364 .023  
Step 5      .332 
   Constant .861 .148  5.809 .000  
   D Behaviour .038 .026 .190 1.485 .145  
   D Durationb -.114 .038 -.360 -2.964 .005  
   PA Habitsc .102 .038 .334 2.652 .011  
   Gender -.106 .038 -.362 -2.764 .008  
Step 6      .313 
   Constant .910 .146  6.214 .000  
   D Durationb -.108 .039 -.341 -2.784 .008  
   PA Habitsc .110 .039 .360 2.843 .007  
   Gender -.123 .037 -.423 -3.350 .002  
D, Disease; PA, Physical Activity; Adj, Adjusted;  P-values significant at the <0.05 threshold are in bold 
a Presented as total months (logarithmic transformed)  b Combined total physical activity minutes, computed as the 
sum of leisure time + work time scores -/+ typical week minutes (logarithmic transformed)  
 
































Appendix 6h: Backwards stepwise logistic regression model for greater trochanter 
 
Table 9. 
Summary of backward stepwise logistic regression model for Greater Trochantera 
Predictors B Std. Error Beta t Sig Adj R2 
Step 1      .078 
   Constant .578 .186  3.109 .004  
   Age .000 .002 .040 .177 .861  
   Alcohol Intake -.002 .004 -.096 -.562 .578  
   D Behaviour .016 .025 .098 .623 .537  
   D Durationb -.057 .056 -.229 -1.021 .314  
   PA Habitsc .094 .040 .389 2.355 .024  
   Gender -.068 .040 -.295 -1.720 .094  
   Smoking Status .013 .033 .060 .393 .696  
   Surgical History .016 .026 .102 .607 .547  
Step 2      .101 
   Constant .589 .173  3.414 .002  
   Alcohol Intake -.002 .004 -.084 -.543 .590  
   D Behaviour .014 .024 .090 .605 .549  
   D Durationb -.050 .039 -.201 -1.277 .209  
   PA Habitsc .092 .037 .379 2.455 .019  
   Gender -.068 .039 -.294 -1.734 .091  
   Smoking Status .011 .031 .051 .361 .720  
   Surgical History .016 .025 .106 .639 .527  
Step 3      .120 
   Constant .612 .158  3.868 .000  
   Alcohol Intake -.002 .004 -.079 -.519 .607  
   D Behaviour .014 .024 .090 .606 .548  
   D Durationb -.050 .039 -.200 -1.286 .206  
   PA Habitsc .092 .037 .381 2.492 .017  
   Gender -.066 .039 -.286 -1.722 .093  
   Surgical History .017 .025 .109 .666 .509  
Step 4      .136 
   Constant .613 .157  3.908 .000  
   D Behaviour .015 .023 .097 .662 .511  
   D Durationb -.051 .039 -.202 -1.312 .197  
   PA Habitsc .086 .035 .355 2.477 .017  
   Gender -.059 .036 -.256 -1.659 .105  
   Surgical History .015 .024 .097 .607 .547  
Step 5      .149 
   Constant .663 .133  4.979 .000  
   D Behaviour .014 .023 .087 .606 .548  
   D Durationb -.061 .034 -.244 -1.775 .083  
   PA Habitsc .085 .034 .351 2.469 .018  
   Gender -.054 .034 -.232 -1.567 .125  
Step 6      .161 
   Constant .681 .129  5.286 .000  
   D Durationb -.059 .034 -.235 -1.734 .090  
   PA Habitsc .088 .034 .363 2.596 .013  
   Gender -.060 .032 -.260 -1.863 .069  
D, Disease; PA, Physical Activity; Adj, Adjusted;  P-values significant at the <0.05 threshold are in bold 
a Presented as total months (logarithmic transformed)  b Combined total physical activity minutes, computed as the 
sum of leisure time + work time scores -/+ typical week minutes (logarithmic transformed) 
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American College of Sports Medicine (ACSM) exercise contraindications  
 
• Recent significant change in resting electrocardiogram which may suggest significant 
ischemia, myocardial infarction or other acute cardiac event  
• Unstable angina 
• Uncontrolled cardiac dysrhythmias causing symptoms or hemodynamic compromise 
• Symptomatic severe aortic stenosis 
• Uncontrolled symptomatic heart failure 
• Acute pulmonary embolus or pulmonary infarction 
• Acute myocarditis or pericarditis 
• Suspected or known dissecting aneurysm 
















Appendix 7a: ACSM absolute contraindications to exercise testing 
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[Version one- Sent to patients on the IBD database] 
 
 
Resistance training in adults with Crohn’s disease 
Chief Investigator: Dr Garry Tew 
 
Dear Patient 
We are undertaking a research study that aims to investigate the effects of a 6 month home 
based exercise programme on fatigue, muscle strength, bone mineral density, quality of life 
and disease activity in adults with inactive or mildly active Crohn’s disease.  
You have been identified as being potentially suitable for this study having previously 
consented to be contacted regarding future IBD research through the IBD database at 
Newcastle Hospitals.   
Enclosed is a participant information sheet explaining the study in further detail, please take 
your time to read this information. If you are interested in participating please complete the 
disease activity diary enclosed 7 days before your next gastroenterology appointment.  
If you have any questions or would like to discuss anything further please contact Katherine 
Jones (Study Co-ordinator) at katherine.jones@northumbria.ac.uk or on 07434668536 
(Mon-Sat 9am-6pm). 
PLEASE NOTE: Choosing not to participate in this study will NOT affect your existing 
gastroenterology appointment or the quality of care you will receive.  
 
Yours sincerely,  
 
 
Dr Garry Tew, PhD, CSci 
Chief Investigator  
Appendix 7b: Recruitment letter 
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Resistance training in adults with Crohn’s disease 
Chief Investigator: Dr Garry Tew 
 
Dear Patient 
We are undertaking a research study that aims to investigate the effects of a 6 month home 
based training programme on fatigue, muscle strength, bone mineral density, quality of life 
and disease activity in adults with inactive or mildly active Crohn’s disease.  
You have been identified as being potentially suitable for this study following your recent 
gastroenterology appointment at Newcastle Hospitals.  
Enclosed is a participation information sheet explaining the study in further detail, please 
take your time to read this information. If you have any questions or would like to discuss 
anything further please contact Katherine Jones (Study Co-ordinator) at 
katherine.jones@northumbria.ac.uk or on 07434668536 (Mon-Sat 9am-6pm). 
 
Yours sincerely,  
 
 
Dr Garry Tew, PhD, CSci 











Resistance training in adults with Crohn’s disease 










1. What is the purpose of the study? 
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract causing 
symptoms such as fatigue, abdominal pain, blood loss and diarrhoea. These symptoms are 
traditionally maintained with medical and surgical treatments, however problems with 
reduced muscle and bone health persist which can be just as debilitating as CD. Although not 
part of routine treatment, regular exercise has demonstrated improvements in fatigue, 
disease activity, psychological health, quality of life and bone and muscle health. Despite 
these potential benefits, the role of exercise in CD has not been well studied and remains 
poorly understood with research primarily focusing on the potential of aerobic exercise 
programmes (e.g. running, cycling).    
 
However, growing evidence in other chronic conditions has shown that resistance (strength) 
training may have a better effect on bone health, muscle strength and endurance than 
aerobic exercise. Despite this, little information exists around the potential of resistance 
training in CD patients.  With the debilitating nature of this disease, further research is needed 
as these findings may have a significant impact upon management in the CD population by 
providing physical activity solutions instead of or alongside current treatments.  
 
Therefore, the purpose of this study is to investigate the effects of a 6 month resistance 
training programme on muscle function, bone mineral density, fatigue, quality of life and 
disease activity in adults with CD.  
 
 
Appendix 7c: Participant information sheet 
You have been invited to take part in a research study. Before you decide whether or not 
to participate it is important for you to understand why the research is being carried out 
and what it will involve.  
Please take time to read the information carefully, discuss it with others and ask any 
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2. Why have I been invited to take part? 
You have been invited to participate in this research study as you have been diagnosed with 
CD for longer than 4 weeks and are currently in a state of inactive or mildly active disease.  
However, you should not partake in this study if: 
• You have any other medical conditions that would make it unsuitable and unsafe to 
undertake resistance exercise 
• You are pregnant or planning pregnancy within the next 6 months 
• You currently participate in more than 2 sessions a week of resistance exercise, such 
as weight lifting 
• You are currently participating in another clinical trial where the two trials may 
influence each other (if unsure please discuss with us) 
• You are under the age of 16 
• You have a moderate or severely active CD 
• You have had or are planned to have major surgery  within the first 6 months of the 
study 
• Your medications have not been stable for at least 4 weeks prior to enrolment 
 
3. Do I have to take part?  
You are under no obligation to take part and you will not experience any loss of benefit or 
penalty if you choose not to participate, this information sheet is to help you make that 
decision. If you do decide to take part you are free to withdraw at any time with no reason 
required, just inform the researcher (contact details below) as soon as possible. They will 
facilitate your withdrawal and discuss how you would like your data to be treated. Unless 
you object the data collected up to that point of treatment will still be kept, as this is 
valuable to the study however as all data is anonymous your individual data will not be 
identifiable in any way. If you do not wish to take part in this study it will not affect the 
ongoing standard care you receive in any way from the NHS. 
4. What would taking part involve? 
After you read this information sheet if you are happy to take part, contact Katherine Jones, 
study co-ordinator on 07434668536 (Mon-Sat 9am-6pm). The study co-ordinator will invite 
you to attend a screening visit and ask you to keep a disease activity diary for 7 days, recording 
number of liquid stools, abdominal pain (between none and severe) and general well-being 
(between well and terrible).  
  
Screening Visit Location: Freeman Hospital/ RVI Time: 1 Hour 
You will be asked to bring your 7 day disease activity diary to this screening. 
During this eligibility screening visit the study will be explained in more detail and any 
questions you may have will be answered. If you’re happy with this, you will be asked to 
sign a consent form indicating you understand the study, what is involved and have had 
the opportunity to ask questions. A copy of this consent form will be given to you along 
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with this participant information sheet. A direct care team member will then assess 
eligibility in more detail and medical records may need to be accessed: 
1. Demographical information (age, gender, smoking history) and information on 
your medical history, surgical history and medications will be collected 
2. A physical examination of your abdomen- consisting of a visual examination 
(inspection), listening to bowel sounds (auscultation)  and feeling for abdominal 
tenderness (palpations)  
3. You will also be required to provide a stool and blood sample, unless this has been 
performed within the previous 4 weeks  
 
If the results from the screening visit confirm you are eligible to take part in the study, you 
will be telephoned and invited to attend a baseline visit. If it is confirmed that you are not 
eligible you will be contacted letting you know your participation is not required. 
 
Baseline Visit Location: Northumbria University Time: 1 hr 30 mins 
During this visit, you will be asked to complete a series of questionnaires and perform a 
series of physical assessments: 
1. Height 
2. Weight 
3. Heart rate and Blood pressure 
4. Questionnaire- Fatigue 
5. Questionnaire- Quality of Life (x2) 
6. Questionnaire- Physical Activity 
7. Bone mineral density- lying flat and still on an X-ray table while a scanning arm is 
passed over your body (Figure 1) 
8. Muscle strength- 10 minute warm up session. Strapped (like a seatbelt) onto a 
chair and required to kick your leg and arm at different speeds with force applied 
(Figure 2). 
9. Grip strength- squeeze a handle with as much force as you can (Figure 3) 
10. Muscle endurance- complete as many chair rises to standing in 30 seconds. 











Figure 1. Bone mineral density Figure 2. Muscle Strength Figure 3. Grip Strength 
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After completing the baseline assessment visit you will have an equal chance of being 
assigned to one of two groups, however both groups will undergo the same measurements 
and are required to attend the two assessment visits: 
• Group One: Half of patients will be enrolled to receive usual care plus a 6 month 
resistance training programme. Patients allocated to this group will be invited to 
complete three sessions a week for 60 minutes on non-consecutive days (e.g Monday, 
Wednesday and Friday). The majority of these sessions will be unsupervised and 
carried out in the comfort of your own home with the equipment provided. However 
to monitor your progress and to provide you with support, 12 supervised exercise 
sessions will be conducted at the University of Northumbria at Newcastle over the 26 
weeks. These supervised sessions will gradually decrease over time. A breakdown of 
these supervised and unsupervised sessions is illustrated below: 
* You decide which week you would like to schedule your supervised session, at your 
soonest convenience. 
• Group Two: Half of patients will be enrolled to receive usual care from The Newcastle 
Upon Tyne Hospitals NHS Foundation Trust. Participants allocated to this group will 
be required to attend assessment visits at week 13 and 26 of the study, details below. 
Week 13 Assessment Visit Location: Northumbria University Time: 1 Hour 
Similar to the baseline visit above, height, weight, heart rate and blood pressure, fatigue, 
quality of life, physical activity, muscle strength, grip strength and muscle endurance will 
be assessed. In addition: 
1. Information on your medications will be updated 
2. You will also be questioned regarding any medical events 
3. Questionnaire- physical activity enjoyment 
Week Supervised 
Session 





1 2 1 3 14 1* 2 or 3 3 
2 2 1 3 15 2 or 3 3 
3 1 2 3 16 2 or 3 3 
4 1 2 3 17 2 or 3 3 
5 1* 2 or 3 3 18 1* 2 or 3 3 
6 2 or 3 3 19 2 or 3 3 
7 1* 2 or 3 3 20 2 or 3 3 
8 2 or 3 3 21 2 or 3 3 
9 1* 2 or 3 3 22 1* 2 or 3 3 
10 2 or 3 3 23 2 or 3 3 
11 2 or 3 3 24 2 or 3 3 
12 2 or 3 3 25 2 or 3 3 
13 Assessment 
Visit 
3 3 26 Assessment Visit 3 3 
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Prior to the final assessment visit you will be asked to keep a disease activity diary for 7 days, 
recording number of liquid stools, abdominal pain (between none and severe) and general 
well-being (between well and terrible). 
 
Week 26 Assessment Visit Location: Freeman Hospital/RVI Time: 1 hr  
You will be asked to bring your 7 day disease activity diary to this assessment. 
Similar to the screening visit above. A direct care team member will assess: 
1. Information on your medical history and medications will be collected 
2. A physical examination of your abdomen- consisting of a visual examination 
(inspection), listening to bowel sounds (auscultation) and feeling for abdominal 
tenderness (palpations)  
3. You will also be required to provide a stool and blood sample, unless this has 
been performed within the previous 4 weeks  
 
Week 26 Assessment Visit Location: Northumbria University Time: 1 hr 45 mins 
Similar to the baseline and assessment visit above, height, weight, fatigue, quality of life, 
physical activity, bone mineral density, muscle strength, grip strength, muscle endurance 
and physical activity enjoyment will assessed.  
 
Following these assessments we would also like to contact you regarding some follow up 
questions about your experience in the study and your thoughts on the intervention you 
received. This telephone interview will last approximately 30 minutes.  
Following completion of the study, participants in group two will receive another phone call 
offering an exercise consultation from the researcher. During this call the benefits and 
guidelines of exercise will be discussed and a personalised action plan for developing and 
achieving your exercise goals will be established.  
 
5. Are there any expenses of payments involved? 
Unfortunately there are no payments involved for taking part in this research study and we 
are unable to reimburse you for any travel expenses incurred. However participants in group 
one will be allowed to keep the exercise equipment (e.g. resistance bands) used at home, 
while participants in group two will be offered a one-to-one exercise consultation, discussing 
personal goals, guidelines and action plans. In addition, free on-site car parking is available at 
the University of Northumbria at Newcastle.  
 
6. If I decide to participate, will my GP be notified? 
Your general practitioner, with your consent will be notified that you are taking part in this 





W12018030       336 | P a g e  
 
7. What are the possible benefits, disadvantages, risks or discomfort of taking part? 
The findings of this study may have a significant impact upon management in the CD 
population by providing physical activity solutions instead of or alongside current treatments. 
By participating in this study you will help develop a greater understanding into this disease, 
raise awareness and encourage further research. As the role of exercise in CD has not been 
well studied and remains poorly understood, we cannot say what benefits you will gain from 
taking part or whether you will benefit. However, previous CD studies have demonstrated 
improvements in bone mineral density, symptoms, psychological health, fatigue and quality 
of life.  
All the procedures used throughout this study are well established clinical assessment 
measures which are routinely used throughout research and health care. However, like with 
many procedures there are very small risks involved.  
The bone mineral density assessment (DEXA scan) uses x-rays to produce pictures and 
information from of inside the body. If you take part in this study you will have two of these 
scans which will be extra to those that you would have if you did not take part. The x-rays are 
a form of ionising radiation which can cause cell damage that may after many years or 
decades turn cancerous. We are all at risk of developing cancer during our lifetime. The 
normal risk is that this will happen to about half of the people in the population at some point 
in their life. Taking part in this study will add only a very small chance of this happening to 
you. 
You may also experience muscular fatigue or soreness as a result from the muscular 
performance testing or from the resistance exercise. However, this is a completely normal 
short term experience but may cause slight discomfort. 
For your safety you will be monitored at various points throughout the programme, as 
mentioned before and at least one researcher will be trained in first aid procedures during all 
supervised exercise sessions. 
 
8. How will my information be kept confidential? How will my data be stored? 
All data collected in this study will be fully anonymised using numerical coding to maintain 
confidentiality. With exception of the healthcare professionals only the researcher will have 
access to any identifiable information which will be kept separate from any data that can 
identify you. In addition, for your safety if clinical measures are indicative of requiring 
treatment the patients named gastroenterologist and GP will be informed. If any serious 
health problems are detected and require immediate attention, you will be referred to the 
nearest hospital. All data will be stored on a password-protected computer in accordance 
with university guidelines and the Data Protection Act (1998) and destroyed after 2 years 
following the conclusion of the study. Some results might be reported in a scientific journal, 
presented at a research conference or shared within other organisations/ institutions, 
however the data will always remain anonymous unless specific consent is obtained 
beforehand. At no point will your personal information or data be revealed unless forced to 
do so by the courts. 
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9. What if I do not wish to take part? 
If you do not wish to take part in this study it will not affect the ongoing standard care you 
receive in any way from the NHS. 
10. What if I change my mind about taking part during the study? Can I withdraw? 
If you do decide to take part during or after the study you are still free to withdraw at any 
time with no reason required. Inform the researcher as soon as possible (contact details 
provided below) and they will facilitate your withdrawal and discuss how you would like 
your data to be treated. We would like to use all your data collected up to this point to help 
with analysis, however if you would prefer your data not be used you may request it to be 
removed from the study. If you do complete the study, after one month of competition it 
may not be possible to withdraw your individual data as the results may have already been 
published. However, as all data are anonymous, your individual data will not be identifiable 
in any way. The care you receive will not be affected in anyway by your withdrawal.  
11. What will happen to the results of the study? 
The results will be used in the formation of a PhD thesis that will be examined as part of a 
postgraduate degree. Occasionally, some results might be reported in a scientific journal or 
presented at a research conference, however the data will always remain anonymous unless 
specific consent is obtained beforehand. Findings may also be shared with other 
organisations/ institutions that have been involved with the study. A summary of the study’s 
findings can be provided to you if the researcher is emailed, details found above and at the 
end of this document. All information and data gathered during this research will be stored 
in line with the Data Protection Act (1998) and will be destroyed after 2 years following the 
conclusion of the study.  
12. What if there is a problem? 
If a problem occurs before, during or after the study you should contact the researcher who 
will do their best to answer your queries. If you feel this is not appropriate, a formal 
complaint can be made through the NHS Complaints Procedure by contacting the local 
clinical commissioning group (CCG), Tel: 0191 217 2996, Email: ngccg.enquiries@nhs.net.  
13. Who is Organising and Funding the study? 
This study has been funded by PROcare LTD and the University of Northumbria at 
Newcastle. The University of Northumbria at Newcastle is responsible for the conduct of the 
study.  
14. What happens if I have a complaint? 
If you are unhappy about the way you have been approached or treated before, during or 
after your participation, the researcher should be contacted. However, if you feel this is not 
appropriate you should contact the Chair of ethics for Sport, Exercise and Rehabilitation Dr 
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Nick Neave, Email: nick.neave@northumbria.ac.uk. Alternatively  you can use the normal 
hospital complaints procedure through the Patient Advice and Liaison Service (PALS), 
Freephone: 0800 0320202, Email: northoftynepals@nhct.nhs.uk, Txt/ SMS: 01670511098 
15. Who has reviewed this study? 
This study has received full ethical approval from the NHS Health Research Authority (HRA) 
and been reviewed by the REC committee, reference number: 17/NE/0308 and from the 
organisation Northumbria university, Department of Sport, Exercise and Rehabilitation 




















If you have any other questions or for further independent information about being 
involved in a research study please contact the Patient Advice and Liaison Service (PALS), 
Freephone: 0800 0320202, Email: northoftynepals@nhct.nhs.uk, Txt/ SMS: 01670511098. 





If you would like to participate in the study, are interested but request further information 
please contact: 
 Katherine Jones (Study Co-ordinator) on Tel: 07434668536(Mon-Sat 9am-6pm) 
◦ Chief Investigator:  Dr Garry Tew,  
Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle 
Tel: 0191 243 7556, Email: garry.tew@northumbria.ac.uk 
◦ Supervisor to Study Co-ordinator:  Dr Katherine Baker 
Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle 
Tel: 0191 215 6723, Email: katherine.baker@northumbria.ac.uk 
◦ Research Nurse: Elaine Stephenson 
 Gastroenterology Department, The Newcastle Upon Tyne Hospitals NHS Foundation Trust 
Tel: 0191 282 6596, Email: elaine.stephenson@nuth.nhs.uk  
◦ Research Nurse: Mary Doona 
 Gastroenterology Department, The Newcastle Upon Tyne Hospitals NHS Foundation Trust 
Tel: 0191 244 8915, Email: mary.doona@nuth.nhs.uk  
◦ Hospital Co- Investigator: Dr Nick Thompson 
Gastrointestinal and Liver Services, Newcastle Upon Tyne Hospitals NHS Foundation Trust 
Tel: 0191 233 7209 
◦ Hospital Principal Investigator: Dr Ally Speight 
Gastrointestinal and Liver Services, Newcastle Upon Tyne Hospitals NHS Foundation Trust 
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Appendix 7d: Disease Activity Diary  
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Appendix 7e: Recruitment poster  
 
































Appendix 7f: Staff study poster  
 

































Appendix 7g: Informed consent form 
 



































































Appendix 7h: Participant and GP contact details form 
 











































Progressive Resistance Training Exercise and Crohn’s 
Disease Trial 
 








Participant ID:  
Visit Date:               /               / 





Appendix 7i: Eligibility case report form 
 
W12018030                348 | P a g e  
 
Instructions for completing the screening case report form: 
These questions and assessments, performed by the hospital principal investigator (PI) or a 
delegated member of the staff listed on the PROTECT Delegation log, are designed to screen 
participants for participation in the PROTECT trial. 
 
PLEASE NOTE: Details on this form and eligibility MUST be confirmed by the PI or delegated medic, 
who sign and date section H. Informed consent must be obtained prior to any screening procedure, 
including the completion of this form 
 
Please complete all sections in this form, using the spaces provided and only skipping sections if the 
text directs you to do so. If the patient is deemed ineligible at any section within this form it is 
important that the reasons are recorded and Sections F and G are completed.  
If you have any questions, please do not hesitate to contact the Chief Investigator (Dr Garry Tew; 
garry.tew@northumbria.ac.uk) or Study Trial Coordinator (Katherine Jones; 
Katherine.jones@northumbria.ac.uk).  
When complete, please make a paper copy of: 
o This case report form 
o Consent form (3 copies required- 1 copy for the patient, 1 to be kept in the patient’s  
               medical notes and one to be sent to the study researcher, Katherine Jones, who 
               is conducting the baseline visit 
o Patient 7-day diary for CDAI 
o Contact details form 
Original signed consent form and contact details need to be filed in the investigator site file at the 
hospital. Originals of this screening case report form and the patient 7-day diary for CDAI should be 
sent to the researcher separately to ensure the data remains anonymised, with copies made and 
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Section A: Demographical Data 
PERSONAL DETAILS 
1. Date of birth                                     /                         / 
                                          DAY                  MONTH       YEAR     
 
NOTE: If aged <16, the patient is ineligible for participation. Please proceed directly to Sections F and 
G and complete as appropriate. 
 
2. Gender                                             Male                        Female 
 
3. Ethnicity- please cross one box 
White 
British Irish Any other white background 
 
Mixed 
White and Black Caribbean White and Black African White and Asian 
Any other mixed background   
 
Asian or Asian background 
Indian Pakistani Bangladeshi 
Any other Asian background   
 
Black or Black British 
Caribbean African Any other Black background 
 
Chinese or Other Ethnic Group 






LIFESTYLE FACTORS  
4. Smoking status                        Current                      Previous                     Never  
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6. On average over the last month, how many resistance-type exercise sessions (e.g weight 
lifting/ bearing- free weights and weight machines) has the patient undertaken? 
 
 
NOTE: If the patient participates in 2 or more sessions of resistance exercise a week they are 
ineligible for participation. Please proceed directly to Sections F and G and complete as appropriate. 
 
EMPLOYMENT HISTORY  
7. Primary employment status  
  Employed            If employed:    Full time  
Self-employed                        Part time 
Unemployed  
  Student  
  Retired   




Section B: Assessment for Pregnancy 
If the patient is male, please proceed to Section C 
 
1. Is there any chance the patient could be pregnant?                       Yes                                No 
 
NOTE: If ‘Yes’, the patient is ineligible to participate. Please proceed to Sections F and G and 
complete as appropriate. 
 
2. Is the patient planning pregnancy within the next 6 months following the anticipated 
baseline visit? 
Yes           No 
 
NOTE: If ‘Yes’, the patient is ineligible to participate. Please proceed to Sections F and G and 
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Section C: Diagnosis and Classification of Crohn’s Disease 
1. Date of diagnosis of Crohn’s disease                              /                         / 
                                                                               DAY                    MONTH                          YEAR 
 
NOTE: If the date is less than 4 weeks before this screening visit, the patient is ineligible for 
participation. Please proceed directly to Sections F and G and complete as appropriate. 
 
CLASSIFICATION OF CROHN’S DISEASE 
2. Age at diagnosis 4. Disease Behaviour 
16 years or younger Non-stricturing, non-penetrating 
Between 17 and 40 years old Stricturing 
Above 40 years old Penetrating 
Unknown age at diagnosis  
3. Location of disease 5. Disease Modifier 
Ileal Crohn’s Perianal Disease 
Colonic Crohn’s  
Ileocolonic Crohn’s  
Isolated upper GI disease  
Ileal Crohn’s and upper GI disease  
Colonic Crohn’s and upper GI disease  
Ileocolonic Crohn’s and upper GI disease  
Disease location unknown  
 
CROHN’S DISEASE ACTIVITY INDEX (CDAI) 
Ahead of the screening visit , the patient should have been given a CDAI diary to complete for 7  
days. Please state the date the patient started completing this diary:                                    
                                                  
                                                                                                  /                      / 
                                                         
                                                                                   DAY                      MONTH                                YEAR 
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Parameter   Factor Subtotal 
Liquid stools  
(total over last 7 days) 
M T W T F S S  




       
Abdominal pain ꝉ 
(total over last 7 days) 





       
General wellbeing * 
(total over last 7 days) 





       
 
Extra-Intestinal 
Arthritis/arthralgia None = 0  
Score = 
x 20  
Yes = 1 
Iritis/uveitis None = 0  
Score = 
x 20  
Yes = 1 
Skin/mouth lesions None = 0  
Score = 
x 20  
Yes = 1 
Peri-anal disease None = 0  
Score = 
x 20  
Yes = 1 
Other fistula None = 0  
Score = 
x 20  
Yes = 1 
Fever > 37.8oC None = 0  
Score = 
x 20  
Yes = 1 
 
Anti-diarrhoeals None = 0  
Score = 
x 30  
Yes = 1 
 





Questionable = 2 
Definite = 5 
 
Haematocrit (Hct) Males (47- Hct)  
Score =              % 
( Typical – Current ) 
x 6 
 





Standard kg                      kg 
100 x ( 1 -         )   
Current kg                     kg  





         6.      CDAI score (cumulative score)  
 
NOTE: If the CDAI is >220, the patient is ineligible for participation. Please proceed directly to 
Sections F and G and complete as appropriate. 
 
 
      Current 
     Standard 
Abdominal pain ꝉ                     
None = 0 
Intermediate = 1 or 2 
Severe = 3 
General wellbeing * 
Well = 0 
Intermediate = 1, 2 or 3 
Terrible = 4 
Weight + 
Skip this section (0) unless weight changes related to 
Crohn’s are known. Maximum deduction of -10 for 
overweight patients) 
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FAECAL CALPROTECTIN 
For the faecal calprotectin test, previous values may be used as long as they have been performed 
within 4 weeks of this screening visit. If previous values cannot be used, please collect a new sample 
from the patient. Please state the date of the stool sample used here: 
                                                                                                                                       /                       / 
                             DAY                      MONTH                                YEAR 
2. Faecal calprotectin result (μg/g)  
 
 
NOTE: If the faecal calprotectin is >250 μg/g, the patient is ineligible for participation. Please 
proceed directly to Sections F and G and complete as appropriate. 
 
BLOOD MARKERS OF INFLAMMATION 
For the C-Reactive Protein, previous values may be used as long as they have been performed within 
4 weeks of this visit. If previous values cannot be used, please collect a new sample from the patient. 
Please state the date of the blood sample used here:   
                                                                                                                                        /                       / 
                             DAY                      MONTH                                YEAR 
1. CRP result (mg/L)  
 
SURGICAL TREATMENT OF CROHN’S DISEASE 
3. Has the patient ever had any surgery for Crohn’s disease?                      Yes                  No 
 
4. If ‘Yes’, please indicate the type of surgery and date of procedure in the list below:  
Procedure Date (format: dd/ mm/ yyyy) 
       Anterior resection  
       Appendicectomy  
       Cholecystectomy  
       Colectomy and ileostomy  
       Creation of rectal mucous fistula  
       Defunctioning ileostomy  
       Drainage of abscess  
       Disease location unknown  
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       Excision of fistula  
      Extended right hemicolectomy  
       Ileal/jejunal resection or stricturoplasty  
       Ileectomy and anastomosis of ileum to colon  
       Ileectomy and anastomosis of ileum to ileum  
       Left hemicolectomy  
      Panproctocolectomy and ileostomy  
        Partial jejunectomy and anastomosis of jejunum to ileum  
        Partial laying open of fistula/insertion of seton  
       Perianal surgery  
       Right hemicolectomy/ileocaecal resection  
       Sigmoid colectomy and anastomosis  
       Small bowel resection with end to end anastomosis  
       Strictureplasty  
       Subtotal colectomy and primary anastomosis  
       Total colectomy and ileorectal anastomosis  




5. Does the patient have any major surgery planned within the first 6 months after 
randomisation? 
        Yes                  No, proceed to Section D 
 
 
NOTE: If ‘Yes’, the patient is ineligible for participation. Please proceed directly to Sections F and G 
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Section D: Current Medications 
Provide details in the table below of all the prescribed medication, over-the-counter medication and 
supplements/ nutraceuticals that the patient is currently taking.  

























































NOTE: If the patient has not had stable/unchanged medication for at least 4 weeks before the 
screening visit, the patient is ineligible for participation. Please proceed directly to Sections F and G 
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Section E: Comorbidities 
1. Absolute contraindications and comorbidities to exercise training and testing: 
Recent (48 hrs) ECG suggestive of ischaemia, acute       
myocardial infarction or other acute cardiac event 
Aortic dissection 
Symptomatic heart failure 
Unstable angina not controlled by medical therapy  
Presence of potentially serious arrhythmias  
Acute systemic infections (influenza, rhinovirus)  





2. Relative contraindications to exercise training and testing: 
 Left main coronary artery stenosis 
 Moderate stenotic valvular heart disease 
 Electrolyte abnormalities (hypokalemia, hypomagnesemia) 
 Severe hypertension (>200 mm Hg/ 110 mm Hg at rest) 
 Tacharrhytmias or bradyarrhythmias 
 Hypertrophic cardiomyopathy/ tract obstruction 













NOTE: If the patient has any absolute contraindications listed above, then they are ineligible for 
participation. Please complete the question below (Q3) and then proceed directly to Sections F and G. 
 
Symptomatic severe aortic stenosis      
Acute pulmonary embolus or pulmonary infarction  
Acute myocarditis or pericarditis 
Deep venous thrombosis  
Suspected or known dissecting aortic aneurysm   
Endocarditis 
 
NOTE: If the patient has any relative contraindications listed above, then participation needs to be 
confirmed by the patients consultant.  
 
High degree AV block 
Ventricular aneurysm 
Uncontrolled metabolic disease (diabetes) 
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Do any comorbidities warrant exclusion from the trial?  Yes            No 
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Section F: Inclusion Criteria 
The following criteria MUST all be answered YES for the patient to be 





1. Is the patient aged 16 and over?   
 
 
2. Has the patient had a clinical disease of Crohn’s disease 4 weeks prior to 




3. Does the patient have a CDAI score of lower than 220  
 
 





5. Have the patients medication been stable/unchanged for at least 4 




6. Is the patient able to provide written informed consent?  
 
 
7. Is the patient capable of completing the study questionnaires?  
 
 
8. Is the patient able and willing to travel to the research sites for 






Section G: Exclusion Criteria 
The following criteria MUST all be answered NO for the patient to be 




















4. Is the patient pregnant?   
 
 





6. Is the patient currently participating in another clinical trial for which 




7. Has the participant been deemed unsuitable by the 




8. Is the patient current participating in 2 or more sessions of resistance 
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Section H: Eligibility and Sign-off 
1. Have all the inclusion criteria been answered YES?                         Yes                              No 
 
2. Have all the exclusion criteria been answered NO?                          Yes                              No 
 
3. Patient status, in Section H: 
If Q1 and Q2 have both or individually been answered as ‘No’,  
the patient is to be excluded. Proceed to Q4 below. 
In Section H, if Q1 and Q2 have both been answered as ‘Yes’,  
the patient is to be included. Proceed to Q4 below.  
In Section H, if Q1 and Q2 have both been answered as ‘Yes’,  





4. Consent form has been signed and dated (version ________)  By patient 
By investigator 
5. Form completed by: (if different than medic assessor in item 6) 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                                         /                       /  
                                                           DAY                  MONTH                       YEAR 
6. Eligibility confirmed by medic assessor: 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                                        /                       /  
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If the individual(s) completing this screening form have any further comments regarding this 
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Schedule of enrolment, interventions and assessments  
TIME FRAME 







































































    
 
  
       
Eligibility screen- 
inclusion/ exclusion 
X X     
 
  
       
Disease Activity 
(CDAI and FC) 
 
 
    
 
  
    
X  
 
Informed consent  
Participant ID 
number 
 X               





    
 
  
       




 X     
 
 X  
   
X  
 
Appendix 7j: Participant timeline of enrolment, interventions and assessments 
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Stature: Stadiometer   X      X    X    






  X      X    X    
 
 
X    
 
  







30-s chair stand test 
and 30-s arm curl 
test 
  X      X    X    
 
 
X    
 
 X 
   X    
Fatigue: (IBD-F)   X      X    X    





X    
 
 X 
   X    
C-reactive Protein 
(CRP) 
 X     
 
  
    
X  
 




X  X X 
 
X X X X X  





X    
 
 X 





     
 
 X 










    
 
 X 
   X    
INTERVENTION                 




 X X (4) X (2) X (4) X (1)  X (1) X (1) X (1) 
  X  




 X   
 
  
      X 
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Visit Date:               /               / 




Appendix 7k: Baseline case report form 
 
W12018030  365 | P a g e  
 
Instructions for the baseline case report form: 
File this case report in the participants anonymised study file. A contact details form should also be 
completed at the Baseline visit and stored separately to the participants anonymised study 
documents. 
Please contact the Chief Investigator (Dr Garry Tew; garry.tew@northumbria.ac.uk) or Trial 
Coordinator (Katherine Jones; Katherine.jones@northumbria.ac.uk) if you have any questions. 
 
 
1.    Has the patient provided written informed consent for the PROTECT trial? 
                                          Yes                                 No 
 
If ‘Yes’, indicate the date on the patients consent form: 
                                                                                                                     /                         / 
                                                                                                     DAY                    MONTH                          YEAR 
2.   Is the patient still eligible for recruitment?                  
(Review the screening CRF before responding)                         Yes                                 No 
 






If ‘Yes’, please indicate the date on the Screening CRF that is to be used for this: 
                                                                                                                     /                         / 
                                                                                                     DAY                    MONTH                            YEAR 
 
If the screening date provided is less than 4 weeks this baseline visit,  
cross the box and proceed to section A. 
If the screening date is more than 4 weeks, then the patient needs to be  
re-screened before a baseline visit can be completed. Cross the box and sign-off  
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Section A: Group Preference 
Inform the patient of the following: 
In this trial, you will be allocated to either a resistance training programme plus usual care or a 
control group, who will receive usual care only. The study investigators have no influence over the 
treatment you will receive, this is done completely by random, for example tossing a coin by an 
independent statistician. 
Before we find out which study group you will be allocated to, we would like to know if you have a 
particular preference on one of the groups? Expressing a preference will not affect the group you will 
be allocated. 
Indicate the patients group preference: 
                                                             Resistance training 
                                                             Usual care 
                                                             No preference 
                             
 
Section B: Physical Measurements 
5. Body Mass (kg to 1 decimal place):                                     . 
 
6. Stature (cm to 1 decimal place):                              . 
 
 
7. Resting Heart Rate (beats/minute): 
 
 
8. Resting Blood Pressure (mmHG):                                    /     
                                                                      SYSTOLIC                        DIASTOLIC 
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Section C: Questionnaires 
Provide the participant with the set of questionnaires contained within this case report form and a 
black/blue pen. Ask the participant to complete the questionnaires. The only help you may provide is 
to read out the question(s) and possible responses as stated in the questionnaires. Do not rephrase 
questions or provide an interpretation of what a question means. Check that the participant has 
completed all sections of each questionnaire before progressing to the next section. 
 
3. Has the participant completed the IBDQ?                                       Yes                              No 
                                                                          
4. Has the participant completed the EQ-5D-5L?                               Yes                              No 
 
 
5. Has the participant completed the IBD-F?                                      Yes                              No 
 
 
6. Has the participant completed the SPAQ?                                      Yes                              No 
 
If ‘No’ to Q1-5, state the reason(s) in the box below. Use this space for any other comments about 
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Section D: Muscle Performance Testing 
Follow the study-specific procedure for muscle performance testing and complete the assessment 
testing data collection sheet contained within this case report form. 
 
6. Has the patient completed the lower muscle strength test?                  Yes                              No 
 
 
7. Has the patient completed the upper muscle strength test?                  Yes                              No 
  
 
8. Has the patient completed the 30’s chair stand test?                               Yes                              No 
 
 
9. Has the patient completed the 30’s arm curl test?                                    Yes                              No 
 
 
10. Has the patient completed the grip strength?                                            Yes                              No 
 
If ‘No’, state the reason(s) in the box below. Use this space for any other comments about muscle 






Section E: Bone Health Assessment  
Follow the study-specific procedure for muscle performance testing and complete the exercise 
testing data collection sheet contained within this case report form. 
2. Has a DXA scan on the patient been carried out?                                  Yes                              No 
 
If ‘No’, state the reason(s) in the box below. Use this space for any other comments about the bone 
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Section F: Check List and Investigator Sign-off 
4. Have all sections of this case report been completed?                   Yes                              No 
 
 
5. Any adverse events reported, or has the participant  
confirmed that no adverse events have occurred?                          Yes                              No 
 
6. Form completed by: 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                          /                       /  
                                                           DAY                  MONTH                       YEAR 
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Dear [INSERT NAME] 
Thank you once again from agreeing to take part in this research study regarding 
resistance training in adults with Crohn’s disease. 
The group you have been randomly assigned to is Group Two, the control group. This means 
you will not receive any exercise sessions and will carry on receiving usual standard care 
from The Newcastle Upon Tyne NHS Hospitals for the next 6 months. Your participation in 
the comparison group is vital as it will help us establish an understanding of the role of 
resistance training for adults with Crohn’s disease.  
The researcher will contact you at week 13 and week 26 to arrange for you to attend an 
assessment visit at the University of Northumbria at Newcastle at a time and date 
convenient for you. A reminder of what these assessment visits will involve: 
Week 13 Assessment Visit Location: Northumbria 
University 
Time: 1 Hour 
Similar to the measures you had taken at your baseline visit at Northumbria University. 
Your height, weight, fatigue (questionnaire), quality of life (questionnaires), physical 
activity (questionnaire), muscle strength (required to move your legs and arms at 
different speeds with force applied; squeeze a handle with as much force as possible), 
muscle endurance (complete as many chair rises to standing in 30 seconds; complete as 
many arm curls in 30 seconds). In addition: 
4. Information on your medications will be updated 
5. You will also be questioned regarding any medical events (issues with your health 
since the previous baseline assessment) 
 
Before your assessment at the Freeman hospital (week 26) you will be asked to keep a 
disease activity diary recording number of liquid stools, abdominal pain and general well-
being. This diary can be found in your pack – if lost contact the researcher: 
katherine.jones@northumbria.ac.uk and another copy can be sent out.   
Week 26 Assessment Visit Location: Freeman Hospital/RVI Time: 1 hr  
You will be asked to bring your 7 day disease activity diary to this assessment. 
Similar to the screening visit you attended at the Freeman Hospital. A direct care team 
member will assess: 
4. Information on your medical history, surgical history and medications will be 
collected 
Appendix 7m: Control group letter 
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5. A physical examination of your abdomen- consisting of a visual examination 
(inspection), listening to bowel sounds (auscultation) and feeling for abdominal 
tenderness (palpations)  
6. You will also be required to provide a stool and blood sample, unless this has 
been performed within the previous 4 weeks  
Week 26 Assessment Visit Location: Northumbria 
University 
Time: 1 hr 45 mins 
During this time we will assess all measures previously been done: height, weight, fatigue 
(questionnaire), quality of life (questionnaires), physical activity (questionnaire), bone 
mineral density, muscle strength, grip strength, muscle endurance and physical activity 




Following these assessments we would also like to have a brief telephone conversation with 
you regarding some follow up questions about your experience in the study, any medical 
events and your thoughts on being in the control group, who does not receive exercise. This 
telephone interview will last approximately 30 minutes. After completion of the study, you 
will receive another phone call offering an exercise consultation from the researcher. During 
this call the benefits and guidelines of exercise will be discussed and a personalised action 
plan for developing and achieving your exercise goals will be established. 
If you have any questions, please contact the researcher Katherine Jones at Email: 
katherine.jones@northumbria.ac.uk  











When attending assessment visits, for your safety and the safety 
of others please ensure to wear suitable exercise clothing. 
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Section A: General Instructions 
o Welcome the participant to the session, confirm their continuing consent and ask if anything 
has changed medically since their last visit 
o Provide a reminder/ explain how the RISE scale works 
o Check first aid equipment is immediately available 
o Please make sure all sections of the CRF are completed 
o If a session is missed, please state the reason why 
 
Section B: Exercise Scales 
RESISTANCE INTENSITY SCALE for EXERCISE 
Using the scale below we would like you to rate your perception of exertion, that is how heavy and 
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EXERCISE SESSION 
Participant Identification Number :    Date of session (dd/mm/yyyy) :        Session Number :  
 
TheraBand Colour:     Jump Training Stage:    Resistance Training Stage: 
 




Number of Sets/repetitions/ exercises 
 
RISE  
(Easy to Maximal) 
Before warm up  
 
    
5 minute warm up 
 
    
Jumping training 
 




    
3 minute cool down 
 
    
10 minutes post-exercise 
 
    
 
1. Was the session completed ?   Yes   No              Please state why 
 
2. Did any adverse events occur during this session?  Yes     No             
                                                                                                       If ‘Yes’, please follow adverse event procedures and provide a brief description:    
 
___ / ___ / ______  
 






Progressive Resistance Training Exercise and Crohn’s 
Disease Trial 
 









Participant ID:  
Visit Date:               /               / 
             DAY                    MONTH                            YEAR 
 
 
Is the patient still eligible and willing to participate?                        Yes                          No 
Appendix 7p: Week 13 case report form 
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If ‘Yes’, complete all sections of this case report form. 





Section A: Current Medications 
Provide details of all prescribed medication, over-the-counter medication and supplements/ 
nutraceuticals that the patient is currently taking.  
Use the medication documented in the Screening Case Report Form to facilitate this process.  















Section B: Physical Measurements 
1. Body Mass (kg to 1 decimal place):                                     . 
 
2. Stature (cm to 1 decimal place):                              . 
 
 
3. Resting Heart Rate (beats/minute): 
 
 
4. Resting Blood Pressure (mmHG):                                    /     
                                                                      SYSTOLIC                        DIASTOLIC 
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Section C: Questionnaires 
Provide the participant with the set of questionnaires (page 8 onwards) and a blue or black pen. Ask 
the participant to complete the questionnaires.  
NOTE: You may read out the question(s) and possible responses as stated in the questionnaire, 
however do not rephrase these questions or provide any interpretation of what the question means. 
Check that the participant has completed all sections of each questionnaire before progressing to 
the next section. 
 
1. Has the participant completed the IBDQ?                                       Yes                              No 
                                    
2. Has the participant completed the EQ-5D-5L?                               Yes                              No 
 
 
3. Has the participant completed the IBD-F?                                      Yes                              No 
 
 
4. Has the participant completed the SPAQ?                                      Yes                              No 
 
 
5. Has the participant completed the PACES?                                     Yes                              No 
(EXERCISE GROUP ONLY) 
 
If ‘No’ to Q1-5, state the reason(s) in the box below. Use this space for any other comments about 
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Section D: Muscle Performance Testing 
Follow the study-specific procedure for muscle performance testing and complete the assessment 
data collection sheet contained within this case report form. 
 
1. Has the patient completed the lower muscle strength test?                   Yes                              No 
 
2. Has the patient completed the upper muscle strength test?                   Yes                              No 
  
 
3. Has the patient completed the 30’s chair stand test?                               Yes                              No 
 
 
4. Has the patient completed the 30’s arm curl test?                                    Yes                              No 
 
 
5. Has the patient completed the grip strength?                                            Yes                              No 
 
If ‘No’, state the reason(s) in the box below. Use this space for any other comments about muscle 




Section E: Check List and Investigator Sign-off 
1. Have all sections of this case report been completed?                   Yes                              No 
 
 
2. Any adverse events reported, or has the participant  
confirmed that no adverse events have occurred?                          Yes                              No 
 
3. Form completed by: 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                          /                       /  
                                                           DAY                  MONTH                       YEAR 
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Participant ID:  
Visit Date:               /               / 
             DAY                    MONTH                            YEAR 
 
Appendix 7q: Week 26 case report form 
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Is the patient still eligible and willing to participate?                        Yes                          No 
 
If ‘Yes’, complete all sections of this case report form. 





Section A: Current Medications 
Provide details of all prescribed medication, over-the-counter medication and supplements/ 
nutraceuticals that the patient is currently taking.  
Use the medication documented in the Screening Case Report Form to facilitate this process.  















Section B: Physical Measurements 
5. Body Mass (kg to 1 decimal place):                                     . 
 
6. Stature (cm to 1 decimal place):                              . 
 
 
7. Resting Heart Rate (beats/minute): 
 
 
8. Resting Blood Pressure (mmHG):                                    /     
                                                                      SYSTOLIC                        DIASTOLIC 
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Section C: Questionnaires 
Provide the participant with the set of questionnaires (page 8 onwards) and a blue or black pen. Ask 
the participant to complete the questionnaires.  
NOTE: You may read out the question(s) and possible responses as stated in the questionnaire, 
however do not rephrase these questions or provide any interpretation of what the question means. 
Check that the participant has completed all sections of each questionnaire before progressing to 
the next section. 
 
6. Has the participant completed the IBDQ?                                       Yes                              No 
                                    
7. Has the participant completed the EQ-5D-5L?                               Yes                              No 
 
 
8. Has the participant completed the IBD-F?                                      Yes                              No 
 
 
9. Has the participant completed the SPAQ?                                      Yes                              No 
 
 
10. Has the participant completed the PACES?                                     Yes                              No 
(EXERCISE GROUP ONLY) 
 
If ‘No’ to Q1-5, state the reason(s) in the box below. Use this space for any other comments about 
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Section D: Muscle Performance Testing 
Follow the study-specific procedure for muscle performance testing and complete the assessment 
data collection sheet contained within this case report form. 
 
6. Has the patient completed the lower muscle strength test?                   Yes                              No 
 
7. Has the patient completed the upper muscle strength test?                   Yes                              No 
  
 
8. Has the patient completed the 30’s chair stand test?                               Yes                              No 
 
 
9. Has the patient completed the 30’s arm curl test?                                    Yes                              No 
 
 
10. Has the patient completed the grip strength?                                            Yes                              No 
 
If ‘No’, state the reason(s) in the box below. Use this space for any other comments about muscle 






Section E: Bone Health Assessment  
Follow the study-specific procedure for muscle performance testing and complete the exercise 
testing data collection sheet contained within this case report form. 
1. Has a DXA scan on the patient been carried out?                                  Yes                              No 
 
If ‘No’, state the reason(s) in the box below. Use this space for any other comments about the bone 
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Section E: Check List and Investigator Sign-off 
4. Have all sections of this case report been completed?                   Yes                              No 
 
 
5. Any adverse events reported, or has the participant  
confirmed that no adverse events have occurred?                          Yes                              No 
 
6. Form completed by: 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                          /                       /  
                                                           DAY                  MONTH                       YEAR 



























Progressive Resistance Training Exercise and Crohn’s 
Disease Trial 
 









Participant ID:  
Visit Date:               /               / 





Appendix 7r: Week 26 hospital case report form 
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Instructions for completing the 26 week hospital case report form: 
These questions and assessments are to be completed by the hospital principal investigator (PI) or 
delegated member of the staff listed on the PROTECT delegation log. 
 
PLEASE NOTE: Details on this form MUST be confirmed by the PI or delegated medic, who sign and 
date section H.  
 
Please complete all sections in this form. If you have any questions, please do not hesitate to contact 
the Chief Investigator (Dr Garry Tew; garry.tew@northumbria.ac.uk) or Study Trial Coordinator 
(Katherine Jones; Katherine.jones@northumbria.ac.uk).  
When complete, please make a paper copy of: 
o This case report form 
o Patient 7-day diary for CDAI 
Originals of this screening case report form and the patient 7-day diary for CDAI should be sent to 
the researcher separately to ensure the data remains anonymised, with copies made and stored in 
the patients study file at the hospital.  
 
 
Is the patient still eligible and willing to participate?                        Yes                          No 
 
If ‘Yes’, complete all sections of this case report form. 
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Section A: Current Medications and Medical History 
Provide details of all prescribed medication, over-the-counter medication and supplements/ 
nutraceuticals that the patient is currently taking.  
Use the medication documented in the Screening Case Report Form to facilitate this process.  
















































1. Has anything changed in regards to your medical history?       Yes       No, proceed to Section B 
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Section B: Disease Activity Assessment 
CROHN’S DISEASE ACTIVITY INDEX (CDAI) 
Ahead of the screening visit , the patient should have been given a CDAI diary to complete for 7 
days. Please state the date the patient started completing this diary:                                   
             /                      /                                     
   DAY                      MONTH                                YEAR 
Use the CDAI calculation form to calculate the CDAI score. 
Parameter   Factor Subtotal 
Liquid stools  
(total over last 7 days) 
M T W T F S S  




       
Abdominal pain ꝉ 
(total over last 7 days) 





       
General wellbeing * 
(total over last 7 days) 





       
 
Extra-Intestinal 
Arthritis/arthralgia None = 0  
Score = 
x 20  
Yes = 1 
Iritis/uveitis None = 0  
Score = 
x 20  
Yes = 1 
Skin/mouth lesions None = 0  
Score = 
x 20  
Yes = 1 
Peri-anal disease None = 0  
Score = 
x 20  
Yes = 1 
Other fistula None = 0  
Score = 
x 20  
Yes = 1 
Fever > 37.8oC None = 0  
Score = 
x 20  
Yes = 1 
 
Anti-diarrhoeals None = 0  
Score = 
x 30  
Yes = 1 
 





Questionable = 2 
Definite = 5 
 
Haematocrit (Hct) Males (47- Hct)  
Score =              % 
( Typical – Current ) 
x 6 
 





Standard kg                      kg 
100 x ( 1 -         )   
Current kg                     kg  
      Current 
     Standard 
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         6.      CDAI score (cumulative score)  
 
FAECAL CALPROTECTIN 
For the faecal calprotectin test, previous values may be used as long as they have been performed 
within 4 weeks of this visit. If previous values cannot be used, please collect a new sample from 
the patient. Please state the date of the stool sample used here: 
                                                                                                                                  /                       / 
                             DAY                      MONTH                                YEAR 
1. Faecal calprotectin result (μg/g)  
 
BLOOD MARKERS OF INFLAMMATION 
For the C-Reactive Protein, previous values may be used as long as they have been performed 
within 4 weeks of this visit. If previous values cannot be used, please collect a new sample from 
the patient. Please state the date of the blood sample used here:   
                                                                                                                                  /                       / 
                             DAY                      MONTH                                YEAR 














Abdominal pain ꝉ                     
None = 0 
Intermediate = 1 or 2 
Severe = 3 
General wellbeing * 
Well = 0 
Intermediate = 1, 2 or 3 
Terrible = 4 
Weight + 
Skip this section (0) unless weight changes related to 
Crohn’s are known. Maximum deduction of -10 for 
overweight patients) 
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Section C: Eligibility and Sign-off 
1. Have all sections of this case report been completed?                   Yes                              No 
 
2. Any adverse events reported, or has the participant  
confirmed that no adverse events have occurred?                          Yes                              No 
 
3. Form completed by: (if different than medic assessor in item 6) 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                          /                       /  
                                                           DAY                  MONTH                       YEAR 
4. Eligibility confirmed by medic assessor: 
 
                                      Signature: 
 
                                      Print name: 
 
                                       Date:                          /                       /  
                                                           DAY                  MONTH                       YEAR 
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Resistance training in adults with Crohn’s disease  




was this study important/ why was it needed? 
Reduced bone mineral density and poor muscular strength and endurance are established 
complications of Crohn’s disease (CD). Although not part of routine treatment, regular exercise has 
demonstrated improvements in fatigue, disease activity, psychological health, quality of life and bone 
and muscle health. Despite these potential benefits, the role of exercise in CD has not been well 
studied and remains poorly understood with research primarily focusing on the potential of aerobic 
exercise programmes (e.g. running, cycling). 
However, growing evidence in other chronic conditions has shown that resistance (strength) training 
may have a better effect on bone health, muscle strength and endurance than aerobic exercise. 
Despite this, little information exists around the potential of resistance training in CD patients. With 
the debilitating nature of this disease, further research is needed as these findings may have a 
significant impact upon management in the CD population by providing physical activity solutions 
instead of or alongside current treatments. 
Q. What was the main purpose of the study which I took part in? 
The primary purpose of this study was to investigate the effects of a 6 month resistance training 
programme on muscle function and bone mineral density. We also assessed the impact it may have 
upon fatigue, disease activity and quality of life.  
Q. Who was studied? 
Between February 2018 and March 2019, 76 people with CD were screened for eligibility and after the 
eligibility assessment, 47 were recruited and randomised. Eligible participants were randomly (given an 
equal chance of being allocated to group one or group two) allocated to either the exercise group who 
completed three weekly, 60 minute sessions of impact and resistance training for 6 months, or to a 
control group who received usual care. Thirty-two participants were female and the average age was 
49 years. Data collection commenced in October 2019.  
Q. How was the study done? 
All participants completed three assessment visits (baseline, at 3 months and 6 months) at the 
University of Northumbria at Newcastle. At each visit, participants completed a series of 
questionnaires regarding quality of life, fatigue and physical activity habits and completed a number of 
muscular strength and endurance measures. Bone mineral density was taken at baseline and 6 months 
only. Following the conclusion of the study, participants completed a telephone-based exit interview. 
Appendix 7s: End of study information sheet 
Reference: IRAS 226369; ISRCTN ISRCTN11470370; REC 17/NE/0308 
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Q. What happens now the study has stopped? 
Now the study has ended the data we collected will be stored on a password-protect computer in 
accordance with the Participant Information Sheet, University guidelines and Data Protection Act 
(1998). None of this information is identifiable. Any identifiable information collected throughout the 
study has been destroyed.  
You will continue to receive the best possible care from the National Health Services. 
Q. Invitation to take part in patient involvement 
The IBD Bioresource is a national platform designed to research into Crohn’s disease and ulcerative 
colitis and help develop new and better therapies. If you are not already part of the Bioresource and 
would like to be, please contact the NuTH IBD Research leads: Ashleigh Hogg at 
ashleigh.hogg@nhs.net or Lesley Jeffrey lesley.jeffrey1@nhs.net.   
Q. How will the results of the research be made available to me? 
Please find below a summary of the findings. However, if you wish to access the results in more detail 
please contact one of the team members (contact details below) who can provide you with the 
information once available.  
Q. What did we find? 
Results from the 3-month assessment: At 3 months, we found a significant improvement in upper and 
lower limb strength and endurance measures. Handgrip strength significantly improved as did quality 
of life and resting heart rate. We found no significant improvements in fatigue severity, duration or 
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Results from the 6-month assessment: At 6 months, improvements were sustained in upper and lower 
limb strength and endurance measures, handgrip strength and resting heart rate. Fatigue severity, 
duration and impact significantly improved from baseline. Bone mineral density significantly improved 
at the lumbar spine and hip. Some aspects of quality of life were significantly improved (social 
function) but no significant improvements were shown in bowel symptoms, systemic systems, 


















Q. What were the limitations of this study? 
Nutritional intake, although important for bone health, were not taken into consideration. This was 
primarily due to the complexity of recording food intake for a prolonged period and the inability to 
determine absorption rates between patients. Future research is needed to determine the potential 
influence of a nutritional intervention alongside different modes of exercise.     
Q. What are the implications of this study? 
Our findings support the promotion of a combined impact and resistance-training programme to 
positively influence bone mineral density, muscle strength and muscle endurance in people with CD. 
Clinicians should consider asking and supporting their patients who are physically inactive.  
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Q. How do we let others know about this study? 
We have submitted a short report of the study to the largest UK meeting of gastroenterologists, the 
BSG annual meeting – this will be held in Liverpool in June.  We have also submitted a longer report for 
publication in a Clinical journal, this will need to be reviewed by others (peer-review) before a decision 
is made on whether the report is accepted for publication.  
 
Thank You 
On behalf of the PROTECT team members, University of Northumbria at Newcastle and The Newcastle 
Upon Tyne Hospitals NHS Foundation Trust we would like to take this opportunity to thank you for 
your interest and participation in the PROTECT (Resistance training in adults with Crohn’s disease) 
study. We value your participation and the time and effort you committed to our research efforts. Your 





















 For further information regarding the results of this study, please contact: 
• Trial Coordinator: Katherine Jones 
Department of Sport, Exercise and Rehabilitation, Northumbria University 
Email: Katherine.jones@northumbria.ac.uk     Telephone: 07434668536 (Mon- Fri 9am-5pm) 
• Chief Investigator: Associate Professor Garry Tew  
Department of Sport, Exercise and Rehabilitation, Northumbria University 
Email: garry.tew@northumbria.ac.uk              Telephone: 0191 243 7556 
Contact Details 
 




Resistance training in adults with Crohn’s disease 




1. What was the purpose of the project? 
The purpose of this study was to investigate the effects of a 6 month resistance training 
programme on muscle function, bone mineral density, fatigue, quality of life and disease activity in 
adults with inactive or mildly active Crohn’s disease (CD). 
2. How will I find out about the results? 
If you have requested to receive a summary of the findings the principal investigator will email you 
approximately 10 weeks after completion of the study. 
3. Have I been deceived in any way during the project? 
No, you have not been deceived at any point during or after this study. 
4. If I change my mind and wish to withdraw the information I have provided, how do I do this? 
If, for any reason you do wish to withdraw from this study, please inform the researcher as soon as 
possible (contact details below) within a month of your participation. They will facilitate your 
withdrawal and discuss how you would like your data to be treated. However, after this date it 

















All data collected in this study will be fully anonymised using numerical coding to maintain 
Appendix 7t: Debrief sheet 
As this study may have caused some emotional discomfort, the details for counselling services that will provide 
support and guidance can be found below: 
Crohn’s and Colitis UK Support 
Tel: 0121 7379931 
Online Support: http://s3-eu-west-
1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/counselling-for-IBD.pdf  
Other Organisations Suggested by CCUK: 
 
 
 British Association for Counselling and 
Psychotherapy 
Tel: 01455 883300 
United Kingdom Council for Psychotherapy 
Tel: 020 7014 9955 
British Association for Behavioural and Cognitive 
Psychotherapies 
Online Support: www.babcp.com 
Improving Access to Psychological Therapies 
Online Support: www.iapt.nhs.uk 
 
IRAS ID:  226369 
Centre Number:………………………………… 
Participant ID Number:…………………… 
Study Number:………………………………….. 
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confidentiality. Only the principal investigator will have access to any identifiable information 
which will be kept separate from any data that can identify the participant. All data will be stored 
on a password-protected computer in accordance with university guidelines and the Data 
Protection Act  
 
(1998) and destroyed within 2 years after the conclusion of the study. Some results might be 
reported  
in a scientific journal, presented at a research conference or shared within other organisations/ 
institutions, however the data will always remain anonymous unless specific consent is obtained 
beforehand. At no point will your personal information or data be revealed unless forced to do so 
by the courts.  
If you wish to receive feedback about the findings of this research study then please contact the 
researcher at katherine.jones@northumbria.ac.uk.  
This study and its protocol have received full ethical approval from the Faculty of Health and Life 
Sciences Research Ethics Committee. If you require confirmation of this, or if you have any 
concerns or worries concerning this research, or if you wish to register a complaint, please contact 
the Chair of this Committee (Dr Nick Neave: nick.neave@northumbria.ac.uk), stating the title of 
the research project and the name of the researcher. 
 
















































Appendix 7u: Audio recording invitation letter 
 

































Appendix 7v: Audio recording informed consent 
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Resistance training in adults with Crohn’s disease 
EXIT INTERVIEW SCRIPT 
 
Introduction 
Hello [INSERT], this is [INSERT]. I’m just calling in regards to the Resistance Training in adults with Crohn’s 
disease study that you participated in. Thank you once again for taking part in this research study. 
Q, At the beginning of the study, you agreed to someone ringing you after the exercise training had ended to 
ask you some questions regarding your experiences of the study. Please can you confirm you are happy to 







Q, Before we begin, our discussion will be recorded as part of the research process and transcribed for 
analysis. Your personal details and everything you say will be anonymised and kept confidential so it cannot be 







Q, Great, is there anything you would like to say or ask before I start the recorder?  
Brief History 
Q, Before we start talking about your experience participating in the research study, could you tell me a bit 
about your Crohn’s disease? From when you were diagnosed up until taking part in the research: 
• What were your presenting symptoms? 
• When were you diagnosed? How long? 
• How were you diagnosed? 
• What is your history with Crohn’s disease- flare ups, problems related to your condition 
• What medications have you tried? 
Appendix 7w: Exit interview script  
YES NO (Time Issues) 
No problem, is there a better time 
I could contact you? 
NO  
(End call) 
No problem, thank you once 
again for taking part.  
YES NO  
(End call) 
No problem, thank you once 
again for taking part.  
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• Any surgical procedures? 
• Have you tried anything yourself to manage your Crohn’s disease? 
• Has this method been successful? How? 
• Do you experience abdominal pain or joint pain as a result of your condition? How long have you 
experienced this pain? Is there anything you do to reduce your pain? Is there anything you find makes 
it worse? 
Research Questions 
Q, The next few questions will be focused on your experience participating in the study. What were your 
thoughts when you heard about the research opportunity? How did you hear about the research? 
Q, From the information you received which of the following was most important and relevant when deciding 
to participate: 
1. Invitation letter 
2. Participant information sheet 
3. Organisation (location/ timing of assessments) 
Q, Was there any additional information you would have liked to receive that might have been helpful when 
you were deciding to participate?   
Q, Why did you choose to participate in the research study? 
Q, How did you find the study assessment at the hospital? 
• What did you think about the setting at the hospital? 
• How did you find the travel and length of the sessions? 
• What was your relationship like with the research nurse and clinical investigators? 
• How did you find the clinical assessments carried out at the hospital, such as the stool and blood 
samples and physical examination? 
Q, How did you find the study assessments at the university?  
• What did you think about the setting at the university? 
• How did you find the travel and length of the sessions? 
• What was your relationship like with the researcher and other investigators? 
• How did you find the clinical assessments carried out at the university such as the bone mineral 
density scan, muscular performance tests and questionnaires 
Intervention Experience (EXERCISE GROUP ONLY) 
The next few questions are going to involve your experience in the group you were placed in. What was your 
initial preference, control or exercise? Why was this you preference? 
Q, What did you think when you were allocated to the exercise group? 
Q, What did you expect from the exercise programme before you began?  
Q, Could you tell me what you thought about the design of the exercise programme? 
• How did you feel about completing three sessions a week? (too often, just right, not enough) 
• How did you find the intensity of the programme? (too often, just right, not enough) 
• What did you think about the length of the session? (too often, just right, not enough) 
• What are your thoughts regarding the length of the programme? (too often, just right, not enough) 
• What are your thoughts on the type of exercise used? (too often, just right, not enough) 
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Q, What are your thoughts about the setting of the exercise programme? Was it appropriate? Could it have 
been better? If so, how? 
Q, Was there anything that made it hard for you’re to complete the exercise programme? 
Q, What made you keep attending the sessions? 
Q, Could you recommend are changes to the exercise programme if the study were to run again? 
Q, In regards to the researcher delivering the exercise programme, can you tell me what your relationship was 
like? How did this relationship compare with your relationship with other healthcare professionals? 
Q, Is there any aspect which could have been better? Do you think that the right sort of person delivered the 
intervention? 
Outcomes 
Q, Has the exercise intervention had any positive or negative changes on you, such as: 
• Physical changes, anything you have noticed as a result of the exercise? 
• Apart physical changes, how do you feel in yourself since completing the exercise programme?  
• Do you see any changes in your condition after completing the exercise programme? 
• Has it affected how you will manage you condition in the future? 
• Has it changed your understanding of your condition? 
• Do you see you condition differently than before? 
• Abdominal pain, has the intervention affected the amount or severity of the abdominal pain you 
experienced before commencing the exercise programme? 
• Joint pain, has the intervention affected the amount or severity of the abdominal pain you 
experienced before commencing the exercise programme? 
Acceptability 
The last few questions will focus on your thoughts of the acceptability of the exercise programme. 
Q, How acceptable do you think the exercise programme was? 
Q, Would you recommend this sort of exercise programme to other people with Crohn’s disease? Why? 
Q, Can you think of any reasons people with Crohn’s disease may not want to participate in this type of 
exercise? Or research study? 
Q, Do you think this type of exercise training should be offered on the NHS for people with Crohn’s? If no, why 
not? If yes, what would the exercise training look like, what would you like to see? 
Q, If exercise training wasn’t available on the NHS, would you be willing to pay for it and if so much would you 
be willing to pay? 
End 
I think we have covered all necessary topics, is there anything you would like to discuss or add? Or do you have 
any questions?  
(End call) Thank you very much for your time its greatly appreciated. 
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Clinical Characteristics a  
 Exercise [n= 23] Control [n= 24] Total [n= 47] 
Disease Location, n (%)    
   Ileal 5 (21.8) 10 (41.6) 15 (31.9) 
   Colonic 8 (34.8) 4 (16.7) 12 (25.5) 
   Ileocolonic 9 (39.1) 9 (37.5) 18 (38.3) 
   Ileocolonic Crohn’s and upper GI disease 1 (4.3) 1 (4.2) 2 (4.3) 
Disease Behaviour, n (%)    
   Non-Stricturing, Non-Penetrating 14 (60.9) 17 (70.8) 31 (66.0) 
   Stricturing 5 (21.7) 6 (25) 11 (23.4) 
   Penetrating 4 (17.4) 1 (4.2) 5 (10.6) 
Disease Modifier, n (%)    
   Peri-anal Disease 6 (12.8) 7 (14.9) 13 (27.7) 
Current Medication, n (%)    
   Oral 5-Aminosalicylate 1 (4.3) 1 (4.2) 2 (4.3) 
  Anti-TNF Treatment  7 (30.4) 12 (50) 19 (40.4) 
   Immunosuppressants 13 (56.6) 7 (29.2) 20 (42.6) 
   Anti-diarrheals 3 (13.0) 7 (29.2) 10 (21.3) 
   Analgesics 2 (8.7) 5 (20.9) 7 (14.9) 
   Iron Supplements 2 (8.7) 2 (8.3) 4 (8.5) 
   Vitamin B12 Injections 7 (30.4) 4 (16.7) 11 (23.4) 
   Calcium Supplementation  4 (17.4) 5 (20.9) 9 (19.1) 
   Vitamin D Supplementation  5 (21.8) 7 (29.2) 12 (25.5) 
   Parenteral/ Enteral Nutrition 1 (4.3) 0 (0.0) 1 (2.1) 
   Folic Acid 6 (26.1) 4 (16.7) 10 (21.3) 
   Antiemetics 1 (4.3) 2 (8.3) 3 (6.4) 
  No Medication  1 (4.3) 2 (8.3) 3 (6.4) 
Surgical History, n (%)    
   Cholecystectomy 0 (0.0) 1 (4.2) 1 (2.1) 
   Colectomy and ileostomy 5 (21.7) 2 (8.3) 7 (14.9) 
   Defunctioning ileostomy 1 (4.3) 0 (0.0) 1 (2.1) 
   Drainage of abscess 0 (0.0) 2 (8.3) 2 (4.3) 
   Excision of fistula 1 (4.3) 0 (0.0) 1 (2.1) 
   Ileal/Jejunal resection  or stricturoplasty 6 (26.1) 6 (25.0) 12 (25.5) 
Appendix 7x: Clinical characteristics at baseline 
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   Ileectomy and anastomosis of ileum to colon 1 (4.3) 1 (4.2) 2 (4.3) 
   Panproctocolectomy and ileostomy 4 (17.4) 1 (4.2) 5 (10.6) 
   Perianal surgery 1 (4.3) 1 (4.2) 2 (4.3) 
   Right hemicolectomy/ ileocecal resection 9 (39.1) 10 (41.7) 19 (40.5) 
   Sigmoid colectomy and anastomosis 2 (8.7) 0 (0.0) 2 (4.3) 
   Small bowel resection with end to end  
    anastomosis 
2 (8.7) 1 (4.2) 1 (6.4) 
   Stricureplasty 2 (8.7) 1 (4.2) 3 (6.4) 
   Subtotal colectomy and primary anastomosis 2 (8.7) 0 (0.0) 2 (4.3) 
   No surgery  6 (26.1) 7 (29.2) 13 (27.7) 
Extra-intestinal Manifestations, n (%)    
   None 15 (65.2) 15 (62.5) 30 (63.4) 
   Enteropathic Arthritis 4 (17.4) 2 (8.3) 6 (12.8) 
   Erythema Nodosum 1 (4.3) 0 (0.0) 1 (2.1) 
   Iritis/ Uveitis 0 (0.0) 2 (8.3) 2 (4.3) 
   Orofacial Granulomatosis 1 (4.3) 0 (0.0) 1 (2.1) 
   Psoriasis 1 (4.3) 3 (12.5) 4 (8.5) 
   Ankylosing Spondylitis  1 (4.3) 2 (8.3) 3 (6.4) 
   Lymphoma/ Malignancy 1 (4.3) 1 (4.2) 2 (4.3) 
   Serious Infections 1 (4.3) 0 (0.0) 1 (2.1) 
   Bile Salt Malabsorption 1 (4.3) 1 (4.2) 2 (4.3) 
   Osteoporosis/ Osteopenia 1 (4.3) 3 (12.5) 4 (8.5) 












Change in clinical variables from baseline, 3 and 6 month  
 Group 
Allocation 
Baseline 3 Months Adjusted Mean 3 
Months (95% CI) 
Mean Difference 
(95% CI) 
P value 6 months Adjusted Mean 6 





Blood Pressure (mmHg) 
   Systolic IG 136 ± 21 126 ± 15 125 (120 to 130) -7 (-14 to 0) 0.060 129 ± 14 128 (122 to 133) -1 (-9 to 8) 0.884 
CG 132 ± 20 131 ± 16 132 (127 to 137)   127 ± 18 128 (122 to 134)   
   Diastolic 
 
IG 81 ± 13 75 ± 11 73 (70-77) -4 (-9 to 2) 0.178 76 ± 9 75 (71 to 78) -3 (-8 to 2) 0.180 
CG 75 ± 9 76 ± 7 77 (73 to 81)   77 ± 10 78 (75 to 82)   
BMI IG  27.7 ± 5.3 27.3 (26.3 to 28.3) 0.8 (-.555 to 2.3) 0.222 27.9 ± 5.3 27.6 (26.7 to 28.5) 0.9 (-.356 to 2.2) 0.151 
 CG  26.1 ± 4.4 26.5 (25.4 to 27.5)   26.4 ± 3.7 26.7 (25.8 to 27.6)   
Resting Heart Rate 
(beats/min) 
IG 79 ± 10 73 ± 8 74 (70 to 77) -5 (-10 to 0) 0.032 75 ± 11 75 (71 to 79) -6 (-12 to -1) 0.032 
CG 80 ± 11 79 ± 12 79 (75 to 82)   82 ± 11 82 (78 to 86)   
Mean ± S.D are indicated for all columns unless stated.  
IG, Intervention Group; CG, Control Group; BMI, Body Mass Index 
 
Appendix 7y: Clinical changes at 3 and 6 months 
 





Best-case sensitivity analysis for primary outcomes at 6 months 
 Exercise group (n=23) Control group (n=24) Difference  P value 
Bone Mineral Density (g/cm2) 
     Lumbar Spine 1·103 (1·062 to 1·144) 1·018 (0·978 to 1·058) 0·085 (0·027 to 0·142) 0.005 
     Greater Trochanter 0·720 (0·693 to 0·746) 0·684 (0·657 to 0·710) 0·036 (-0·002 to 0·074) 0.065 
     Femoral Neck 0·823 (0·793 to 0·853) 0·770 (0·741 to 0·800) 0·052 (0·010 to 0·095) 0.017 
Muscle Strength (Nm) 
     Knee Extension-60°/sa 104·9 (94·1 to 115·7) 71·6 (61·1 to 82·2) 33·2 (18·1 to 48·4) <0.001 
     Knee Extension-180°/s a 68·0 (60·4 to 75·6) 44·0 (36·5 to 51·5) 24·0 (13·3 to 34·7) <0.001 
     Elbow Flexion-60°/sb 36·1 (32·6 to 39·6) 25·8 (22·4 to 29·2) 10·3 (5·4 to 15·2) <0.001 
     Elbow Flexion-120°/sb 30·8 (27·7 to 33·9) 21·7 (18·7 to 24·8) 9·0 (4·7 to 13·4) <0.001 
     HGS (kg) 41·8 (38·9 to 44·6) 30·7 (27·8 to 33·5) 11·1 (7·0 to 15·2) <0.001 
Muscle Endurance (repetitions) 
     30-s-BCT 24 (23 to 25) 16 (15 to 17) 8 (6 to 9) <0.001 
     30-s-CST 19 (18 to 20) 14 (13 to 15) 5 (3 to 6) <0.001 
Data are mean and adjusted mean differences with 95% CI’s in parentheses  
Appendix 7z: Best-case and worst-case sensitivity analysis  
 




Worst-case sensitivity analysis for primary outcomes at 6 months 
 Exercise group (n=23) Control group (n=24) Difference  P value 
Bone Mineral Density (g/cm2) 
     Lumbar Spine 1·090 (1·059 to 1·122) 1·076 (1·045 to 1·107) 0·014 (-0·030 to 0·059) 0.521 
     Greater Trochanter 0·709 (0·686 to 0·733) 0·711 (0·688 to 0·734) -0·002 (-0·035 to 0·032) 0.928 
     Femoral Neck 0·809 (0·787 to 0·831) 0·803 (0·781 to 0·825) 0·006 (-0·026 to 0·037) 0.704 
Muscle Strength (Nm) 
     Knee Extension-60°/sa 100·5 (92·7 to 108·3) 80·2 (72·6 to 87·8) 20·2 (9·3 to 31·2) 0·001 
     Knee Extension-180°/s a 65·4 (59·4 to 71·4) 52·2 (46·3 to 58·1) 13·2 (4·7 to 21·6) 0·003 
     Elbow Flexion-60°/sb 34·5 (32·2 to 36·8) 28·7 (26·4 to 30·9) 5·8 (2·5 to 9·1) 0.001 
     Elbow Flexion-120°/sb 29·7 (27·4 to 32·0) 24·4 (22·1 to 26·7) 5·3 (2·0 to 8·6) 0.002 
     HGS (kg) 40·8 (39·0 to 42·7) 33·4 (31·6 to 35·2) 7·4 (4·8 to 10·1) <0.001 
Muscle Endurance (repetitions) 
     30-s-BCT 24 (22 to 25) 17 (16 to 18) 7 (5 to 8) <0.001 
     30-s-CST 18 (17 to 19) 15 (14 to 16) 4 (2 to 5) <0.001 
Data are mean and adjusted mean differences with 95% CI’s in parentheses  
